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I N T R O D u C T I O N
The field of interventional cardiology was characterized during the last decades by 
a continuous improvement in terms of materials, techniques and ultimately clinical 
outcomes. The initial use of bare metal stents enhanced the procedural success rate 
compared with simple balloon angioplasty(1) and the subsequent introduction of drug-
eluting coronary stents (DES) was associated with a remarkable inhibition of neointimal 
growth, translating into a reduction in in-stent restenosis, lowering the need for repeated 
revascularizations (2,3) 
Second generation DES further improved the clinical results and they are currently 
considered extremely well performing devices and the gold standard for percutaneous 
coronary artery interventions.(4-6) 
However, metallic stent placement is not devoid of important long-term limitations. 
The metallic implant results in a permanent caging of the vessel, preventing late lumen 
enlargement, jailing side branches, precluding non-invasive imaging and further surgical 
revascularization of stented segments.(7) 
Furthermore, beside the beneficial effect of neointimal inhibition, the antiproliferative 
drug elution could interfere with the vascular healing processes thus providing the 
background for delayed strut coverage and persistent or acquired malapposition, all 
possibly related to late and very late stent thrombosis.(8,9) 
Given this background bioresorbable vascular scaffolds have been introduced in the 
attempt to overcome the above-mentioned limitations of the current generation metallic 
DES. 
In addition to the theoretical advantages, of future surgical revascularization and a 
potential reduction of very late thrombotic events,(7) the implantation of the Absorb 
BVS has been demonstrated to allow the non-invasive imaging follow-up of the treated 
arteries (10,11) and the restoration of coronary vasomotion, observed to return already after 
1 year post-implantation.
The vasomotor activity plays an important role in the regulation of coronary blood flow, 
ensuring the maintenance of an appropriate coronary flow pressure, while an impaired 
vasomotion could be associated with an increased risk of future cardiovascular events.
(12-15) Moreover scaffold placement has been associated with the formation of a neointimal 
layer that may potentially represent a de	novo circumferential plaque thick cap, with the 
potential function of plaque stabilization, after scaffold bioresorption. (16) 
From a physiological perspective, complete scaffold bioresorption exposes the vessel wall 
to the cyclical strain of blood pulsatility. Previous studies proposed mechanical stimuli 
induced by a pulsatile blood flow as a factor increasing the release of nitric oxide (NO) and 
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prostacyclin (17) and associated with a reduction of monocyte adhesion, thus providing 
a fundamental atheroprotective effect.(18-21) Biomechanical stimuli also modulate 
endothelial cell morphology, proliferation, apoptosis, (22,23) elongation and realignment, 
(24) extracellular matrix production(25) and inflammatory signals.(26) Pulsatile flow and its 
mechanical action on vessel wall is associated with a down regulation of NADPH oxidase 
activity, present in the endothelium, vascular smooth muscle cells, fibroblasts, and 
monocytes (27,28) with a consequent reduction in reactive oxygen species formation. (29,30 
Previous reports have demonstrated that reactive oxygen species, such as superoxide 
and hydrogen peroxide inactivates nitric oxide and provokes the formation of oxidants 
that induces both low-density lipoprotein (LDL) oxidation and expression of monocyte 
chemo-attractant proteins on endothelial cells with subsequent monocyte binding and 
trans-endothelial migration, that are both fundamental processes in atherogenesis. (31-34) 
The restoration of the beneficial cyclical strain, (15,35) and the consequent reduction in 
reactive oxygen species formation may therefore have an impact on both endothelium-
dependent vasodilation and atherogenesis. 
In the new scenario of a coronary vessel free of metallic caging, the concomitant scaffold 
drug elution at early stages, (36) and medical therapy in the early and late phase (37-39) 
may both play a key additional role to facilitate phenomena such as plaque regression, 
expansive remodeling and late luminal enlargement. 
An analysis of vasoreactivity in scaffolded segments at 12- and 24- month follow-up with 
both endothelial-depend and -independ agents, showed that endothelial dysfunction in 
those regions is correlated to the amount of plaque burden and necrotic core content. 
(40) These data support the hypothesis that an improvement of plaque composition and 
plaque burden could have a beneficial impact also on post scaffolding vasomotion 
resembling the behaviour of native non-stented segments. 
Given this background the concept of bioresorbable device for treatment of coronary 
atherosclerotic lesions has been rapidly embraced by the scientific community and an 
initial clinical experience in relatively simple lesions and stable patients showed promising 
results in terms of restoration of vasomotion already at 1-year post implantation(15) and 
long-term clinical outcomes(41).
However, at the current state of the art, a profound knowledge of the performance of 
the bioresorbable technology in real world complex lesions and patents is still lacking. In 
addition, the higher complexity if the implantation technique and the observation of a 
slightly higher rate of thrombotic events tempered the initial enthusiasm related to this 
novel paradigm for treatment of coronary atherosclerosis.
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The present thesis represents a journey through our initial experience with the 
bioresorbable scaffold up to the implementation of this technology in complex scenarios 
such as unstable patients with acute thrombotic lesions, calcified plaques, coronary 
bifurcations, and even complex chronic total occlusions thus resembling as much as 
possible the entire spectrum of our daily clinical practice.
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A B S T R AC T
Objectives The aim of this study was to evaluate the progression of atherosclerotic 
coronary plaques at bifurcations, using combined intravascular ultrasound–virtual 
histology (IVUS-VH) and optical coherence tomography (OCT).
Background Pathological findings reveal that atherosclerotic plaques characterized 
by the presence of large necrotic cores (NCs) with fibrous cap thicknesses < 65 μ.m 
are more prone to rupture. Accuracy in the detection of high-risk plaques could be 
improved by the combined use of IVUS-VH and OCT.
Methods IVUS-VH and OCT are 2 imaging modalities with different lateral 
resolutions and different depths of penetration. To provide a precise matching 
of the images, bifurcations were used as landmarks. IVUS-VH and OCT were 
performed in 56 bifurcations from 24 patients at baseline and at 6-month follow-
up. All patients were treated with standard medical therapy. Bifurcations were 
studied at the proximal, in-bifurcation, and distal regions. Plaques were classified 
according to their composition as assessed by IVUS-VH and fibrous cap thickness 
as quantified by OCT.
Results At baseline, 27 NC-rich plaques were found. At 6-month follow-up, 22 (81%) 
did not show any significant change. Four new NC-rich lesions developed. At both 
time points, percent NC was higher and the fibrous cap was thinner at the proximal 
bifurcation rim compared with the distal. There were no significant changes in 
percent NC and fibrous cap thickness in the 3 bifurcation regions between baseline 
and follow-up examinations. No major cardiovascular events due to bifurcation 
lesion progression were observed.
Conclusions The combined use of IVUS-VH and OCT is a reliable tool to serially assess 
plaque progression and regression, and in the present study it was demonstrated 
to be safe and feasible. At 6-month follow-up, in this post–percutaneous coronary 
intervention patient population, most high-risk plaques remained unchanged, 
retaining their imaging classifications, nevertheless appearing to have remained 
clinically silent. 
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I N T R O D u C T I O N
Plaque rupture and subsequent activation of the clotting cascade resulting in sudden 
intraluminal thrombosis are thought to be the most frequent cause of acute coronary 
syndromes (1,2). In pathology, precursor lesions, known as thin-cap fibroatheromas (TCFA), 
are characterized by a large pool of necrotic core (NC) covered by a thin fibrous cap <65 
μ.m (3). The resolution of current intravascular ultrasound (IVUS) systems (100 to 200 μ.m) 
constitutes an important limitation of this technique for the measurement of fibrous cap 
thickness (4). Optical coherence tomography (OCT), in contrast, has higher resolution (10 
to 20 μ.m) but low signal penetration. This can be a source of inaccurate assessment of 
NC size, especially in plaques with large plaque bur- den and positive remodeling, which 
is a characteristic of TCFA lesions (5). Therefore, combining the 2 imaging techniques 
might provide a more accurate method to investigate TCFAs (6,7). There are only a few 
published reports of the combined use of IVUS and OCT in vivo (6,7) and none describing 
the longitudinal assessment of plaque progression and regression at bifurcations. The 
aim of the present study was therefore to evaluate serial changes in plaque type and 
composition at bifurcations of the main coronary arteries using combined IVUS–virtual 
histology (VH) and OCT.
M E T h O D S 
Study population
 Fifty-six bifurcations were selected from 24 patients presenting with stable angina, unstable 
angina, or silent ischemia. All patients were treated at the Thoraxcenter, Erasmus Medical 
Center (Rotterdam, the Netherlands), and enrolled in 2 different stent studies (ABSORB 
cohort B and SECRITT). Both studies used IVUS-VH and OCT as part of their protocols. The 
bifurcations selected for this study were more than 5 mm away from the stented region 
and had side branch orifice diameters >1.5 mm as measured by OCT. Only bifurcations 
imaged with both modalities and for which imaging was of high quality were considered. 
All bifurcations fitting this inclusion criteria were included. All patients re- ceived standard 
medical therapy, including aspirin, clopidogrel, and statins, for at least 6 months.
IVuS-Vh acquisition and analysis
IVUS acquisitions were performed using an Eagle Eye catheter (Volcano Corporation, 
Rancho Cordova, California) with automatic continuous pullback at a speed of 0.5 mm/s. 
IVUS grayscale and IVUS-VH analyses were performed offline using dedicated software (8). 
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OCT acquisition
 The OCT M3 (Time Domain- OCT) and C7 (Fourier Domain-OCT) systems were used in this 
study (LightLab Imaging, Inc., Westford, Massachusetts). For each patient, the same system 
was used for baseline and follow-up examinations. Measurements were performed offline 
by 2 independent observers using LightLab imaging software.
OCT analysis
Fibrous cap thickness measurement was performed in each bifurcation frame at the 
thinnest part of the fibrous cap overlying the pool of NC. The reproducibility of this 
variable has been previously reported by our group (9).
Bifurcation matching analysis
IVUS-VH and OCT are 2 imaging modalities with different lateral resolutions and different 
depths of penetration. To provide a precise matching of the images, a strict selection of 
frames was followed using a method previously described (7). Only the main branches were 
analyzed, and for each bifurcation the following frames were considered: 1) the proximal 
rim of the side branch ostium; 2) the in-bifurcation site (the frame with the largest ostial 
diameter of the side branch); and 3) the distal rim of the side branch ostium (Fig. 1).
Plaque type classiﬁcation
Plaques were classified ac- cording to the following previously described (7) hierarchical 
classification: 1) those with high percents of fibrotic tissue (adaptive intimal thickening, 
pathological intimal thickening, fibrotic plaque, and fibrocalcific plaque); and 2) NC-
rich plaques (those with more than 10% confluent NC) (fibroatheroma and calcified 
fibroatheroma); if covered by fibrous caps thinner than 65 μ.m, they constitute TCFA 
and calcified TCFA. These plaque types are reported per location within the bifurcation 
(at the distal, in-bifurcation, and proximal frames) and per bifurcation, defined as the 
worst plaque type within the bifurcation detected among the 3 frames considered. In 
addition, we introduce an IVUS-VH and OCT– derived plaque risk index, defined as the 
ratio between the sum of NC-rich plaques and the sum of non-NC-rich plaques in a given 
bifurcation region. This index was calculated for each bifurcation region at both baseline 
and follow-up. 
Statistical analysis
Categorical variables are presented as frequencies and percents. Continuous variables are 
presented as medians and interquartile ranges and were compared using the Wilcoxon 
signed rank test. A p value <0.05 was considered statistically significant. The bifurcation 
IVUS-VH and OCT of Coronary Bifurcations    |   25
PART
I
was the unit of analysis, without correction for correlated observations in the same 
subjects. Statistical analyses were performed using SPSS version 16.0 for Windows (SPSS, 
Inc., Chicago, Illinois).
R E S u LT S 
Patients’ baseline clinical characteristics are reported in Table 1. The median age was 67 
years, and most patients were men (79%). At follow-up, all patients were treated with 
statins: 6 received rosuvastatin (4 received 10 mg and 2 received 20 mg), 9 patients 
received simvastatin (7 received 20 mg and 2 received 40 mg), and 9 patients received 
atorvastatin (6 received 40 mg, 2 received 20 mg, and 1 received 10 mg).
table 1. Baseline Clinical Characteristics (n = 24).
n=24
Age (yrs)  67 (58–73)
Men 19 (79)
Presentation
Stable angina 16 (67) 
Unstable angina 5 (20) 
Silent ischemia 3 (13)
Hypertension 18 (75)
Hypercholesterolemia 17 (71)
Diabetes 4 (17)
Smoking 5 (20)
Family history of CAD 13 (54)
Previous AMI 9 (37)
Previous PCI 10 (42)
Vessel
LAD 11 (46) 
LCX 5 (20)
RCA 8 (33)
Therapy
Antiplatelet therapy 24 (100) 
Beta-blockers 15 (62) 
ACE inhibitors/ARBs 13 (54) 
Statins 16 (67) 
Insulin 1 (4)
Values are median (interquartile range) or n (%). ACE = angiotensin-converting enzyme; AMI = acute myocardial 
infarction; ARB = angiotensin II receptor blocker; CAD = coronary artery disease; LAD = left anterior descending 
coronary artery; LCX = left circumflex coronary artery; PCI = percutaneous coronary intervention; RCA = right 
coronary artery.
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table 2. Geometrical and Compositional Data in Each Region of the Bifurcation at Baseline and Follow-Up.
Variable Baseline Follow-up p Value
Distal 14.01 (10.75–18.06) 13.52 (10.32–16.49) 0.051
In-bifurcation 15.62 (12.47–20.14) 14.75 (12.11–18.77) 0.543
Proximal 15.84 (12.86–20.85) 14.89 (12.23–20.83) 0.262
Luminal CSA (mm2)
Distal 7.23 (6.19–9.27) 7.20 (6.19–9.27) 0.012
In-bifurcation 8.46 (7.25–11.05) 7.93 (7.04–10.68) 0.184
Proximal 7.62 (6.80–9.85) 7.27 (6.00–9.75) 0.005
Plaque CSA (mm2)
Distal 5.68 (3.74–8.50) 6.26 (4.07–8.30) 0.231
In-bifurcation 5.79 (3.93–8.23) 6.07 (4.36–8.96) 0.144
Proximal 6.84 (5.11–10.72) 7.54 (6.00–10.86) 0.046
Plaque burden (%)
Distal 42.74 (33.30–57.12) 49.13 (36.61–57.87) 0.004
In-bifurcation 39.38 (30.30–48.86) 42.76 (34.37–48.42) 0.027
Proximal 48.67 (39.32–58.69) 51.50 (46.39–59.54) 0.008
Minimal luminal diameter (mm)
Distal 2.80 (2.44–3.24) 2.65 (2.29–3.18) 0.007
In-bifurcation 2.87 (2.56–3.21) 2.77 (2.48–3.29) 0.033
Proximal 2.90 (2.60–3.28) 2.78 (2.47–3.16) 0.039
Minimal vessel diameter (mm)
Distal 3.95 (3.48–4.54) 3.88 (3.41–4.31) 0.075
In-bifurcation 4.06 (3.77–4.59) 4.06 (3.61–4.45) 0.489
Proximal 4.22 (3.81–4.69) 4.13 (3.71–4.72) 0.194
Fibrous CSA (mm2)
Distal 1.33 (0.13–3.23) 1.44 (0.45–2.72) 0.423
In-bifurcation 1.53 (0.52–2.83) 1.48 (0.94–2.96) 0.368
Proximal 1.65 (1.20–4.20) 2.57 (1.31–3.49) 0.329
Fibrous tissue (%)
Distal 60.36 (40.41–70.90) 61.03 (50.83–68.17) 0.922
In-bifurcation 62.63 (50.21–69.14) 59.68 (52.75–66.83) 0.094
Proximal 58.85 (51.09–69.24) 58.18 (50.65–64.23) 0.150
Fibrofatty CSA (mm2)
Distal 0.18 (0.02–0.75) 0.30 (0.03–0.87) 0.498
In-bifurcation 0.26 (0.06–0.68) 0.29 (0.07–0.72) 0.739
Proximal 0.50 (0.18–1.09) 0.45 (0.23–1.16) 0.870
Fibrofatty tissue (%)
Distal 10.54 (1.56–18.02) 10.47 (6.07–18.88) 0.299
In-bifurcation 10.99 (5.24–16.78) 10.55 (3.79–18.84) 0.504
Proximal 13.12 (6.24–23.88) 10.46 (5.53–18.48) 0.339
NC CSA (mm2)
Distal 0.19 (0.02–0.62) 0.39 (0.06–0.82) 0.374
In-bifurcation 0.38 (0.05–0.70) 0.50 (0.12–0.88) 0.089
Proximal 0.44 (0.44–0.13) 0.62 (0.28–1.28) 0.265
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Results from the geometrical and compositional analysis at the distal rim, in-bifurcation, 
and proximal rim of the side branch ostium are reported in Table 2. At follow-up, the 
median vessel cross-sectional area remained unchanged at the distal, in- bifurcation, 
and proximal frames, while median luminal cross-sectional area decreased slightly, 
resulting in an increase in plaque burden (Table 2). Fibrous and fibrofatty tissue did not 
change between baseline and follow-up. Median NC cross-sectional area and percent NC 
nonsignificantly increased in each region. Dense calcium cross- sectional area significantly 
increased at the distal, in-bifurcation, and proximal segment (Table 2). In NC-rich plaques 
(NC > 10% [fibroatheroma, calcified fibroatheroma, TCFA, and calcified TCFA]), the percent 
of NC nonsignificantly decreased over time at the distal rim (21.65% vs. 18.54%, p = 0.193), 
in-bifurcation (22.38% vs. 20.25%, p = 0.573), and proximal rim (23.15% vs. 18.06%, p = 
0.317).
Distribution of IVuS-Vh and OCT– derived plaque types at the 3 bifurcation 
regions
The distribution of NC-rich and NC-poor plaques is presented in Table 3. There was 
a gradient of disease from the proximal to the distal rim. NC-rich plaques were more 
frequently located at the proximal rim. Non– NC-rich plaques showed an inverse gradient. 
In addition, the highest value of the IVUS-VH and OCT– derived plaque risk index was 
found in the proximal rim of the bifurcations at both baseline and follow-up. From baseline 
to follow-up, the index increased in each region, implying that the number of NC regions 
relative to non-NC regions also increased (Table 3).
Variable Baseline Follow-up p Value
NC (%)
Distal 9.90 (1.79–18.13) 13.95 (7.42–21.94) 0.261
In-bifurcation 12.31 (6.52–18.15) 16.10 (8.81–21.65) 0.199
Proximal 12.44 (5.92–23.15) 16.24 (8.65–20.43) 0.280
Dense calcium CSA (mm2)
Distal 0.08 (0.00–0.42) 0.20 (0.00–0.40) 0.021
In-bifurcation 0.10 (0.01–0.48) 0.20 (0.01–0.40) 0.005
Proximal 0.17 (0.02–0.53) 0.30 (0.01–0.70) 0.002
Dense calcium (%)
Distal 3.29 (0.00–9.52) 4.87 (0.43–15.71) 0.031
In-bifurcation 6.70 (0.46–13.85) 7.62 (1.74–13.30) 0.124
Proximal 3.74 (0.92–9.86) 6.60 (1.89–14.55) 0.003
Values are median (interquartile range). CSA = cross-sectional area; NC = necrotic core.
table 2. Continued.
28   |    Chapter 2
figure 1. Frame Selection at Bifurcations.
A strict selection of the analyzed cross-sections was followed to provide a correct match between the 2 imaging 
modalities and between baseline and follow-up. Plaques were analyzed only in the main coronary arteries at the 
proximal rim of the ostium of the side branch (the first frame proximal to the takeoff  of the side branch), at the in-
bifurcation site (the frame with the larger ostial diameter of the side branch), and at the distal rim of the ostium of the 
side branch (the first frame distal to the takeoff  of the side branch).
figure 2. Changes in Bifurcation Plaque Type.
Changes in bifurcation plaque type at 6-month follow-up. For each plaque type, the percent of changes is reported. 
AIT = adaptive intimal thickening; CaFA = calcified fibroatheroma; CaTCFA = calcified thin-cap fibroatheroma; FA = 
fibroatheroma; FC = fibrocalcific plaque; FT = fibrotic plaque; PIT = pathological intimal thickening; TCFA = thin-cap 
fibroatheroma.
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table 3. Plaque Type at Distal Rim, In-Bifurcation, and Proximal Rim at Baseline and Follow-Up and IVUS-VH and 
OCT–Derived Plaque Risk Index.
            Non–NC-Rich Plaques NC-Rich Plaques
Segment AIT  PIT FT FC FA CaFA TCFA CaTCFA Plaque Risk Index*
23 (41) 4 (7.1) 9 (16.1) 3 (5.4) 6 (10.7) 10 (17.9) 0 (0) 1 (1.8) 17/39 = 0.43
In-bifurcation BL 17 (30.4) 4 (7.1) 9 (16.1) 7 (12.5) 7 (12.5) 10 (17.9) 0 (0) 2 (3.6) 19/37 = 0.51
In-bifurcation FU 12 (21.4) 6 (10.7) 8 (14.3) 8 (14.3) 9 (16.1) 10 (17.9) 1 (1.8) 2 (3.6) 22/34 = 0.65
Proximal rim BL 14 (25.0) 5 (8.9) 7 (12.5) 6 (10.7) 6 (10.7) 12 (21.4) 2 (3.6) 4 (7.1) 24/32 = 0.75
Proximal rim FU 8 (14.3) 7 (12.5) 9 (16.1) 5 (8.9) 6 (10.7) 14 (25.0) 1 (1.8) 6 (10.7) 27/29 = 0.93
Values are n (%). *Sum of NC nrich/non-NC-rich plaques. AIT = adaptive intimal thickening; BL = baseline; CaFA = 
calcified fibroatheroma; CaTCFA = calcified thin-cap fibroatheroma; FA = fibroatheroma; FC = fibrocalcific plaque; 
FT = fibrotic plaque; FU = follow-up; IVUS = intravascular ultrasound; NC = necrotic core; OCT = optical coherence 
tomography; PIT = pathological intimal thickening; TCFA = thin-cap fibroatheroma; VH = virtual histology.
Bifurcation plaque types
At baseline, 27 NC-rich plaques were found, of which 6 were classified as thin-cap lesions 
(TCFA and calcified TCFA). Two fibroatheroma plaques became fibrotic and fibrocalcific 
(regressed), and 1 TCFA became a fibroatheroma (regressed). Two fibroatheromas became 
TCFAs (progressed), and 22 (81%) did not change. Four new NC-rich lesions developed 
from fibrotic and fibrocalcific plaques. Most (83%) thin-cap lesions did not change at 
6-month follow-up (Fig. 2).
Fibrous cap thickness, distribution, and changes over time
Fibrous cap thickness significantly decreased from the distal to the proximal region at 
both baseline and follow-up (Fig. 3). However, no changes in cap thickness were observed 
from baseline to follow-up within each of the 3 regions (Table 4, Fig. 4). The same held for 
frames with thin-cap lesions, for which no changes in cap thickness were observed over 
time (Table 4).
table 4. Minimal Fibrous Cap Thickness at Distal, In-Bifurcation, and Proximal Segments in All NC-Rich Plaques.
NC-Rich Plaques Segment Baseline
(m)
Follow-up
(m)
P Value
Non–thin-cap lesions Distal 100 (80–130) 90 (70–110) 0.206
In-bifurcation 80 (70–100)  80 (60–100)  0.670
Proximal 70 (50–90)  70 (60–100)  0.065
Thin-cap lesions Distal 50 (40–50)  70 (40–90) 0.317
In-bifurcation 50 (40–60)  50 (40–50) 0.564
Proximal 50 (40–60)  50 (50–60) 0.084
Values are median (interquartile range). NC = necrotic core.
30   |    Chapter 2
figure 3. Fibrous Cap Thickness in the Three Regions of the Bifurcation.
The fibrous cap was measured in each frame with a plaque more than 600 μ.m thick assessed by optical coherence 
tomography and with more than 10% of confluent necrotic core detected by intravascular ultrasound–virtual 
histology. The fibrous cap showed a progres- sive reduction in thickness from the distal to the proximal frame at 
baseline (A) and follow-up (B).
figure 4. Thin Fibrous Cap at Baseline and Follow-Up.
Thin fibrous cap did not show a statistically significant diff erence in cap thickness at 6-month follow-up (red arrows). 
The matching of the frames was done using bifurcations and also microstructures (white arrows) as landmarks.
A B
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D I S C u S S I O N 
The main findings of our study are as follows: 1) dual-modality acquisition and analysis at 2 
different time points for the evaluation of coronary atherosclerosis is feasible, addressing 
the complementary limitations of the 2 imaging modalities. 
2) In a post–percutaneous coronary intervention patient population treated with standard 
medical therapy, most NC-rich plaques remained unchanged in their composition as 
measured by IVUS-VH at 6-month follow-up, and most thin-cap lesions remained thin 
capped (<65 μ.m) as measured by OCT. 3) Although the study population was small, the 
serial imaging findings of plaque morphology were in line with the clinical outcomes.
Moreover, we observed that the proximal rim of the side branch ostium is more likely to 
contain a larger amount of NC and the thinnest fibrous cap within the bifurcation. The 
plaque index, defined as the ratio of NC-rich to non-NC-rich frames, increased, implying a 
progression of the disease at 6 months. This finding is supported by the observation that 
in this small series, 4 new NC-rich plaques developed and 2 additional plaques became 
TCFAs. This progression was due mostly to an increase of NC in non–NC-rich plaques 
(development of new NC-rich areas). To our knowledge, this is the first in vivo study 
evaluating longitudinal changes in plaque type and composition using combined plaque 
assessment with IVUS-VH and OCT.
Sawada et al. (6) recently reported in a small series that 54% of IVUS-VH– derived TCFAs 
were non- thin-cap lesions by OCT, and 6.3% of OCT-derived TCFAs were not definitively 
TCFAs. This study strongly supports the combined use of these 2 imaging modalities, 
which appears to be necessary for the correct detection of high-risk plaques. In addition, 
Manfrini et al. (5) reported that if used alone, OCT can lead to misinterpretations due to its 
low signal penetration, which does not allow an accurate detection of signal-poor areas 
with heterogeneous compositions.
Previously, Kubo et al. (10) reported in a serial population that 75% of TCFAs detected 
on VH healed at 1-year follow-up. Takarada et al. (11) reported that therapy with statins 
significantly increased fibrous cap thickness detected with OCT in a population with 
untreated hypercholesterolemia. However, potentially all single-modality imaging 
studies could have obtained different results by combining the 2 modalities, virtually 
increasing accuracy for TCFA detection. Therefore, further investigations are needed to 
better understand the evolution of high-risk plaques in patients with optimal medical 
treatment, and the combined use of IVUS-VH and OCT could be a key tool to characterize 
the coronary model of future events (12).
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Study limitations
This study might have been under- powered to detect differences in plaque composition, 
and the length of follow-up was short, so the study should be considered exploratory and 
hypothesis generating, without formal statistical hypotheses.
Local endothelial shear stress was not measured. We cannot exclude that different plaque 
progression and regression might be also associated in the present series to different 
shear stress conditions. Because the BVS (Abbott Laboratories, Abbott Park, Illinois) is a 
drug-eluting device, in bifurcations located distally to the scaffold, the drug might have a 
considerable impact on the progression or regression of atherosclerosis.
CO N C Lu S I O N S 
The combined use of IVUS-VH and OCT is a reliable tool to serially assess plaque progression 
and regression, and in the present study, it was demonstrated to be safe and feasible. At 
6-month follow-up, in this post–percutaneous coronary intervention patient population, 
most high-risk plaques remained unchanged, retaining their imaging classification, 
nevertheless appearing to have remained clinically silent.
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I N T R O D u C T I O N
Atherosclerosis is the main cause of coronary heart disease, which is today the leading 
cause of death worldwide and will continue to be the first in the world in 2030 [1]. In the 
formation of atherosclerotic coronary lesions, a critical primary step is the accumulation 
and oxidation of low-density lipoprotein (LDL) particles. Oxidized-LDL favors leukocyte 
recruitment and their activation, as well as cell death. This leads to generation of complex 
atherosclerotic plaques [2]. These plaques have a high content of necrotic core, a thin 
inflamed fibrous cap (intense accumulation of macrophages) and scarce presence of 
smooth muscle cells (i.e. thin capped fibroatheroma – TCFA).
At early stages of the formation of the atheroma, the remodeling of the vessel wall usually 
prevent plaque from encroaching the lumen, thereby masking the presence of atheroma 
on angiography. In contrast, greyscale intravascular ultrasound (IVUS) can fully assess the 
extension of the disease axially and longitudinally. This intravascular imaging technique 
has played a vital role in advancing our understanding of the pathophysiology of 
coronary artery disease, and in the development of novel cardiovascular drugs and device 
therapies [3, 4]. In the last decade, IVUS based imaging modalities have been introduced 
such as backscatter data analysis and echogenicity, facilitating characterisation of plaque 
components and its mechanical properties. This intravascular imaging technology and its 
clinical and research applications are discussed in detail in the different sections of this 
chapter.
R AT I O N A L E  F O R  I N T R AVA S C u L A R  I M AG I N G
Coronary angiography depicts arteries as a planar silhouette of the contrast-filled lumen. 
Importantly, angiography does not provide visualisation of the vessel wall and is not 
suitable for assessment of atherosclerosis. Angiographic disease assessment is based on 
the comparison of the stenotic segment with the adjacent, “normal appearing” coronary, 
which is often an incorrect assumption due to the diffuse nature of atherosclerosis as 
shown by pathological and IVUS studies. [7, 8] (Figure 1) . Angiography interpretation is 
flawed by large inter- and intra-observer variability and usually underestimates the severity 
of the disease and vessel dimensions. Although quantitative coronary angiography (QCA) 
has reduced the visual error, the ability of arteries to enlarge to compensate for plaque 
growth makes angiography an unreliable method to assess atherosclerosis burden [8]. 
Three-dimensional angiography obtained with systems such as DynaCT (Siemens Medical 
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Solutions) at the time of the contrast injection may provide more accurate and precise 
assessment of the luminogram, addressing some of the limitations of conventional 
angiography, but it still does not allow visualisation of the arterial wall and plaque burden. 
These limitations of angiography can be minimised by the intravascular tomographic 
visualisation of lumen and vessel wall architecture. In addition, IVUS enables assessment 
of ambiguous disease in vessels with aneurysmal dilatation, ostial stenoses, disease 
located at branching points or in the left main; tortuous or calcified segments; eccentric 
disease, complex disease morphology, intraluminal filling defects, thrombus, dissection 
and lumen dimensions after coronary intervention.
figure 1. Coronary angiography and IVUS. This figure illustrates the heterogeneity of atherosclerotic disease and 
the lack of correlation of IVUS findings (Panels A through D) and angiography appearance (Panel E). The patient 
presented with stable angina and a significant stenosis in the right coronary artery which was stented (not shown). A 
greyscale IVUS pullback in the left anterior descending (LAD) was performed in order to better characterise the mild 
stenosis in its mid segment. Panel A shows a large eccentric plaque in the ostium of the LAD that angiographically 
has minimum lumen compromise. Panel B depicts a soft concentric plaque. Panel C shows a mixed plaque. Panel D 
depicts an eccentric, soft lesion.
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I N T R AVA S C u L A R  u LT R A S O u N D
Basic principles
The IVUS image is the result of reflected ultrasound waves that are converted to electrical 
signals and sent to an external processing system for amplification, filtering and scan-
conversion. After leaving the transducer, the beam remains almost parallel for a short 
distance (“near field”; better image quality) and then begins to diverge (“far field”). After 
encountering a transition between different materials, for example the interface between 
blood and the intimal arterial layer, the beam will be partially reflected and partially 
transmitted, depending on tissue composition and differences in mechanical impedance 
between materials. For example, calcium produces nearly complete backscattering of 
the signal and is displayed as a bright image with a characteristic acoustic shadowing. 
Ultimately, greyscale IVUS imaging is formed by the envelope (amplitude) of the obtained 
radiofrequency signal (Figure 2 ).
The quality of ultrasound images can be described by spatial resolution and contrast 
resolution. Its axial resolution is approximately 100 microns, while lateral resolution 
reaches 200-250 microns in conventional IVUS system (20-40 MHz). Contrast resolution is 
the distribution of the grey scale of the reflected signal, and is often referred to as dynamic 
range.
An image of low dynamic range appears as black and white with a few levels of grey; 
images at high dynamic range are often softer.
Catheter designs
The IVUS equipment consists of a catheter incorporating a miniaturised transducer and a 
console to reconstruct and display the image. (Figure 3) . Lately, IVUS consoles have been 
incorporated into the cathlab equipment for easier operation. Current catheters range 
from 2.6 to 3.2 Fr in size and can be introduced through conventional 6 Fr guide catheters.
Rotational, mechanical IVUS probes rotate a single piezoelectric transducer at 1800 rpm 
and operate at frequencies between 30 and 40 Mhz, while electronic phased-array systems 
operate at a centre-frequency of approximately 20 MHz. Higher ultrasound frequencies 
are associated with better image resolution, but increasing the frequency beyond 40 MHz 
has been limited because of decreased tissue penetration [9, 10]. Electronic systems have up 
to 64 transducer elements in an annular array that are activated sequentially to generate 
the cross-sectional image [10]. In general, electronic catheter designs are slightly easier to 
set-up and use, whereas mechanical probes offer superior image quality. Electronic IVUS 
catheters have the ability to display blood flow in colour to facilitate distinction between 
lumen and wall boundaries.
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Autoregressive spectral analysis of IVUS backscattered data has been incorporated into 
conventional IVUS systems to facilitate image interpretation of different tissue components 
(i.e., necrotic core in red, dense calcium in white, fibrous in dark green, and fibrofatty in 
light green) [11]. ( Figure 2 ). In a post mortem validation study, RF analysis demonstrated 
sensitivity and specificity for detection of necrotic core of 92 % and 97 %, respectively [11]. The 
first commercially available IVUS backscattering image analysis, named virtual-histology™ 
(IVUS-VH), was built on the electronic 20 MHz IVUS platform. This system has been utilised 
in clinical trials to monitor progression of atherosclerosis. Lately rotational mechanical IVUS 
systems have also integrated a backscattering regression algorithm. ( Figure 2 ). [179]
Another approach is to assess the deformability of coronary plaque using also the analysis 
figure 2. Assessment of atheromatous plaque components with different IVUS modalities.Intravascular ultrasound 
signal is obtained from the vessel wall (A). Greyscale IIVUS imaging is formed by the envelope (amplitude) (B) of 
the radiofrequency signal (C). By greyscale, atherosclerotic plaque can be classified into 4 categories: soft, fibrotic, 
calcified and mixed plaques. Panel D shows a cross-sectional view of a greyscale image. The blue lines limit the actual 
atheroma. The frequency and power of the signal commonly differ between tissues, regardless of similarities in the 
amplitude. From the backscatter radiofrequency data different types of information can be retrieved: virtual histology 
(E), palpography (F), integrated baskscattered (IB), IVUS (G) and iMAP (H). Virtual histology is able to detect four tissue 
types: necrotic core, fibrous, fibro-fatty and dense calcium. Palpography plaque deformability is reported in strain 
values, which are subsequently categorized into four grades according to the ROtterdam Classification (ROC). The 
tissues characterised by integrated baskscattered(IB) IVUS are lipidic, fibrous and calcified; and iMAP detects fibrotic, 
lipidic, necrotic and calcified.
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of radiofrequency signals at different diastolic pressure levels, normalised to a pressure 
difference of 2.5 mmHg per frame. This allows the construction of a “strain” image, in 
which harder (“low strain”) and softer (“high strain”) regions of the coronary arteries can 
be identified, with radial strain values ranging between 0 % and 2 % [12]. ( Figure 2 ). Post 
mortem coronary arteries were investigated with histology and IVUS palpography. The 
sensitivity and specificity of palpography to detect vulnerable plaques are 88%, and 89%, 
respectively. [12]
Examination technique
The IVUS procedure is performed under full anticoagulation with an activated clotting 
time of > 250 sec. Following intracoronary infusion of intracoronary nitroglycerine 
(100-200 micrograms) to minimise vasospasm, the rapid exchange IVUS catheters are 
introduced in the coronary over a standard 0.014” guidewire. Mechanical IVUS systems 
require infusion of heparinised saline to clear air bubbles inside the sheath covering the 
transducer before inserting the catheter in the guide catheter. The IVUS catheter should 
be advanced under fluoroscopy guidance approximately 10 mm distal to an anatomical 
landmark (i.e., side branch) ( Video 1 ) and retracted slowly to straighten the catheter shaft 
which may have built some slack during insertion in order minimise non-uniform rotation 
distortion (NURD) artifacts.
Motorised pullback devices should be used to withdraw the catheter at a constant speed 
(most frequently at 0.5 mm/sec) to allow proper examination of the entire coronary 
and calculation of distances. Unless coronary ischaemia ensues, the catheter should be 
withdrawn up to the aortic coronary junction, as the guide catheter should be retracted 
slightly to allow imaging of the coronary ostium.
Safety
IVUS imaging has been performed safely in a large number of subjects enrolled in research 
studies with no apparent increase in the incidence of adverse effects. In general, the rate 
of complication related to IVUS is small across several studies. In one study, the rate of 
complications was 2.9 % of patients who experienced transient spasm and 0.4 % of the 
patients who had acute vessel occlusions, dissections, and/or embolism. The complication 
rate was higher in patients with unstable angina or acute myocardial infarction, and in 
patients undergoing intervention compared with diagnostic IVUS [13]. Another group 
reported a 1.1 % rate of complications, without adverse clinical consequences [14]. In 
7,085 IVUS studies from 51 centres [15], vasospasm occurred in 3 %. Major complications 
(dissection, thrombosis, ventricular fibrillation, and refractory spasm) occurred in 10 
(0.14%). There was only one major event.
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In 103 patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary 
PCI, the feasibility of multimodality imaging (with optical coherence tomography and 
intravascular ultrasound) and the procedural and long-term safety of intracoronary (i.c) 
imaging for documentary purposes has been reported. [180]These patients underwent serial 
three-vessel coronary imaging during primary PCI and at 13 months. Clinical outcomes 
were compared with the results from a cohort of 485 STEMI patients undergoing primary 
PCI without additional imaging. Imaging of the infarct-related artery at baseline (and 
follow-up) was successful in 92.2 % (96.6 %) of patients using OCT and in 93.2 % (95.5 %) 
using IVUS. Imaging of the non-infarct-related vessels was successful in 88.7 % (95.6 %) 
using OCT and in 90.5 % (93.3 %) using IVUS. Periprocedural complications occurred in 2.0 
% of OCT and none during IVUS. There were no differences throughout 2 years between 
the imaging and control group in terms of MACE (16.7 vs. 13.3 %, adjusted HR1.40, 95 % 
CI 0.77–2.52, p = 0.27). Authors concluded that multi-modality three-vessel i.c. imaging 
in STEMI patients undergoing primary PCI can be performed safely without impact on 
cardiovascular events at long- term follow-up.
The long-term safety of IVUS in transplant recipients has been reported [16]. Subsequent 
angiographic stenoses were observed in 19.5 % (107/548) of imaged arteries vs. 16.2 
% (21/130) of non-imaged arteries (p = 0.4). Another study [17] reported 18-24 months 
quantitative coronary angiographic analysis comparing IVUS-imaged and non-
IVUSimaged arteries in 525 patients. New stenoses lesions occurred in 3.6 % and 3.9 % 
of IVUS-imaged and non-IVUSimaged arteries, respectively (p = 0.84). When all coronary 
lesions were considered, the incidence of lesion progression was not significantly different 
between IVUS-imaged (11.6 %) and non-IVUS-imaged (9.8 %) arteries.
We can conclude that the use of IVUS imaging is safe as confirmed by the low rate of 
complications and the absence of lesion progression in coronary arteries imaged with 
this technique.
Limitations in plaque assessment and image artifacts Greyscale IVUS provides a limited 
insight into atheroma composition. Soft (echolucent) plaques have been related either to 
high lipid content [18, 19] or presence of smooth muscle cells [20]. While fibrous plaques 
usually have an intermediate echogenicity, but sometimes very dense fibrous plaques can 
also appear as calcified lesions [21]. Traditionally, acoustic shadowing has been considered 
as a sign of calcification, but necrotic tissue can also cause shadowing [20]. In addition, 
the inter-observer variability in the plaque type assessment by greyscale IVUS reported 
in the literature varies considerably, with percentages of concordance between observers 
ranging from 88 % to only 47 % [22, 23, 24].
Most artifacts of IVUS imaging are specific to the construct of each system. NURD is 
specific to mechanical catheters, and arises from friction of the transducer in the coronary 
Assessment of stenosis structure with intravascular ultrasound    |   43
PART
I
or guiding catheter or from a poor connection of the IVUS catheter in the motor drive 
unit, which causes a typical onion skin image appearance. Tortuosity, severely stenotic 
segments, small guide lumen size, guide catheters with sharp secondary curves or slack in 
the catheter shaft or tightened haemostatic valve are common causes of NURD.
The ring-down artefact, however, is specific to electronic systems due to transducer 
oscillations that obscure the near field image [21]. Side lobes artefacts are intense reflections 
that come from strong reflectors such as calcium and stent struts. These usually follow 
the circumferential sweep of the beam. The presence of the side lobes may mask the 
actual lumen edge or may also be taken as tissue prolapse or dissection flaps. Another 
artefact that is also coming from strong reflectors is the reverberation. Reverberations are 
concentric repetitions at equidistant locations of the same image.
An eccentric or non perpendicular position of the IVUS catheter produces geometric 
distortions and an artificially elliptical appearance of the cross-sectional image leading to 
overestimation of lumen area [21].
The speed of catheter pullback is also prone to errors which may lead to incorrect 
assessment of the length of the segment of interest [25]. At a difference with non-sheath 
based catheters (electronic systems), sheath-based, mechanical catheter systems 
allow more uniform pullbacks during image acquisition and are more precise length 
measurements [25].
All these factors should be considered when assessing IVUS images to avoid 
misinterpretation and thereby making erroneous clinical decisions.
Combined intravascular imaging modalities
Another imaging modality able to characterise coronary atherosclerosis invasively is 
near infrared spectroscopy (NIRS.) [26]. A commercially available catheter employing 
NIRS to detect lipid core plaque has been developed and combined with simultaneous 
coregistered IVUS (Infraredx, Inc., Burlington, MA USA). (Figure 4) Unique from all 
other technologies currently purported to detect lipid core, the system was rigorously 
prospectively validated and carries specific label claims for the detection of lipid core in 
multiple countries including the US FDA. [27]. This 3.2 Fr NIRS-IVUS catheter is compatible 
with a conventional 0.014” guidewire, has a rotating core 960 RPM), and is pulled back by 
a motor drive unit at 0.5mm/sec. 30. (Video 2) The next generation of the catheter has 
recently been introduced, which incorporates a novel extended bandwidth transducer 
centered at 50MHz, tailored detection electronics, and a specialized processing stream. 
These improvements are expected to result in a best-in-class IVUS resolution and image 
quality. The system design is intended to gain the finer resolution afforded by higher 
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transducer frequencies, but through the strategic full utilization of a wider bandwidth, 
avoids the potential drawbacks of increased blood speckle and reduced imaging depth. A 
number of studies [SPECTACL - NCT00330928 [1402].SAVOIR - NCT00901446, SAVOIR 2 – 
NCT02154295, COLOR – NCT00831116, CANARY – NCT01268319, Atheroremo – VPS, IBIS-
3, YELLOW, YELLOW II – NCT01837823, ORACLE-NIRS – NCT02265146, Lipid Rich Plaque – 
NCT02033694, PROSPECT II and PROSPECT ABSORB - NCT02171065] have been completed 
or are in progress to assess the clinical value of NIRS-IVUS. Early studies focused on proof 
of concept of the technology, reproducibility, comparison to other modalities, prediction 
of stenting complications, optimization of stenting strategy, monitoring of drug effect, 
and early indications of major adverse event prediction. Three large events trials are in 
progress that aim to definitively tie lipid cores found at index catheterization with the 
risk of subsequent events, both at the patient and plaque level. At least two of those trials 
figure 3. Intravascular ultrasound catheters. The consoles of the Boston Scientific (Natick, MA, USA) iLab® ultrasound 
imaging system (not shown) and the iCross™, is the coronary imaging catheter (A). The Console of the Volcano’s s5™ 
Ultrasound Imaging System (not shown) and the Eagle Eye™ Gold Coronary Imaging Catheter are shown in Panel 
B. Panel C shows the IVUS catheter ViewIT (Terumo Corp., Tokyo, Japan) and the console of Terumo Corporation is 
named Visiwave (not shown).
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figure 4. A picture of the Apollo catheter tip indicating the relative positions to each other of the NIRS light source 
and IVUS probe. (A) The combined intravascular ultrasound images and chemical information from a pullback 
through the right coronary artery obtained using the Apollo catheter. The chemogram obtained from the Apollo 
catheter pullback, with the stented area as indicated. (B) The chemogram is a map of the measured probability of 
lipid core plaque (LCP) from each scanned arterial segment; the yellow regions represent those with the highest 
probability for the presence of LCP, whilst red regions represent those the lowest. The chemogram displays pullback 
position against circumferential position of the measurement in degrees. The § represents a region of the coronary 
artery where insufficient NIRS signals were obtained to generate a chemogram. In this image the proximal end of 
the stent is located in an area with a high probability of LCP (yellow). The block chemogram provides a summary 
of the raw data from the chemogram and displays the probability that an LCP is present for all measurements in 
a 2 mm block of coronary artery. The order of probability for the presence of LCP from highest to lowest is yellow, 
light brown, brown and red. (C) The longitudinal IVUS pullback, with NIRS overlay. (D) The lilac and blue lines mark 
the anatomical position on the IVUS, and the corresponding position on the chemogram during pullback, enabling 
simultaneous assessment of plaque structure and composition. Panel E shows a cross sectional intra-vascular 
ultrasound image with the chemogram obtained from b, demonstrating well opposed clearly identifiable stent 
struts (ss), highlighting the ability of the Apollo catheter to be used as a standalone IVUS catheter if required. The 
corresponding longitudinal IVUS image and chemogram is indicated by the lilac line on b, c and d. The chemogram 
indicates that there is a low probability of lipid present in the stented plaque. In panel F, cross-sectional IVUS image 
distal to the stent demonstrating the presence of echolucent plaque between 1 and 7 o’clock. The chemogram 
displays a high probability of lipid in this plaque. The corresponding longitudinal IVUS image, and chemogram is 
indicated by the blue line on b, c and d.
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(LRP and PIIA) will explore new treatments (i.e. BVS) of non-flow-limiting lesions that show 
other signs of vulnerability. 
C h A R AC T E R I S AT I O N  O F  AT h E R O S C L E R O S I S
Normal coronary artery structure
Adequate knowledge of the structure of the arterial wall andatheromatous plaques 
is of paramount importance for the interpretation of IVUS images. The coronary wall is 
composed of three layers. The innermost tunica intima is in direct contact with the blood 
and is constituted by an endothelial cell monolayer resting upon a basement membrane. 
Ageing of human arteries is associated with the presence of smooth muscle cells in the 
tunica intima.
These cells produce extracellular matrix molecules leading to intimal layer thickening. 
This process is not necessarily associated with pathological lipid accumulation and 
atherosclerosis formation. The second layer, tunica media, is separated from the tunica 
intima by the internal elastic membrane (IEM) and is formed by concentric layers of 
smooth muscle cells. The adventitia is the outermost arterial layer which is separated from 
the media by the external elastic membrane (EEM) and contains fibroblasts and mast cells, 
collagen fibrils, vasa vasorum and nerve endings.
The normal coronary architecture can be assessed using intravascular imaging. The 
circulating blood elements may assist IVUS image interpretation and differentiate lumen 
from vessel wall, as these produce characteristic speckles in the image. However, blood 
speckles are dependent on flow velocity and may have increased intensity in situation of 
slow blood flow, which may have similar appearance as the vessel wall. The reported normal 
value for intimal thickness in young subjects is 0.15 ± 0.07 mm. Thus, the thin tunica intima 
reflects ultrasound poorly and is not visualised as a separate layer. The media is typically 
less echogenic than the intima, but may appear thick because of signal attenuation and 
weak reflectivity of the internal elastic membrane. A monolayer appearance is a common 
finding in normal coronary arteries, while a trilayered appearance suggests the presence 
of intimal thickening. [29] A trilaminar appearance is dependent not only on the age but also 
on the histologic characteristics of the vessel. The adventitia has the strongest echo signal 
which is used a reference to determine plaque components. Importantly, the IVUS beam 
penetrates beyond the adventitial layer allowing visualisation of perivascular structures, 
including the cardiac veins and the pericardium. Based on histologic and ultrasound data, 
coronary vessel wall with an intimal thickness ≥0.5 mm is considered to be diseased. [21]
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Atheroma
A detailed description of the structure of atheromatous plaques can be found in Chapter 
6 of this book. In brief, atheromatous plaques are formed by an intricate sequence 
of events, not necessarily in a linear chronological order, that involves extracellular 
lipid accumulation, endothelial dysfunction, leukocyte recruitment, intracellular lipid 
accumulation (foam cells), smooth muscle cell migration and proliferation, expansion of 
extracellular matrix, neoangiogenesis, tissue necrosis and mineralisation at later stages. 
The ultimate characteristic of an atherosclerotic plaque at any given time depends on the 
relative contribution of each of these features [2]. Thus, the pathologic intimal thickening 
(PIT) is rich in proteoglycans and lipid pools, but no trace of necrotic core is seen. The 
earliest lesion with a necrotic core is the fibroatheroma (FA), and this is the precursor 
lesion that may give rise to symptomatic heart disease. Thin-capped fibroatheroma is 
a lesion characterised by a large necrotic core containing numerous cholesterol clefts. 
The overlying fibrous cap is thin and rich in inflammatory cells, macrophages and 
T-lymphocytes with few smooth muscle cells. A cut-off value for cap thickness of < 65 
microns to define a vulnerable coronary plaque has been based on pathology studies [30],
but in vivo confirmation of such threshold is lacking. Figure 5 outlines the virtual histology 
plaque and lesion types that are proposed based on the above pathologic data [31]. Based 
on tissue echogenicity (i.e., their appearance) and not necessarily histological composition, 
atheromas have been classified into four categories by greyscale IVUS: 
1.  soft plaque (lesion echogenicity less than the surrounding adventitia - hypoechoic); 
2.  fibrous plaque [intermediate echogenicity between soft (echolucent or isoechoic) 
atheromas and highly echogenic calcified plaques]; 
3.  calcified plaque (echogenicity higher than the adventitia with acoustic shadowing); 
and 
4.  mixed plaques (no single acoustical subtype represents > 80% of the plaque) [21]. Figure 1
Another greyscale IVUS classification has been widely used: 
1.  Echo-attenuated plaques have no ultrasound signal behind plaque. This plaque can be 
either hypoechoic or isoechoic but contained no bright calcium [181]. 
2.  Echolucent plaque present an intraplaque hypoechoic zone surrounded by tissue of 
greater echodensity.
Detection of calciﬁcation
The mechanisms of coronary calcification are not fully known. Extent of coronary 
calcification as assessed by computed tomography (CT), has been shown to be a better 
predictor of future events than the Framingham risk index alone [182] This may be partly due 
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figure 5. Virtual histology plaque types. FF: fibrofatty; FT: fibrous tissue; NC: necrotic core and DC: dense calcium.
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to the close relationship between the presence of calcium and atherosclerotic coronary 
plaque burden. [183]
On IVUS, calcium appears as bright echoes that obstruct the penetration of ultrasound 
(acoustic shadowing). (Figure 1 [C] and Video 3). Therefore, IVUS detects only the leading 
edge of calcium and cannot determine its thickness. Calcification on IVUS is usually 
described based on its circumferential angle (arc), longitudinal length and its depth. 
Calcification can be located deeper in the arterial wall or in the surface of the plaque, 
in close contact with the lumen wall interface. The presence, depth and circumferential 
distribution of calcification are not only important factors for selecting the type of 
interventional device, and estimating the risk of vessel dissection and perforation during 
PCI [32], but also in designing and conducting studies on progression/regression of 
coronary atheroma. Plaques with moderate to severe calcification showed not change or 
progression of atheroma size [33]. Thus, careful selection of coronary segments to evaluate 
the effect of drugs on coronary atherosclerosis should be considered.
IVUS has shown significantly higher sensitivity than fluoroscopy in the detection of 
coronary calcification [34]. Virtual histology, in comparison with histology, has a predictive 
accuracy of 96.7 % for detection of dense calcium [35].
Arterial remodelling
Arterial remodelling refers to a continuous process involving changes in vessel size 
measured by the EEM crosssectional area (also called vessel cross-sectional area – CSA). 
“Positive remodelling” occurs when there is an outward increase in EEM. “Negative 
remodelling” occurs when the EEM decreases in size (shrinkage of the vessel) [21]. The 
magnitude and direction of remodelling can be expressed by following index: EEM cross-
sectional area at the plaque site divided by EEM CSA at the reference “non-diseased” vessel. 
Positive remodelling will demonstrate an index > 1.0; while negative remodelling has an 
index < 1.0. Direct evidence of remodelling can only be demonstrated in serial studies 
showing changes in the EEM CSA over time, since remodelling may also be encountered 
at the “normal-appearing” reference coronary segment [21].
The limitation of angiography in determining disease burden and stenosis severity is 
largely due to vessel remodelling. Detection of remodelling is extremely important 
during PCI to define plaque burden and appropriate size of devices. Pathological studies 
have also suggested a relationship between positive vessel remodelling and plaque 
vulnerability. Vessels with positive remodelling showed increased inflammatory marker 
concentrations, larger lipid cores, paucity of smooth muscle cells and medial thinning 
[36, 37, 38]. Several IVUS studies have linked positive vessel remodelling with culprit [39] and 
ruptured coronary plaques [40, 41]. Positive remodelling has been observed more often in 
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patients with acute coronary syndromes than in those with stable coronary artery disease 
[42, 43], and has been identified as an independent predictor of major adverse cardiac events 
in patients with unstable angina [44]. Plaques exhibiting positive remodelling also had more 
often thrombus and signs of rupture [45]. Pattern of remodelling has also been correlated 
with plaque composition, soft plaques are associated with positive remodelling while 
fibrocalcific plaques more often have negative or constrictive remodelling [46]. Similar 
findings have been observed in studies utilising IVUS radiofrequency data (RFD) analysis, 
a technique developed specifically for tissue characterisation. Positive remodelling was 
directly correlated with the presence and size of necrotic core, and inversely associated 
with fibrotic tissue [47].
Vulnerable plaque and thrombi Acute coronary syndromes are often the first 
manifestation of coronary atherosclerosis, making the identification of plaques at 
high-risk of complication an important component of strategies to reduce casualties 
associated with atherosclerosis. Our current understanding of plaque biology suggests 
that ~ 60 % of clinically evident plaque rupture originates within an inflamed thin-capped 
fibroatheroma (TCFA) [48, 49]. Pathological studies demonstrated that ruptured plaques are 
mainly located in the proximal portions of the LAD and LCX and are more disperse in the 
RCA [50]. This tendency of advanced plaques to develop preferentially in these locations 
has been explained by the low shear stress conditions generated in areas with tortuosity 
or many branches. Low shear stress may induce the migration of lipid and monocytes into 
the vessel wall leading to the progression of the lesion towards a plaque with high risk of 
rupture [51].
The definition of an IVUS-derived TCFA is a lesion fulfilling the following criteria in at 
least 3 frames: 1) plaque burden ≥ 40 % and 2) confluent necrotic core ≥10 % in direct 
contact with the lumen (i.e., no visible overlying tissue) [52]. Using this refined definition 
of IVUS-derived TCFA, in patients with ACS who underwent IVUS of all three epicardial 
coronaries, on average, there were 2 IVUS-derived thin cap fibroatheroma per patient, 
with half of them showing outward remodelling [52]. Hong et al., reported the frequency 
and distribution of TCFA identified by virtual histology intravascular ultrasound in acute 
coronary syndrome (ACS = 105 pts) and stable angina pectoris (SAP = 107 pts) in a 3-vessel 
IVUS-VH study [53]. There were 2.5 ± 1.5 in ACS and 1.7 ± 1.1 in SAP TCFAs per patient, p < 
0.001. Presentation of ACS was the only independent predictor for multiple ID-TCFA (p = 
0.011). Eighty-three percent of ID-TCFAs were located within 40 mm of the coronary.
The potential value of these VH IVUS-derived plaque types in the prediction of adverse 
coronary events has been evaluated in three trials—Providing Regional Observations to 
Study Predictors of Events in the Coronary Tree (PROSPECT) [184], VH-IVUS in Vulnerable 
Atherosclerosis (VIVA) [185], and the European Collaborative Project on Inflammation and 
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Vascular Wall Remodeling in Atherosclerosis (ATHEROREMO-IVUS) [186] - studied the value 
of VH in detecting plaque characteristics associated with future events and identifying 
high-risk prone-to-rupture plaques. In PROSPECT a VH TCFA with a minimum lumen area 
of ≤4mm2 and a large plaque burden (≥70%), had a 17.2% likelihood of causing an event 
within 3 years [HR 10.8, (95%CI 4.3, 27.2), p<0.001]. While in the VIVA study, the presence 
of a non-calcified TCFA lesion was the only factor that was associated with MACE, which 
was mainly driven by coronary revascularizations (unadjusted HR 1.79; 95% CI 1.20-2.66, 
p=0.004). Lastly, in ATHEROREMO IVUS study, the presence of TCFA was an independent 
predictor for MACE (adjusted HR 1.98, 95% CI 1.09-3.60; p=0.026). Furthermore, the 
predictive value of TCFA lesions for the occurrence of acute cardiac events (composite of 
death or ACS only) was even stronger (adjusted HR 2.51, 95% CI 1.15-5.49; p=0.021). These 
findings emphasize the biological importance of TCFA for plaque rupture.
Although the three trials showed the same association, namely the presence of high-risk 
plaque characteristics with clinical outcomes, the following should be acknowledged: i. 
in the PROSPECT trial the total number of events was low, particularly the incidence of 
myocardial infarction (~1%). Most of MACE were either unstable angina or revascularization; 
ii. The VIVA study has a limited sample size and; the ATHEROREMO study has performed 
only one vessel imaging (vs. three-vessel imaging in the PROSPECT and VIVA studies) and 
associations were performed in a patient-level basis (vs. lesion level in the PROSPECT and 
VIVA studies). 
The transition to plaque rupture has been characterised by the presence of active 
inflammation (monocyte/macrophage infiltration), thinning of fibrous cap (< 65 μm), 
development of large lipid necrotic core, endothelial denudation with superficial platelet 
aggregation and intraplaque haemorrhage [54, 55]. The remaining plaques that cause ACS 
contain calcium nodules (~ 10 %), or have none of the pathological features described 
above (~ 20 %). Superficial plaque erosion explains at least a portion of the latter events, 
particularly in women and diabetics [56]. The lack of cellular or anatomical signature of 
plaque erosion makes it difficult for existing imaging methods to have high accuracy 
in predicting ACS events. In addition, most plaque ruptures are silent without clinical 
manifestation, and repetitive healed ruptures may contribute to stable progression into 
obstructive disease [57].
Although plaque characteristics do not yet influence current therapeutic guidelines, 
the available clinical imaging modalities, IVUS and IVUS-based tissue characterisation 
techniques such as virtual histology, integrated backscattered IVUS and iMap, have the 
ability to identify some of the pathological atheroma features described above Figure 
2. Ruptured plaques may have a variable appearance. Most commonly, IVUS may reveal 
an “axial”, abrupt ulceration depicted as an echolucent “void” or cavity beginning at the 
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luminal-intimal border. ( Video 4 ) These features should be distinguished from longitudinal 
tear of the intima and media associated with spontaneous or iatrogenic dissection. The 
tear of the rupture in the fibrous cap can be identified in approximately 60 % of the cases 
and occurs more often at the shoulder of the plaque than in the centre [40, 58, 59]. Due to its 
relatively poor resolution, IVUS is unsuitable to detect a thin fibrous cap, but IVUS often 
reveals other features of ruptured plaques which are large in volume, eccentric, have 
mixed or soft composition and irregular surface, and are associated with positive vessel 
remodelling [40, 41, 60, 61]. Ruptured plaques have been shown to have quantitatively less 
calcium, especially superficial calcium, but a larger number of small (< 90º arc) calcium 
deposits, particularly deep calcium deposits [62]. IVUS can also reveal blood speckles 
passing through intraplaque channels created by the rupture, which usually produces the 
typical hazy, complex and non stenotic angiographic appearance of ruptured plaques.
Several IVUS studies have reported the frequency and distribution of plaque ruptures 
investigating the three coronary epicardial vessels. Rioufol et al. studied 24 patients (72 
arteries) with ACS and found a mean prevalence of two ruptured plaques per patient. 
Interestingly, 12.5 % of these patients had ruptured plaques in the three major coronary 
arteries. Only 37.5 % of the ruptured plaques were located on the culprit lesion, and 
79 % of the patients had also a ruptured plaque somewhere other than on the culprit 
lesion [63]. In a similar study in 45 patients with acute myocardial infarction (AMI), plaque 
rupture was observed in 21 patients (47 %) at the culprit site and 17 additional plaque 
ruptures were found at sites in 11 patients (24 %) [64]. Hong et al. evaluated the incidence 
of plaque rupture depending on the clinical presentation. They performed 3-vessel IVUS 
examination in 235 patients (122 AMI and 113 stable angina pectoris – SAP). Plaque 
rupture of infarct-related or target lesions occurred in 66 % of AMI patients and in 27 % of 
SAP patients. Non-infarct related or non-target artery plaque ruptures occurred in 17 % 
AMI patients and 5 % SAP patients. Multiple plaque ruptures were observed in 20 % AMI 
and 6 % SAP patients [65]. The same authors evaluated the distribution of plaque rupture in 
native coronary arteries in 392 patients (231 ACS and 161 SAP). Threevessel IVUS imaging 
showed that plaque ruptures occurred mainly in proximal segments of the LAD (83 % of 
LAD ruptured plaques), the proximal and distal segments of the RCA (48 % and 32 % of 
RCA ruptured plaques, respectively), and the entire LCX [66]. These results are in line with 
another study that included 104 patients and studied 160 ruptured plaques in the LAD, 
the majority were located within the proximal 30 mm of the artery [67].
A study aiming at characterising plaque ruptures in the left main coronary artery 
(LMCA) found 16 plaque ruptures in 17 patients (2 AMI, 13 unstable angina and 1 SAP). 
The ruptures were located in the distal portion and/or bifurcation of the LMCA, often 
did not compromise the lumen, and had an angiographic complex appearance. When 
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ruptured plaques involved the bifurcation LAD-LCX, they occurred opposite to the flow 
divider [68]. This is in line with our findings, lesions involving the bifurcation LAD-LCX were 
predominantly located in the outer wall of the carina, and such location was associated 
with larger necrotic core content [69].
Ruptured atherosclerotic plaques in native coronary arteries, but not in saphenous vein 
grafts (SVGs), have been well described with intravascular ultrasound. In 791 preintervention 
IVUS SVG studies, 95 ruptured plaques in 76 SVGs (73 patients) were identified (prevalence 
of 9.7 %). These ruptured plaques were found to be associated with complex angiographic 
characteristics and positive remodelling [70, 71]. Likewise, in an analysis of 300 ruptured plaques 
in 254 patients, Maehara et al. described that ruptured plaques detected by IVUS strongly 
correlated with complex angiographic lesion morphology: ulceration in 81 %, intimal flap in 
40 %, thrombus in 7 %, and aneurysm in 7 % [40].
IVUS has also been used to assess the natural evolution of ruptured plaques. IVUS studies 
have suggested that up to 50 % of the ruptured plaques detected in a first ACS event heals 
with medical therapy, without significant change in plaque size [72]. One study revealed 
complete healing of plaque rupture in 29 % of the patients treated with statins and 
incomplete healing in untreated patients [73].
The ruptured plaque profile in 40 patients referred for cardiac catheterisation has been 
described [74]. There were 13 with stable angina, 12 with unstable angina and 15 with acute 
myocardial infarction. Ruptured plaque was identified in 26 patients and, as expected, was 
more frequent in patients with acute myocardial infarction and unstable angina. Patients 
with ruptured plaques have larger body mass index when compared with those without 
plaque rupture and were more likely smokers, patients with ruptures had more diffuse 
calcification and necrotic core area. Of note, the location of plaque ruptures in this study 
mirrors the pathological findings [75]. In our study, the proximal left anterior descending 
coronary artery was the most common site of plaque rupture. In a pathological series of 79 
ruptures, Burke et al. [75] have found 74 % in the proximal left anterior descending. Similarly, 
in the report by Hong et al., the frequency and distribution of ruptured plaques identified 
by IVUS-VH in acute coronary syndrome (ACS = 105 pts) and stable angina pectoris (SAP 
= 107 pts) in a 3-vessel IVUS-VH study were reported [53]. There were 76 ruptured plaques 
(55 in ACS and 21 in SAP). Presentation of ACS was the only independent predictor for 
multiple ruptured plaques (p = 0.013).
Thrombus represents the ultimate pathological feature leading to ACS. Thrombus is usually 
recognised as an echolucent intraluminal mass, often with a layered or pedunculated 
appearance by IVUS [21]. Fresh or acute thrombus may appear as an echo-dense intraluminal 
tissue, which does not follow the circular appearance of the vessel wall, while older, more 
organised thrombus has a darker ultrasound appearance. However, none of these IVUS 
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features are a hallmark for thrombus, and one should consider slow flow (fresh thrombus), 
air, stagnant contrast or black hole, an echolucent neointimal tissue observed after DES 
and radiation therapy, as differential diagnoses [21].
C L I N I C A L  A P P L I C AT I O N S :  D I AG N O S T I C
Determination of the severity and extent of atherosclerosis
The determination of the severity and extent of atherosclerosis remains one of the main 
diagnostic clinical applications of intravascular imaging, as angiography and noninvasive 
methods lack spatial or temporal resolution for accurate coronary disease assessment. 
Standards for acquisition, measurement and reporting of IVUS has been proposed in a 
clinical expert consensus document [21]. Luminal area stenosis describes the relative 
decrease in luminal cross-sectional area (CSA) at the site of disease, in percentage, 
compared to lumen CSA in a “normal appearing” reference segment in the same coronary. 
The lumen area relative to the reference lumen area is analogous to the angiographic 
definition of diameter stenosis.
Proximal and distal reference lumen areas are calculated at sites with the largest lumen 
located prior to large side branches, and within 10 mm proximal and distal to the plaque, 
respectively. The image analyst should be aware of potential post stenotic dilatation of 
the vessel wall when using these measurements to guide clinical decision.
Minimal lumen area (MLA) describes the smallest lumen CSA area along the length of the 
target lesion. As most vessels depict an oval rather than a perfect circular shape, maximum 
lumen diameter and minimal lumen diameters are calculated along a vector passing 
through the lumen centre at the reference segments. Reference vessel lumen diameter is 
essential to guide section of interventional devices. Measurements of distances (length) 
are based on the automated pullback speed during image acquisition. Disease length can 
be calculated based on number of seconds or frames between the first and last image 
frames depicting the atherosclerotic plaque.
Intimal thickening
IVUS cannot distinguish between tunica intima and media.
Hence, IVUS-determined “intimal thickening” in non-stented vessels combines the 
thickness of both layers. Based on histologic and ultrasound data, coronary vessel wall 
with an intimal thickness ≥0.5 mm is considered to be diseased [21].
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Assessment of atheroma burden
Quantification of atheroma or plaque area in cross-sectional IVUS images is performed 
by subtracting the lumen area from the EEL area. Hence, IVUS defined atheroma area is 
a combination of plaque plus media area. The atheroma area can be calculated in each 
frame (cross-sectional image), and total atheroma volume (TAV) can be calculated based 
on pullback speed during imaging acquisition. Atheroma volume can be reported as the 
percent of the volume of the external elastic membrane occupied by atheroma namely 
percent atheroma volume (PAV). Parameters commonly used to report the extent of the 
coronary atherosclerosis are shown in Figure 6 . Measurements are performed between 
the inner lumen border and the media, delimited by the IEL, which corresponds to the 
“true” histological area of the atheroma.
Assessment of ambiguous anatomy
The 3-dimensional and dynamic nature of the coronary vasculature cannot be fully 
appreciated by planar angiography. Frequently, defining the proper angiographic 
angulation that provides a straight, non-foreshortened view of the target coronary 
segment without overlapping of other vessels may be a challenge in the cathlab. As 
discussed previously, determination of disease severity by angiography is hampered 
by the diffuse nature of atherosclerosis and its most common eccentric growth in the 
vessel wall. Hence, lesions can appear more stenotic in one orthogonal view than in the 
other, making clinical decisions difficult. The so-called “intermediate lesion” is the more 
figure 6. Parameters commonly used to report the extent of the coronary atherosclerosisare total atheroma volume 
(TAV) and percent atheroma volume (PAV).EEM: external elastic membrane; CSA: cross-sectional area.
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prevalent phenotype in the coronary tree. The American Heart Association/American 
College of Cardiology/Society for Angiography and Interventions (AHA/ACC/SCAI) 
guidelines define intermediate coronary lesion as a plaque producing a 30-70 % stenosis 
between by angiography [76]. These plaques represent a heterogeneous group of coronary 
lesions, which can be either haemodynamically flow limiting or not. Intravascular imaging, 
particularly IVUS, was granted a class IIa indication (level of evidence C) for “evaluation of 
coronary obstruction at a location difficult to image by angiography in a patient with a 
suspected flow-limiting stenosis” [77].
IVUS minimum luminal cross sectional area (MLA) proved to be a good morphometric 
surrogate of coronary physiology.
IVUS MLA showed a direct correlation with coronary flow reserve determined by Doppler 
flow-wire (r = 0.831, p < 0.001) [77]. In 73 patients studied pre-intervention, a MLA of 
≥4.0 mm2 had a diagnostic accuracy of 89 % in predicting a coronary flow reserve > 2.0. 
Likewise, IVUS has been correlated with non-invasive single-photon emission computed 
tomography (SPECT) [79]. A 4 mm2 MLA by IVUS had 88 % sensitivity and 90 % specificity 
to discriminate the SPECT (+) group from the SPECT (-) group. This cut-off of 4.0 mm2 
MLA does not apply to small vessels [80] or large segments such as the left main (LM) or 
venous bypass grafts. In a larger study (FIRST registry [187), 350 patients (367 lesions) were 
studied. In general, an MLA <3.07 mm2 (64.0% sensitivity, 64.9% specificity, area under 
curve [AUC] 0.65) was the best threshold value for identifying FFR <0.8. Yet, stratifying by 
vessel size, an MLA <2.4 mm2 (AUC 0.66) was best for reference vessel diameters (RVD) 
<3.0 mm, an MLA <2.7 mm2 (AUC 0.71) for RVD of 3.0 to 3.5 mm, and an MLA <3.6 mm2 
(AUC 0.68) for RVD 3.5 mm. 
Left main coronary artery
There is no absolute consensus regarding the CSA at which a left main obstruction is 
considered critical. A study evaluating IVUS assessment of 121 patients with intermediate 
LM lesions found no significant difference in MACE (death, non-fatal MI and TVR) after 3 
years follow-up between patients with MLA < 7.5 mm2 who underwent revascularisation 
and those with MLA > 7.5 mm2 in whom revascularisation was deferred (21 % vs. 12 %). 
By contrast patients with MLA < 7.5 mm2 who did not undergo revascularisation had a 3 
year MACE rate of 50 % [80]. In another study, an IVUS-determined MLD of 2.8 mm and an 
MLA of 5.9 mm2 had the highest sensitivity and specificity (93 % and 98 % for MLD, 93 % 
and 95 % for MLA, respectively) for detecting haemodynamic significant left main stenosis 
compared with FFR [82].
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Ostial and bifurcation disease
The continuous dynamic variation in the three-dimensional anatomical configurations of 
coronary bifurcations poses significant challenges to planar coronary imaging modalities.
Intravascular imaging plays an important role in evaluating severity and distribution of 
atheroma in the bifurcation segment. IVUS has been also used to identify and characterise 
aorto-ostial disease. The concept of “plaque shift” to explain side branch occlusion during 
intervention in the main branch is not supported by IVUS and necropsy studies that have 
shown plaques most commonly located in the opposite side of side branches origins [69, 
83]. The in vivo frequency and distribution of high-risk plaques (i.e., necrotic core rich) at 
bifurcations using a combined plaque assessment with IVUS virtual histology and optical 
coherence tomography have been reported. A total of 30 patients (103 bifurcations) were 
imaged. Twenty-seven fibroatheromas (26.2 %) and 18 thin-cap fibroatheromas (17.4 %) 
were found. Overall the % of necrotic core decreases from proximal to distal rim (16.8 % 
vs. 13.5 % respectively p = 0.01) while the cap thickness showed an inverse tendency (130 
± 105 vs. 151 ± 68 ìm for proximal and distal rim respectively p = 0.05). 44.1 % of the thin 
caps were located in the proximal rim, 41.2 % followed by the in-bifurcation segment and 
were less frequent in the distal rim (14.7 %). The proximal rim of the ostium of the side 
branch has been identified as a region more likely to contain thin fibrous cap and a greater 
proportion of necrotic core [84].
Cardiac allograft disease
Most clinical adverse events in transplant patients occur after 1 year. Cumulative incidence 
of cardiac events per patient year was 0.9 % within the first year, increasing to 1.9 % by 
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5 years. Cardiac events accounted for 3.8 % of the deaths by the end of the first year, 
rising to 18 % of total mortality by 7 years after heart transplantation. After the first 
year of transplantation, 36 % (20/55) of the patients died because sequelae of coronary 
artery disease [85]. Death is usually silent because heart is denervated. Therefore, there is 
a need for screening in order to early detect coronary atherosclerosis. The presence of 
obstructive coronary disease in angiography is a predictor of any cardiac event (odds 
ratio 3.44, p < 0.05), as well as a predictor of cardiac death (OR 4.6, p < 0.05). However, a 
pathological study reported 10 patients who died or underwent re-transplantation within 
2 months of coronary angiography. One quarter of the patients had intermediate lesions 
or atheromatous plaques. Fresh or organising thrombus was most often associated with 
discrete lesions and accounted for all complete occlusions. Authors concluded that 
transplant coronary artery disease has a heterogeneous histologic and angiographic 
appearance, with angiographic underestimation of disease in some patients. Accordingly, 
many active transplant centres incorporated IVUS imaging into their post-transplant 
surveillance, but there is no consensus on how frequent IVUS should be performed. The 
predictive value of IVUS has been explored in a study that included 143 patients who 
underwent 3-vessel IVUS investigation at 1 and 12 months after transplantation. The 
change in intimal thickness was calculated (≥ 0.5 mm was defined as rapidly progressive 
vasculopathy). At one year, rapid progression was demonstrated in 37 % of the patients 
and in 47 % of them a new lesion was found. At 5.9 years, patients with rapid progression 
died more than their counterparts (26 % vs. 11 %, p = 0.03). The combined endpoint of 
death and MI was also more frequently seen in patients with rapid progression (51 % vs. 
16 %, p < 0.0001) [86].
IVUS has been also used to assess novel therapies in heart transplantation recipients. Eisen 
et al., randomised 634 patients to receive 1.5 mg of everolimus per day (209 patients), 3.0 
mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram 
of body weight per day (214 patients), in combination with cyclosporine, corticosteroids 
and statins. The primary efficacy endpoint was a composite of death, graft loss or re-
transplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection 
with haemodynamic compromise. At 1 year, IVUS showed that the average increase in 
maximal intimal thickness was significantly smaller in the two everolimus groups than in 
the azathioprine group [87].
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C L I N I C A L  A P P L I C AT I O N S :  I N T E R V E N T I O N A L
The utilisation of intravascular imaging to guide percutaneous coronary interventions (PCI) 
is heterogeneously distributed across the world, varying from > 60 % of use during PCI in 
Japan to less than 20 % in Europe and United States. The explanation for such disparity 
is multifactorial, but likely involves local reimbursement practices for the procedure, 
differences in clinical practice and training, and a relative lack of scientific evidence.
Pre-interventional imaging
Intravascular imaging provides the only means to accurately determine vessel size, 
severity, character, extent and location of disease and guide therapeutic decision-
making in the catheterisation laboratory. The main limitation of intravascular imaging is 
that, despite the extreme miniaturisation of IVUS catheters, these probes may occlude 
vessels with severe stenoses, which may disturb image acquisition and interpretation. The 
additional information provided by IVUS on lesion composition, eccentricity and length 
may change treatment strategies in up to 20 % of the cases [88]. As discussed previously, 
the presence, depth and circumferential distribution of calcification are very important 
factors for selecting the type of interventional device [89].
Non-stent based percutaneous coronary interventions
Contemporary PCI techniques are essentially based on stents, but balloon angioplasty 
remains an integral step of the procedure. In addition, atherectomy and plaque 
modification strategies remain necessary in some procedures. Thus, understanding of 
mechanisms and the proper utilisation of these techniques remains important in the 
modern era [90]. The importance of intravascular imaging is likely amplified in non stent-
based interventions, with the goal of maximal luminal gain and minimal risk of dissection 
and vessel perforation. Selection of the device size can be based on measurements of 
the total vessel (i.e., EEM) diameter, although a more conservative approaches matching 
balloon size to that of lumen diameter of the distal reference segments is most routinely 
performed in practice. In the landmark CLOUT study [91], angioplasty was initially performed 
using angiography-define balloon sizes; then repeat angioplasty was performed guided 
by IVUS imaging. Even after achieving an “optimal” angiographic result, 73 % of the lesions 
needed larger sized balloons. These findings have been confirmed in other studies [70, 71, 72].
Modifications of the dilatation strategy based on IVUS results include changes in balloon 
diameter, length, type and inflation pressure. IVUS is also critical to define circumferential 
and longitudinal extension of plaque fracture or dissection, and to guide the need for 
further intervention. 
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Dissections can be classified into five categories: 1) intimal; 2) medial; 3) adventitial; 4) 
intramural haematoma (an accumulation of blood within the medial space, displacing the 
internal elastic membrane inward and EEM outward); and 5) intrastent [21].
The severity of a dissection can be quantified according to: 1) depth; 2) circumferential 
extent (in of arc); 3) length; 4) size of residual lumen (CSA); and 5) CSA of the luminal 
dissection [9].
Additional descriptors of a dissection may include the presence of a false lumen, the 
identification of mobile flap(s), the presence of calcium at the dissection border, and 
dissections in close proximity to stent edges.
IVUS studies have also been performed to define predictors of restenosis after balloon 
angioplasty. One of the main contributions of intravascular imaging to this field was 
the realisation that negative remodelling, not neointimal hyperplasia, was the most 
important mechanism of long-term failures of non-stented coronary interventions, 
namely restenosis. This was initially demonstrated in the peripheral vessels [92] and later 
reported in the coronary circulation [93]. These studies revealed that > 70 % of lumen loss 
was attributable to the decrease in EEM area, whereas the neointimal area accounted 
for only 23 % of the loss. Although stand-alone atherectomy coronary intervention is 
not used in modern practice, these techniques still play a role for plaque modification 
and facilitate stent deployment. The use of IVUS during atherectomy results in a more 
aggressive strategy, leading to a greater plaque removal and a larger lumen diameter 
[94]. The adjunctive use of IVUS-guided directional coronary atherectomy (DCA) prior to 
stenting was proposed in the SOLD registry [95], but the AMIGO randomised trial failed to 
show a benefit in terms of angiographic restenosis of DCA followed by coronary stenting 
compared to coronary stenting alone. While DCA technologies have been removed from 
the United States market, rotational atherectomy remains a niche technique to facilitate 
stent delivery in patients with severe coronary lesion calcification. IVUS can detect 
calcification, define the location and extent of calcification and help define the need for 
the use of rotational atherectomy in clinical practice. However, vessel calcification impacts 
delivery of the IVUS catheter and the quality of images, which hinders pre-intervention 
IVUS utilisation in many cases.
Stent-based percutaneous coronary interventions
Stents have become standard in virtually every percutaneous coronary intervention. IVUS 
has played a critical role in the establishment of modern stent deployment techniques. 
IVUS provides cross-sectional views of the stent and its interaction with the vessel wall 
enabling unique assessment of expansion, apposition, vessel dissection and residual 
untreated disease that cannot be properly defined by angiography. ( Video 5 ) The pioneer 
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report of Colombo and co-workers revealing a mean residual stenosis of 51 % percent 
following angiography guided stent deployment and a high prevalence of incomplete 
stent apposition significantly altered the understanding of optimal stent deployment 
and prevention of subacute thrombosis [96]. After balloon inflations at higher pressures 
(typically 18-20 atm), use of a larger balloon or both, the operators were able to reduce 
the residual stenosis to 34 % which likely led to a 0.3 % rate of subacute thrombosis 
without the need for systemic post-procedure anticoagulation [96]. However, restenosis 
remained an important limitation of bare metal stents (BMS) affecting approximately 20 
to 40 % of patients. “The bigger the better” adage which has dominated the interventional 
cardiology approach for decades [97] derived from angiography assessment of lumen gain 
and late loss, but it also suggests the importance of IVUS to optimise stent expansion 
and maximise lumen gain without the risk of vascular complication. The landmark MUSIC 
registry [5] helped defined IVUS criteria for optimal stenting and was based on 3 variables: 
1) complete apposition of the stent over its entire length; 2) symmetric stent expansion 
defined by the ratio of minimal/maximal lumen diameter ≥ 0.7; 3) in-stent minimal 
lumen area ≥ 90 % of the average area of distal and proximal references or ≥ 100 % of 
the lumen area of the reference segment with the smallest lumen area. The subgroup of 
patients who met the criteria had a record 8 % rate of restenosis after bare metal stent 
implantation. However, the criteria are difficult to achieve in real practice. In the Optimal 
Stent Implantation Trial, stent were post-dilatated at 18 atmospheres and only 60 % 
reached the MUSIC criteria. In the Angiography Versus Intravascular Ultrasound Directed 
stent placement (AVID) trial, the more liberal goal of in-stent lumen CSA ≥ 90 % of the 
distal reference area was not achieved in > 70 % of 225 patients [5]. Other adaptations to 
the criteria have been suggested: a) 80 % average reference area and 90 % lumen area of 
the reference segment with smallest area, b) minimal in-stent lumen area ≥ 9 mm2 and 
c) ratio of stent area to reference EEM area ≥ 0.55. However, these commonly employed 
IVUS endpoints based on a predefined stent-to-reference ratio are also difficult to achieve.
Several prospective clinical studies were conducted to test the hypothesis that IVUS 
guidance of stent deployment improves outcomes, but results are conflicting.
CRUISE was a large observational substudy involving 538 patients from the Stent 
Anticoagulation Regimen Study (STARS) a randomised multicentre trial testing different 
antithrombotic regimens and compared angiographic versus ultrasound guidance on a 
centre-by-centre basis. The study showed improvement in the rates of target vessel repeat 
revascularisation after 9 months in patients treated at centres using the IVUS-guided 
approach [99]. In the Optimisation with ICUS (OPTICUS) study, IVUS and angiographicguided 
approaches resulted in similar rates of both angiographic restenosis and need for target 
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vessel revascularisation [100]. The TULIP study [101] suggested that routine IVUS guidance 
for stent deployment was likely to be of benefit only in patients with a high risk for 
restenosis. A large retrospective study including 884 patients compared outcomes of 
IVUS-guided versus a propensity-score matched population undergoing drug-eluting 
stent (DES) implantation with angiographic guidance alone [6]. The study showed that 
IVUS-guidance during DES implantation reduced both DES thrombosis and the need for 
repeat revascularisation. These considerations may also explain the mortality reduction 
observed after 3 years in the patients treated with left main stenoses under IVUS guidance 
in the unpublished MAIN-COMPARE IVUS Registry. For restenoses after both conventional 
bare metal stents and DES. Knowledge of the initial mechanism of restenosis (under-
expansion, hyperplasia, incomplete lesion coverage) is important for selecting the proper 
length and diameter of stent to be deployed and for guiding its expansion. Table 1 .
The focus of contemporary interventional cardiology has shifted towards improving the 
safety rather than efficacy of DES, as these devices virtually eliminated the problem of 
restenosis, but have been associated with late thrombosis.
IVUS studies were important to provide a morphological analysis of the local biological 
effects of the implantation of DES. Initial IVUS studies [102, 103] were essentially to confirm 
suppression of neointimal hyperplasia by DES. These studies also revealed the occurrence 
of new late incomplete stent apposition, which has been anecdotally associated with 
thrombosis. While no large randomised study has been conducted to support the 
approach of IVUSguided DES deployment, the use of IVUS has increased over the past 
decade. [6]. Clinical benefit has been suggested in large metaanalysis (14 studies involving 
29,029 patients), with reductions in death (hazard ratio [HR]: 0.66, 95% confidence 
interval [CI]: 0.55-0.78, p<0.001), stent thrombosis (HR: 0.57, 95% CI: 0.44-0.73, p<0.001), 
myocardial infarction (MI) (HR: 0.74, 95% CI: 0.62-0.90, p=0.002) [189]; IVUS guidance has 
been advocated particularly in selected high-risk lesions (i.e. ACS patients as shown in 
ADAPT DES study-[189]) results from randomised clinical trials are still warranted to justify 
routine IVUS-guided DES implantation.
Diseased bypass grafts have been a challenge for both interventionists and cardiac 
surgeons. Intravascular imaging is important to guide stent size selection and define 
extent of disease. IVUS has also been used to monitor outcomes after treatment of vein 
grafts with DES. The SECURE study included 76 patients (n = 94 lesions) with graft disease 
treated with a sirolimus eluting stent, and 14 patients had IVUS follow-up performed at 
8 months. Overall, the percentage of intimal hyperplasia was 11.8 ± 16.5 % and half of 
the patients with graft sirolimus-eluting stent had < 1 % intimal hyperplasia [104]. In the 
setting of a randomised trial, 75 patients with graft disease (96 lesions) that received 
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either sirolimus-eluting stents or bare metal stents (RRISC study) were assessed by IVUS 
at 6 months.
Sirolimus-eluting stents showed smaller neointimal hyperplasia volume compared with 
BMSs (1.3 vs. 24.5 mm3 , p < 0.001). In the sirolimus-eluting stent group, there was a greater 
intimal hyperplasia at overlapping sites as compared to non-overlapping segments [105].
Assessment of complications after percutaneous coronary intervention 
thrombosis
Intravascular imaging can play an important role in both prevention and diagnosis of stent 
thrombosis. Stent underexpansion, incomplete wall apposition and vessel dissection, 
features easily identified by intravascular imaging, have been associated with increased 
risk of stent thrombosis [106]. The minimum stent cross-sectional area (4.3 ± 1.6 mm2 vs. 6.2 
± 1.9 mm2, p < 0.001) and the degree of stent expansion (0.65 ± 0.18 vs. 0.85 ± 0.14, p < 
0.001) were significantly smaller patients with DES versus those without DES thrombosis 
[107]. The same study also showed that residual edge, defined as edge lumen CSA < 4 
mm2, and a plaque burden > 70 % was associated with risk of thrombosis. Intravascular 
imaging is also essential to identify mechanical abnormalities in patient presenting with 
stent thrombosis. Cook S. et al. [108] reported that very late DES thrombosis is associated 
with eosinophilic infiltrates and intravascular ultrasound evidence of vessel remodelling. 
Degree of inflammation correlated with the extent of stent malapposition.
Dedicated studies have been reported in which the use of IVUS is central during index 
PCI in order to prevent a future stent thrombosis. The Assessment of Dual Antiplatelet 
Therapy With Drug-Eluting Stents (ADAPT-DES) was a nonrandomized “all-comers” study 
of 8583 consecutive patients aiming at charaterizing the frequency, timing, and correlates 
of stent thrombosis and adverse clinical events after DES. IVUS guidance compared with 
angiography guidance reduced definite/probable stent thrombosis (0.6% [18 events] 
versus 1.0% [53 events]; adjusted hazard radio, 0.40; 95% confidence interval, 0.21-0.73; 
P=0.003), myocardial infarction (2.5% versus 3.7%; adjusted hazard radio, 0.66; 95% 
confidence interval, 0.49-0.88; P=0.004), and composite adjudicated major adverse cardiac 
events (ie, cardiac death, myocardial infarction, or stent thrombosis) (3.1% versus 4.7%; 
adjusted hazard radio, 0.70; 95% confidence interval, 0.55-0.88; P=0.002) at 1-year. [190]
Restenosis
Unlike restenosis after balloon angioplasty or atherectomy, IVUS studies have shown that 
in-stent restenosis is essentially a result of neointimal hyperplasia. ( Video 6 ) Predictors of 
stent restenosis have been identified by multivariate analyses and include small reference 
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vessel and lumen size, the larger plaque burden and small in-stent lumen area. While the 
prevalence of restenosis has decreased dramatically with DES, maximising luminal gain 
remains an important approach to prevent restenosis. Receiver operating characteristic 
curves identified a post-stenting minimum stent CSA of 5 mm2 for sirolimus-eluting stent, 
6.5 mm2 for bare metal stents were associated with lumen CSA > 4 mm2 at 8-months 
follow-up [109]. Others have shown that the highest restenosis rate was observed in lesions 
with stent area < 5.5 mm2 and stent length > 40 mm after deployment of sirolimus-eluting 
stents [110].
Intravascular imaging is also essential to guide therapy of in-stent restenosis as mechanical 
problems related to stent deployment procedures contribute to approximately 25 % of in-
stent restenosis [111]. Stent fracture has been reported as a cause of stent restenosis in the 
modern era of long stent implantation, which can be identified by intravascular imaging 
[112]. Intravascular imaging has shown that characteristics of neointimal hyperplasia may 
differ between bare metal and DES. Neointimal hyperplasia in DES may have an echolucent 
appearance, also known as a black hole [112].
In addition, while diffuse in-stent restenosis is common after bare metal stents, the pattern 
of restenosis associated with DES is most frequently focal. One of the most common 
variables used to report restenosis is percentage intimal hyperplasia volume in the stent 
segment [114]. This variable normalises the intimal hyperplasia to the stent length therefore 
allowing the comparison of different stent types (BMS vs. DES), as well as different drug 
types (i.e., SES vs. PES). Table 2 . The percentage of intimal hyperplasia, however, minimises 
the impact of focal restenosis. A metaanalysis of TAXUS IV, V and VI demonstrated that 
nearly half of the stent length was free of IH in the Taxus group (48.8 ± 36.0 % vs. 13.4 ± 22.1 
% in the control group, p < 0.0001) [115]. In another study comparing the paclitaxel stent 
and sirolimus stent, 46.1 vs. 5.4 % of the stent length had covering, p < 0.001, respectively 
[116]. A similar intimal hyperplasia distribution to the Taxus stent has been reported for 
the zotarolimus-eluting stent [117]. It has been suggested that the “patchy” distribution of 
intimal growth associated with DES (i.e., lack of neointimal tissue in the mid-portion of the 
stent) could be related to a higher concentration of drug in that portion of the stent [118].
The use of IVUS-VH to assess in-stent restenosis in metal stents is hampered by the 
following factors: lack of validation of the technique in this context, misclassification of the 
stent struts as “dense calcium” surrounded by necrotic core, and the potential interference 
of the superficial stent struts on the backscattering of the tissue behind them [119]. On the 
contrary, IVUS-VH can be used in research protocols evaluating serial changes in plaque 
type and composition in bioabsorbable stents.
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Trial Subgroup Follow-up % IH Vol (Mean ± SD)
Sirolimus ES trials
RAVEL [132] SES (n = 48)
BMS (n = 47) 
6 mo 1 ± 3 %
29 ± 20 %
RAVEL [133] SES, diabetes mellitus (n = 19)
SES, no diabetes (n = 25) 
9 mo 0.82 ± 1.38 %†
30.2 ± 22.9 %
SIRIUS [134] SES (n = 23)
BMS (n = 20) 
9 mo 3.1 %
Sao Paulo registry [135, 137] SES fast release 1 yr (n = 15)
2 yr (n = 14)
4 yr (n = 13) 
2.3 ± 5.5 %
6.3 ± 5.5 %
9.1 ± 5.4 %
Sao Paulo registry SES slow release 1 yr (n = 15
2 yr (n = 14)
4 yr (n = 13)
2.2 ± 3.4 %
7.5 ± 7.3 %
5.7 ± 4.25 %
SICTO [138] SES for CTO (n = 25) 6 mo 4.9 ± 6.8 %
Sao Paulo [139] SES (n = 25)
_ radiation (n = 25)
12 mo 6.6 ± 3.0 %
38.0 ± 7.8 %
DIABETES I [140] SES for diabetics (n = 75)
BMS for diabetics (n = 65)
9 mo 1.31 ± 3.5 %
28.4 ± 21.9 %
RIBS II§ [141] SES (n = 76)
Balloon angioplasty (n = 74)
9 mo 279 mm3 [IQR 227 to 300]
197 mm3 [IQR 177 to 230]
FIM&RAVEL (Sao Paulo)
(TCT 2008-426,p164i)
SES (n = 38) 9 mo
21 mo
1.1 ± 2.2 %
1.8 ± 1.9 %
Paclitaxel ES trials
TAXUS II [142] Polymeric PES slow release (n = 131)
BMS (n = 136) 
6 mo 7.84 ± 9.9 %
23.17 ± 18.19 %
TAXUS II [143] Polymeric PES moderate release (n = 135)
BMS (n = 134) 
6 mo 7.84 ± 9.7 %
20.54 ± 16.68 %
TAXUS IV [144] Polymeric PES slow release (n = 88)
BMS (n = 82)
9 mo 12.2 ± 12.4 %
TAXUS V Polymeric PES (n = 149) 
BMS (n = 135) 
9 mo 10.7 ± 10.8 %
31.8 ± 15.1 %
Meta-analysis of TAXUS IV, 
TAXUS V, and TAXUS VI [144]
Polymeric PES (n = 45) 
Overlapping 
Nonoverlapping
BMS (n = 35)
Overlapping
Nonoverlapping
9 mo
9.8 ± 12.0 %
11.3 ± 10.9 %
39.0 ± 17.1 %
33.4 ± 16.6 %
Meta-analysis of TAXUS IV, 
TAXUS V, and TAXUS VI [145]
Patients with diabetes mellitus
Polymeric PES (n = 84)
BMS (n = 70) 
Patients without diabetes mellitus 
Polymeric PES (n = 208)
BMS (n = 204) 
9 mo
9 mo
13.7 %
34.9 %
11.9 %
30.1 %
Meta-analysis of TAXUS IV, 
TAXUS V, and TAXUS VI [146]
Lesions ≥ 26 mm 
Polymeric PES (n = 38) 
BMS (n = 29) 
9 mo
13.4 ± 9.2 %
34.6 ± 15.7 %
TAXUS V ISR 
i2 Summit 2006. Abstract 2402.
BMS in-stent restenosis 
Polymeric PES (n = 42) 
Brachytherapy (n = 41) 
9 mo
12.2 ± 10.3 %
32.4 ± 11.7 %
ASPECT [147] Low-dose nonpolymeric PES (n = 17) 
High-dose nonpolymeric PES (n = 19)
BMS (n = 17) 
6 mo 12.3 ± 8.7 %
9.0 ± 10.4 %
21.6 ± 13.7 %
Table 2
Percentage of intimal hyperplasia volume in drug-eluting stent trials assessed by intravascular ultrasound.
table 2. Percentage of intimal hyperplasia volume in drug-eluting stent trials assessed by intravascular ultrasoundSES: 
sirolimus-eluting stents; PES: paclitaxel-eluting stents; ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent.† 
median (inter-quartile range).‡ percentage of neointimal volume index.Table modified from Mintz G. [111].
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Trial Subgroup Follow-up % IH Vol (Mean ± SD
ASPECT [147] Low-dose nonpolymeric PES (n = 17)
High-dose nonpolymeric PES (n = 19)
BMS (n = 17) 
2 yr 15.9 ± 9.0 %
21.9 ± 13.7 %
23.3 ± 16.2 %
DiabeDES [116]† SES (n = 66)
PES (n = 64)
8 mo 0.0 % (0.0-0.0)
7.5 % (0.1-27.0)
Other DES trials
ENDEAVOR II [148]‡ BMS (n = 165)
Polymeric ZES (n = 178) 
8 mo 29.4 ± 17.2 %
17.6 ± 10.1 % 
ENDEAVOR III [117] Polymeric ZES (n = 190)
Polymeric SES (n = 68)
8 mo 1.1 ± 0.8 mm3/mm
0.2 ± 0.1 mm3/mm
ENDEAVOR IV [149] Polymeric ZES (n = 79)
Polymeric PES (n = 86)
8 mo 16.6 ± 12.0 %
9.9 ± 8.9 %
ENDEAVOR in real world (registry) 
[150]
Polymeric ZES (n = 100) 6 mo 14.4 ± 13.4 %
RESOLUTE FIM [151] Polymeric ZES (n = 30) 4 mo 2.23 ± 2.43 %
RESOLUTE [152] Polymeric ZES (n = 130) 9 mo 3.73 ± 4.05 %
NOBORI I [153] Polymeric Biolimus A9 (n = 36)
Polymeric PES (n = 15)
9 mo 2.2 ± 6.0 %
8.9 ± 9.2 %
STEALTH
SOLACI 2007 by Abizaid A
Polymeric Biolimus A9 (n = 80)
BMS (n = 40) 
6 mo 3.2 ± 2.5 %
32 ± 18 %
CUSTOM II &III
(TCT 2008-345,p137i)
Polymeric Biolimus A9 long lesion (n = 20) 
Polymeric Biolimus A9 short lesion (n = 48)
6 mo 5.9 ± 8.0 %
2.6 ± 5.2 %
AXXESS PLUS [154] Polymeric Biolimus A9 (n = 49) 6 mo 2.3 ± 2.2 %
AXXENT [155] Polymeric Biolimus A9 (n = 26) 6 mo 3.0 ± 4.1 %
SPIRIT I [156] Polymeric EES (n = 21)
BMS (n = 24)
6 mo 8.0 ± 10.4 %
28.1 ± 14 %
SPIRIT I [157] Polymeric EES (n = 16)
BMS (n = 21)
12 mo 10.0 ± 7.0 %
28.0 ± 12.0 %
SPIRIT II [158] Polymeric EES (n = 225)
Polymeric PES (n = 75)
Polymeric EES (n = 64)
Polymeric PES (n = 31)
6 mo
24 mo
2.5 %
7.4 %
5.2 %
5.8 %
SPIRIT III
TCT 2008-347,p138i)
Polymeric EES (n = 115)
Polymeric PES (n = 45)
EES Japan (n = 79)
8 mo 7.0 ± 6.7 %
11.1 ± 10.5 %
3.4 ± 4.1 %
EXCELLA FIM [159] Novolimus eluting stent (n = 15) 4 mo 
8 mo
2.6 ± 2.6 %
6.0 ± 4.4 %
GENESIS [160] Costar PES (n = 16)
SymBio P and Pimecrolimus ES (n = 26)
Corio Pimecrolimus ES (n = 16)
6 mo 16.6 ± 12 %
27.1 ± 12.4 %
41.2 ± 11.5 %
Non-polymer SES [161] Non-polymer Vestasync SES(VES) (nn = 15) 9 mo 4.0 ± 2.2 % 
ABSORB [162, 163] Bioresorbable vascular scaffold (n = 29) 6mo 5.54 % (8.45)
Table 2
Percentage of intimal hyperplasia volume in drug-eluting stent trials assessed by intravascular ultrasound (continued).
SES: sirolimus-eluting stents; PES: paclitaxel-eluting stents; ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent.
† median (inter-quartile range).
‡ percentage of neointimal volume index.
Table modiﬁed from Mintz G. [111].
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ASPECT [147] Low-dose nonpolymeric PES (n = 17)
High-dose nonpolymeric PES (n = 19)
BMS (n = 17) 
2 yr 15.9 ± 9.0 %
21.9 ± 13.7 %
23.3 ± 16.2 %
DiabeDES [116]† SES (n = 66)
PES (n = 64)
8 mo 0.0 % (0.0-0.0)
7.5 % (0.1-27.0)
Other DES trials
ENDEAVOR II [148]‡ BMS (n = 165)
Polymeric ZES (n = 178) 
8 mo 29.4 ± 17.2 %
17.6 ± 10.1 % 
ENDEAVOR III [117] Polymeric ZES (n = 190)
Polymeric SES (n = 68)
8 mo 1.1 ± 0.8 mm3/mm
0.2 ± 0.1 mm3/mm
ENDEAVOR IV [149] Polymeric ZES (n = 79)
Polymeric PES (n = 86)
8 mo 16.6 ± 12.0 %
9.9 ± 8.9 %
ENDEAVOR in real world (registry) 
[150]
Polymeric ZES (n = 100) 6 mo 14.4 ± 13.4 %
RESOLUTE FIM [151] Polymeric ZES (n = 30) 4 mo 2.23 ± 2.43 %
RESOLUTE [152] Polymeric ZES (n = 130) 9 mo 3.73 ± 4.05 %
NOBORI I [153] Polymeric Biolimus A9 (n = 36)
Polymeric PES (n = 15)
9 mo 2.2 ± 6.0 %
8.9 ± 9.2 %
STEALTH
SOLACI 2007 by Abizaid A
Polymeric Biolimus A9 (n = 80)
BMS (n = 40) 
6 mo 3.2 ± 2.5 %
32 ± 18 %
CUSTOM II &III
(TCT 2008-345,p137i)
Polymeric Biolimus A9 long lesion (n = 20) 
Polymeric Biolimus A9 short lesion (n = 48)
6 mo 5.9 ± 8.0 %
2.6 ± 5.2 %
AXXESS PLUS [154] Polymeric Biolimus A9 (n = 49) 6 mo 2.3 ± 2.2 %
AXXENT [155] Polymeric Biolimus A9 (n = 26) 6 mo 3.0 ± 4.1 %
SPIRIT I [156] Polymeric EES (n = 21)
BMS (n = 24)
6 mo 8.0 ± 10.4 %
28.1 ± 14 %
SPIRIT I [157] Polymeric EES (n = 16)
BMS (n = 21)
12 mo 10.0 ± 7.0 %
28.0 ± 12.0 %
SPIRIT II [158] Polymeric EES (n = 225)
Polymeric PES (n = 75)
Polymeric EES (n = 64)
Polymeric PES (n = 31)
6 mo
24 mo
2.5 %
7.4 %
5.2 %
5.8 %
SPIRIT III
TCT 2008-347,p138i)
Polymeric EES (n = 115)
Polymeric PES (n = 45)
EES Japan (n = 79)
8 mo 7.0 ± 6.7 %
11.1 ± 10.5 %
3.4 ± 4.1 %
EXCELLA FIM [159] Novolimus eluting stent (n = 15) 4 mo 
8 mo
2.6 ± 2.6 %
6.0 ± 4.4 %
GENESIS [160] Costar PES (n = 16)
SymBio P and Pimecrolimus ES (n = 26)
Corio Pimecrolimus ES (n = 16)
6 mo 16.6 ± 12 %
27.1 ± 12.4 %
41.2 ± 11.5 %
Non-polymer SES [161] Non-polymer Vestasync SES(VES) (nn = 15) 9 mo 4.0 ± 2.2 % 
ABSORB [162, 163] Bioresorbable vascular scaffold (n = 29) 6mo 5.54 % (8.45)
Table 2
Percentage of intimal hyperplasia volume in drug-eluting stent trials assessed by intravascular ultrasound (continued).
SES: sirolimus-eluting stents; PES: paclitaxel-eluting stents; ZES: zotarolimus-eluting stent; EES: everolimus-eluting stent.
† median (inter-quartile range).
‡ percentage of neointimal volume index.
Table modiﬁed from Mintz G. [111].
table 2. Continued
[111].
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Intravascular imaging has played an important role in the understanding of 
atherosclerosis disease in humans and translation of novel therapies to the clinical 
arena.
Drug effects on atherosclerosis
The initial observations about a positive continuous relationship between coronary heart 
disease risk and blood cholesterol levels led to the conduction of a number of IVUS-
based studies to evaluate the effect of different lipid lowering drugs on atheroma size. 
Changes in plaque characteristics may be a more relevant endpoint to predict risk of 
vascular thrombosis than plaque progression or regression of mild to moderate disease, 
but imaging tools to accurately evaluate plaque characteristics were not available until 
recently. Other limitations of using conventional greyscale IVUS to assess the natural 
history of atherosclerosis should be enumerated: 1) catheterisation, which is an invasive 
procedure, is required for serial imaging; 2) only a segment of the coronary tree can 
be studied; 3) plaque composition is not obtained; and 4) there is no direct evidence 
linking changes in coronary plaques and clinical events. The efficacy of lowering LDL-C 
with inhibitors of hydroxymethylglutaryl coenzyme A reductase (statins) is unequivocal; 
however the change in atheroma size by statins is not constant across all IVUS studies. 
There are many potential explanations for these discrepancies in IVUS studies such as 
drug properties, dose, and duration of treatment. In early studies like the GAIN study 
[120], atheroma volume was not reduced by atorvastatin despite the reduction in LDL-C 
(86 vs. 140 mg/dL) at 12 months. In contrast, the REVERSAL study [3] showed that LDL-C 
levels were further lowered by atorvastatin versus pravastatin (110 mg/dL vs. 79 mg/dL), 
which was associated with an increased of 2.7 percent of atheroma volume in pravastatin-
treated patients, and in a 0.4 percent reduction in atheroma volume in atorvastatin-
treated patients. The clinical significance and accuracy of IVUS for such measurements 
are still debatable, but these results were “statistically significant”. The PROVE-IT study [121], 
showed that the lower the LDL-C and CRP values, the greater the reduction in clinical 
events and atheroma progression.
The first study showing regression of plaque size was the ASTEROID trial (A Study to 
Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary 
Atheroma Burden) [4]. At 24 months, treatment with rosuvastatin 40 mg daily resulted in 
lowering of LDL-C to 60.8 mg/dL and elevation of high-density lipoprotein cholesterol 
(HDL-C) by 14.7 %. These lipid effects were associated with statistically significant, albeit 
small reductions in percent atheroma volume (0.79 %) and total atheroma volume (6.8 %).
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 In another cohort of patients similar to ASTEROID, so called IBIS 4 [191], 103 STEMI patients 
were imaged with IVUS and radiofrequency ultrasonography (IVUS-VH) of the two non-
infarct-related epicardial coronary arteries (non-IRA) after successful primary PCI. Patients 
received rosuvastatin (40 mg/day) for 13 months and serial intracoronary imaging with 
the analysis of matched segments was available for 82 patients with 146 non-IRA. After 13 
months, PAV of the non-IRA decreased by -0.9% (95% CI: -1.56 to -0.25, P = 0.007). Patients 
with regression in at least one non-IRA were more common (74%) than those without 
(26%). Percent necrotic core remained unchanged (-0.05%, 95% CI: -1.05 to 0.96%, P = 
0.93) as did the number of RF-IVUS defined thin cap fibroatheromas (124 vs. 116, P = 0.15).
IVUS studies have also demonstrated coronary plaque modification in HDL-treated 
patients. The infusion of synthetic HDL-C particles containing the variant apolipoprotein, 
apoA-I Milano, complexed with phospholipids (ETC-216) reduced the percent atheroma 
volume by – 1.06 % (3.17 % p = 0.02 compared with baseline) in the combined ETC-216 
group at 5 weeks. On the contrary, in the placebo group, percent atheroma volume 
increased by 0.14 % (3.09 %; p = 0.97 compared with baseline. In the ERASE study [122], 60 
patients were randomly assigned to receive 4 weekly infusions of placebo (saline), 111 to 
receive 40 mg/kg of reconstituted HDL (CSL-111); and 12 to receive 80 mg/kg of CSL-111. 
The latter was discontinued due to liver function test abnormalities. Within the treated 
group, the percentage change in atheroma volume was −3.4 % with CSL-111 (p < 0.001 
vs. baseline), whilst for the placebo group was – 1.6 % (P = 0.48 between groups). It is still 
unclear what the future holds for these therapeutical agents.
Patients with human deficiency of cholesterylester transfer protein (CETP) have elevated 
circulating levels of HDL-C. This has led to investigation on CETP inhibition as a novel 
and potentially effective approach to elevate HDL-C. In the ILLUSTRATE trial, the percent 
atheroma volume (the primary efficacy measure) increased was similarly low in patients 
receiving atorvastatin monotherapy versus in those receiving the combined torcetrapib–
atorvastatin therapy after 24 months (0.19 % vs. 0.12 %, respectively) [123].
The enzyme acyl–coenzyme A:cholesterol acyltransferase (ACAT) esterifies cholesterol 
in a variety of cells and tissues. Inhibition of ACAT1, by blocking the esterification of 
cholesterol, could prevent the transformation of macrophages into foam cells and 
slow the progression of atherosclerosis, while inhibition of ACAT2 would be expected 
to decrease serum lipid levels. In the ACTIVATE study, the change in percent atheroma 
volume was similar in the pactimibe (100 mg daily) and placebo groups (0.69 percent and 
0.59 percent, respectively; P = 0.77) [124].
Systolic blood pressure has been shown to be an independent predictor of plaque 
progression by IVUS [124]. A randomised study of patients with CAD and a diastolic blood 
pressure < 100 mmHg treated with placebo or antihypertensive therapy using either 
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amlodipine 10 mg daily or enalapril 20 mg daily showed that patients treated with 
amlodipine had a reduction in plaque size and also a reduction in cardiovascular events 
as compared to placebo at 24 months [125]. The PERSPECTIVE study [126], a substudy of 
the EUROPA trial, evaluated the effect of perindopril on coronary plaque progression 
in 244 patients. There were no differences in changes in IVUS plaque measurements 
detected between the perindopril and placebo groups. Thiazolidinediones (TZDs) 
increase insulin sensitivity in peripheral tissues thereby lowering glucose. In addition, 
TZDs (i.e., rosiglitazone and pioglitazone) lower blood pressure, inflammatory markers, 
and improve lipid profile, endothelial function, and carotid IMT. TZDs may therefore 
reduce progression of coronary atherosclerosis compared to other antidiabetic drugs. 
Two studies have addressed this question. The APPROACH study and the PERISCOPE 
(Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis 
in Patients With Type 2 Diabetes) trials [127]. Rosiglitazone significantly reduced normalised 
total atheroma volume (TAV) by 5.1 mm3 (95 % CI −10.0, –0.3; p = 0.04) when compared 
to glipizide, whereas pioglitazone just failed to achieve statistically significant in change 
in total atheroma volume (−5.5 ± 1.6 vs. −1.5 ± 1.5 mm3 , p = 0.06) when compared to 
glimepiride. Change in PAV in the APPROACH study was not different in patients allocated 
to glipizide or rosiglitazone (–0.64 %, 95 % CI –1.46, 0.17; p = 0.12), while in the PERISCOPE 
study pioglitazone vs. glimepiride was associated with favorable effects on change 
of PAV (–0.16 ± 0.21 vs. 0.73 ± 0.20 %, p = 0.002). Pioglitazone resulted in comparable 
plaque size reduction as rosiglitazone but this reduction was associated with an almost 
double reduction in vessel size so that the change in normalised lumen volume was quite 
comparable. Change in percent atheroma volume with as numerator change in atheroma 
volume and as denominator change in vessel volume, may mask the specific directional 
changes in its numerator and denominator when used as primary endpoint to compare 
two pharmacological agents.
There are several recent reports showing serial changes of plaque composition in 
patients treated with various statin treatments. In one of them, patients with stable 
angina pectoris (n = 80) treated with fluvastatin for one year had significant regression 
of plaque volume, and changes in atherosclerotic plaque composition with a significant 
reduction of fibrofatty volume (p < 0.0001). This change in fibrofatty volume had a 
significant correlation with change in LDL-cholesterol level (r = 0.703, p < 0.0001) and 
change in hsCRP level (r = 0.357, p = 0.006) [128]. Of note, the necrotic core did not change 
significantly. In a second study, Hong et al. randomised 100 patients with stable angina 
and ACS to either rosuvastatin 10 mg or simvastatin 20 mg for 1 year. Overall necrotic 
core volume significantly decreased (p = 0.010) and fibrofatty plaque volume increased 
(p = 0.006) after statin treatments. Particularly, there was a significant decrease in necrotic 
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core volume (p = 0.015) in rosuvastatin-treated subgroup. By multiple stepwise logistic 
regression analysis, they showed that the only independent clinical predictor of decrease 
in necrotic core volume was baseline HDL-cholesterol level (p = 0.040, odds ratio: 1.044, 
95 % confidence interval (CI): 1.002 to 1.089) [129].
The IBIS 2 study compared the effects of 12 months of treatment with darapladib (oral Lp-
PLA2 inhibitor, 160 mg daily) or placebo in 330 patients [130]. Endpoints included changes 
in necrotic core size (IVUS-VH), and atheroma size (IVUSgreyscale).
Background therapy was comparable between groups, with no difference in LDL-
cholesterol at 12 months (placebo: 88 ± 34 and darapladib: 84 ± 31 mg/dL, p =0.37). In the 
placebo-treated group, however, necrotic core volume increased significantly, whereas 
darapladib halted this increase, resulting in a significant treatment difference of –5.2 mm3 
(p = 0.012). These intra-plaque compositional changes occurred without a significant 
treatment difference in total atheroma volume ( Table 3 ).
Vascular response to endovascular devices
IVUS has been extensively used as surrogate endpoint in stent trials, primarily to assess 
effectiveness of devices as it relates to neointimal proliferation. IVUS was an essential 
investigational tool during initial clinical testing of DES [102, 103], confirming the dramatic 
suppression of neointimal proliferation, revealing new patterns of restenosis and 
establishing intravascular imaging metrics of stent optimisation as described above.
Recently, the feasibility and safety of a bioabsorbable everolimus-eluting vascular scaffold 
(BVS) was also assessed with intravascular imaging. In a prospective, open label study, 30 
patients with a single de novo lesion that was suitable for treatment with a single BVS were 
enrolled. At 6-month follow-up, the angiographic in-stent late loss was 0.44 (0.35) mm and 
was mainly due to a reduction of the stent area (-11.8%) as measured by intravascular 
ultrasound. The neointimal area was small (0.30 [SD 0.44] mm2), with a minimal area 
obstruction of 5.5% [192]. At 2 years, intravascular ultrasound showed a significant increase 
in minimal luminal area and average luminal area and volume, together with a significant 
decrease in plaque area and volume between 6 months and 2 years [193]. At 5 years, some 
patients were re-imaged and the complete IVUS findings are shown in figure 15 [194].
In the backscatter radiofrequency analysis, stent struts are classified as dense calcium (DC) 
and necrotic core (NC) by IVUS-VH. IVUS-VH changes at 6 months suggest alteration of the 
BVS with reduction of RF backscattering by polymeric struts. [119].
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CHAPTER 14 Intravascular ultrasound in the assessment of coronary stenosis
Study Design Year Treatment n FU Primary endpoint Results (mean ± SD)
Statin trials
GAIN [120] RCT 2001 atorvastatin 48 12 months Plaque volume 2.5 ± 24.9 mm3
 control 51 11.8 ± 31 mm3 
ESTABLISH [164] RCT 2004 atorvastatin 24 6 months % change in plaque volume  13.1 ± 12.8 % 
control 24 ± 14.9 % 8.7 
REVERSAL [3] RCT 2004 atorvastatin 253 18 months % change in plaque volume 4.1 ± 29.6 % 
 pravastatin 249 5.4 ± 20.1 % 
Jensen [165] Observational 2004 simvastatin 40 12 months % change in plaque volume 6.30 % 
Petronio [166] RCT 2005 simvastatin 36 12 months Plaque volume –2.5 ± 3.0 mm3/mm 
control 35 1.0 ± 3.0 mm3/mm 
Nishioka [167] Observational 2004 pravastatin,
 atorvastati, simvastatin and 
ﬂuvastatin 
22 6 months Plaque volume 30.9 ± 15.6 mm3
control 26 35.5 ± 12.7 mm3 
Tani [168] RCT 2005 pravastatin 52 6 months % change in plaque volume –14.4 ± 23 % 
control 23 1.1 ± 4.6 % 
ASTEROID [169] Observational 2006 rosuvastatin 349 24 months  Change in PAV –0.98 ± 3.15 % 
Takashima [170] Observational 2007 pitavastatin 41 6 months % change in plaque volume –10.6 ± 9.4 % 
control 41 8.1 ± 14.0 % 
COSMOS [171] Observational 2009 rosuvastatin 126 18 months  Change in PAV –5.1 ± 14.1 % 
JAPAN-ACS [172] RCT 2009 atorvastatin 127 8-12 months % change in plaque volume –18.1 ± 14.2 % 
pitavastatin 125 –16.9 ± 13.9 % 
Hirayama Observational 2009 atorvastatin 28 28 weeks % change in plaque volume –9.4 ± 10.3 % 
80 weeks –18.9 ± 14.1 % 
ACAT (acyl coenzyme A:cholesterol acyltransferase) inhibitor trials
A-PLUS [173] RCT 2004 avasimibe 50 mg 108 24 months Change in PAV  0.7 ± 0.4 % 
avasimibe 250 mg  98 0.8 ± 0.4 % 
avasimibe 750 mg 117 1.0 ± 0.3 % 
placebo 109  0.4 ± 0.4 % 
ACTIVATE [124] RCT 2006 pactimibe 206 18 months  Change in PAV  0.69 ± 0.25 %
placebo 202 -0.59 ± 0.25 % 
Increasing high-density lipoprotein therapies
ApoA-I Milano [174] RCT 2003 ApoA-I Milano 15mg/kg 21 5 weeks Change in PAV –1.29 ± 3.5 % 
ApoA-I Milano 45mg/kg 15 – 0.73 ± 2.8 % 
Placebo 11  0.14 ± 3.09 % 
ERASE [122] RCT 2007 CSL-111 
(reconstituted 
HDL infusion) 
89 4 weeks % change in plaque volume –3.41
 (IQR, –6.55 to 2.25) 
placebo 47 –1.62 (IQR, -5.95 to 1.94) 
CART-2 [175] RCT 2008 Succinobucol 
(AGI-1067) 
183 12 months Absolute change 
in plaque volume 
–3.4 ± 14.5 mm3
placebo 49 –0.6 ± 13.4 mm3 
Other therapies
CAMELOT [125] RCT 2004 amlodipine 91 24 months Change in PAV 0.5 ± 3.9 % 
 enalapril 88 0.8 ± 3.7 %
Waseda Observational 2006 losartan 41 7 months Change in plaque area –9.9 ± 3.1 mm2
non ARB 23 7 months –9.1 ± 2.7 mm2 
Table 3
Intravascular ultrasound progression/regression studies.
table 3. Intravascular ultrasound progression/regression studies.IVUS: intravascular ultrasound; IB: integrated 
backscatter; VH: vir tual histology.
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Study Design Year Treatment n FU Primary endpoint Results (mean ± SD)
ILLUSTRATE [123] RCT 2007 torcetrapib + atorvastatin 464 24 months Change in PAV 0.12 ± 2.99 % 
atorvastatin 446 0.19 ± 2.83 % 
PERSPECTIVE [126] RTC 2007 perindopril 75 36 months Change in plaque area – 0.2 ± 1.6 mm2 
placebo 69 –0.1 ± 1.2 mm2 
PERISCOPE [127] RCT 2008 pioglitazone 179 18 months Change in PAV –0.16 % 
 (9 5 % CI, –0.57 % 
to 0.25 %) 
glimepiride 181 0.73 %
 (95 % CI, 0.33 % 
to 1.12 %)
STRADIVARIUS [176] RCT 2008 rimonabant 335 18 months Change in PAV 0.25 % 
(95 % CI, –-0.04 % 
to 0.54 %)
placebo 341 0.51 %
(95 % CI, 0.22 % 
to 0.80 %) 
ENCORE II [177] RCT 2009 nifedipine 97 18-24 months % change in plaque volume 5.0 
(95 % CI, –1.3, 11.2) 
placebo 96 3.2 (95 % CI,-1.9, 8.3) 
APPROACH RCT 2010 rosiglitazone 233 18 months Change in PAV –0.21
(95 % CI, –0.86, 0.44) 
glipizide 229 0.43
(95 % CI, –0.22, 1.08) 
IVUS-based tissue characterisation studies
Yokoyama RCT 2005 atorvastatin 25 6 months Overall plaque size and 
tissue characterisation by 
IB IVUS 
Atorvastatin reduced 
plaque size and changed 
plaque composition
control 25 
Kawasaki [178] RCT 2005 pravastatin 17 6 months Overall tissue 
characterisation by IB IVUS 
Statins reduced lipid 
without changes 
in plaque size
atorvastatin 18 
diet 17 
IBIS 2 [130] RCT 2008 darapladib 175 12 months Necrotic core vol by IVUS 
VH 
Darapladid reduced 
signiﬁcantly necrotic core 
placebo 155
Nasu [128] Observational 2009 ﬂuvastatin 40 12 months Overall tissue 
characterisation by IVUS VH 
Fluvastatin reduced plaque 
volume and ﬁbro-fatty 
control 40 
Hong [129 RTC 2009 simvastatin 50 12 months Overall tissue 
characterisation by IVUS VH 
Both reduced necrotic core 
and increased in ﬁbrofatty 
volume 
rosuvastatin 50 
Toi RCT 2009 atorvastatin 80 2-3 weeks Overall tissue 
characterisation by IVUS VH 
Pitavastatin reduced 
plaque volume 
and ﬁbrofatty 
pivastatin 80 
Miyagi Observational 2009 statin (pravastatin, 
pitavastatin, atorvastatin, 
ﬂuvastatin, simvastatin) 
non statin
44 6 months Overall tissue 
characterisation by IB IVUS 
Statins reduced lipid 
and increased ﬁbrous 
Table 3
Intravascular ultrasound progression/regression studies (continued).
IVUS: intravascular ultrasound; IB: integrated backscatter; VH: vir tual histology.
table 3. Continued
IVUS: intravascular ultrasound; IB: integrated backscatter; VH: vir tual histology.
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In the future, integration of multiple image technologies in a single catheter is likely to 
provide a more comprehensive assessment of the coronary vasculature. The combined 
use of IVUS-VH analysis and OCT seems to improve the accuracy for TCFA detection [83, 131]. 
Another potential combination is NIR spectroscopy and OCT; both imaging techniques 
are light-based, which may facilitate their combination in one single catheter. Using NIRS, 
an accurate characterisation of necrotic core can be achieved, while OCT will provide 
morphological information about the relationship of the necrotic core and lumen, as well 
as information on the fibrous cap overlying the pool of necrotic core.
IVUS guidance during some interventional procedures may increase the likelihood of a 
greater success rate. Specifically, in the context of the treatment of chronic total occlusions, 
in which the most exacting parts of the procedure are to enter into the proximal part of 
the occlusion and to keep the guidewire within the limits of the vessel to avoid coronary 
perforations. Forward-looking intravascular ultrasound (FL-IVUS) holds promise because 
it is able to visualise the vessel, plaque morphology, and true and false lumens in front 
of the imaging catheter. The Preview catheter is currently undergoing preclinical and 
early clinical evaluation. It is a single-use, over-the-wire imaging catheter, and the distal 
imaging tip is shown in Figure 7. This catheter is advanced over a conventional 0.014-inch 
guidewire to the site of occlusion. It rotates at a rate of 3 to 5 revolutions per a second at 
a frame rate of 3 to 5 frames per second. The current generation of this catheter has a 45 
MHz transducer at the tip and is compatible with a 7 Fr guide.
figure 7. Forward-looking intravascular ultrasound (FL-IVUS; Volcano Corp., Rancho Cordova, CA, USA) is a 45-
MHz transducer oriented at a 45º angle at the tip of the catheter, which rotates providing a forward-looking cone of 
visualisation (A). A 0.014-inch chronic total occlusion (CTO) dedicated guidewire can be advanced through the catheter. 
Thus, a true lumen position can be maintained under FL-IVUS guidance while treating CTO via antegrade. An FL-IVUS 
view of the proximal end of CTO phantom model (B), and directed in real time to maintain a true lumen position.
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A B S T R AC T
New advances in image and signal processing have allowed the development of 
numerous invasive and noninvasive imaging modalities that have revealed details 
of plaque pathology and allowed us to study in vivo the atherosclerotic evolution. 
Recent natural history of atherosclerosis studies permitted us to evaluate changes 
in the compositional and morphological characteristics of the plaque and identify 
predictors of future events. The idea of being able to identify future culprit lesions 
and passivate these plaques has gradually matured, and small scale studies 
have provided proofs about the feasibility of this concept. This review article 
summarizes the recent advances in the study of atherosclerosis, cites the current 
evidence, highlights our limitations in understanding the evolution of the plaque 
and in predicting plaque destabilization, and discusses the potentiality of an early 
invasive sealing of future culprit lesions. 
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I N T R O D u C T I O N
The miniaturization of medical devices, technological innovations, new developments 
in image and signal processing, and advances in biological and molecular imaging 
have provided us with a variety of imaging modalities that permit detection of 
local inflammation and detailed evaluation of changes in atheroma burden and its 
composition. These techniques demonstrated that coronary atherosclerosis has focal and 
eccentric manifestations that evolve in an independent manner, which is affected by the 
composition of the plaque, the presence of inflammation, and the local hemodynamic 
environment. Prospective natural history of atherosclerosis studies shed light into the 
mechanisms involved in this process and allowed us to identify predictors of future culprit 
lesions. 1-3 
The idea of being able to predict plaque development has gradually evolved and recently 
the Shield Evaluated at Cardiac Hospital in Rotterdam for Investigation and Treatment 
of TCFA study has been reported, which examined the feasibility of sealing non– flow-
limiting lesions that have features associated with increased vulnerability (Figure 1).4
The aim of this review article is to summarize the technological advances in the study 
of atherosclerosis, cite the current evidence, and discuss the potentiality of an invasive 
passivation of future culprit lesions.
E F F E C T  O F  T h E  CO M P O S I T I O N  O F  T h E  P L Aq u E  
O N  T h E  N AT u R A L  CO u R S E  O F  AT h E R O S C L E R O S I S
Even before the development of intravascular imaging, it was apparent that the 
composition of the atheroma has significant prognostic implications and affects its natural 
course. Pathology-based studies have shown that the type of the plaque is associated 
with the final act of atherosclerosis and allowed identification of plaque characteristics 
associated with acute coronary events.5
Today, it is known that most of the acute myocardial infractions (MIs) are due to plaque 
rupture, which occurs in lesions referred as thin-capped fibroatheromas (TCFAs). These 
plaques exhibit positive remodeling, have a large lipid core that is covered by a thin 
fibrous cap, and are rich in macrophages. 6,7 
Other features associated with increased vulnerability are the presence of 
microcalcifications and neoangiogenesis.8,9 The introduction of intravascular imaging 
permitted in vivo visualization of these characteristics and opened new horizons in the 
study of plaque growth.
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IVuS-Vh and OCT of Coronary Bifurcations
Intravascular	ultrasound
Intravascular ultrasound (IVUS) was the first invasive modality that allowed imaging 
of the lumen and vessel wall, quantification of plaque burden, and characterization of 
its composition. The analysis of the radiofrequency backscatter IVUS signal (RF-IVUS) 
permitted more reliable detection of the type of the plaque and has been extensively 
implemented to quantify and assess changes in the composition of the atheroma.10-12 
Numerous studies used RF-IVUS at 1 time point to assess the distribution of the atheroma 
and evaluate differences in the composition of the plaque in patients with different clinical 
presentations, whereas others implemented serial RF-IVUS to evaluate atherosclerotic 
 
figure 1. Stent implantation in a high-risk plaque leads to neointimal formation and increases the thickness of the 
tissue that covers a lipid core (LC) (A) resulting in the potential passivation of the plaque (B). Imaging data acquired 
at baseline from a patient recruited in the SECRITT study: palpography demonstrated high strain (C), radiofrequency 
analysis of the backscattered intravascular ultrasound signal showed a lipid-rich plaque, which, however, did not 
cause luminal obstruction (D), whereas optical coherence tomography demonstrated a TCFA (cap thickness 40 μm) 
(E). The results of the study are summarized in panel (F): at 6-month follow-up, the thickness of the fibrous cap was 
increased by 170 μm, there was a minor reduction in the mean lumen area, minimal malapposition, and most of the 
struts were fully covered. Panel A and B were obtained with permission from Moreno.73
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process and the effect of medical treatment on plaque growth.11-13 The most recent study 
with serial assessment was reported by Kubo et al13 and included 99 patients who had 
RF-IVUS examination at baseline and at 12-month follow-up. Two hundred sixteen lesions 
were examined at these 2 time points. At baseline, 20 TCFAs were identified, 5 of which 
were unchanged at follow-up, whereas 15 regressed to more stable forms. On the other 
hand, 12 new TCFAs appeared at the follow-up examination. 
These findings demonstrated the dynamic nature of atherosclerosis and the value of RF-
IVUS in assessing this process.13
The PROSPECT trial was the largest natural history of atherosclerosis study and used RF-
IVUS to detect anatomical and compositional features associated with an increased risk 
for a plaque to evolve to a culprit lesion.1 Six hundred ninety-seven patients treated for 
an acute coronary syndrome underwent RF-IVUS post intervention at the 3 epicardial 
coronary arteries. At 3- year follow-up, 104 new symptomatic lesions became manifest 
in the non-treated segments. Multivariable analysis demonstrated that the presence of 
TCFA, a minimum lumen area ≤4 mm2, and a plaque burden ≥70% were associated with 
future events. Similar results were reported by the VH-IVUS in Vulnerable Atherosclerosis 
Study study that had a similar design. 3 The PROSPECT trial not only showed the potential 
predictive value of intravascular imaging but also highlighted its limited prognostic 
accuracy as only 4% of the detected TCFA evolved to culprit lesions. This should be 
attributed to the fact that the included patients were on optimal treatment and to the 
inherited limitations of IVUS imaging.14
Optical	coherence	tomography
Optical coherence tomography (OCT) is the light-based analogous of IVUS. It provides 
high-resolution cross-sectional images and permits visualization of details, which cannot 
be imaged by other intravascular techniques such as evaluation of the thickness of the 
fibrous cap, detection of macro- phages, and neovascularization and identification of 
plaque erosion. 15 Optical coherence tomography is the method of choice for characterizing 
the superficial plaque and detecting culprit lesions, and it has been used to assess the 
distribution of different plaque types in patients with different clinical presentations.16-18 A 
limitation of OCT is its poor penetration, which often does not allow complete visualization 
of the vessel wall and assessment of vessel remodeling. In addition, OCT signal cannot 
penetrate lipid tissue, and thus, it is unable to quantify the lipid component. To overcome 
these pitfalls, multimodality imaging has been proposed, and currently, the Integrated 
Biomarkers and Imaging Study (IBIS) 4 is underway that implements serial IVUS and OCT 
examination to investigate the effect of pharmaceutical treatment on plaque burden and 
characteristics in patients who have sustained an acute coronary event.18,19
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Other	invasive	imaging	techniques	—	Upcoming	hybrid	imaging	modalities
Angioscopy and intravascular magnetic spectroscopy have been used in the past in the 
study of atherosclerosis, but today, they have limited use. On the other hand, near-infrared 
spectroscopy (NIRS) is a relatively new modality, introduced to provide more accurate 
identification of lipid component, and has already applications in research arena. Further- 
more, intravascular magnetic imaging, photoacoustic imaging, Raman spectroscopy, and 
time-resolved fluorescence spectroscopy are emerging techniques, which are currently 
under evaluation and are expected to provide additional information about plaque 
evolution (online Appendix Supplementary Table I).
In parallel, an effort is being made to overcome the limitations of the prominent 
intravascular imaging modalities either by developing new methodologies that would 
allow better processing of the acquired data (eg, focused acoustic computed tomography, 
micro-OCT, polarized OCT) or by creating hybrid catheters that would permit multimodality 
intravascular imaging, pro- vide complete visualization of coronary pathology, and more 
accurate detection of future culprit lesions.20,21 A hybrid catheter that combines an IVUS 
and a NIRS probe (TVC, MC 7 system; InfraRedx, Burlington, MA) is currently available 
and being used in research arena, whereas catheters that permit fusion of IVUS with 
OCT, photoacoustic imaging, or time resolved fluorescence spectroscopy are under 
evaluation. 22 Initial experimental studies have shown promising results. 23-25 However, the 
large dimensions of the available catheters, the concerns regarding the safety of the new 
techniques, and the low image acquisition rate as well as the moderate image quality that 
they provide have not allow their implementation in humans yet.
Noninvasive imaging modalities
Advances in computed tomographic imaging (eg, the use of dual x-ray sources, the 
increased number of detectors, the decreased slice thickness, and the faster rotation 
gantry) have permitted imaging of coronary anatomy and pathology and reduced the 
radiation dose. Several studies used intravascular imaging techniques as criterion standard 
to validate computed tomographic coronary angiography (CTCA) and demonstrated that 
it can accurately measure the luminal and vessel wall dimensions, identify the presence of 
vessel wall remodeling, and discriminate calcified from non-calcified plaques. 26,27 On the 
other hand, CTCA has limited capability in differentiating lipid-rich from fibrotic plaques 
and has low resolution, which does not permit visualization of plaque characteristics 
associated with increased vulnerability. 28
Although CTCA has considerable limitations, it seems that it provides useful prognostic 
information. A study conducted by Motayama et al29 that included N 1,000 patients who 
underwent CTCA because of suspected coronary artery disease (CAD) demonstrated 
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that the detected by CTCA vessel wall remodeling and the low- attenuated plaques were 
independent predictors of cardiac morbidity. Moreover, the Coronary CT Angiography 
Evaluation for Clinical Outcomes: An International Multicenter registry showed that in 
symptomatic patients the combination of the Morise risk score and the CTCA derived 
data—in particular, the number of the epicardial vessels with obstructive (≥50%) 
stenoses—allowed more accurate prediction of the 2-year major adverse cardiac 
events (all-cause mortality, nonfatal myocardial infarction, and revascularization) than 
the Morise score (accuracy 0.83 vs 0.68, respectively).30 In view of these findings, an 
ambitious prospective study commenced, the BioImage trial that aims to include N6,000 
asymptomatic subjects who will undergo noninvasive imaging (including CTCA if they 
have a high-risk cardiovascular profile) to identify new imaging-based predictors of future 
cardiovascular events.31
Magnetic resonance imaging (MRI) appears to be able to detect the composition of 
the plaque and has been used to study the atherosclerotic process in the aorta and 
the carotids, but it has a limited value in assessing coronary pathology, as it requires 
prolonged acquisition time and has poor spatial resolution.32 Further improvements in 
external coils as well as the development of contrast agents that will allow more accurate 
plaque characterization are required so as this modality to be useful in this setting.
R O L E  O F  I N F L A M M AT I O N  O N  P L Aq u E  D E V E LO P M E N T  
A N D  D E S TA B I L I Z AT I O N
Cumulative evidence has demonstrated that inflammation plays an important role 
in atherogenesis as it regulates the expression of mediators associated with plaque 
development. Several metabolic pathways triggered by increased inflammation appear 
to contribute to plaque destabilization and promote thrombus formation and collagen 
breakdown, which increase the fragility of the fibrous cap. 33,34 Appreciating the prominent 
role of inflammation on plaque rupture research focused on developing methodologies 
to detect and quantify its presence on vessel wall.
Invasive techniques for the detection of inflammation
Thermography
Thermography is the first invasive imaging technique developed to identify vessel 
wall inflammation and relies on the measurement of plaque heat. High temperatures 
indicate increased inflammatory activity and vulnerability of the plaque. Initial reports 
98   |    Chapter 4
demonstrated the efficacy of thermography in detecting high-risk plaques, but recent 
studies have raised concerns about its effectiveness in patent coronaries suggesting that 
blood flow obstruction is necessary to obtain accurate estimations, fact that has limited 
its current applications. 35,36
Near-infrared	fluorescence	molecular	imaging	
Near-infrared fluorescence (NIRF) imaging is a novel technique introduced to detect 
vascular activity. It involves injection of agents that bind molecules related to plaque’s 
inflammation and have the ability to fluoresce after being irradiated with near-infrared 
light emitted by a specially designed catheter. Experimental studies demonstrated the 
feasibility and the potential of thistechnology.37 Recently, a hybrid NIRF-OCT catheter 
(diameter 2.4F) has been designed that allows simultaneous molecular functional imaging 
(provided by NIRF) and visualization of vessel pathology (given by OCT).38 The feasibility 
of this approach has been tested ex vivo and in vivo in animal models and the first results 
appear promising. However, the safety of this technique has to be proven before being 
implemented in humans.39
Noninvasive imaging of vessel wall inflammation
Nuclear	imaging
Nuclear imaging constitutes the leading noninvasive modality for the evaluation of 
vascular activity. Initial positron emission tomography (PET) studies, conducted to detect 
malignant tumors, demonstrated an increased 18F-fluorodeoxyglucose (18F- FDG) uptake 
in large arteries and later reports confirmed a correlation between 18F-FDG and vessel 
wall inflammation.40 Recent reports demonstrated the feasibility of the combined CTCA-
18F-FDG imaging for the identification of inflamed plaques on the coronary tree.41,42 The 
concept of fusing 2 noninvasive modalities that provide anatomical (derived from CTCA) 
and biological (given by PET) information constitutes a breakthrough in the study of 
atherosclerosis as it will allow detailed imaging of plaque pathology in larger populations 
and it is expected to provide additional information about the distribution of plaque 
inflammation and its association with different plaque components.
Apart from 18F-FDG, several other tracers have been developed to assess vascular activity, 
such as the 99mTc- AA5, which binds phosphatidylserine produced by apoptotic cells; the 
99mTc matrix metalloproteinase inhibitor that binds active metalloproteinases; and the 
IK17 tracer, which is labeled with 125I and is able to detect the presence of oxidized low 
density lipoprotein, without however being used in clinical setting yet.43-45
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Other	noninvasive	techniques
A significant limitation of nuclear imaging is the increased radiation dose required, 
which restricts its research applications. Therefore, an effort has been made toward the 
development of alternative imaging techniques, which would be able to evaluate vessel 
wall inflammation. Injection of iodinate nanoparticles has been recently proposed to 
detect the presence of macrophages with CTCA.46 Initial validation of this methodology in 
rabbit models using histology as criterion standard showed that it is accurate and that it 
compares favorably to the estimations of PET.47
The current value of MRI in assessing vascular activity is limited as most of the paramagnetic 
contrast agents are not able to deliver the necessary amount of gadolinium ions that would 
permit MRI detection. Moreover, most of the MRI contrast agents have large dimensions, 
which do not allow them to access to biochemical epitopes within the vessel wall.32
R O L E  O F  B LO O D  F LO W  O N  T h E  AT h E R O S C L E R OT I C 
E V O Lu T I O N  A N D  P L Aq u E  D E S TA B I L I Z AT I O N
The implications of blood flow on plaque development have been observed several 
years ago by Caro et al48 who speculated the athero-promoting effect of low endothelial 
shear stress (ESS). This observation was supported later by studies conducted in cadaver 
specimens and experimental models. Recent advances in invasive and noninvasive 
imaging permitted in vivo reconstruction of coronary anatomy and allowed detailed 
assessment of the role of the hemodynamic forces on atherosclerotic evolution.
Blood flow simulation in models derived from invasive and noninvasive 
imaging modalities
Several small scale studies fused IVUS and coronary angiographic data to reconstruct 
coronary anatomy and showed that low or oscillating ESS promotes plaque growth 
and neointimal formation and alters the composition of the plaque.49-51 Recently, the 
PREDICTION study examined prospectively in a large number of patients the implications 
of ESS on plaque development.2 This trial included 506 patients who were admitted for an 
acute coronary event and underwent 3-vessel IVUS examination at baseline and at 6- to 
10-month follow-up. The baseline IVUS and angiographic data were used to reconstruct 
coronary anatomy and evaluate the ESS distribution. It was found that low ESS promoted 
plaque growth and was independent predictor of future revascularizations.
Although today there are robust data to support the effect of the hemodynamic 
environment on plaque progression, there is little evidence about its role on plaque 
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destabilization.52,53 It has been speculated that high ESS and increased axial tensile stress 
may cause plaque deformation and disruption of the fibrous cap leading to rupture.54 
However, further research is required toward this direction to test the validity of this 
hypothesis.
Computed tomographic coronary angiography and MRI have limited resolution and 
cannot provide meticulous visualization of luminal morphology. This limitation has 
raised concerns about the value of CTCA- and MRI-derived models in the assessment of 
ESS distribution. However, recent experimental studies demonstrated that noninvasive 
imaging reconstructions allow reliable blood flow simulation supporting their applications 
in research.55
Initial reports have confirmed the potential use of CTCA patient-derived models for the 
evaluation of ESS distribution and provided the substrate for the conduction of large scale 
prospective trials, which will examine the impact of the hemodynamic milieu on plaque 
growth.56
F u T u R E  T R E N D S  I N  T h E  S T u Dy  O F  AT h E R O S C L E R O S I S
Today, our ability to predict plaque rupture is limited.
In the PROSPECT study, the quantitative and qualitative information provided by RF-
IVUS predicted future culprit lesions with a positive predictive value of 18%, whereas 
in the PREDICTION study, the positive predic- tive value of the ESS and IVUS-derived 
measurements for identifying future significant stenoses was 42%.1,2 It worth to be 
mentioned that, in both studies, only few of the reported events/revascularizations were 
related to acute coronary syndromes. The aforementioned results highlight the potential 
value of multimodality imaging in the identification of future culprit lesions among 
high-risk plaques. Today, it is impossible to perform a complete study of the coronary 
tree using multiple intravascular imaging catheters that would permit evaluation of 
vessel morphology (given by IVUS or OCT), composition (obtained by RF-IVUS, OCT, or 
NIRS), and inflammation (derived by OCT or NIRF) and provide reliable reconstruction of 
coronary anatomy for blood flow simulation. This, however, is likely to become feasible 
in the near future with the development of hybrid catheters that will allow simultaneous 
data acquisition (eg, a combined IVUS— intravascular photoacoustic catheter would 
permit assessment of the plaque burden, characterization of the type of the plaque, and 
detection of vessel wall inflammation) and a thorough assessment of coronary pathology 
(Figure 2).
Similarly, the integration of CTCA, nuclear imaging, and computational fluid dynamics 
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is expected to provide a holistic noninvasive evaluation of the plaque, whereas the 
introduction of nanoparticles for the detection of inflammation is anticipated to reduce 
the radiation dose and allow the conduction of large scale studies that will enhance our 
understanding about atherosclerotic evolution (Figure 3).
 
figure 2. Output of hybrid imaging techniques. A, Fusion of coronary angiography and IVUS imaging. In the 
obtained model, the outer vessel wall is portrayed in a semitransparent fashion. B, Output of a dual-modality IVUS-
NIRS catheter. Intravascular ultrasound permits visualization of the lumen, plaque, and outer vessel wall, whereas 
NIRS allows detection of the lipid tissue. C, Fusion of computed tomography, IVUS, and NIRS. The obtained models 
provide information about vessel geometry, and the distribution of the lipid tissue on the plaque and can be 
used to simulate blood flow and evaluate the endothelial shear stress. D, Combination of IVUS and intravascular 
photoacoustic imaging. Intravascular photoacoustic imaging allows detection of the lipid tissue (portrayed in an 
orange color), whereas IVUS provides visualization of the luminal morphology and the plaque. E, Fusion of OCT 
and IVUS radiofrequency backscatter images. The integration of different information acquired by these techniques 
permits more accurate characterization of the plaque. F, Output of a dual-modality catheter that allows simultaneous 
acquisition and coregistration of OCT and near-infrared fluorescence data. Optical coherence tomography provides 
information about the luminal morphology and the composition of the plaque, whereas near-infrared fluorescence 
allows identification of vessel wall inflammation portrayed in a color-coded map with the white-yellow color 
corresponding to increased inflammation. Images were obtained with permission from Bourantas et al, Wentzel et 
al, Wang et al, Raber et al, and Yoo et al.38,74-77
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figure 3. Implications of CTCA in the study of atherosclerosis. A, Ability of CTCA to detect the composition of the 
plaque. The arrows indicate the location of the IVUS and CTCA cross-sectional images. Panels (I’-I”’) portray IVUS, 
IVUS radiofrequency backscatter analysis, and CTCA cross-sections for the distal calcified plaque, whereas the panels 
(II’-II”’), the corresponding cross-sections for the proximal plaque. The luminal morphology and the distribution of the 
plaque are similar in the CTCA and IVUS images. CTCA appears to allow accurate differentiation between calcified 
from noncalcified plaques. B, Fusion of CTCA and positron emission computed tomography. Increased 18F-FDG uptake 
was noted in the aorta, left main stem, and left anterior descending artery (arrows) of a patient admitted with an 
acute coronary syndrome. C, On the other hand, minor inflammation was detected in the aorta and coronary tree 
of a patient with stable angina. D, Reconstruction of coronary tree from CTCA. E, These data were used to model the 
distal circumflex, simulate blood flow, and evaluate the shear stress distribution (portrayed in a color-coded map). F, 
Superimposition of the reconstructed model onto the coronary tree provided by CTCA. Panels B and C were obtained 
with permission from Rogers et al, whereas panels D to F were provided by Sakellarios AI and Fotiadis DI.41
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CO N S I D E R AT I O N S  T h AT  N E E D  TO  B E  A D D R E S S E D  B E F O R E 
A D V O C AT I N G  A N  I N VA S I V E  T R E AT M E N T  O F  V u L N E R A B L E 
P L Aq u E S 
how accurate can we predict an upcoming event in patients with known 
coronary artery disease?
Although our knowledge about plaque vulnerability has increased over the last few years, 
our ability to predict the time of a future event remains low. The traditional risk models 
appear to predict with a moderate accuracy the short-term cardiovascular morbidity and 
mortality (cardiac death, MI, and repeat revascularization) in patients who have sustained 
an acute coronary syndrome (range 0.26-0.84) (online Appendix Supplementary Table 
II). To improve the performance of these scores, several new variables have been added 
such as the SYNergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) score or 
biomarkers related with worse outcomes (eg, activated protein C, N-terminal pro-brain 
natriuretic peptide, glucose, cardiac troponin T). However, the information regarding 
coronary anatomy, given by the SYNTAX score, has only slightly increased the accuracy 
of these models, whereas the scores that included biomarkers were designed to predict 
all-cause mortality and not to estimate the risk of future cardiac events (online Appendix 
Supplementary Table II).
how accurately can we predict a future event in an asymptomatic population?
Most of the conventional models, designed for asymptomatic populations, focus on the 
prediction of the long-term cardiac outcomes (death, MI, coronary revascularization), and 
have low predictive accuracy. The new risk models that include bio- markers or genetic 
information have a slightly better predictive accuracy, whereas the ones that include 
CTCA data appear to allow accurate prediction of major adverse cardiovascular events but 
focus on the long-term outcomes (range 3.9-10 years) (online Appendix Supplementary 
Table III).
Over the last few years, several new markers associated with increased vulnerability 
have been identified (eg, patient genotype, myeloperoxidase, A2 phospholipase, blood 
monocytes subsets count, pregnancy associated plasma protein A, etc), and in a recent 
report, Brennan et al 57 combined the traditional with new risk factors, provided by 
patients’ hematology profile (including leukocyte peroxidase-, erythrocyte- and platelet-
related parameters), into a model that permitted prediction of 1-year MI and death with 
an accuracy of almost 80%.57-60 Further research is required toward this direction to find 
new predictors and construct novel models that would give precise short- term risk 
stratification and potentially reliable estimation of upcoming coronary events.
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Should we always treat a ruptured plaque?
Even if we were able to foresee which plaque and when this will rupture, it would be 
still debatable whether we should seal it. Several intravascular imaging studies have 
demonstrated the presence of ruptured plaque in the coronary tree of asymptomatic 
patients and of patients with CAD indicating that plaque rupture does not always cause 
an acute coronary event (Figure 4).61,62
Furthermore, chronically ruptured plaques appear clinically silent and do not require 
an interventional treatment.63 Which of the ruptured plaques will cause MI and which 
will heal are still unclear. A small study that compared culprit and nonculprit ruptured 
plaques demonstrated that the culprit lesions had increased length, plaque burden, and 
remodeling index and exhibited a smaller luminal area comparing with the asymptomatic 
ulcerated plaques.64 Apart from the morphological characteristics of the plaque, systemic 
factors and more specifically blood viscosity, platelet activity, fibrinogen levels, von 
Willebrand factor, and the interplay between coagulation and fibrinolytic system seem 
also to determine the final clinical consequences of plaque rupture.65-67 Therefore, 
further effort should be made to identify predictors associated with extensive thrombus 
formation, blood flow obstruction, and the clinical manifestation of an acute coronary 
syndrome.
Should we focus only on thin capped ﬁbroatheromas? 
Histology-based studies have demonstrated that one- third of the acute coronary 
syndromes are due to plaque erosion occurring in plaques, which do not have the typical 
characteristics of a high-risk lesion. These plaques have the histologic appearance of 
pathologic intimal thickening or fibroatheroma and are rich in proteoglycan and smooth 
muscle cells.68 The underlying mechanism of plaque erosion is poorly understood, and it 
has been speculated that it can be due to coronary vasospasm. Today, it is impossible to 
predict which of these stable-looking plaques will erode and cause MI.
Is there an ideal device to seal future culprit lesions?
The invasive treatment of a potential culprit lesion in asymptomatic patients can be 
justified only if stent implantation is safe. Initial reports demonstrated an unacceptable 
high risk of complications in non–flow- limiting lesions treated with balloon angioplasty 
or bare metal stents, whereas the new developments in stent design may have reduced 
the risk of complications, but they have not eradicated them.69 The distortion of vessel wall 
physiology as well as the risk of neoatherosclerosis and of an inflammatory reaction to a 
permanent foreign body remains considerable pitfalls of metallic stents. Bioresorbable 
scaffold is a recent technology introduced to address the abovementioned drawbacks. 
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These devices have the ability to dissolve after restoring the patency of the vessel allowing 
the coronary artery to maintain its physiologic integrity.70 Recent reports demonstrated 
that the neointimal tissue developed postimplantation of a bioresorbable scaffold can 
seal the underlying plaques, whereas studies in animal models showed that the neotissue 
has features associated with plaque stability.71,72
These initial reports may support the use of bioresorbable scaffolds for paving diseased 
coronary segments with vulnerable plaques, but long-term follow-up data are required to 
elucidate this prospective (Figure 5).
 
figure 4. In vivo OCT imaging of an asymptomatic plaque rupture. Angiographic images showing 2 lesions, a distal 
(white arrow), which was stented successfully and a proximal (yellow arrow) that was left untreated (AI-AII). Optical 
coherence tomographic examination revealed a TCFA at the proximal lesion (red arrow) (BI, BI’). Repeat imaging 
few minutes later demonstrated plaque disruption (yellow arrow) (BII, BII’) and an intimal flap (BIII, BIII’). Thrombus 
was gradually formed, which covered the created crater (BIV, BIV’). Longitudinal images (CI, CII) and 3-dimensional 
reconstruction of the OCT data (CIII) showed increased macrophages accumulation (indicated with a green color) at 
the ruptured plaque (arrow), which was located at the distal site of the lipid core.
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figure 5. a, Three-dimensional reconstruction of a left anterior descending coronary artery from coronary 
angiographic and OCT data acquired immediate after an Absorb bioresorbable vascular scaffold implantation. 
The ESS is portrayed in the reconstructed surface with the use of a color-coded map. low ESS in noted in the 
scaffolded segment with 61% of the ESS being <l Pa. Panels Al and A2 illustrate 2 OCT cross-sectional images an d 
the estimated ESS along the luminal circumference. The asterisk indicates a side branch. A fibroatheroma is shown 
al panel Al with a cap thickness of 90 IJm. Panel B portrays the reconstructed vessel al 2-year follow-up. The ESS 
in the scaffolded segment (B, B2) is normalized (only 17% of the ESS estimations are <17%) al follow-up creating 
an atheroprotective for the vessel environment. In addition, as it is shown in the magnified view, a thin layer of 
neointimal tissue is developed with a mean thickness of 160 IJm that covers the vessel wall and the fibroatheroma 
detected al baseline (B l). lmage was obtained modified and used with permission from Bourantas et al.78
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S u M M A R y
New developments in invasive and noninvasive imaging have allowed detailed visualization 
of coronary pathology and have considerably increased our knowledge about plaque 
growth and rupture. Prospective natural history of atherosclerosis studies permitted 
evaluation of changes in plaque composition and assessment of the complexity of plaque 
evolution. Our inability to accurately predict which of the detected vulnerable plaques 
will rupture, when this will occur, and whether this event will have clinical implications 
cannot justify an invasive sealing of potential culprit lesions. However, this is likely to 
change in the future. The revolution occurring in invasive and noninvasive imaging and 
the advances in molecular biology are expected to provide additional information about 
atherosclerotic disease progression/regression, allow us to study this process in larger 
populations, and probably predict with a higher accuracy events and plaque ruptures. 
Although, few years ago, the early detection and invasive passivation of future culprit 
lesions appeared as an unrealistic dream, nowadays, it is regarded as a future potentiality.
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A B S T R AC T
Aims The first generation of the everolimus-eluting bioresorbable vascular scaffold 
(BVS 1.0) showed an angiographic late loss higher than the metallic everolimus-
eluting stent Xience V due to scaffold shrinkage. The new generation (BVS 1.1) 
presents a different design and manufacturing process than the BVS 1.0. This 
study sought to evaluate the differ- ences in late shrinkage, neointimal response, 
and bioresorption process between these two scaffold generations using optical 
coherence tomography (OCT).
Methods and results A total of 12 lesions treated with the BVS 1.0 and 12 selected 
lesions treated with the revised BVS 1.1 were imaged at baseline and 6-month 
follow-up with OCT. Late shrinkage and neointimal area (NIA) were derived from 
OCT area measurements. Neointimal thickness was measured in each strut. 
Strut appearance has been classified as previously described. Baseline clinical, 
angiographic, and OCT characteristics were mainly similar in the two groups. At 6 
months, absolute and relative shrinkages were significantly larger for the BVS 1.0 
than for the BVS 1.1 (0.98 vs. 0.07 mm2 and 13.0 vs. 1.0%, respectively; P = 0.01). 
Neointimal area was significantly higher in the BVS 1.0 than in the BVS 1.1 (in-
scaffold area obstruction of 23.6 vs. 12.3%; P < 0.01). Neointimal thickness was also 
larger in the BVS 1.0 than in the BVS 1.1 (166.0 vs. 76.4 mm; P < 0.01). Consequently, 
OCT, intravascular ultrasound, and angio- graphic luminal losses were higher with 
the BVS 1.0 than with the BVS 1.1. At 6 months, strut appearance was pre- served in 
only 2.9% of the BVS 1.0 struts, but remained unchanged with the BVS 1.1 indicating 
different state of strut microstucture and/or their reflectivity.
Conclusion The BVS 1.1 has less late shrinkage and less neointimal growth at 6-month 
follow-up compared with the BVS 1.0. A difference in polymer degradation leading 
to changes in microstructure and reflectivity is the most plausible explanation 
for this finding.
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B AC kG R O u N D
The first generation of the everolimus-eluting bioresorbable vascu lar scaffold (BVS 1.0) 
was tested in 30 patients enrolled in the ABSORB Cohort A study. At 6-month follow-
up, this device showed a late shrinkage of the scaffold area of 11.8% as assessed by 
intravascular ultrasound (IVUS) and rapid changes in strut appearance, documented by 
multiple imaging modalities.1
At variance with metallic stents, which do not exhibit late shrink- age,2 the reduction of 
the BVS 1.0 scaffold area was the main component of late luminal loss at 6 months.
The BVS 1.1 represents a new generation of bioresorbable devices. It utilizes a novel platform 
design and polymer processing different than the previous BVS 1.0. This new generation 
is designed to improve the radial force and to slow-down the loss in mechanical integrity, 
without substantially affecting the bioresorption process.3 It has been investigated in 101 
patients enrolled in the ABSORB cohort B trial. Forty-five of these patients were scheduled 
for a 6-month control with conventional angiography and multiple intravascular imaging 
techniques.
Optical coherence tomography (OCT) is a high resolution imaging technique capable of an 
accurate assessment of the polymeric struts, changes in luminal and scaffold dimensions, 
and the quantification of neointimal hyperplasia.4 – 6
Our aim is to compare the late shrinkage and neointimal response of the two polymeric 
devices using OCT imaging and to assess the qualitative changes in strut appearance as a 
marker of bioresorption at 6-month follow-up.
M AT E R I A L S  A N D  M E T h O D S
Study design and population
The ABSORB trial is a non-randomized, multicentre, single-arm, efficacy – safety study. The 
first Cohort (A) included 30 patients treated with the BVS 1.0; the trial design and results 
up to 3-year follow-up have been already published.1,4,7 The second Cohort (B) included 
101 patients with 102 lesions treated with a single size 3 × 18 mm of the BVS 1.1 design; 
the study design is available at clinicaltrials.gov (NCT00856856).
The inclusion criteria were similar in both studies: patients aged 18 years or older diagnosed 
with stable, unstable, or silent ischaemia, with a de novo lesion in a native coronary 
artery between 50 and 99% of the luminal diameter and a Thrombolysis In Myocardial 
Infarction (TIMI) flow grade of 1 or more. Exclusions included patients with an evolving 
myocardial infarction, stenosis of an unprotected left main or ostial right coronary artery 
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(RCA), presence of intracoronary thrombus or heavy calcification. Excessive tortuosity and 
lesions involving a side branch more than 2 mm in diameter were also exclusion criteria. 
The ethics committee at each participating institution approved the protocol and each 
patient gave written informed consent before inclusion.
Four centres (Auckland, Aarhus, Krakow, and Rotterdam) participated in the Absorb 
Cohort A in 2006 using the BVS 1.0.1 In this first-in-man study, angiography and IVUS were 
mandatory investigations at 6 and 24 months of follow-up. Optical coherence tomography 
was an optional investigation that was only executed and performed in Rotterdam with 
the available system at that time (M2 Light Lab). Subsequently, the Rotterdam group 
performed OCT follow-up of their patients at 6 and 24 months. As a result, 13 patients in 
Cohort A had sequential OCT investigation at baseline and 6 months.4 The Cohort B study 
was started during 2009 using the BVS 1.1. In this study, 7 of the 12 participating centres 
performed OCT at baseline and follow-up and three of them (Rotterdam = 9, Melbourne 
= 2, and Bern = 1) used the most advanced system (C7 Light Lab). As a result, 12 patients 
in Cohort B have been imaged with the OCT C7 system. This limited but almost equal 
number of patients represents a unique opportunity to analyse, with the high resolution 
of OCT, the mechanical behavior of the first and second generation of everolimus-eluting 
BVS at baseline and at 6-month follow-up.
Devices
The BVS 1.0 (Abbott Vascular, Santa Clara, CA, USA) is a balloon expandable device built 
on a backbone of semi-crystalline poly-L-lactide (PLLA) polymer. The polymer consists of 
crystalline and amorphous domains. The balance between the crystalline and amorphous 
fractions and the molecular orientation state of these phases depends on their thermal 
and deformation history. The plat- form is coated with the poly-D,L-lactide (PDLLA) 
copolymer that contains and controls the release of the antiproliferative everolimus 
(Novartis, Switzerland). Both PLLA and PDLLA are fully bioresorbable. The strut thickness 
is 150 mm and the struts are distributed as circumferential out-of-phase zigzag hoops 
linked together by three longitudinal bridges between each hoop. The BVS 1.0 design is 
shown in Figure 1.
The manufacturing process the BVS 1.1 (Abbott Vascular, Santa Clara, CA, USA) has been 
modified to enhance the mechanical strength and mechanical durability of the struts. 
Moreover, the new design has in-phase zigzag hoops linked by bridges that allow for a 
more uniform strut distribution, reduce maximum circular unsupported surface area, and 
provide more uniform vessel wall support and drug transfer.3 The polymer mass, coating 
content, amount of drug, and the strut thickness remain the same. The BVS 1.1 design is 
also shown in Figure 1.
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figure 1. Design of the diff erent bioresorbable vascular scaff old (BVS). (A) BVS 1.0 design. The struts are distributed as 
circumfer- ential out-of-phase zigzag hoops linked together by three longi- tudinal bridges between each hoop. The 
maximal circular unsupported surface area is drawn as a red circle. (B) BVS 1.1 design. The struts are arranged as in-
phase zigzag hoops linked together by three longitudinal bridges. The strut distribution is more uniform and allows 
the maximal circular unsupported surface area (red circle) to be smaller than in the BVS 1.0.
Treatment procedure
All procedures were performed electively. Lesions were treated with routine interventional 
techniques that included mandatory pre- dilatation. The study protocol forbade the use 
of pre-dilatation bal- loons longer than the pre-specifi ed length of the device (18 mm), 
and recommended using balloons 0.5 mm smaller in diameter than the reference vessel 
diameter (RVD). The BVS had to be implanted at a pressure not exceeding the rated 
burst pressure (16 atmospheres). Post-dilation was allowed at the operator’s discretion 
with shorter balloons than the BVS length and infl ated at diameters that fi t within the 
boundaries of the scaff old. Bail-out stenting was also allowed at operator’s discretion.
quantitative angiography analysis
The 2D angiograms were stored in DICOM format and analysed offl  ine by the core lab 
(Cardialysis, Rotterdam, The Netherlands) using the CASS II analysis system (Pie Medical 
BV, Maastricht, The Netherlands). In each patient, the treated region and the peri-treated 
regions (defi ned by a length of 5 mm proximal and distal to the device edge) were 
analysed. The following quantitative coronary angiography (QCA) analysis parameters 
were measured: computer-defi ned minimal luminal diameter (MLD), RVD obtained by an 
interpolated method, and percentage of diameter stenosis (DS). Late loss was defi ned as 
the diff erence between MLD post-procedure and MLD at follow-up.8
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Optical coherence tomography acquisition
In the ABSORB Cohort A, baseline and follow-up OCT acquisition was executed with an 
M2 Time-Domain System (LightLab Imaging, West- ford, MA, USA) using the balloon 
occlusion method. The occlusion balloon Helios (Goodman, Japan) was advanced distal 
to the treated region over a conventional angioplasty guidewire of 0.014’’ . Then, the 
conventional guidewire was replaced by the OCT ImageWire (LightLab Imaging, Westford, 
MA, USA) and the occlusion balloon catheter was positioned proximal to the segment of 
interest. Pullback of the ImageWire was performed with automated pullback at 1 mm/s 
and 15.6 frames/s during the occlusion of the artery by the balloon at low pressure (0.5 
– 0.7 atm), and during simultaneous flushing of the vessel distal to the occlusion with 
lactated Ringer’s solution at 378C (flow rate 0.8 mL/s).
In ABSORB Cohort B, the baseline and follow-up OCT acquisitions were performed with the 
C7 XR Fourier-Domain System (LightLab Imaging, Westford, MA, USA) without occluding 
the coronary artery. In these cases, a conventional wire was placed distal to the segment 
of interest. Then the OCT imaging catheter (RX ImageWire II; LightLab Imaging, Westford, 
MA, USA) was advanced distally to the treated region. Removal of the conventional wire 
was left to the operator’s discretion. The pullback was performed during a continuous 
injection of 3 mL/s of contrast medium (Iodixanol 370, Visipaque, GE Health Care, Cork, 
Ireland) injected at a maximum pressure of 300 psi through the guiding catheter using an 
injection pump. In this case, the automated pullback rate was 20 mm/s and the frame rate 
was 100 images/s. The resolution of both OCT systems is exactly the same (15 – 20 mm of 
lateral resolution and 15 – 20 mm of axial resolution).9
Optical coherence tomography analysis
The OCT measurements were performed with proprietary software for offline analysis 
(LightLab Imaging, Westford, MA, USA). Adjusting for the pullback speed, the analysis of 
contiguous cross-sections was performed at each 1 mm longitudinal intervals within the 
treated segment.
The monochromatic peak wavelength of the OCT is differently reflected, refracted, 
and absorbed by the polymeric or metallic struts. A great deal of the OCT light energy 
is transmitted through the polymeric struts, such that only part of it is reflected at the 
endoluminal and abluminal sides of the struts generating a visible optical frame border; 
the core of the polymeric struts is imaged as a black square at baseline. As a consequence, 
the vessel wall is easily imaged through the struts without any major signs of shadowing 
(Figure 2). Thus, OCT analysis of the BVS has several advantages over that of metallic 
stents. First, at baseline, the vessel wall/lumen and its luminal area can be readily 
measured behind the polymeric struts. At follow-up, most of the struts are fully covered 
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and embedded in the vessel wall and the luminal area can be drawn with an automated 
detection algorithm available in the Light Lab proprietary software; manual corrections 
are performed if necessary. Second, since polymeric struts are accurately imaged at 
baseline, the device area can be obtained manually by joining the middle point of each 
consecutive strut around the circumference. In frames with only a few struts, the BVS area 
was adjusted to follow the lumen area in the regions where its contour was outside the 
lumen area. At follow-up, the BVS area was also measured by joining the middle point of 
the struts (Figure 3).
Device shrinkage is defi ned as the decrease over time of the device area with respect to 
the area measured immediately after the deployment. 10,11
Absolute late shrinkage has been measured as the diff erence between the mean BVS 
area at baseline minus the mean BVS area at follow-up. Relative late shrinkage has been 
figure 2. Optical coherence tomography (OCT) imaging of the bioresorbable scaff olds and metallic platform stents. 
(A) Bioresorbable vascular scaff old imaged with OCT. The strut appearance is translucent and allows a perfect imaging 
of the vessel wall. (B) Metallic platform stent imaged with OCT. The metallic struts are opaque to the OCT light and 
produce the typical shadow into the vessel wall.
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measured as: [(absolute late shrinkage)/baseline mean BVS area] × 100 (Figure 3).
In case of incomplete scaff old/strut apposition (ISA), the area between the backside of 
the struts and the vessel wall has been measured as ISA area. The neointimal area (NIA) 
has been measured at follow-up as: BVS area – (Lumen Area – ISA area). The neointimal 
thickness (NIT) has been measured at follow-up with the ‘thickness ruler’ tool from the 
endoluminal border of the black strut core to the lumen.
Moreover, a qualitative assessment of the appearance of polymeric struts has been 
obtained at follow-up. Basically, the struts were classi- fi ed as preserved box, open box, 
dissolved bright box, and dissolved black box in order of decreasing refl ectivity (Figure 
4).1 The kappa index to detect the four types of strut appearance was 0.58.12 Strut tissue 
coverage was assessed qualitatively when clear neointimal tissue covered the polymeric 
strut.
Intra-vascular ultrasound acquisition and analysis
The scaff olded segments were examined with phased array IVUS cath- eters (EagleEye; 
Volcano Corporation, Rancho Cordova, CA, USA) with an automated pullback at 0.5 
mm/s. Lumen area was measured with a validated computer-based contour detection 
figure 3. Late shrinkage assessment. Optical coherence tomography (OCT) imaging of the BVS 1.0 and 1.1. At 
baseline, the scaff old area (SA; blue line) is usually drawn into the luminal area (LA; green line). At follow-up, the 
neointima covers the polymeric struts and then, the scaff old area usually is drawn outside of the luminal area. The 
absolute late shrinkage for the BVS 1.0 is 2.06 mm2 (relative shrinkage of 25.6%) and for the BVS 1.1 is 0.12 mm2 
(relative shrinkage of 1.5%).
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programme (CURAD BV, Wijk bij Duurstede, The Netherlands) that allows for semi-
automatic detection of lumen.13
Statistical analysis
Normality distribution of continuous variables was explored with the Kolmogorov – 
Smirnov test. All continuous variables had normal distribution and have been expressed 
as means and 1 standard deviation (SD). Categorical variables are presented as counts 
(%). Paired comparisons of continuous variables within groups between the diff erent time 
points were done by the Wilcoxon’s signed rank test. Comparison of continuous variables 
between Cohorts A and B has been made using the U-Mann – Whitney test. Comparisons 
of absolute diff erences between baseline and follow-up have also been made with the 
U-Mann – Whitney test. Comparisons of categorical variables between groups have been 
made using the Chi-square test or the Fisher test when one of the cells had less than fi ve 
events. A two-sided P-value ≤ 0.05 was considered statistically signifi cant. All the statistics 
have been per- formed with the SPSS 15.0 version for Windows (IL, US). 
figure 4. Strut appearance of the bioresorbable vascular scaff old at follow-up. (A) Preserved box appearance: sharp 
defi ned, bright refl ection borders with preserved box-shaped appearance; strut body shows low refl ection; (B) open 
box: luminal and abluminal long-axis borders thickened bright refl ection; short-axis borders not visible; (C ) dissolved 
bright box: partially visible bright spot, contours poorly defi ned; no box-shaped appearance; (D) dissolved black box: 
black spot, contours poorly defi ned, often confl uent; no box-shaped appearance.
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R E S u LT S
Study population
A total of 13 lesions in 13 patients had baseline and follow-up OCT imaging in the ABSORB 
Cohort A study.1 One of these patients underwent a non-ischaemia driven target lesion 
revascularization treated with a metallic platform stent at Day 42. The OCT imaging at that 
time showed strut discontinuation with attached thrombi probably due to overstretching 
of the BVS during implantation.7 This patient has not been included in the present study. In 
the ABSORB Cohort B study, 28 patients with scheduled imaging control at 6-month follow-
up were studied with OCT at baseline. Two of them were excluded due to the sub-optimal 
quality of the imaging, and of the remaining 26 patients, 13 were imaged with the M3 OCT 
system and 13 were imaged with the OCT C7. None of the 13 patients imaged with the 
M3 system needed an unscheduled angiography and all of them were studied with OCT 
at 6 months. One patient imaged with the C7 system presented with a symptomatic peri-
procedural myocardial infarction at the index procedure secondary to an occlusion of a 
small diagonal after the implantation of the BVS in the left anterior descending. This patient 
refused invasive imaging at 6-month follow-up. Finally, 24 patients were included in the 
present study: 12 were treated with the BVS 1.0 and 12 were treated with the BVS 1.1. None 
of those patients had BVS fractures at baseline or 6-month follow-up. The baseline clinical 
characteristics are shown in Table 1. Both groups were similar in gender and age. There was 
a trend toward lower percentage of hypercholesterolaemia (72.7 vs. 100.0%; P = 0.06) and 
prior acute myocardial infarction (8.3 vs.41.7%; P = 0.06) in the BVS 1.0 than in the BVS 1.1 
group, respectively. There was a significant difference in the smoking status favouring the 
BVS 1.1 group (33 vs. 0%, respectively; P = 0.03). A total of 11 patients in ABSORB Cohort A 
were treated with a BVS 1.0 of 3 × 12 mm and 1 was treated with a BVS 1.0 of 3 × 18 mm. All 
patients of the ABSORB Cohort B were treated with a BVS 1.1 of 3 × 18 mm.
quantitative coronary angiography results
Baseline and follow-up angiographic parameters are shown in Table 2. Both groups had 
similar angiographic characteristics at pre-implantation. Patients treated with the BVS 1.0 
tended to have a larger RVD than patients treated with the BVS 1.1 (2.95 vs. 2.69 mm; P = 
0.14). At 6-month follow-up, patients treated with the BVS 1.0 had a significant decrease 
in MLD (angiographic late loss) of 0.43 mm (P = 0.01), whereas a non-significant 0.08 mm 
decrease was seen in those treated with the BVS 1.1. The difference in late loss between the 
BVS 1.0 and 1.1, although numerically appreciable, failed to reach statistical significance at 
6 months (P = 0.07). The serial individual changes in MLD between baseline and follow-up 
are shown in Figure 5.
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Optical coherence tomography results
Baseline and follow-up quantitative OCT and IVUS findings are shown in Table 3. Both 
groups had similar OCT findings at baseline after the deployment of the BVS. At 6 months, 
the BVS 1.0 had a significantly higher late shrinkage than the BVS 1.1 (absolute shrink- 
age of 0.98 vs. 0.07 mm2 and relative shrinkage of 13.0 vs. 1.0%, respectively; P = 0.01). 
Neointimal area was significantly higher with the BVS 1.0 when compared with the BVS 1.1 
(1.44 vs. 0.87 mm2, respectively; P < 0.01). NIH was also larger in the findings at 6 months 
caused a significantly higher reduction in mean lumen area (relative difference of 35.1 vs. 
16.1%; P < 0.01) and in minimal luminal area (47.0 vs. 20.7%; P < 0.01) with the BVS 1.0 
than with the BVS 1.1 as assessed by OCT. Serial individual changes of the BVS area and 
table 1. Baseline clinical and angiographic characteristics.
BVS 1.0 (n = 12) BVS 1.1 (n = 12) P-value
Male 8 (66.7) 9 (75.0) 0.65
Age (years + SD)  59.5 + 8.3 61.2 + 9.6 0.76
Hypertension  6 (50.0) 7 (58.3) 0.68
Hypercholesterolaemia 8 (72.7) 12 (100.0) 0.06
Diabetes mellitus 1 (8.3) 1 (8.3) 1.00
Smoke  4 (33.3) 0 0.03
Prior MI  1 (8.3) 5 (41.7) 0.06
Prior PCI 2 (16.7) 3 (25.0) 0.62
Clinical indication 0.27
   Stable or silent angina  11 (91.7) 9 (75.0)
   Unstable angina 1 (8.3) 3 (25.0)
Number of vessel disease 0.14
   One 12 (100.0) 10 (83.3)
   Two 0 2 (16.7)
Culprit vessel 0.22
   LAD 4 (33.3) 6 (50.0)
   LCX 6 (50.0) 2 (16.7)
   RCA 2 (16.7) 4 (33.3)
BVS size < 0.01
3 × 12 mm 11 (91.7) 0
3 × 18 mm 1 (8.3) 12 (100.0)
Values are expressed as count (%), except for age.
MI, myocardial infarction; PCI, percutaneous coronary intervention; LAD, left anterior descending; LCX, left circumflex; 
RCA, right coronary artery; BVS, bioresorbable vascular scaffold.
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of the minimal lumen area as assessed by OCT are shown in Figure 5. The ISA area of the 
BVS 1.0 at 6 months increased signifi cantly with respect to the baseline (0.10 mm2; CI 95%: 
from 20.02 to 0.21 mm2; P = 0.04), while the ISA area of the BVS 1.1 remained unchanged 
(0.02 mm2; 20.18 to 0.22 mm2; P = 0.26). A total of 662 struts of the BVS 1.0 and 1575 of 
the BVS 1.1 were detected at baseline. After deployment, all struts appear as preserved 
box in both BVS devices. At follow-up, 620 struts and 1639 struts were analysed. The strut 
appearance of the BVS 1.0 showed substantial changes in appearance: at 6 months struts 
had changed from 100% preserved black box to 29.7% open box, 51.4% dissolved bright 
figure 5. Serial changes in angiographic late lumen loss, BVS area (late shrinkage) and minimal lumen area as 
assessed by optical coherence tomography.
OCT in the first and second generation BVS    |   129
PART
II
ta
b
le
 2
. Q
ua
nt
ita
tiv
e 
co
ro
na
ry
 a
ng
io
gr
ap
hy
 fi
nd
in
gs
 a
t b
as
el
in
e 
an
d 
6-
m
on
th
 fo
llo
w
-u
p.
B
V
S
Pr
e-
d
ep
lo
ym
en
t
Po
st
-d
ep
lo
ym
en
t
6-
m
on
th
 F
u
D
iff
er
en
ce
 p
os
t
–p
re
 (C
I 9
5%
)
P-
va
lu
e*
D
iff
er
en
ce
p
os
t –
 6
 m
Fu
 (C
I 9
5%
)
P-
va
lu
e*
*
P-
va
lu
e†
Q
C
A
  L
es
io
n 
le
ng
th
 (m
m
)a
BV
S 
1.
0
9.
86
 (3
.4
6)
10
.3
4 
(1
.7
0)
10
.1
7 
(2
.2
0)
-0
.4
8 
(-2
.9
0 
to
 1
.9
4)
0.
18
0.
18
 (-
0.
26
 to
 0
.6
1)
0.
64
0.
93
BV
S 
1.
1
8.
99
 (2
.8
9)
17
.0
8 
(1
.1
2)
16
.0
8 
(1
.4
8)
-8
.0
9 
(-9
.8
2 
to
 -6
.3
5)
<
0.
01
1.
00
 (-
0.
16
 to
 2
.1
6)
0.
13
RV
D
 (m
m
)
BV
S 
1.
0
2.
95
 (0
.3
8)
3.
03
 (0
.3
9)
2.
87
 (0
.4
1)
0.
08
 (-
0.
10
 to
 0
.2
6)
0.
31
0.
16
 (0
.0
1 
to
 0
.3
1)
0.
04
0.
24
BV
S 
1.
1
2.
69
 (0
.3
5)
2.
64
 (0
.2
3)
2.
53
 (0
.2
2)
-0
.0
5 
(-0
.2
1 
to
 0
.1
1)
0.
70
0.
11
 (0
.0
2 
to
 0
.2
0)
0.
03
M
LD
 (m
m
)
BV
S 
1.
0
1.
13
 (0
.3
0)
2.
46
 (0
.3
8)
2.
03
 (0
.3
0)
1.
32
 (1
.0
3 
to
 1
.6
2)
<
0.
01
0.
43
 (0
.1
3 
to
 0
.7
3)
0.
01
0.
07
BV
S 
1.
1
1.
23
 (0
.4
4)
2.
26
 (0
.2
8)
2.
18
 (0
.2
5)
1.
03
 (0
.6
9 
to
 1
.3
7)
<
0.
01
0.
08
 (-
0.
14
 to
 0
.3
0)
0.
24
D
S 
(%
)
BV
S 
1.
0
60
.8
 (1
3.
4)
18
.6
 (9
.4
)
27
.8
 (1
6.
0)
-4
2.
3 
(-5
0.
8 
to
 -3
3.
7)
<
0.
01
-9
.3
 (-
18
.7
 to
 0
.2
)
0.
07
0.
24
BV
S 
1.
1
57
.6
 (1
3.
1)
14
.7
 (7
.5
)
15
.7
 (9
.3
)
-4
2.
9 
(-5
0.
9 
to
 -3
5.
0)
<
0.
01
-1
.0
 (-
5.
5 
to
 3
.5
)
0.
66
D
at
a 
ar
e 
ex
pr
es
se
d 
as
 m
ea
n 
(S
D
).
Q
C
A
, q
ua
nt
ita
tiv
e 
co
ro
na
ry
 a
ng
io
gr
ap
hy
; B
VS
, b
io
re
so
rb
ab
le
 v
as
cu
la
r 
sc
aff
ol
d;
 F
U
, f
ol
lo
w
-u
p;
 R
VD
, r
ef
er
en
ce
 v
es
se
l d
ia
m
et
er
; M
LD
, m
in
im
al
 lu
m
en
 d
ia
m
et
er
; D
S,
 
di
am
et
er
st
en
os
is
.
aL
es
io
n 
le
ng
th
 a
t p
os
t-
pr
oc
ed
ur
e 
an
d 
at
 fo
llo
w
-u
p 
ha
s 
be
en
 m
ea
su
re
d 
be
tw
ee
n 
th
e 
pl
at
in
um
 m
ar
ke
rs
 o
f t
he
 B
VS
.
*P
ai
re
d 
co
m
pa
ris
on
 b
et
w
ee
n 
pr
e-
 a
nd
 p
os
t-
de
pl
oy
m
en
t w
ith
in
 e
ac
h 
gr
ou
p.
**
Pa
ire
d 
co
m
pa
ris
on
 b
et
w
ee
n 
po
st
-d
ep
lo
ym
en
t a
nd
 fo
llo
w
-u
p 
w
ith
in
 e
ac
h 
gr
ou
p.
†C
om
pa
ris
on
 o
f t
he
 d
iff
er
en
ce
 p
os
t-
de
pl
oy
m
en
t—
fo
llo
w
-u
p 
be
tw
ee
n 
th
e 
tw
o 
gr
ou
ps
. C
om
pa
ris
on
 b
et
w
ee
n 
gr
ou
ps
 a
t p
re
-d
ep
lo
ym
en
t a
nd
 p
os
t-
de
pl
oy
m
en
t w
er
e
no
n-
si
gn
ifi
ca
nt
 (P
 =
 0
.1
0)
.
130   |    Chapter 5
BVS (n 5 12 vs. 12) Baseline
(post-
deployment)
6-month
Fu
Absolute difference
between BL and Fu
(CI 95%)
Relative difference 
between BL 
and Fu (%)
P-value* P-value**
OCT
Mean luminal area (mm2)
1.0 BVS 7.63 (0.79) 4.94 (1.10) 2.69 (1.99–3.39) 35.07 (13.31) <0.01 <0.01
1.1 BVS 7.67 (0.94) 6.44 (0.93) 1.23 (0.89–1.57) 16.09 (6.48) 0.01
Minimal luminal area (mm2)
1.0 BVS 5.99 (0.57) 3.19 (1.28) 2.81 (2.03–3.59) 46.97 (19.67) <0.01 <0.01
1.1 BVS 6.32 (0.96) 5.01 (0.97) 1.32 (0.83–1.80) 20.65 (10.94) <0.01
Mean BVS area (mm2)
1.0 BVS 7.18 (0.73) 6.20 (0.64) 0.98 (0.42–1.54) 12.95 (11.70) 0.01 0.01
1.1 BVS 7.21 (0.82) 7.14 (0.84) 0.07 (-0.10 to 0.24) 0.97 (3.73) 0.37
Minimal BVS area (mm2)
1.0 BVS 5.82 (0.60) 4.75 (0.83) 1.07 (0.49 – 1.66) 17.90 (14.26) <0.01 0.01
1.1 BVS 6.21 (0.98) 6.00 (0.85) 0.21 (-0.14 to 0.56) 2.81 (8.11) 0.29
ISA area (mm2)
1.0 BVS 0.14 (0.25) 0.22 (0.31) -0.10 (-0.21 to 0.02) -36.36 (10.33) 0.04 0.88
1.1 BVS 0.15 (0.30) 0.17 (0.18) -0.02 (-0.22 to 0.18) -11.76 (15.35) 0.26
NIA (mm2)
1.0 BVS NA 1.44 (0.32) NA NA NA <0.01a
1.1 BVS NA 0.87 (0.22) NA NA NA
NIT (mm)
1.0 BVS NA 0.17 (0.04) NA NA NA <0.01 a
1.1 BVS NA 0.08 (0.02) NA NA NA
In-device area obstruction  (%)
1.0 BVS NA 23.62 (6.55) NA NA NA <0.01 a
1.1 BVS NA 12.28 (3.38) NA NA NA
IVuS
Mean luminal area (mm2)
1.0 BVS 6.84 (0.74) 5.94 (0.67) 0.90 (0.43–1.37) 12.71 (9.89) <0.01 0.17
1.1 BVS 6.69 (0.81) 6.20 (0.76) 0.47 (0.24–0.69) 6.93 (4.68) <0.01
Minimal luminal area (mm2)
1.0 BVS 5.75 (0.52) 4.41 (0.70) 1.34 (0.83–1.84) 22.83 (12.73) <0.01 <0.01
1.1 BVS 5.51 (0.78) 5.15 (0.73) 0.28 (-0.01 to 0.57) 4.81 (7.20) 0.09
Data are expressed as mean (SD).
QCA, quantitative coronary angiography; BVS, bioresorbable vascular scaffold; FU, follow-up; RVD, reference vessel 
diameter; MLD, minimal lumen diameter; DS, diameter stenosis.
aLesion length at post-procedure and at follow-up has been measured between the platinum markers of the BVS.
*Paired comparison between pre- and post-deployment within each group.
**Paired comparison between post-deployment and follow-up within each group.
†Comparison of the difference post-deployment follow-up between the two groups. Comparison between groups 
at pre-deployment and post-deployment were non-significant (P> 0.10).
table 3. Quantitative optical coherence tomography and intravascular ultrasound findings at baseline and 6-month 
follow-up.
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box, 16.0% dissolved black box, and only 2.9% were preserved black box. For the BVS 1.1, 
all struts maintained a preserved black box appearance at 6 months (P < 0.01). Uncovered 
struts were less frequent in the BVS 1.0 (1.1%) than in the BVS 1.1 (5.3%) (P = 0.01).
Intravascular-ultrasound results
IVUS results are shown in Table 3. The reduction in mean lumen area was larger with the 
BVS 1.0 than with the BVS 1.1 (12.71 vs. 6.93%), but this difference was not statistically 
significant (P = 0.17). The reduction in minimal lumen area was significantly larger with 
the BVS 1.0 than with the BVS 1.1 (22.83 vs. 4.81%; P<0.01).
Reproducibility of optical coherence tomography measurements
The scaffold area reproducibility using our method has been assessed specifically  for our 
study. Two independent analysts measured the scaffold area in 100 images at follow-up. 
After 1 week, one of the analysts re-analysed the same frames. The inter- observer R2 for 
repeated measures was 0.88 and the intraobserver R2 was 0.98.
D I S C u S S I O N
The main findings of our study are: (i) the BVS 1.1 does not show late shrinkage at 6 months 
with respect to the baseline scaffold area; (ii) the BVS 1.0 has higher neointimal response 
and higher in-scaffold area obstruction than the BVS 1.1; (iii) these changes resulted in a 
higher OCT and IVUS luminal losses and angiographic late loss in the BVS 1.0 than in the 
BVS 1.1; (iv) the overall strut appearance at 6-month follow-up is dramatically different 
between the two generations of BVS, which may reflect differences in the polymer’s 
interaction with light, arising from differences in microstructure and its degradation. A 
pre-clinical animal study involving histological samples at differing time points divided 
the evolution process of the BVS into two parts:12 first, the BVS resorption process, which 
consists of the disappearance of the polymeric PLA and the subsequent filling of the strut 
voids with proteoglycan material; second, the BVS integration process, which consists 
of the formation of organized tissue with connective cells and connective extracellular 
matrices replacing the polymeric and the proteoglycan material. In the same study, the 
strut appearance as assessed by OCT was compared with matched histological sections.12 
At 24 months, all the struts were discernible by OCT and 80.4% of them were classified as 
having the preserved box appearance (similar to the BVS 1.1 at 6 months). At that point 
of time, matched histological samples showed that almost all the strut footprints were 
occupied by proteoglycans and the analysis with gel permeation chromatography did 
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not find traces of the polymeric material. This demonstrated that the polymer was already 
resorbed at that time, and therefore OCT imaging was not able to assess the resorption 
process. At 3- and 4-year follow-up, almost all the struts were not discernible and the few 
observed struts were classified as a dissolved bright or dissolved black box (similar to the 
BVS 1.0 at 6 months). There was poor correlation of these types of OCT strut appearance 
with the particular patterns observed on histology. But, the indiscernible struts and the 
dissolved black box appearance as assessed by OCT were observed as circumscribed 
regions of dense connective tissue with low cellularity on histology.
Therefore, as assessed by OCT, the most advanced resorption/ integration states were 
characterized as: (i) observation of other types of strut appearance rather than the 
preserved box; and (ii) the reduction of discernible struts over time jointly with the 
observation of a dissolved black box strut appearance.12
In our study, the number of discernible struts of the BVS 1.1 was slightly lower at baseline 
than at follow-up (1575 vs. 1639, respectively; P = 0.06). At 6 months, the strut appearance 
was ‘preserved’ in all the patients. In contrast, the number of discernible struts of the 
BVS 1.0 was higher at baseline than at follow-up (662 vs. 620, respectively; P = 0.05) 
and at 6 months, only 2.9% of the discernible struts had a preserved box appearance. 
The correlation of our findings with the animal study shows that the BVS 1.0 had a more 
advanced resorption/integration state than the BVS 1.1 at 6 months. Our hypothesis is 
that this faster resorption/integration state is the main cause of the higher late shrinkage 
and greater neointimal response of the BVS 1.0 compared with the BVS 1.1.
Late shrinkage is a phenomenon resulting from the loss of structural integrity of the 
polymeric scaffold in conjunction with fatigue and constrictive remodelling of the vessel 
in the first months following the vessel injury. Loss of structural integrity is an inevitable 
part of the resorption process of these polymeric devices. The poly-L-lactic acid (PLLA) 
polymer has a lifecycle which can be divided in five phases.14 First, immediately after the 
deployment, the polymer absorbs water from blood and surrounding tissues. Second, 
the long chains of PLLA degrade by hydrolysis into smaller chains without affecting the 
device’s structure. Third, the hydrolysis process continues and causes a loss in integrity, 
with fragmentation of the struts and loss of radial strength. Fourth, soluble monomeric 
anions dissolve into the intercellular fluid and microparticles of less than 2 mm may be 
phagocyted by the macrophages; manifesting in mass loss and bioresorption. Finally, the 
soluble L-lactate is converted into pyruvate, which enters the Krebs cycle, being eventually 
converted into carbon dioxide and water. The initial degradation process of the PLLA semi-
crystalline polymer depends on the length of the polymers chain (molecular weight), 
the hydrophilicity, and the degree of crystallinitiy. In BVS 1.1, initial degradation rate (i.e. 
losses in molecular weight leading to structural degradation) has been reduced through 
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changes in the manufacturing process. This slower degradation allows for maintenance of 
the radial strength over months following the implantation.
The second cause of late shrinkage is the constrictive remodel- ling of the treated vessel 
in the first few months after implantation. In the era of balloon angioplasty, more than 
70% of the restenotic process was attributed to negative remodelling of the vessel in the 
treated segment, and less than 30% was done to neointimal growth.15 In the metallic stent 
era, late lumen loss within the stent correlated strongly with tissue growth (r = 0.975), 
eliminating negative remodelling as the common cause of restenosis.16,17
Thus, the key question for intracoronary bioresorbable scaffolds is for how long radial 
strength (i.e. scaffolding) must be maintained to avoid constrictive remodelling. In a 
cohort of patients consecutively re-catheterizated at 1, 2, 3, and 4 months, Serruys et al.18 
demonstrated that the restenotic process after balloon angioplasty ceases to progress 
after 4 months. It is possible that after this time, scaffolding is no longer needed, and 
the structural degradation and bioresorption processes can commence. It is uncertain 
whether the constrictive remodelling is more focused in the regions of the vessel with 
more plaque burden or is equally distributed. This can affect the results of our study due 
to the differences in the BVS lengths according to the lesion length. The lesion length prior 
to the implantation was similar in both groups (around 9 – 10 mm), but the device length 
as assessed by QCA at post-deployment was significantly higher in the BVS 1.1 than in 
the BVS 1.0 (17.08 vs. 10.34 mm; P < 0.01). This difference resulted from the fact that all 
patients treated in the ABSORB Cohort B study received a single size device (3 × 18 mm), 
while in the ABSORB Cohort A there were two different sizes (3 × 12 and 3 × 18 mm). A 
sub-analysis of the 12 central millimeter of the scaffold imaged by OCT (that part of the 
scaffold is more likely to be located at the nadir of the narrowing) in the patients treated 
with a 3 × 18 mm showed that the mean scaffold area at baseline and at 6-month follow-
up was 7.18 and 6.19 mm2 with the BVS 1.0 (relative shrinkage of 13.09%) and 7.14 and 
7.10 mm2 with the BVS 1.1 (relative shrinkage of 0.50%); P = 0.01.
Until now, four different fully bioresorbable scaffolds have been tested in humans. The 
polymeric PLLA non-drug-eluting Igaki-Tamai device was the first fully bioresorbable 
scaffold used in humans. The IVUS analysis did not show bioresorption of the polymeric 
struts at 6 months and this absence of ultrasonic changes in struts was parallel to the 
absence of scaffold shrinkage. This device presented a target vessel revascularization of 
6.7% at 6 months and a low rate of major cardiac events at 10 years.19,20
Conversely, the PROGRESS-AMS magnesium platform non-drug-eluting bioresorbable 
scaffold had a rapid resorption which was complete at 4-month follow-up. This swift 
resorption produced an important reduction of the lumen (60% of the late lumen loss) 
and a high incidence of restenosis (47.5% assessed by QCA).21 The REVA device is a poly 
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(iodinated desaminotyrosyltyrosine ethyl ester) carbonate non-drug-eluting scaffold. The 
closed design and the lifecycle of the carbonate provide enough radial strength during the 
first 3 months following the implantation without appreciable shrinkage. However, focal 
mechanical failures driven by polymer embrittlement led to a high rate of TLR (66.7%) 
between 4- and 6-month follow-up.22 Finally, the IDEALTM Poly (Anhydride Ester) Salicylic 
acid sirolimus-eluting device has been tested in only 11 patients.23
The shrinkage phenomenon observed in the BVS 1.0 was linked to a significant increase 
of the ISA area with respect to baseline and with higher neointimal response with respect 
to the BVS 1.1. The increasing of the ISA area with the BVS 1.0 can be explained by the 
scaffold shrinkage itself. At baseline, 95% of the struts were apposed or aligned, while in 
the follow-up only 93% of the struts were apposed to the vessel wall. Moreover, less than 
10% of the malapposed struts at baseline were resolved at follow-up.1 The NIA measured 
in this population was significantly different between the two generations of BVS (1.44 
mm2 for the BVS 1.0 vs. 0.87 mm2 for the BVS 1.1). In-scaffold area obstruction was also 
different between BVS 1.0 and 1.1 (23.6 vs. 12.3%, respectively). The significantly lower 
neointimal response of the BVS 1.1 with respect to the BVS 1.0 has no clear explanation. 
Both generations of BVS are built with the same polymer mass, strut thickness, drug, and 
coating elution and the same amount of drug. One hypothesis is that the loss in scaffold 
area leads to a decreased efficiency in drug transfer to the vessel wall and thus, a reduction 
in antiproliferative efficacy. Another hypothesis is that the more accelerated resorption/
integration process of the BVS 1.0 com- pared with the BVS 1.1 could generate a larger 
neointimal response. Unfortunately, this cannot be assessed by OCT due to the lack of 
correlation between the different types of strut appear- ance and the histological findings 
based on animal studies.12 An exploratory analysis of the patients treated with the BVS 
1.0 in our study relating the NIT measured above the preserved box appearance (0.15 ± 
0.04 mm) with the NIT measured above the other types of strut appearance (0.18 ± 0.06) 
failed to be significant (P = 0.27). The same patients treated with the BVS 1.0 studied with 
OCT at 2 years showed few discernible struts with no measurable neointima. Nevertheless, 
the mean lumen area increased up to 19% from 6-month to 2-year follow-up.4 This fact 
may be a sign of vessel remodelling at the neointimal level but the low number of patients 
are a clear limitation to this conclusion. This hypothesis will be examined further when 
the strut appearance of patients treated with the BVS 1.1 changes in future scheduled 
imaging controls.
The OCT performance of the BVS 1.1 can be compared with some drug-eluting stents 
(DES). The NIT observed in the BVS 1.1 (0.08 mm) is similar to that seen with the sirolimus-
DES (from 0.05 to 0.12 mm) at 6-month follow-up.24,25 Paclitaxel-DES and zotarolimus-DES 
showed an NIT of 0.20 and 0.33 mm, respectively.24 The late shrinkage of metallic DES 
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has not been yet explored with OCT. Using IVUS, the everolimus-DES showed a relative 
difference in mean stent area of 0.3% at 6-month follow-up.26 This value is similar to the 
1.0% found in our study with the BVS 1.1. Based on this information, the BVS 1.1 presents 
a similar profile as the metallic DES as assessed by OCT.
In summary, our study represents the first comparison of two generations of bioresorbable 
devices in terms of late shrinkage, neointimal response, and bioresorption state using the 
most sophisticated intravascular imaging technique (OCT) and the same methodology for 
both devices. The OCT findings at 6 months show the improvement of the new generation 
of BVS with respect to the previous generation. The slower bioresorption process of 
the BVS 1.1, compared with the BVS 1.0, is the most plausible explanation for the near 
elimination of the late shrinkage and for the higher inhibition of the neointimal response. 
Further investigations will be required to assess the preservation of these results after 
6-month follow-up for the BVS 1.1. A more advanced bioresorption state can contribute 
to a very late shrinkage of the device or later neointimal responses studied with OCT at 
2 years showed few discernible struts with no measurable neointima. Nevertheless, the 
mean lumen area increased up to 19% from 6-month to 2-year follow-up.4 This fact may 
be a sign of vessel remodelling at the neointimal level but the low number of patients 
are a clear limitation to this conclusion. This hypothesis will be examined further when 
the strut appearance of patients treated with the BVS 1.1 changes in future scheduled 
imaging controls.
Limitations
The result of the present analysis must be interpreted with caution as a major limitation 
of our study is the small number of patients who have been enrolled in a non-randomized 
comparison. Figure 5 shows that there is a homogeneous trend of higher late shrinkage 
and higher loss in minimal lumen area in the BVS 1.0 than in the BVS 1.1. The histogram 
distribution of the NIA in the two populations also shows this trend of higher neointimal 
growth in the BVS 1.0 than in the BVS 1.1 (data not shown). This trend, however, is not 
observed with the angiographic late lumen loss in which one outlier can be influencing 
the higher late lumen loss in the BVS 1.0. Moreover, two eligible patients imaged at 
baseline and scheduled for an invasive follow-up at 6 months did not undergo repeat 
invasive imaging. It is uncertain how this lack of serial imaging in those patients affects 
the global results of our study. Although the small number of patients, we have used the 
maximal number of ‘historical’ cases performed with the BVS 1.0 and imaged with the best 
available OCT system M2 at that time and compared with the same number of patients of 
the BVS 1.1 imaged with the best available system nowadays (OCT C7 system).
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These differences in OCT systems are inherent to the fact that the ABSORB Cohort A 
trial was conducted in 2006, when a balloon occlusive technique was needed due to 
the lower frame/ rate and acquisition speed of the available systems at that time. One 
in vitro study showed less accuracy in the lumen area measurement with lower frame 
rate and acquisition speed than with higher frame/rate and speed.27 An in vivo study, 
comparing the non- occlusive and the occlusive technique in the same non-scaffolded 
native coronary artery, showed systematically smaller mean and minimal lumen areas 
with the occlusive technique than with the non-occlusive technique (relative differences 
of 13.2 and 28.2%, respectively).28 These differences were probably produced by the lack 
of physiological pressurization of the vessel during the occlusive technique imaging and/
or the over-pressurization of the vessel during the contrast infusion of the non-occlusive 
tech- nique.28 These differences represent an important limitation of our study because the 
two different devices were imaged with different OCT techniques (occlusive for the BVS 
1.0 and non- occlusive for the BVS 1.1). However, in our study, the baseline and follow-up 
acquisition were performed using the same imaging technique in each cohort of patients 
and also, the analysed region is scaffolded by the BVS. The scaffolded region is probably 
less susceptible to changes in volumetric parameters according to the intravascular 
pressure. Unfortunately, there is no current information comparing the changes in 
lumen areas within the scaffolded regions with the two different OCT techniques. The 
method of analysis used in our study is slightly different from the current method of OCT 
measurement of polymeric scaffold. The strut appearance of the BVS 1.0 at 6 months (and 
probably the appearance of the BVS 1.1 in later controls) does not permit the delineation 
of the strut contour at the front or backside of the strut. Using the central part of the 
strut as landmark for measurement is the most reliable method to assess the scaffold area. 
However, it must be recognized that the neointima area as such determined is an arbitrary 
entity resulting from the difference between the luminal area and the scaffold area, and 
does not depict accurately the neointimal tissue that has grown between, on the top and 
behind the struts either biologically altered in the case of the BVS 1.0 or almost intact in 
the case of the BVS 1.1. Finally, the differences in device lengths in the two groups may be 
favourable to the BVS 1.1 due to a better anchoring in the healthy part of the vessel that 
can be subjected to a less constrictive modelling of the vessel.
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CO N C Lu S I O N
The two generations of the everolimus-eluting bioresorbable vascular scaffold have 
different OCT findings at 6-month follow-up. The BVS 1.1 has less late shrinkage and 
less neointimal growth at 6-month follow-up compared with the BVS 1.0. Consequently, 
less angiographic late loss and less OCT and IVUS luminal losses were observed with the 
BVS 1.1. A difference in polymer degradation leading to changes in microstructure and 
reflectivity is the most plausible explanation for this finding.
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A B S T R AC T
Aims To compare the intravascular ultrasound virtual histology (IVUS-VH) 
appearance of the polymeric struts of the first (Revision 1.0) and the second 
(Revision 1.1) generation bioresorbable vascular scaffold (BVS).
Methods and results IVUS-VH misrepresents polymeric struts as dense calcium (DC) 
and necrotic core (NC) so that their presence and disappearance could be used as 
potential artifactual surrogate of bioresorption. DC and NC were assessed in both 
revisions of the BVS by analysing IVUS-VH from all patients in the ABSORB cohort A 
(Revision 1.0) and cohort B (Revision 1.1) study who had an IVUS-VH post-treatment 
and at 6-month follow-up. Post-treatment and 6-month follow-up IVUS-VH results, 
available in 60 patients (BVS 1.0 n=28; BVS 1.1 n=32), indicated an insignificant 
rise in DC+NC area compared to baseline with Revision 1.1 (0.10±0.46mm2, p=0.2), 
whilst a significant reduction was seen with Revision 1.0 (–0.57±1.3 mm2, p=0.02). 
A significant correlation has been found between the change in the DC+NC area 
and the change in external elastic membrane area (y=0.68×–0.1; r=0.58, p=0.03).
Conclusions Based on 6-months IVUS-VH analysis, the BVS 1.1 appears to have 
a different backscattering signal compared to the BVS 1.0, which may reflect 
differences in the speed of chemical and structural alteration.
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I N T R O D u C T I O N
The bioresorption process of new bioresorbable vascular scaffolds (BVS) is crucial in 
the determination of their performance at medium and long-term. A BVS should have 
enough radial strength to counteract acute vessel recoil following angioplasty and should 
also be able to maintain its mechanical integrity until late recoil forces subside. The fully 
resorbable BVS (Abbott Vascular, Santa Clara, CA, USA) has been tested in 30-patient in the 
first-in-man ABSORB cohort A study and demonstrated excellent long-term clinical results 
up to two years with a major adverse cardiac event rate of 3.6%.1 However, due to faster 
degradation, the first generation BVS showed higher late recoil than conventional metallic 
platform stents.1-3 To prolong the mechanical strength of the scaffold and reduce late recoil, 
a second generation BVS –Revision 1.1– has recently been introduced, and this is currently 
undergoing clinical evaluation in the ABSORB cohort B study.4 Compared to the Revision 
1.0 which was used in the ABSORB cohort A study, the Revision 1.1 has a smaller maximum 
circular unsupported surface area,5 a more uniform strut distribution and improved 
stent retention. Importantly, these changes have not resulted in an increased amount 
of polymeric material or an increase in strut thickness. Proprietary process changes have 
been implemented to increase radial strength. In addition, these changes have reduced 
polymer degradation rates at early time points and thus prolonged mechanical integrity 
of the scaffold throughout the first few months following implantation. Intravascular 
ultrasound virtual histology (IVUS-VH), a tool developed to assess tissue composition of 
intact native coronary arteries, misclassifies polymeric stent struts as “dense calcium” and 
“necrotic core” (white and red in the VH colour code).6 This could potentially be used as 
surrogate marker of alteration of the polymeric struts and to assess in vivo the degradation 
process of a BVS.7,8 Shin’s method, for IVUS-VH analysis, allows a more accurate detection 
of dense calcium and necrotic core so that the bioresorption process can be better 
explored.9 The aim of this study was; 1) to evaluate temporal changes in the IVUS-VH signal 
of the BVS 1.1 and BVS 1.0; 2) to assess the correlation between the changes in IVUS-VH 
signal for BVS 1.1 and 1.0, and the change in external elastic membrane (EEM) area.
M E T h O D S
Study design
All patients from cohort A and cohort B of the ABSORB trial with paired post-BVS 
implantation and 6-month follow-up IVUS-VH data were included. The ABSORB cohort A 
study is described elsewhere.1 In brief, for cohort A and cohort B, patients were suitable 
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for inclusion if they were older than 18 years, with adiagnosis of stable, unstable or silent 
ischaemia. All treated lesions were de	 novo lesions in a native coronary artery with a 
reference vessel diameter of 3.0 mm, with a percent diameter stenosis ≥50% and <100% 
and a thrombolysis in myocardial infarction (TIMI) flow grade of ≥1. The BVS 1.0 was used 
in patients in cohort A, whilst Revision 1.1 was used in cohort B.4 Major exclusion criteria 
were: patients presenting with an acute myocardial infarction, unstable arrhythmias or 
patients who had left ventricular ejection fraction ≤30%, restenotic lesions, lesions located 
in the left main coronary artery, lesions involving a side branch >2 mm in diameter, and 
the presence of thrombus or another clinically significant stenosis in the target vessel. 
Both ABSORB trials were approved by ethics committee at each participating institution 
and each patient gave written informed consent before inclusion.
Study device
The BVS has an amorphous poly-DL-lactide (PDLLA) coating that contains and controls 
the release of the anti-proliferative drug everolimus. The scaffold body is made of 
semi-crystalline poly-L-lactide (PLLA). PLA is completely degraded via hydrolysis and 
bioresorbed via the lactate shuttle. There are no differences in polymeric material, drug 
dose, drug release or strut thickness between BVS Revisions 1.0 and 1.1. Of note, the 
BVS Revision 1.1 has a smaller maximum circular unsupported surface area compared to 
Revision 1.0.5 Processing changes in Revision 1.1 have resulted in higher and prolonged 
mechanical strength and stability post implantation. (Figure 1) the lactate shuttle. 
BVS implantation procedure
In both cohorts, lesions were treated with routine interventional techniques that included 
mandatory pre-dilatation using a balloon shorter than the study device and 0.5 mm less in 
diameter. All patients were pre-treated with aspirin and a loading dose of at least 300 mg 
of clopidogrel was administered according to local hospital practise. After the procedure, 
all patients received aspirin ≥75 mg for the study duration (five years) and clopidogrel 75 
mg daily for a minimum of six months. Anticoagulation and glycoprotein IIb/IIIa use was 
according to local hospital practice.
Imaging procedure and acquisition
IVUS-VH post-BVS implantation and at 6-month follow-up were obtained from patients 
from both cohorts. Imaging techniques were acquired simultaneously with a phased 
array 20MHz intravascular ultrasound catheter (EagleEye™; Volcano Corporation, Rancho 
Cordova, CA, USA) using an automated pullback of 0.5 mm per second. Four tissue 
components (necrotic core – red; dense calcium – white; fibrous – green; and fibrofatty – 
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light green) were identified with autoregressive classification systems.10,11 Each individual 
tissue component was quantified and colour coded in all IVUS cross sections as previously 
described.10 All IVUS-VH analyses were performed offline using pcVH 2.1 (Volcano 
Corporation, Rancho Cordova, CA, USA). We carefully matched the region received BVS 
implantation using anatomical markers to compare the post implantation and 6-month 
follow-up IVUS-VH images. Regions received non-BVS stent implantation were not 
analysed. For each cross section, polymeric struts were detected as areas of apparent 
“dense calcium” and “necrotic core”. The quantitative changes in dense calcium (DC) and 
necrotic core (NC) content were used as a surrogate marker of alteration of the polymeric 
struts, as previously described.1,7,12,13 Only changes in DC and NC, which can be seen as 
the fingerprint of the BVS, were required, therefore the lumen contour was drawn around 
the IVUS catheter without following the leading edge of the interface lumen intima, as 
previously described by Shin et al.9 Using this approach, the BVS struts closest to the 
lumen were better detected and recognised as DC and NC by the VH software and the 
ones overlying small plaques (thinner side of an eccentric plaque) were not obscured 
by the imposed grey medial stripe seen with IVUS-VH. (Figure 2) We also recorded in all 
patients the interface between plaque+media and the adventitia (EEM area). Lumen area 
and plaque area cannot be recorded using this method. 
figure 1. Although the scaffold design is different between revision 1.0 and revision 1.1, the content of polymer 
is nearly the same. MCUSA: maximum circular unsupported surface area; BVS: bioresorbable vascular scaffold; PLA: 
polylactide
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Statistical analysis
Discrete variables are presented as counts and percentages. Continuous variables are 
presented as mean ± standard deviation (SD). The DC and NC values have been statistically 
tested separately post-procedure and 6-month follow-up. The VH fingerprint of the BVS in 
the artery was defined as the sum of the changes in DC and NC, as IVUS-VH detects stent 
struts as dense calcium surrounded by necrotic core halo.6  The calculation of the changes 
between post-treatment and six months was as follows: mean six month area minus mean 
post-procedure area for both NC and DC. Paired comparisons between post-procedure 
and 6-month follow-up were performed using the Wilcoxon signed rank test. Comparisons 
between groups were assessed using non parametric tests, whilst correlations between 
parameters were performed by using a Spearman test. A two-side p-value of less than 
0.05 indicated statistical significance. Statistical analyses were performed with use of SPSS 
13.0 software (SPSS Inc., Chicago IL, USA).
R E S u LT S
The comparison between post-procedure and 6-month follow-up IVUS-VH included 28 
patients from cohort A and 32 patients from cohort B. (Figure 3). Table 1 shows clinical 
and angiographic data in both cohorts. Compositional changes from post-treatment to 
six month follow-up by IVUS-VH (Table 2). In cohort A, there was a relative 20% decrease 
in both DC and NC (p=0.08 and p=0.02) between post-procedure and 6-month follow-up. 
figure 2. The conventional method (A and B) does not show some necrotic core and dense calcium (two white 
arrow heads), hidden by the grey medial stripe (two white arrow heads), that are showed by the Shin’s method (C and 
D). DC: dense calcium, NC: necrotic core
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Conversely, over the same time period in cohort B, a small relative increase in DC and NC 
of 9% (p=0.2) and of 4% (p=0.1) respectively, was observed. (Figure 4) At 6-month follow-
up, while in cohort A there was regression in the calcified pattern in 16 out of 27 patients 
(59%) and in the necrotic pattern in 20 out of 27 patients (74%), in cohort B there was 
regression in the calcified pattern in 11 out of 26 patients (42%) and in necrotic pattern 
table 1. Baseline demographics, risk factors and lesion characteristics. 
Cohort A 
(N=28)
(Lesions=28)
Cohort B
(N=32)
(Lesions=32)
P-Value
Age (years)
Mean±SD 62.03±9.00 62.83±10.01 0.671
Men,% (n) 57.1% (16) 65.6% (21) 0.432
Smokers, % (n) 21.4% (6) 12.5% (4) 0.492
Diabetes, % (n) 3.6% (1) 15.6% (5) 0.192
Hypertension requiring medication, % (n) 57.1% (16) 59.3% (19) 0.792
Hyperlipidaemia requiring medication, % (n) 63.0% (17) 87.5% (28) 0.022
Previous target vessel intervention, % (n) 3.6% (1) 6.2% (2) 1.002
Previous myocardial infarction, % (n) 3.5% (1) 37.5% (12) <0.012
Stable angina, % (n) 67.9% (19) 68.7% (22) 1.002
Unstable angina, % (n) 28.6% (8) 15.6% (5) 0.342
Silent ischaemia, % (n) 3.6% (1) 0.0% (0) 0.472
Target vessel, % (n)
Left anterior descending 50.0% (14) 37.5% (12) 0.302
Left circumflex 28.6% (8) 25.0% (8) 1.002
Right coronary artery 21.4% (6) 37.5% (12) 0.172
AHA/ACC lesion classification, % (n)
A 0.0% (0) 3.1% (1) 1.002
B1 64.3% (18) 43.8% (14) 0.192
B2 35.7% (10) 50.0% (16) 0.432
C 0.0% (0) 3.1% (1) 1.002
Mean reference vessel diameter (mm), Mean±SD (n) 2.70±0.47 (28) 2.60±0.45 (32) 0.391
Minimum luminal diameter (mm), Mean±SD (n) 1.08±0.25 (28) 1.08±0.31 (32) 0.771
Diameter stenosis (%), Mean±SD (n) 59.13±11.28 (28)) 57.81±12.60 (32 0.871
Lesion length (mm), Mean±SD (n) 8.79±3.67 (28) 10.08±3.50 (32) 0.091
1. from Wilcoxon’s rank sum test; 2. from Fisher’s exact test; AHA/ACC: American Heart Association/American College 
of Cardiology; SD: standard deviation
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in seven out of 26 patients (27%). Overall, the absolute DC+NC decrease was significantly 
larger in cohort A than cohort B, suggesting an earlier IVUS-VH alteration of the polymeric 
struts with the BVS 1.0 as compared to the BVS 1.1.
Grey-scale intravascular ultrasound data and correlation with IVuS-Vh 
alteration of BVS 1.0 and 1.1
On average, at six month follow-up, the EEM area did not significantly differ from post-
treatment status in both cohorts (Table 2). Classifying patients according to reduction in 
the EEM area at 6- month follow-up, we analysed changes in absolute area of DC and NC 
figure 3. Flow chart of paired IVUS-VH data available for both cohorts
figure 4. DC and NC area at six months compared to post-treatment in BVS 1.0 and BVS 1.1. Error bars portray 
standard error of the mean. DC: dense calcium; NC: necrotic core
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figure 5. In the A panels, an extreme example of bioresorption at 6-months correlated with EEM area reduction. 
In the B panels, the persistence of the stent at six months is not associated with EEM area reduction. With the Shin 
method, blood surrounding ultrasound catheter is detected as fibrous and fibrous-fatty tissues. The boundaries of 
the lumen area are not depicted or superimposed on the figures. EEM: external elastic membrane; DC: dense calcium; 
NC: necrotic core
figure 6. Bioresorption of the scaffold, measured by sum of absolute change in dense calcium and necrotic core area 
is significantly correlated with change of EEM area in cohort B (Panel B), but not in cohort A (Panel A). In the lower 
left quadrant of both panels, patients with bioresorption of BVS and reduction of EEM area are shown. EEM: external 
elastic membrane; DC: dense calcium, NC: necrotic core; BVS: bioresorbable vascular scaffold
core in both cohorts. In patients from cohort A, those with reduction of the EEM area at 
6-month (n=15) showed a significantly lower absolute area change of NC compared to 
other patients (n=13) (-0.69±0.73 mm2 vs. 0.05±0.68 mm2, p=0.017) (Figure 5). Reduction 
of DC was no different (-0.40±0.63 mm2 vs. –0.02±0.56 mm2, p=0.1). Overall no correlation 
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was found between changes in EEM area and the sum of absolute change in DC+NC area 
(Figure 6A).On the other hand, in patients from cohort B with a reduction in the EEM area 
(n=16), there was a significantly lower change in absolute area of DC and NC at follow-up 
compared to other patients (n=16) (respectively for DC –0.12±0.41 mm2 vs. 0.30±0.42 mm2, 
p=0.007; for NC –0.38±0.84 mm2 vs. 0.50±0.45 mm2, p<0.001). In the overall population, 
the change in DC+NC area correlated significantly with the change in EEM area. (R=0.58, 
p=0.003). (Figure 6B).
D I S C u S S I O N
The major findings of our study are: 1) the changes in design, degradation rate and 
mechanical durability of the BVS 1.1 compared to BVS 1.0 significantly influenced its IVUS-
VH changes over a period of six months (i.e., less reduction in DC and NC at six months); 
2) a relationship exists between change overtime in EEM area and in DC+NC area. Kim et 
al. have previously shown that metallic stents eluting sirolimus and paclitaxel introduce 
artifacts in IVUS-VH images, that interfere with the classification of plaque behind the 
struts.6 Normally struts of drugeluting stents appear as DC, surrounded by a red halo. 
Although the BVS is made of non-metallic materials, it was also recognised by IVUS-VH 
software as DC and NC. For this scaffold, the presence of “pseudo”DC and NC could be used 
as surrogate marker of alteration of the polymeric struts.1,7,8,12-14 Garcia-Garcia et al have 
already shown in a sub-study of ABSORB cohort A trial that polymeric struts are identified 
with radiofrequency backscattering as calcific structures. Using IVUS-VH, it has been shown 
that there was an important increase in DC and NC immediately after BVS implantation.7 
This sudden change in DC and NC has been attributed to the introduction of polymeric 
struts and might represent their VH fingerprint. Our data confirm that polymeric struts 
appear as DC and NC and that IVUS-VH is a potential approach to semi-quantify or state the 
presence of the polymer. The ability of IVUS-VH to recognise polymeric struts is important 
also to potentially follow the mechanical support or bioresorption process. Our study 
demonstrated that while for the BVS Revision 1.0 there is a reduction in DC and NC after 
six months,7 for the BVS Revision 1.1 the IVUS-VH signature appears to be unchanged over 
the same period. This stable backscattering signal with the BVS 1.1 suggests unchanging 
polymeric structure and/or stable mechanical properties due to slower degradation in	
vivo, as intended. The first revision of the BVS showed slightly higher acute recoil than 
conventional metallic platform stents2 and at six months an 11.7% reduction in scaffold 
area of the BVS 1.0 area was documented.3 Of note, the longer-lasting mechanical integrity 
of the BVS Revision 1.1, – as suggested by unaltered IVUS-VH signature over a period of 
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six months, may prevent this loss in structural integrity and reduction in scaffold area.1,15 
This observation of constancy in radiofrequency backscattering of BVS 1.1 is largely 
confirmed by the absence of qualitative alterations of the appearance of the polymeric 
struts of BVS 1.1 with optical coherence tomography (OCT).4 They uniformly keep their 
“preserved box” appearance, whereas with the BVS 1.0 only 3% of preserved box were 
present at six months follow-up.12 Our data also showed that the change in DC+NC area 
detected by IVUS-VH may be associated with shrinkage of the EEM area. For Revision 1.1, 
we found a significant correlation between the reduction of the EEM area at follow-up 
and changes in the sum of DC and NC. In particular, it seems to be a trend between the 
EEM shrinkage and the positive/negative value of sum of changes in DC and NC. In the 
case of Revision 1.0, the absence of any relationship between the change in IVUS-VH and 
the change in EEM area may be the result of a different phenomenon, or it may relate to a 
broader biological and/or sample variability; in particular looking at Figure 6, the two lines 
for both the cohorts seem similar and one is significant but not the other probably because 
of less variability. It is interesting to note that for both scaffolds the IVUS-VH changes (and 
potentially the bioresorption process) are not uniform in all patients. It depends not only 
on the hydrolysis of the scaffold, but probably also on the nature of the underlying plaque 
(composition and inflammatory state), and the further recruitment of macrophages to 
the site of the scaffold implantation. OCT of the presence of macrophages surrounding 
the scaffold, and the analysis of plaque composition behind the scaffold will enhance the 
understanding of the bioresorption process of the BVS. In conclusion, IVUS-VH is a clinical 
method that can detect differences in behaviour between BVS Revision 1.0 and 1.1. Their 
IVUS-VH fingerprints may be influenced by changes in mechanical design or in product 
processing. Stability in the IVUS-VH signal of the BVS 1.1 through to 6-months follow-up 
might suggest a more durable mechanical integrity than the BVS 1.0.
Limitations
We acknowledge that the classification tree of IVUS radiofrequency analysis has not been 
validated for polymeric struts. We did not collect data about change in fibrous tissue, 
because it is known that polymeric struts only appear as dense calcium and necrotic core 
on IVUS-VH. At the same time, using Shin’s method, we did not collect data on changes 
to the lumen area and plaque burden. Changes in DC and NC at follow-up are probably 
not only related to the BVS, but also to the natural history of the atherosclerotic disease.
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A B S T R AC T 
Aims Bioresorbable vascular scaffolds (BVS) present different mechanical properties 
as compared to metallic platform stents. Therefore, the standard procedural 
technique to achieve appropriate deployment may differ. 
Methods and results Fifty-two lesions treated with a 3x18 mm BVS were imaged 
with optical coherence tomography (OCT) post-implantation and screened 
for parameters suggesting non-optimal deployment. These included minimal 
scaffold area (minSA)<5 mm2, residual area stenosis (RAS)>20%, edge dissections, 
incomplete scaffold/strut apposition (ISA)>5% and scaffold pattern irregularities. 
The angiographic proximal and distal maxi mal lumen diameters (DMAX) were 
measured by quantitative coronary angiography. Based on the DMAX values, the 
population was divided into three groups: DMAX <2.5 mm (n=13), DMAX between 
2.5-3.3 mm (n=30) and DMAX >3.3 mm (n=9). All three groups presented with 
similar pre-implantation angiographic characteristics except for the vessel size 
and were treated with similar balloon/artery ratios. The group with a DMAX <2.5 
mm presented with a higher percentage of lesions with minSA <5 mm2 (30.8% vs. 
10.0% vs. 0%; p=0.08) and edge dissections (61.5% vs. 33.3% vs. 11.1%; p=0.05). 
Lesions with >5% of ISA were significantly higher in the group with DMAX >3.3 mm 
(7.7% vs. 36.7% vs. 66.7%; p=0.02). RAS >20% was similar between all groups (46.2 
vs. 53.3 vs. 77.8%; p=0.47) and scaffold pattern irregularities were only documented 
in three cases. 
Conclusions BVS implantation guided with quantitative angiography may 
improve the OCT findings of optimal deployment. The clinical significance of these 
angiographic and OCT findings warranted long term follow-up of larger cohort of 
patients.
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I N T R O D u C T I O N 
Everolimus-eluting bioresorbable vascular scaffolds (BVS) are a promising new generation 
of intravascular devices that may poten tially circumvent many of the drawbacks of 
permanently implanted metallic coronary stents1,2. The mechanical properties of the 
poly meric platforms undoubtedly differ from the features of metallic platform stents and 
should be taken into account during the proce dure for appropriate deployment of the 
BVS. 
Previous studies using intravascular ultrasound (IVUS)-guided percutaneous coronary 
intervention (PCI) reported that the presence of minimal scaffold area (minSA) <5 mm2, 
residual area stenosis >20%, edge dissec tions, incomplete scaffold/strut apposition (ISA) 
and scaffold pat tern disruptions have an impact on the short and long-term outcomes3-8. 
Optical coherence tomography (OCT) is a high resolu tion imaging technique that allows 
more accurate assessment of these parameters as compared to IVUS9, although the 
prognostic value of these refined observations measured or documented by OCT are so 
far unknown. 
The ABSORB cohort B study used a single size BVS (3x18 mm). The study protocol did not 
allow the inclusion of patients with an interpolated reference diameter (RVD) <2.5 mm or 
>3.3 mm, although it was not mandatory to perform quantitative coronary angiography 
(QCA) prior to the implantation. 
The interpolated-RVD, as indicated by its name, is the virtual reference diameter 
measured at the site of the minimal lumen diameter (MLD) prior to the implantation. 
The interpolated-RVD can differ from any refer ence diameter arbitrary selected and 
measured in the segment located either proximal or distal to the MLD10. Amongst the 
multi ple values of reference diameters measured in the proximal or distal segments to the 
MLD, the DMAX values (proximal or distal) rep resented the two single largest values of 
reference diameters observed in the segments proximal or distal to the lesions (Figure 1). 
The aim of this study is to describe the angiographic DMAX prior to BVS implantation 
and to relate these angiographic meas urements to the OCT criteria of appropriate BVS 
deployment. In addition, we report the inappropriate adverse events at medium term 
follow-up of 180 days potentially associated with the non-respect of the angiographic 
exclusion criteria and the consequent impact on scaffold deployment as documented by 
OCT.
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figure 1. Assessment of the DMAX and interpolated-RVD values. Panel A shows a lesion in the mid right coronary 
artery at pre- treatment. The length of the region “to be scaffolded” is super- imposed on the pre-treatment angiogram 
(Panels B and C) with the corresponding diameter function obtained with quantitative coronary angiography. Image 
B shows the DMAX assessment. The three non-ambiguous points of the diameter function are: the proximal DMAX 
(3.10 mm), the MLD (1.21 mm) and the distal DMAX (2.52 mm). Panel C shows the interpolated-RVD assessment. 
According to the diameter function of the proximal and distal segments to the BVS edges an interpolated diameter 
line is generated. The “predicted” diameter at the site of the MLD (2.64 mm) defines the interpolated-RVD. DMAX: 
maximal lumen diameter; MLD: minimal lumen diameter; RVD: reference vessel diameter..
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M AT E R I A L  A N D  M E T h O D S 
Study design and population
The ABSORB Cohort B trial was a non-randomised, multicentre, single arm, efficacy-safety 
study that included 101 patients with 102 lesions treated with BVS. All the implanted 
devices were 3.0 mm in diameter and 18 mm in length. OCT imaging was an optional 
investigation performed in selected participating centers. The study design of the ABSORB 
Cohort B is available at clinicaltrials.gov (NCT00856856). 
In brief, the common inclusion criteria were patients aged 18 years or older, with a 
diagnosis of stable, unstable or silent ischaemia, which presented with a de	novo	stenosis 
in a native coronary artery. 
Exclusion criteria included patients with ste nosis of an unprotected left main or ostial 
right coronary artery (RCA), presence of intracoronary thrombus or heavy calcification. 
The present study is a post	hoc	analysis of the subset of patients included in the ABSORB 
Cohort B trial who had optical coherence tomography (OCT) imaging performed post-
BVS implantation. 
The population included in the present study was divided in three groups based on the 
proximal and distal DMAX prior to the BVS implantation: group 1 included those patients 
with proximal or dis tal DMAX <2.5 mm; group 2 included those patients with proximal 
and distal DMAX between 2.5-3.3 mm; group 3 included those patients with proximal or 
distal DMAX >3.3 mm.
Bioresorbable Vascular Scaffold 
The BVS 1.1 revision (Abbott Vascular, Santa Clara, CA, USA) is a balloon expandable 
device, consisting of a polymer backbone of Poly-L lactide (PLLA) coated with a thin layer 
of a 1:1 mixture of an amorphous matrix of Poly-D, L lactide (PDLLA) polymer con taining 
100 micrograms/cm2 of the antiproliferative drug everoli mus. The implant is radiolucent, 
but has two platinum markers at each edge, that allow visualization on angiography and 
other imag ing modalities. Physically, the scaffold has struts with an approxi mate thickness 
of 150 μm arranged in-phase zigzag hoops linked together by three longitudinal bridges. 
Treatment Procedure
Lesions were treated with routine interventional techniques that included mandatory 
pre-dilation. The operator was requested to select an angiographic view with minimal 
foreshortening of the lesion and limited overlap with other vessels. This view was used 
for all phases of the treatment, including the inflation of the deliv ery system balloon or 
the post-dilation balloons at the highest pres sures. The study protocol forbade the use 
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of pre-dilation balloons longer than the pre-specified length of the device. According to 
the protocol, the BVS had to be implanted at a pressure not exceeding the rated burst 
pressure (16 atmospheres) corresponding to a pre dicted diameter of 3.3 mm as per the 
manufacturer’s chart. Post-dilatation with a balloon shorter than the implanted device and 
a maximum diameter of 3.25 mm was allowed at the operator’s dis cretion, as was post-
dilatation balloon size, use of non-compliant balloons or bailout treatment. During the 
BVS implantation or the post-dilatation with other balloons, the highest inflated pressure 
of the largest balloon was used to calculate the “predicted device diameter” according to 
the manufacturer’s BVS or post-dilatation balloon charts, which describes the theoretical 
diameter of the BVS achieved at the end of the procedure. 
quantitative coronary angiography analysis 
The 2D angiograms were stored in DICOM format and analysed by the core lab (Cardialysis, 
Rotterdam, The Netherlands) using the CASS II analysis system (Pie Medical BV, Maastricht, 
The Nether lands). In each patient, the treated region and the peri-treated regions (defined 
by a length of 5 mm proximal and distal to the device edge) were analyzed. The following 
QCA analysis parame ters were computed: MLD, interpolated-RVD and percentage of 
diameter stenosis (DS). The DMAX was measured as previously described (Figure 1). 
During the BVS implantation or post-dilation with other bal loons, the highest inflated 
pressure of the largest balloon was quan titatively measured as the ‘mean inflated-balloon 
diameter’. Balloon / artery ratio (B:A ratio) was estimated as: (mean inflated-balloon 
diameter/interpolated-RVD). 
Optical coherence tomography acquisition 
OCT imaging was performed using two different OCT systems (M3 Time-Domain System 
and C7XR Fourier-Domain System; Light Lab Imaging, Westford, MA, USA) with the non-
occlusive tech nique. The imaging was performed after the last dilatation and after a 
nitroglycerine infusion. The acquisition method of both systems has been previously 
described11. 
Optical coherence tomography analysis 
Offline quantitative and qualitative OCT data analysis was carried out by the core 
laboratory (Cardialysis BV, Rotterdam, The Nether lands) with proprietary software for 
offline analysis (LightLab Imaging, Westford, MA, USA). 
Adjusting for the pullback speed, the analysis of contiguous cross-sections was performed 
at each 1 mm longitudinal intervals within the treated segment. The BVS demonstrated 
important differences as compared to metallic stents when imaged by OCT1. The optically 
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translucent polymeric struts did not shadow the vessel wall thereby allowing complete 
imaging of the struts and the lumen vessel wall contours. 
Qualitative assessments of strut apposition, scaffold pattern con tinuity and edge 
dissections could therefore easily be performed (Figure 2). Incomplete strut apposition 
(ISA) was diagnosed when the back-side of the polymeric strut was separated from 
the vessel wall. The scaffold pattern was assessed for irregularities such as two struts 
overhanging each other in the same angular sector of the lumen perimeter, with or 
without malapposition, or for isolated struts located more or less at the centre of the 
vessel without obvi ous connection to the expected adjacent strut pattern12. An endolu-
minal flap at the BVS edge was reported as an edge dissection. 
Quantitative assessment of the scaffold area was measured at the back-side of the apposed 
struts. In the case of two consecutive frames with ISA, the area between the lumen and 
the scaffold was measured as the ISA area. Reference vessel area (RVA) was esti mated as 
the mean between the two largest luminal areas in the outer 5 mm proximal and distal 
segments to the edges of the BVS11. In the cases of absence of any of the proximal or 
distal segments due to ostial lesions or the presence of near side branches the oppo site 
segment was instead used as the RVA. Residual area stenosis (RAS) was calculated as: 
(1-[minSA / RVA])×100. 
The corelab reproducibility for ISA, scaffold area and edge dissection assessment has been 
previously reported and showed an excellent inter and intra-observer agreement using 
OCT13.
The detection of scaffold pattern irregularities was performed by two experienced analysts 
who analyzed qualitatively the full length of the device in all the frames. 
 
figure 2. Optical coherence tomography optimal deployment criteria. A) Minimal scaffold area <5 mm2. This picture 
shows a scaffold area (blue line) of 4.2 mm2 in (minimum scaffold area of the BVS); B) Residual area stenosis >20%. This 
patient presents a minimal scaffold area of 5.7 mm2 (white line) and a reference vessel area of 7.9 mm2. The estimated 
residual area stenosis is 27.8%; C) Edge dissection distally to the BVS; D) Incomplete scaffold/strut apposition; E) 
Scaffold pattern irregularity with an overhanging strut (arrow) at the centre of the vessel without obvious connection 
to the expected/adjacent strut pattern.
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Non-optimal deployment endpoints 
Non-optimal deployment endpoints were: presence of minSA <5 mm2, presence of RAS 
>20%, presence of edge dissections as assessed by OCT, presence of ISA per scaffold >5% 
and presence of any scaffold pattern irregularities3-8. 
Statistical analysis 
The Kolmogorov-Smirnov test was used to evaluate the normality assumptions of 
all continuous variables. Continuous variables were expressed as a mean ± standard 
deviation and categorical variables were presented as counts (%). Comparisons of 
continuous variables at lesion level and frame level analysis were estimated with the non-
parametric Mann-Whitney test when comparing two groups or Kruskall-Wallis test when 
comparing three groups. Categorical variables were compared with the chi-square test. 
All measurements were obtained by SPSS 15 software version (SPSS Inc, Chi cago IL, USA).
R E S u LT S 
Population
A total of 54 out of the 101 lesions included in the ABSORB cohort B trial were imaged by 
OCT after BVS deployment in 53 patients. Two of the pullbacks were not included because 
lack of visualization of the full length and size of the device. Finally, 52 lesions in 51 patients 
are therefore reported in this study. A C7 OCT system was used in 36 lesions (69.2%) and 
a M3 system in 16 (30.8%). According to the baseline DMAX, either proximal or distal, 13 
lesions were included in group 1 (DMAX <2.5 mm), 30 in group 2 (DMAX between 2.5 and 
3.3 mm) and nine lesions in group 3 (DMAX >3.3 mm). The interpolated-RVD, the proximal 
and distal DMAX distribution values are shown in Figure 3.
Baseline clinical, angiographic and procedural characteristics 
Baseline clinical characteristics are shown in Table 1. Briefly, 37 patients (72.5%) were 
males, mean age was 62.1±10.0 years, 88.2% of patients presented with stable angina 
as an indication for the procedure and only seven patients (13.8%) had more than single 
vessel disease.
Angiographic and procedural characteristics are summarised in Table 2. The treated vessel 
was similar between all groups. Prior to BVS implantation, the interpolated-RVD value 
rose incrementally according to the DMAX subgroups (2.44 mm vs. 2.61 mm vs. 2.87 mm; 
p=0.02). The use of post-dilatation with other balloons was similar in all groups (53.8% vs. 
56.7% vs. 66.7%; p=0.82) with no diff erences in balloon length or nominal sizes. 
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table 1. Baseline clinical characteristics (n=51).
Age* 62.1±10.0
Males 37 (72.5)
Hypertension 31 (60.8)
Hypercholesterolaemia 44 (86.3)
Diabetes mellitus 4 (7.8)
Smoking status 12 (23.5)
Previous MI 16 (31.4)
Previous PCI 12 (23.5)
Unstable angina 6 (11.8)
Number vessel disease:
One 44 (86.2)
Two 6 (11.8)
Three 1 (2.0)
Values are expressed as n (%). *Age is reported as mean±SD
However, the mean bal loon-inflated diameter of the largest balloon inflated at highest 
pressure tend to be larger in group 3 (2.66 mm vs. 2.76 mm vs. 2.88 mm; p=0.22). The 
balloon/artery ratios were similar in all groups (1.07 vs. 1.07 vs. 1.02; p=0.53). Quantitative 
analysis of the final result showed larger MLD, interpolated-RVD and DMAX in group 3. 
 
figure 3. Distribution of the interpolated-reference vessel diameter and the proximal and distal DMAX in the global 
population.
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table 2. Angiographical and procedural characteristics. 
n=52 DMAx <2.5 mm 
(n=13)
DMAx 2.5 to 3.3 
mm (n=30)
DMAx >3.3 mm 
(n=9)
All 
p 
Target vessel, n (%) 0.99
LAD 7 (53.8) 15 (50.0) 5 (55.6)
LCX 3 (23.1) 6 (20.0) 2 (22.2)
RCA 3 (23.1) 9 (30.0) 2 (22.2)
QCA Pre-treatment
D max proximal 2.40±0.20 2.91±0.24 3.54±0.34 <0.01
Interpolate RVD (mm) 2.44±0.35 2.61±0.24 2.87±0.47 0.02
Dmax distal 2.46±0.34 2.79±0.24 3.03±0.36 <0.01
MLD (mm) 1.07±0.32 1.19±0.39 1.17±0.40 0.66
DS (%) 54.4±9.9 57.4±10.4 63.8±10.7 0.16
Post-dilatation with other balloon, n (%): 7 (53.8) 17 (56.7) 6 (66.7) 0.82
Length of the largest post-dilatation balloon (mm) 14.3±4.2 14.8±3.7 13.4±4.2 0.63
Nominal diameter (mm) 3.1±0.2 3.1±0.1 3.2±0.2 0.20
Predicted device diameter (mm) 3.32±0.10 3.30±0.15 3.50±0.21 0.01
QCA mean - inflated balloon diameter (mm) 2.66±0.20 2.76±0.21 2.88±0.36 0.22
Balloon / artery ratio 1.07±0.14 1.07±0.12 1.02±0.14 0.53
Bail-out stenting for edge dissection, n (%) 1 (7.7) 2 (6.7) 0 0.71
QCA Post-treatment
RVD (mm) 2.44±0.33 2.55±0.30 2.81±0.42 0.13
MLD (mm) 2.01±0.28 2.23±0.30 2.48±0.32 0.01
DS (%) 13.1±4.7 14.4±4.6 16.2±6.7 0.62
Dmax post (mm) 2.90±0.24 3.07±0.27 3.31±0.46 <0.01
All values are expressed as mean±SD; LAD: left anterior descending; LCX: left circumflex; RCA: right coronary artery; 
QCA: quantitative coronary angiography; DMAX: maximal lumen diameter; RVD: reference vessel diameter; MLD: 
minimal lumen diameter; DS: diameter stenosis. 
Optical coherence tomography ﬁndings 
OCT findings are summarised in Table 3. A total of 1,001 frames and 8,634 struts were 
analyzed. The lumen area, scaffold area, RVA, minSA and RAS were increasingly larger 
amongst the three subgroups. 
ISA analysis at lesion level showed a slight trend towards higher per centages of ISA struts 
in groups 2 and 3 (2.2% vs. 5.5% vs. 14.4%; p=0.16). At frame level analysis, the percentage 
of frames with malap posed struts was significantly higher in group 3 (15.4% vs. 21.5% 
vs. 26.9%; p=0.02) and the percentage of ISA struts per frame was signifi cantly higher in 
group 3 (2.4% vs. 5.4% vs. 10.9%; p<0.01).
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table 3. Optical coherence tomography findings. 
n=52 DMAx <2.5 m
 (n=13)
DMAx 2.5 to
3.3 mm (n=30)
DMAx >3.3 mm
(n=9)
All
p
1 vs. 2
p
2 vs. 3
p
Lesion level
Average lumen area (mm2) 6.9±1.2 7.5±0.9 8.9±1.6 0.01 0.12 0.01
minLA (mm2) 5.6±1.3 6.2±1.0 6.7±1.0 0.07 0.12 0.18
Scaffold area (mm2) 7.1±1.3 7.6±0.8 8.6±1.0 0.01 0.18 0.01
minSA (mm2) 5.8±1.4 6.3±0.9 6.8±1.3 0.18 0.20 0.22
ISA area (mm2)* 0.2±0.5 0.2±0.4 0.5±0.8 0.69 0.56 0.76
RVA (mm2) 7.0±1.2 8.2±1.6 10.3±3.1 0.01 0.02 0.05
RAS (%) 16.1±12.1 20.9±12.8 27.9±22.8 0.34 0.38 0.42
Lesion level (ISA analysis)
Lesions with at least 1 ISA, n (%) 10 (76.9) 23 (76.7) 7 (77.8) 0.82 0.99 0.55
Percentage of ISA per lesion, mean 2.2±2.5 5.5±6.5 14.4±15.0 0.16 0.14 0.27
ISA frames per lesion,% 15.0±15.4 21.9±20.2 29.4±27.3 0.44 0.33 0.52
Frame level (ISA analysis)
Frames with ISA,% 15.4 21.5 26.9 0.02 0.05 0.15
ISA struts per frame,% 2.4±7.1 5.4±13.0 10.9±22.5  <0.01   0.02  0.05 
Values are expressed as mean ± SD; DMAX: maximal lumen diameter; minLA: minimal lumen area; BVS: bioresorbable 
vascular scaffold; minSA: minimal scaffold area; RVA: reference vessel area; ISA: incomplete scaffold/strut apposition; 
Percentage of ISA per lesion: number of ISA/total number of struts per lesion *ISA area has been estimated only in 
patients with ISA. 
table 4. Non-optimal deployment endpoints (lesion level analysis). 
n=52  DMAx <2.5 mm DMAx 2.5 to DMAx >3.3 mm All
 (n=13) 3.3 mm (n=30) (n=9) p
 1 vs. 2 2 vs. 3
 p p
minSA <5 mm2 4 (30.8) 3 (10.0) 0 0.08 0.09 0.32
RAS >20% 6 (46.2) 16 (53.3) 7 (77.8) 0.31 0.67 0.19
Edge dissections¶ 8 (61.5) 10 (33.3) 1 (11.1) 0.05 0.08 0.19
ISA struts >5% 1 (7.7) 11 (36.7) 6 (66.7) 0.02 0.05 0.11
Structural discontinuities 0 2 (6.7) 1 (11.1) 0.52 – –
Values are expressed as count (%). minSA: minimal scaffold area; RAS: residual area stenosis; ISA: incomplete scaffold/strut 
apposition. ¶ Edge dissections detected by OCT including the three cases of dissection, detected by angiography and 
treated with bail-out stent.
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Non-optimal deployment endpoints 
Non-optimal deployment endpoints are showed in Table 4. Lesions with minSA<5 mm2 
were more frequent in group 1 (30.8% vs. 10.0% vs. 0%; p=0.08). Edge dissections as 
assessed by OCT were more frequently observed in group 1 (61.5% vs. 33.3% vs. 11.1%; 
p=0.05). Lesions with >5% of ISA struts were found in greater per centage in group 3 (7.7% 
vs. 36.7% vs. 66.7%; p=0.02). Lesions with RAS >20% were not related with DMAX and 
scaffold pattern irregularities were only documented in three cases at baseline. 
d I s C u s s I o n 
The main findings of our study are: 1) DMAX measured prior to the implantation has some 
bearing on the appropriate deployment of the BVS as assessed by OCT criteria; 2) Lesions 
with DMAX <2.5 mm showed a trend toward higher incidence of minSA <5 mm2 and pre-
sented with higher rates of edge dissections; 3) Lesions with DMAX >3.3 mm presented 
with a higher incidence of malapposed struts.
The assessment of the lumen size using QCA has been exten sively used since the 
beginning of the interventional cardiology field. There are different methods to assess 
the lumen size taking into account different regions of the vessel10. The interpolated-RVD 
predicts the “expected lumen diameter” at the site of the MLD tak ing as a reference the 
proximal and distal segments to the stenotic region. However, the interpolated-RVD does 
not assume the actual lumen dimensions of the predicted “landing zone” and is highly 
influenced by proximal or distal side branches not included in the scaffolded segment. The 
Dmax estimation is an interactive meas urement that helps the investigator to select the 
appropriate “land ing zone”, especially in the setting of a single size device study (Figure 1). 
Figure 3 shows that in the majority of occasions the interpolated-RVD underestimated the 
maximal lumen diameter within the scaffolded region. 
Since there are no widely accepted OCT criteria for optimal stent deployment, our OCT 
endpoints have been directly inferred from the IVUS criteria previously used for the 
evaluation of metallic platform stents. IVUS criteria of non-optimal deployment have been 
validated with 1-year clinical outcomes as previously described in the literature5-9. 
Minimal scaffold area: Baseline minSA<5 mm2 imaged after the implantation of sirolimus-
eluting stents resulted on average in a minSA <4 mm2 at eight months follow-up as 
assessed by IVUS6; this threshold has been associated with adverse events, especially with 
restenosis14,15. In our study, seven lesions (13.5%) did not achieve a minSA ≥5 mm2 at the 
end of the procedure and one of them (1.9%) presented with a minSA <4 mm2. These 
percentages are similar to those reported for metallic platform stents (29% had minimal 
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stent area <5 mm2 and 4% had <4 mm2)15. However, in our series, none of those patients 
presented with clinical events in the first 180 days. 
Residual area stenosis: IVUS studies measured the RAS as the expansion index (minimal 
stent area/reference vessel area)5,15. In the setting of metallic platform stents, which do not 
suffer from acute or late recoil, this index reflects the grade of the device expansion at the 
site of the minimum area with respect to the normal vessel area. This value is commonly 
higher than one when the final procedure result shows the typical angiographic image of 
“step-up / step-down”. An expansion index below 0.80 (that corresponds to a RAS >20%) 
was previously related with acute/subacute stent thrombosis3,5. In these studies, the mean 
expansion index and the rate of patients with a RAS >20% at the end of the procedure in the 
group of patients without adverse events were 0.85 and 23%, respectively3,5. In our study, 
the mean expansion index was 0.79 (RAS=21%), but 29 patients (56%) presented with a 
residual area stenosis ≥20%, independently from the DMAX subgroups. We hypothesise 
that this slightly higher incidence of underexpansion compared to the metallic stents is 
the result of weaker radial forces of the BVS as compared to metallic stents16. However, 
this moderate level of under-expansion does not seem to have any acute or subacute 
thrombosis as well as restenosis implica tions in these patients. 
Edge dissections: Non-treated edge dissections, as assessed by IVUS, is a controvert topic 
in the current literature. Nishida et al did not find different acute clinical outcomes in 97 
patients with edge dissection compared to 100 patients without IVUS-detected edge 
dissections17. On the other hand, Cheneau et al demonstrated that non-obstructive edge 
dissections were related to subacute stent thromboses5. The incidence of edge dissection 
reported in these studies was around 9.2%17,18. Since the resolution of OCT is 10 times 
higher than IVUS, OCT has better accuracy in detecting edge dissections9; and indeed, 
the reported incidence of edge dissections higher (25-40%)19,20. Our study found 19 
edge dissections (36.5%) with only one patient (5.3%) presenting with an adverse event 
(periprocedural myocardial infarction). This patient belonged to the group with DMAX 
<2.5 mm and presented with an angiographi cally-detected dissection that caused slow-
flow and required bail-out treatment with a metallic stent. Apparently, the higher rate of 
edge dissections in group 1 was not related with the balloon/artery ratio, which was very 
similar in the three groups. (1.07 vs. 1.07 vs. 1.02; p=0.53). However, the predicted device 
diameter achieved at the end of the procedure as assessed by the manufacture’s chart 
was similar between groups 1 and 2, showing that the group with DMAX <2.5 mm was 
treated more aggressively according to the reference vessel size. A correct assessment of 
the vessel size prior to the BVS implantation can potentially discourage the operator from 
performing additional aggressive post-dilatation in under-sized vessels, possibly avoiding 
edge dissection in these undersized vessels. Nevertheless, there is little information 
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regarding the clini cal implications of OCT-detected dissections. Two reports even failed 
to relate these findings to acute clinical events19,20. Incomplete scaffold/strut apposition: 
Despite angiographic and IVUS-guided PCI procedures, acute ISA as assessed by IVUS is 
still common following the deployment of metallic platform stents. In elective patients, 
IVUS-studies have reported rates of stents with at least one ISA ranging between 2.6 to 
11.6%8,21; and more than 30% in patients with ST-elevation myocardial infarction22. OCT 
imaging has a considerably higher resolution and sensitivity in detecting ISA as compared 
to IVUS and therefore, detects higher rates of malapposed struts9. Translucency of the BVS 
struts enhances this detection capability. Recent OCT studies have reported a percentage 
of lesions with at least one ISA of 88% and a percentage of malapposed struts between 4.5 
to 9.1%23,24. Our study reports 39 lesions (75.0%) with at least one malapposed strut and 
a mean percentage of ISA of 6.2%. 
The clinical impact of acute ISA is not completely understood, considering the small rate 
of adverse events observed with drug-elut ing stents. IVUS studies with baseline and 6 
month follow-up imag ing showed that the presence of post-procedural and follow-up 
ISA were not related to death, myocardial infarction, target vessel revas cularisation or 
stent thrombosis21,25. Nevertheless, around 40-70% of the acute ISA persisted at follow-
up25. The presence of late ISA has been clearly related with a delay in or lack of neointimal 
coverage at follow-up26; and patients who had sustained late or very late stent thromboses 
presented with higher rates of ISA and a lack of neointi mal coverage27,28. In our study, two 
out of four patients with adverse events in the firsts 180 days presented with ISA >5% 
after the deploy ment. In one patient the ISA was related to significant disruption of the 
scaffold at deployment. At day 33, the patient presented with chest pain with documented 
exercise induced ischaemia. Although angiographically patent, the patient underwent 
target lesion revascu larisation. A second patient suffered a periprocedural acute myocar-
dial infarction due to the occlusion of a diagonal branch. 
Due to the high rate of lesions with at least one ISA imaged by OCT, the same IVUS criteria 
to define optimal deployment cannot be applied to OCT. Therefore, we defined a 5% of 
malapposed struts in each device as one of the criteria of non-optimal BVS deployment. This 
value is arbitrary but corresponds to the highest tertile of our population with malapposed 
struts and has been reported in previous studies as a widely accepted cut-off29. 
Scaffold pattern irregularities: Metallic stent fractures have been related to metal fatigue, 
mostly detected at follow-up. Stent frac tures were more frequently found in overlapping 
stents, hinging points, angulated vessels and with some specific types of drug-elut ing 
stents30,31. Moreover, stent fractures were also related with adverse events, especially 
with target lesion revascularisation32. The incidence of stent fracture ranged from 1.3% to 
28.8%, and it depended on the used imaging technique30,33. 
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In our study, BVS pattern irregularities were observed with OCT at baseline. These 
irregularities ranged from local overhanging sin gle struts shifted out of their expected 
pattern position during deployment, to complete pattern disruptions possibly involving 
structural discontinuities. We report three cases of scaffold pattern irregularities at 
baseline (5.8%). All of them were associated with the use of post-dilatation balloons that 
over-stretched the polymeric device beyond 3.3 mm (as assessed by the balloons charts). 
Post-dilatation with other balloons was needed in two cases due to a sub-optimal residual 
stenosis after the BVS deployment and in one case because of the presence of severe ISA 
as assessed by OCT. The last one was observed in a patient with a DMAX >3.3 mm and 
required target lesion revascularisation after 33 days. 
Clinical outcomes: A total of four out of 51 patients (7.8%) included in the present study 
had an adverse cardiac event at follow-up in the first 180 days after the procedure. Two 
patients presented with adverse events not related to mismatch of the vessel / device size: 
one patient suffered a periprocedural myocardial infarction without further complications 
due to the occlusion of a small side branch and the other patient presented a myocardial 
infarction during an unscheduled angiogram not related with the device. The adverse 
event of the first patient with vessel / device mismatch was caused by a periprocedural 
myocardial infarction during the BVS implantation (the troponin value raised 2.5 times 
after the procedure without any further complications). The patient presented with a 
mild lesion (DS 52%) of a small second marginal (proximal and distal DMAX of 2.4 and 
2.2 mm, respectively). After the predilation with a 2.75×10.00 mm compliance balloon 
a flow-limiting dissection was observed. The BVS implantation was not enough to seal 
the dissection and the patient did not recover the TIMI flow 3. Finally, a bail-out stenting 
with a metallic stent was implanted successfully and the patient recovered TIMI flow 3. 
The second patient presented with a moder ate lesion in a large obtuse marginal (Figure 
4). After the 3×18 mm BVS implantation the OCT imaging showed severe ISA in the 
proxi mal part of the device and the patient was treated with a 3.5×9 mm post-dilatation 
compliance balloon. The predicted device diameter at the end of the procedure was 3.96 
mm. After the post-dilatation, a new OCT pullback showed scaffold pattern irregularities 
that were not treated and the patient was discharged the day after. At day 33, the patient 
complained of chest pain with documented exercise induced ischaemia. The angiography 
showed a patent coronary vessel with a diameter stenosis of 23% by QCA. However, OCT 
confirmed multi ple signs of scaffold pattern irregularities. It was decided to treat with a 
metallic stent. After the procedure, the troponin value raised three times the upper limit 
of normality.34 
For all these reasons it seems advisable to perform BVS implan tation using precise 
measurements for accurate vessel sizing. We recommend a mandatory predilatation in 
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all patients ensuring an optimal expansion of the balloon. The quantification of the maxi-
mal lumen diameter (DMAX) in the proximal and distal segments of the MLD is currently 
viewed as one of the preventative measures used to ensure accurate sizing of the BVS 
with respect to the target vessel dimensions (Figure 1). According to the DMAX results, 
an appropriate device size and inflated balloon pressure should be cho sen to achieve 
optimal device apposition and expansion. Post-dilation can be performed but without 
over-stretching the BVS beyond 3.3 mm. Consequently, in the on-going ABSORB EXTEND 
single-arm study, currently recruiting more than 1000 patients, the operator is requested 
to assess the DMAX prior to BVS implanta tion. In the case of DMAX <2.5 mm or >3.3 mm 
the patient should not be included in the study. A third generation of the device with a 
 
figure 4. Coronary angiography and OCT of a patient with scaffold pattern irregularity at post-implantation. Patient 
affected of a moderate lesion in the obtuse marginal. The interpolated-RVD was 3.26 mm (A) and the proximal and 
distal Dmax of the scaffolded segment (prior to the implantation) were 4.09 and 3.34 mm respectively (B). After the 
BVS implantation the OCT imaging showed severe malapposition of the scaffold (C); and the operator decided to 
post-dilate with a compliance balloon up to 3.96 mm of predicted diameter. A second OCT pullback showed scaffold 
pattern irregularities highly suggestive of fracture (D) that were untreated. At day 33, the patient presented with 
ischaemia and was re-catheterised (E). A new OCT (F) showed scaffold pattern irregularities with attached thrombi 
(arrow).
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slightly modified pattern is intended to raise the current upper limit of deployment of the 
3.0 mm (nominal diameter) device to 3.8 mm. 
Limitations 
The first limitation is the few number of patients included in our study, despite the 
data representing one of the largest studies ever made with baseline optical coherence 
tomography. The second limitation refers to the OCT endpoints of non-optimal 
deployment. Due to a lack of expert consensus we decided to infer the IVUS definitions 
to the OCT technology; these criteria have however not yet been validated with clinical 
outcomes in formal randomised controlled trials. Third, this study is a description of the 
OCT find ings observed in the ABSORB Cohort B study. The selected DMAX cut-offs of 
2.5 and 3.3 mm are arbitrary and not evidence-based. They are however inferred from 
the knowledge of the mechanical properties of the polymeric BVS device. The BVS chart 
of the 3.0 mm nominal size diameter sets the burst pressure at 16 atmos pheres, which 
corresponds to a predicted device diameter of 3.35 mm. The expansion of the device 
exceeding this boundary can potentially fracture the polymeric struts. On the other hand, 
when the BVS is under-expanded below 2.5 mm, the actual diameter may potentially be 
even smaller than 2.2 mm since the 150 μm thickness of the apposed struts to each side 
of the lumen (2×150 μm=0.3 mm) has to be subtracted from the scaffold diameter of 2.5 
mm. 
CO N C Lu S I O N S 
Appropriate deployment of the bioresorbable vascular scaffold as assessed by optical 
coherence tomography is related to the quantita tive angiographic assessment of the 
maximal lumen diameter prior to the implantation. Lesions between 2.5 to 3.3 mm of 
maximal lumen diameter achieved better deployment criteria than those with a maximal 
lumen diameter <2.5 mm and >3.3 mm. Further investi gations are warranted to correlate 
the angiographic guidelines with the OCT findings and clinical outcomes at short, medium 
and long-term follow-up. 
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A B S T R AC T
Objective To compare the geometrical parameters of a bioresorbable vascular 
scaffold (BVS) with a standard metallic stent. Background: The introduction of 
polymeric bioresorbable materials in the design of novel coronary scaffolds may 
affect some geometrical parameters, such as eccentricity and symmetry indices, 
previously introduced as IVUS criteria for optimal metallic stent deployment. 
Methods From ABSORB Cohort A, ABSORB Cohort B, SPIRIT I, and SPIRIT II, all 
patients implanted with BVS 1.0, BVS 1.1, or XIENCE V, respectively and intravascular 
ultrasound analyses post-implantation were selected. The eccentricity index was 
calculated frame by frame and expressed as an average per device (minimum 
diameter/maximum diameter). The symmetry index of the device was reported 
as ([maximum diameter 2 minimum diameter]/maximum diameter). Six months 
major adverse cardiac events (MACE) were analyzed.
Results A total of 242 patients were selected (BVS 1.0: n = 28, BVS 1.1: n = 94, XIENCE 
V: n = 120). The BVS exhibited a significantly lower eccentricity index (BVS 1.0: 0.83 
± 0.09; BVS 1.1: 0.85 ± 0.08; XIENCE V: 0.90 ± 0.06; P < 0.01) and a significantly higher 
symmetry index (BVS 1.0: 0.30 ± 0.07; BVS 1.1: 0.31 ± 0.06, XIENCE V 0.26 ± 0.07; P 
< 0.01) as compared to the XIENCE V. An inverse correlation was found between 
the symmetry and eccentricity indices for both (BVS r = -0.69, P < 0.01; XIENCE V 
r = -0.61, P < 0.01). No differences in MACE were detected between the groups 
according to their geometrical parameters.
Conclusions The introduction of a new polymeric material in the design of BVS 
resulted in a lower eccentricity index and a higher symmetry index as compared to 
metallic stents, without detectable impact in MACE, at 6 months.
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I N T R O D u C T I O N
The introduction of intravascular ultrasound (IVUS) and high pressure implantation 
of coronary stents in interventional cardiology practice have had a significant impact 
on stent deployment [1,2]. The MUSIC trial showed how the use of IVUS criteria (such as 
complete apposition of the stent against the vessel wall; in-stent minimal lumen area 
≥90% of the average reference lumen area; eccentricity index
≥0.7), may positively contribute to the immediate and 6-month clinical and angiographic 
outcomes [3]. A meta-analysis from the BENESTENT and MUSIC trials further confirmed 
how the IVUS guidance is responsible for reduction in restenosis rate [4,5].
Some geometrical stent parameters, such as eccentricity and symmetry, easily detectable 
by IVUS, have previously been demonstrated to be related to either favorable or adverse 
clinical outcomes [3,6]. With the transition from a metallic stent to a polymeric bioresorbable 
platform, the need for the re-evaluation of these geometrical parameters is required at 
short and long term.
In the present analysis, we evaluated the eccentricity and symmetry indices of the 
bioresorbable vascular scaffold (BVS) in the ABSORB trials and compared these to the 
XIENCE V stent from the SPIRIT trials.
M E T h O D S
Study Population
For the present analysis, we screened all patients from ABSORB (Cohort A and B) and 
SPIRIT I [7] and II [8] trials, and selected all the patients with available IVUS data post-device 
implantation. These patients were then subdivided into three groups according to the 
device implanted (BVS 1.0, BVS 1.1 and XIENCE V, all Abbott Vascular, Santa Clara, CA). The 
design of the ABSORB studies has been previously described [9–11]. Briefly, in the ABSORB 
Cohort A trial (NCT00300131), patients with a diagnosis of stable or unstable angina or 
silent ischemia, were enrolled. All treated lesions were single and de novo in a native 
coronary artery of 3.0 mm diameter, shorter than 8 mm for the 12-mm stent and shorter 
than 14 mm for the 18-mm stent, with a diameter stenosis greater than 50% and less than 
100%, and with a thrombolysis in myocardial infarction (TIMI) flow grade more than 1. 
All lesions were treated by implantation of BVS 1.0 (3.0 x 12 mm and 3.0 x 18 mm). The 
ABSORB Cohort B trial (NCT00856856) enrolled patients with the same clinical profile and 
lesion type. All lesions were treated by implantation of a BVS 1.1 (3.0 x 18 mm) [11].
The SPIRIT trials were planned to assess the safety and efficacy of the everolimus eluting 
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stent (XIENCE V) in patients with coronary artery disease. SPIRIT I and II were prospective, 
multicenter, single-blinded, randomized-controlled clinical investigations which compared 
XIENCE V with either the bare Multi-Link VISION metal (Abbott Vascular, Santa Clara, CA, 
SPIRIT I trial, NCT00180453) or paclitaxel-eluting (Boston Scientific, Natick, MA, SPIRIT II 
trial, NCT00180310) stents [7,8]. The exclusion criteria of the two SPIRIT trials were similar 
to those of the ABSORB trials. All the trials had previously been approved by the ethics 
committee at each participating institution with written informed consent obtained for 
each patient before inclusion.
quantitative Coronary Angiography Analysis of Vessels Pretreatment
Quantitative coronary angiography (QCA) pre-treatment was performed by an independent 
core laboratory (Cardialysis BV, Rotterdam, The Netherlands), using the CAAS II analysis 
system (Pie Medical BV, Maastricht, Netherlands). For each pre-treatment angiogram, the 
treated and the peri-treated regions (defined by a length of 5-mm proximal and distal to 
the device edge) were analyzed. The following QCA parameters were computed: computer-
defined minimum lumen diameter (MLD), reference vessel diameter (RVD), obtained by the 
interpolate method, and percentage diameter stenosis [12].
Study Devices
The BVS has an amorphous poly-DL-lactide (PDLLA) coating that contains and controls 
the release of the anti- proliferative drug everolimus (Figure 1). The scaffold body is made 
of semi-crystalline poly-L-lactide (PLLA). PLLA is completely degraded via hydrolysis and 
bioresorbed via the Krebs cycle [9,10]. Physically, the scaffold has struts with an approximate 
thickness of 150 lm. There are no differences in polymeric material, drug dose, drug 
release, or strut thickness between BVS revisions 1.0 and 1.1. Of note, the BVS revision 1.1 
has a smaller maximum circular unsupported surface area compared to revision 1.0, with 
the struts arranged as in- phase zigzag hoops linked together by three longitudinal links, 
similar to the XIENCE V design [13].
The XIENCE V stent is an everolimus-eluting, cobalt chromium alloy device with a platform 
consisting of serpentine rings connected by links fabricated from a single piece. The strut 
thickness is 81 μm with the polymer and drug coating adding a further thickness of 7 μm 
to the overall thickness.
Lesions were treated with standard interventional techniques, with mandatory pre-
dilatation, using a balloon shorter and 0.5 mm smaller in diameter than the study device. 
The study device was implanted at a pressure not exceeding the rated burst pressure. 
Post- dilatation with a balloon shorter than the implanted device was allowed at the 
operator’s discretion, as was bailout treatment.
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Intravascular ultrasound Analysis
Post-procedure treated vessel segments were examined with mechanical (Atlantis, 
Boston Scientific, Natick, MA) or phased array (Eagle-eye Volcano, Rancho Cordova, CA) 
intravascular ultrasound (IVUS), using automated pullbacks at 0.5 mm per second after 
administration of 0.2 mg intracoronary nitroglycerin. IVUS analyses were performed by 
an independent core laboratory (Cardialysis BV, Rotterdam, The Netherlands). Only the 
lesions implanted with a BVS 1.0, BVS 1.1, or a XIENCE V were included in the analysis. A 
computer-based contour detection program was used for automated 2D reconstruction 
of the treated segment. The lumen, stent/scaff old boundaries and external elastic 
membrane (vessel boundaries) were detected using a minimum cost algorithm [14].
For each treated vessel segment, we analyzed frame by frame the lumen, device implanted 
(stent/ scaff old), plaque, and vessel area and upfront selected the site (single frame) of 
minimum stent/ scaff old area (MSA). The MSA is classically described as the flow-limiting 
area and has been previously related to angiographic and clinical outcomes [15,16]. In each 
frame, we obtained the ‘‘projected’’ diameters of the stent/scaff old, as previously described 
and validated [17]. 
For each device implanted we therefore calculated:
•  Eccentricity index at the MSA frame, as a ratio between the minimum and maximum 
diameters in that frame; [3,18]
 
figure 1. Pictures of BVS 1.0, BVS 1.1, and XIENCE V. [Color fi gure can be viewed in the online issue, which is available 
at wileyonlinelibrary.com.]
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•  Eccentricity index, as the average of all eccentricity indices of each frame; [3,18]
•  Symmetry index as [maximum stent/scaff old diameter in a single frame minus minimum 
stent/scaff old diameter in a single frame] divided by the maximum stent/scaff old 
diameter [19]. Note that the maximum and the minimum stent/scaff old diameters in this 
calculation were possibly located in two diff erent frames over the length of the device 
implanted (Figure 2).
Intravascular ultrasound Assessment of Lesion Calciﬁcation
The MSA frames selected upfront for each lesion were also assessed by two experienced 
cardiologists to quantify calcium, as previously described [19–22]. Calcium produced bright 
echoes (using the adventitia as reference) with acoustic shadowing (attenuation) of 
deeper arterial structures. The extent and distribution of lesion calcification were assessed 
as follows:
•  The location of the calcium was defined as superficial (calcium at the intimal/lumen 
interface or closer to the lumen than to the adventitia), deep (calcium at the media/
adventitia border or closer to the adventitia than to the lumen), or both.
•  The largest arc of calcium was measured in degrees with a protractor centered on the 
lumen. If there was more than one deposit of calcium in the frame, the total arc of 
calcium for that frame was obtained by adding up the arcs of each individual deposit. 
Calcification was then classified an none, one-quadrant (≤90° ), two- quadrant (91° to 
180° ), three-quadrant (181° to 270° ), or four-quadrant (271° to 360° ) calcification.
 figure 2. Relationship between the symmetry and eccentricity indices of a intracoronary device. Minimum and 
maximum diameters over the length of the device are shown. Two cross-sections with diff erent eccentricity indices 
are also shown. [Color fi gure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Statistical Analysis
Categorical variables are presented as counts and percentages and compared by means 
of the Chi-square test. Continuous variables are presented as means ± standard deviation 
(SD). The distribution of the variables was tested as normal or non normal by Kolmogorov-
Smirnov test. Depending on the distribution of the data, comparison between groups 
was made with the ANOVA test with Bonferroni correction or with the Kruskal-Wallis test 
with Dunn correction for multiple comparisons. Correlation between parameters was 
performed by Pearson or Spearman test, depending on their distribution. Cardiac death, 
any acute myocardial infarction and ischemia-driven target lesion revascularization at 
6-month follow-up were considered as major cardiac events (MACE), according to the 
original protocol of ABSORB A and B trials, and SPIRIT I and II trials [7,8,10]. The threshold 
between the considered normal and non normal value for the eccentricity index was ≥0.7, 
as previously described [3,11]. A multivariate linear regression analysis was tested for the 
independent predictors of eccentricity index: symmetry index, type of lesion according to 
AHA/ACC classification, target vessel, size of the device as a categorical variable (size of 3.0 
x 18 mm or not) and device implanted (BVS vs. XIENCE V) were introduced in the model. A 
two side P-value <0.05 was considered as significant. Statistical analyses were performed 
with use of SPSS 13.0 software (SPSS, Chicago, IL).
R E S u LT S
Baseline Clinical and Angiographic Characteristics
We studied 242 patients (249 lesions) with available post-stent/scaffold implantation 
IVUS analyses and subdivided these into three groups according to the device implanted. 
Group 1 (28 patients): ABSORB Cohort A trial, BVS 1.0; group 2 (94 patients): ABSORB 
Cohort B trial, BVS 1.1, and group 3 (120 patients/127 lesions): SPIRIT I and II trials, XIENCE 
V stent. Table 1 shows the baseline clinical characteristics.
No significant differences were found between the groups in the pre-treatment QCA 
analysis. The diameter and the length of the stents/scaffold implanted were significantly 
different between the groups (both P < 0.0001). In particular, only two (7.1%) patients 
from group 1 received a BVS 1.0 3.0 x 18 mm, while all the patients (100%) from group 2 
received a BVS 1.1 3.0 x 18 mm, and 37 patients (31%) from group 3 received a XIENCE V 
3.0 x 18 mm. Six-month follow-up data were available in 225 patients (92.9%). A total of 7 
MACE were recorded: 1 (3.5%) MACE was recorded for BVS 1.0 [9], 4 (4.2%) MACE for BVS 1.1 
[11], and 2 (1.9%) MACE for XIENCE V [7,8].
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table 1. Clinical and Angiographic Baseline Characteristics.
BVS 1.0
(patients/lesions = 28)
BVS 1.1
(patients/lesions = 94)
xIENCE V
(patients = 120; 
lesions = 127)
P-value
Age, mean ± SD 62.0 ± 9.0 60.7 ± 8.9 61.6 ± 10.5 0.90
Male, % (n) 57.1 (16) 61.7 (58) 76.6 (92) 0.23
Hypertension requiring medication, % (n) 57.1 (16) 56.3 (53) 68.3 (82) 0.49
Hyperlipidaemia requiring medication, % (n) 60.7 (17) 65.9 (62) 77.5 (93) 0.57
Smokers, % (n) 21.4 (6) 15.9 (15) 36.6 (44) 0.05
Diabetes, % (n) 3.5 (1) 15.9 (15) 20 (24) 0.20
Previous PCI, % (n) 3.5 (1) 4.2 (4) 6.6 (8) 0.82
Previous AMI, % (n) 7.1 (2) 17.0 (16) 40 (48) 0.04
Renal Impairment, % (n) 3.5 (1) 2.1 (2) 1.6 (2) 0.71
Stable angina, % (n) 71.4 (20) 63.8 (60) 64.1 (77) 0.41
Unstable angina, % (n) 25.1 (7) 31.9 (30) 33.3 (40) 0.01
Silent ischaemia, % (n) 3.5 (1) 4.3 (4) 2.6 (3) 0.48
Target vessel, % (n)
Left anterior descending 53.5 (15) 44.6 (42) 48.8 (62) 0.83
Left Circumflex 25.0 (7) 22.3 (21) 22.8 (29) 0.69
Right coronary artery 21.5 (6) 33.1 (31) 28.4 (36) 0.78
AHA/ACC lesion classification, % (n)
A 0 (0) 1 (1.1) 2 (1.5) 0.46
B1 18 (64.3) 52 (55.3) 34 (26.7) 0.01
B2 10 (35.7) 8 (40.4) 76 (59.8) 0.01
C 0 (0) 3 (3.2) 15 (12) 0.01
Diameter of stent implanted (mean ± SD, mm) 3.0 ± 0.0 3.0 ± 0.0 3.17 ± 0.3 0.01
Length of stent implanted (mean ± SD, mm) 12.2 ± 1.1 18.0 ± 0.0 22.8 ± 8.5 0.01
QCA analysis pre-treatment
RVD (mean ± SD, mm) 2.69 ± 0.47 2.61 ± 0.37 2.66 ± 0.44 0.71
MLD (mean ± SD, mm) 1.05 ± 0.26 1.06 ± 0.28 1.10 ± 0.30 0.67
Diameter stenosis (mean ± SD, %) 60 ± 11 58 ±9 58 ± 8 0.83
PCI = percutaneous coronary interventions; AMI = acute myocardial infarction; AHA/ACC = American heart 
association/American college of Cardiology; QCA = quantitative coronary angiography; RVD = reference vessel 
diameter; MLD = minimum lumen diameter.
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Intravascular ultrasound Analysis After Implantation
Both the mean lumen area and the MSA were significantly lower for the BVS 1.0 and 1.1 
compared to XIENCE V (P < 0.001; Table 2). However, in a further sub-analysis, including 
only the stents with the same size (3.0 x 18 mm), no significant differences were found 
between the groups in terms of mean lumen area (P = 0.368) and post-procedural MSA 
(P = 0.268).
Eccentricity and Symmetry Index After Implantation
The eccentricity index, either average-of-all-frames or at the MSA, was significantly lower 
for BVS 1.0 and 1.1 as compared to XIENCE V (both P < 0.001). Conversely, the symmetry 
index was significantly lower for XIENCE V compared to BVS 1.0 and BVS 1.1 (P < 0.001) 
(Figure 3). Analyzing the 3.0 x 18 mm stents alone, the BVS maintained a lower eccentricity 
index and a higher symmetry index compared to XIENCE V (both P < 0.001). No significant 
differences were found, in terms of eccentricity and symmetry index, when comparing the 
3.0 x 18 mm devices against other sizes (Table 3).
Whilst no patients demonstrated an average eccentricity index per stent below the 
threshold of 0.7, 10 patients (4.1%) exhibited an eccentricity index at the MSA below 0.7: 
two (7.1%) of these had a BVS 1.0, seven (7.4%) a BVS 1.1, and one (0.8%) a XIENCE V (P 
= 0.023). Only one MACE (10%) occurred in the patients with a value <0.7 (n = 10), whilst 
the remaining six MACE (2.5%) occurred in those patients with a value > 0.7 (n = 239) (log 
rank test P = 0.283).
There was an inverse correlation between the symmetry and eccentricity indices for the 
XIENCE V (r = -0.61, P < 001) and BVS (r =-0.69, P < 0.001) (Figure 4). 
table 2. Intravascular Ultrasound Postprocedure Data.
BVS 1.0  
(28 lesions)
BVS 1.1 
(94 lesions)
xIENCE V 
(127 lesions)
P-value between 
the groups
P-value 
xIENCE V vs. 
BVS 1.0 and BVS 1.1
Mean vessel area (mm2) 13.22 ± 3.65 14.13 ± 3.38 14.84 ± 3.91 0.113 0.151 vs. BVS 1.0
0.632 vs. BVS 1.1
Mean lumen area (mm2) 6.01 ± 1.09 6.42 ± 1.03 7.22 ± 1.65 <0.001 <0.001 for both
Mean plaque area (mm2) 7.21 ± 2.78 7.68 ± 2.64 7.65 ± 2.72 0.726 1.000 for both
Minimum stent/scaffold area (mm2) 5.04 ± 1.00 5.28 ± 0.99 5.96 ± 1.52 <0.001 <0.001 for both
Eccentricity index 0.86 ± 0.05 0.88 ± 0.03 0.92 ± 0.03 <0.001 <0.001 for both
Eccentricity index at MSA frame 0.83 ± 0.09 0.85 ± 0.08 0.90 ± 0.06 <0.001 <0.001 for both
Stent/scaffold symmetry index 0.30 ± 0.07 0.31 ± 0.06 0.26 ± 0.07 <0.001 <0.001 for both
Data are expressed as mean ± SD. BVS: bioresorbable vascular scaffold; MSA: Minimum stent/scaffold area.
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figure 3. Distribution of symmetry (left panel) and eccentricity index at MSA (right panel) between the groups. 
XIENCE V shows the lowest symmetry index and highest eccentricity index, signifi cantly diff erent compared to that of 
BVS 1.0 and BVS 1.1 (P < 0.001 in the comparison between all the groups, and P < 0.001 in post-hoc statistical analysis 
between XIENCE V vs. BVS 1.0 and BVS 1.1). MSA 5 minimum stent/scaff old area.
table 3. Eccentricity and Symmetry Index According to the Size of the Device.
3.0 x 18 mm Other sizes P-value
Eccentricity index XIENCE V 0.91 ± 0.03 0.92 ± 0.03 0.256
Symmetry index XIENCE V 0.27 ± 0.07 0.25 ± 0.07 0.101
Eccentricity index BVS 0.88 ± 0.03 0.86 ± 0.05 0.126
Symmetry index BVS 0.31 ± 0.06 0.30 ± 0.07 0.759
Data are expressed as mean ± SD. BVS: bioresorbable vascular scaff old.
table 4. Frequency and Distribution of Calcium Between the Groups.
BVS 1.0 
(28 lesions)
BVS 1.1 
(94 lesions)
xIENCE V 
(127 lesions)
P value between 
the groups
Presence and location of calcium, n (%)
No calcium 16 (57) 48 (51) 56 (44) 0.151
Only superficial 1 (3) 16 (17) 27 (21) 0.032
Only deep 9 (32) 20 (21) 28 (22) 0.346
Both superficial and deep 2 (8) 10 (11) 16 (13) 0.335
Distribution of the maximum arc, n (%)
One quadrant (≤90o ) 10 (83) 34 (74) 32 (45) 0.041
Two-quadrant (91o –180o ) 2 (17) 11 (24) 28 (39) 0.038
Three-quadrant (181o –270o ) 0 (0) 1 (2) 11 (16) 0.061
Four-quadrant (271o –360o ) 0 (0) 0 (0) 0 (0) na
BVS: bioresorbable vascular scaff old.
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figure 4. Correlation between the symmetry and the eccentricity indices for BVS (Panel A) and XIENCE V (Panel B). 
Dotted lines represent the median value of symmetry and eccentricity indices in the overall population. Full dots and 
stars represent the patients who developed a MACE during the 6-month follow-up. Note that the majority of the BVS 
are distributed in the quadrant lower/right, while the XIENCE V in the quadrant upper/left. TLR 5 ischemia-driven 
target lesion revascularization; non-Q MI 5 non-Q myocardial infarction. [Color fi gure can be viewed in the online 
issue, which is available at wileyonlinelibrary.com.]
190   |    Chapter 8
Multivariate analysis demonstrated that independent predictors of eccentricity index 
were the symmetry index (P < 0.001) and the implanted device (P < 0.001).
Eccentricity Index at MSA According to Lesion Calciﬁ cation
By IVUS, calcium was identifi ed at MSA in 129 frames (52%). When present, it was only 
superfi cial in 44 (34%), only deep in 57 (44%) and both superfi cial and deep in 28 (22%). 
The maximum arc of calcium measured was 42° ± 57°. The distribution of the maximum 
arc of calcium was one-quadrant in 76 (59%), two-quadrant in 41 (32%), three-quadrant 
in 12 (9%). 
Table 4 shows the frequency and distribution of calcium between the groups.
Both BVS (0.82 ± 0.09 vs. 0.87 ± 0.08, P < 0.01) and XIENCE V (0.89 ± 0.04 vs.0.92 ± 0.04, P < 
0.01) exhibited a signifi cantly lower eccentricity index at the MSA in presence of calcium 
compared to its absence. The eccentricity index at the MSA of BVS was signifi cantly lower 
compared to XIENCE V, either with or without the presence of calcium, (both P < 0.01) 
(Figure 5). No diff erence in eccentricity index was found between the groups according to 
the localization of calcium (deep, superfi cial or both). We observed that when there was a 
maximum arc of calcium in two or three quadrants, the eccentricity indices for both BVS 
(one-quadrant 0.85 ± 0.08, two-quadrant 0.81± 0.08, three-quadrant 0.72, P = 0.101) and 
Xience V (one quadrant 0.91 ± 0.05, two-quadrant 0.87 ± 0.06, three-quadrant 0.87 ± 0.05, 
 
figure 5. Two examples of eccentricity index of XIENCE V and BVS in MSA frames in presence of calcium (from 7 to 11 
o’clock). Red circles with dotted lines represent the stent/scaff old contours; the minimum and maximum diameters 
are drawn inside as continuous red line. Green lines represent the external elastic membrane. Note that the polymeric 
struts of the BVS are brighter and thicker than struts of XIENCE. [Color fi gure can be viewed in the online issue, which 
is available at wileyonlinelibrary.com.]
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P = 0.005) were lower as compared to the maximum arc of calcium being present in only 
one quadrant.
D I S C u S S I O N
The major findings of our analysis are: (1) BVS exhibits a lower eccentricity index when 
compared to a metallic stent; (2) BVS tends to have a higher symmetry index compared 
to a metallic stent; nevertheless (3) these differences in geometrical parameters did not 
seem to generate clinical events in the small cohort of patients studied at 6 months.
Some properties influenced by stent material and design, such as conformability and 
flexibility, have previously been studied in various metallic stent platforms [23–25]. However, 
these geometrical parameters seen in the metallic stent era have to be re-evaluated with 
the recent introduction of the polymeric bioresorbable scaffolds [26,27].
The BVS 1.0 and 1.1 have different geometrical designs, but are manufactured from the 
same material. The BVS 1.1 and the XIENCE V have similar designs, but are made from 
differing materials. Our study shows that different values of eccentricity and symmetry 
are observed when comparing BVS with conventional metallic stents. We found that 
while an everolimus-eluting metallic stent tends to exhibit a symmetrical shape and a 
high eccentricity index after deployment, the everolimus-eluting BVS tends to have a less 
symmetrical shape and a low eccentricity index (Fig. 5). The relationship between these 
two parameters is inversely correlated for both devices, but the slope of this correlation is 
different (Fig. 3). Thus, device symmetry and eccentricity seem to be related to the material 
rather to the device design itself. The size of the device, and in particular its length, do not 
seem to have any significant influence on the eccentricity and symmetry of the devices, 
but—as expected—differences in device sizes appear to have an impact on the mean 
lumen area and the MSA after implantation. The characteristics of the lesion treated, 
evaluated by the ACC/AHA classification, do not seem to influence the eccentricity index, 
although they were differently distributed between the groups. Multivariate analysis, 
indeed, demonstrated symmetry index and type of the device implanted (BVS vs. XIENCE 
V) to be the only independent predictors of the eccentricity index.
We explored also the influence of lesion’s calcification, estimated by IVUS, on the 
eccentricity index in the MSA frame. As not all the patients included in the analysis 
received an intravascular ultrasound virtual histology (VH) imaging, we used a validated 
greyscale IVUS methodology for calcium quantification [22]. In addition use of greyscale 
IVUS data overcomes the problem of VH dense calcium overestimation in the presence 
of a BVS or metallic stent, as the stent/scaffold struts are recognized as dense calcium 
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by the VH [28,29]. We found that in presence of calcium the eccentricity at MSA frame for 
both devices is lower, confirming that BVS exhibits a lower eccentricity index compared 
to XIENCE V (Figure 5). 
It is noteworthy to consider that despite these differences in geometrical properties, BVS 
has previously been shown to have an acute recoil only slightly higher, but insignificantly 
different, from that of theXIENCE V, implying for both devices a sufficient radial strength 
to counteract the recoil of the vessel [26].
The different grade of eccentricity and symmetry of the BVS does not seem to generate 
clinical events, although our study was obviously underpowered to demonstrate this. An 
eccentricity value of 0.7 has previously been shown to be an acceptable cut-off in the 
evaluation of good stent expansion in the MUSIC trial, with favorable angiographic results 
seen at 6-month follow-up [3]. Otake et al. found that a low eccentricity index may be 
associated with thrombus formation after sirolimus-eluting stent implantation [6]. Alfonso 
et al., analyzing the IVUS data of 12 consecutive patients with stent thrombosis, found 
that MUSIC criteria were not fulfilled in any patient [30]. Nevertheless, closer analysis of 
the single MUSIC criteria in each patient showed that the eccentricity index was above 
0.7 in every case. Stent under-expansion or malapposition, inflow/outflow disease or 
edge dissections were suggested to be more important. These findings have also been 
confirmed in larger IVUS studies [31–33].
Limitations
The low risk nature of these patients may have contributed to their favorable outcomes 
and lower rate of MACE during follow-up. Therefore, the results may be difficult to 
generalize or to apply to a less selected patient population treated in different settings. A 
more complex type of lesions and patients are currently recruited in the ABSORB EXTEND 
registry that will enroll 1,000 patients.
CO N C Lu S I O N
The bioresorbable vascular scaffold appears to have reduced eccentricity index and 
increased symmetry index, when compared to conventional metallic stents, without 
detectable impact on 6-month MACE. Long term IVUS follow-up is required to assess 
the geometrical outcome of these devices and to ascertain the impact of these peri-
procedural IVUS parameters on the long-term outcome.
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A B S T R AC T
Aims Optical coherence tomography (OCT) of a bioresorbable vascular scaffold 
(BVS) produces a highly reflective signal outlining struts. This signal interferes 
with the measurement of strut thickness, as the boundaries cannot be accurately 
identified, and with the assessment of coverage, because the neointimal 
backscattering convolutes that of the polymer, frequently making them 
indistinguishable from one another. We hypothesise that Gaussian line spread 
functions (LSFs) can facilitate identification of strut boundaries, improving the 
accuracy of strut thickness measurements and coverage assessment.
Methods and results Forty-eight randomly selected BVS struts from 12 patients 
in the ABSORB Cohort B clinical study and four Yucatan minipigs were analysed at 
baseline and follow-up (six months in humans, 28 days in pigs). Signal intensities 
from the raw OCT backscattering were fit to Gaussian LSFs for each inter- face, from 
which peak intensity and full-width-at-half-maximum (FWHM) were calculated. 
Neointimal coverage resulted in significantly different LSFs and higher FWHM 
values relative to uncovered struts at baseline (p<0.0001). Abluminal polymer-
tissue interfaces were also significantly different between baseline and follow-up 
(p =0.0004 in humans, p <0.0001 in pigs). Using the location of the half-max of the 
LSF as the polymer tissue boundary, the average strut thickness was 158±11 µm at 
baseline and 152±20 µm at six months (p=0.886), not significantly different from 
nominal strut thickness.
Conclusions Fitting the raw OCT backscattering signal to a Gaussian LSF facilitates 
identification of the interfaces between BVS polymer and lumen or tissue. Such 
analysis enables more precise measurement of the strut thickness and an objective 
assessment of coverage.
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I N T R O D u C T I O N
The ABSORB™ bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA, 
USA) consists of a semi-crystalline poly(L-lactide) (PLLA) backbone and conformal coating 
of amorphous poly(D,L-lactide) (PDLLA) and the antiproliferative agent everolimus. The 
ABSORB BVS struts are fully resorbed approximately two years after implantation,1,2 
following a process in which the long chains of PLLA and PDLLA are progressively 
shortened as the ester bonds present in each lactic acid repeat unit are hydrolysed. 
Ultimately, PLLA and PDLLA degrade to lactic acid, which is metabolised via the Krebs’ 
cycle.3 ABSORB has exhibited excel- lent clinical and angiographic results up to two years 
follow-up.1,4
A BVS is particularly suitable for optical coherence tomography (OCT) imaging, given the 
translucency of the polymers from which it is manufactured. The transmitted light can 
readily penetrate the material and any backscattering stems from changes in refractive 
index on a length scale greater than or equal to the wavelength of the light. Immediately 
post-implantation, backscattering associated with the BVS is only significant at the 
borders of the strut, and changes in backscattering at later time points suggest an 
evolution in polymer microstructure on the length scale described above. Struts imaged 
with OCT post-implantation typically appear as a box-shaped highly reflective frame that 
marks the refractive index change at the lumen-polymer and polymer-tissue interfaces.1,4
However, measuring the strut thickness from leading-edge to leading-edge of the 
adluminal and abluminal boundaries of this frame results in values greater than the 
nominal 158 μm value characteristic of the backbone and coating of the ABSORB BVS 
strut. This discrepancy highlights a lack of precision in the measurement and the need 
to develop a methodology by which OCT signals may be used to accurately discern the 
true edges of BVS struts. Even histological assessment may not provide accurate strut 
measurements at all-time points due to processing artifacts,2 reinforcing the importance 
of improving the accuracy of OCT measurements.
OCT is an experimental tool for the evaluation of neointimal coverage after implantation 
of metallic stents5-10 and translucent polymeric scaffolds.2 Coverage assessed by OCT in	
vivo	 correlates well with neointimal coverage assessed by histology in experimental 
animal models.2,5-10 Unlike metallic stents, the assessment of coverage in the ABSORB BVS 
is more challenging, because the backscattering from thin neointimal layers mixes with 
that from the polymer interface and can be difficult to discern in a conventional analysis 
of the log-transformed OCT signal.
The basic principles of light and its interaction with matter provide the means by 
which these challenges may be addressed. A point-spread function (PSF) describes the 
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response of an imaging system to a point source or point object. Similarly, the spreading 
of light along a perfect line or slit has been called the line spread function (LSF).11 Because 
OCT is a measurement of backscattering intensity, the edge of a BVS strut forms a 
relatively uniform line from which a LSF can be measured. However, when tissue or other 
backscattering media are present, the uniformity of the optical response at the edge 
may vary. By smoothing the edge response variance due to backscattering tissue, the LSF 
may facilitate the definition of BVS strut edges and provide an objective criterion for the 
measurement of strut thickness and tissue coverage.
M E T h O D S
Clinical study
The ABSORB Cohort B study (NCT00856856) design has been published elsewhere.12 It 
enrolled patients older than 18 years with diagnosis of stable or unstable angina pectoris or 
silent ischaemia and de	novo	lesions in native coronary arteries amenable to percutaneous 
treatment with the ABSORB BVS. Target lesions were required to be characterised 
by percent diameter stenosis greater than or equal to 50% by visual estimation and 
reference vessel diameter of 2.5-3.5 mm. Major exclusion criteria were: acute myocardial 
infarction, unstable arrhythmias, left ventricular ejection fraction less than or equal to 
30%, restenotic lesions, lesions located in the left main coronary artery or in bifurcations 
involving a side branch greater than 2 mm, a second clinically or haemodynamically 
significant lesion in the target vessel, documentation of intracoronary thrombus, or initial 
TIMI 0 flow. All the study lesions were treated with the ABSORB BVS revision 1.1 (3.0×18 
mm). Fifty percent of the cohort underwent scheduled invasive follow-up six months 
after the implantation, including OCT study whenever available at the participating site. 
The registry was approved by the ethics committee at each participating site, and each 
patient gave written informed consent before inclusion in the study.
Preclinical (Porcine) study
All experimentation conformed with the Animal Welfare Act, the Guide for Care and Use 
of Laboratory Animals (NIH Publication 85-23, 1996), and the Canadian Council on Animal 
Care regulations. All procedures were performed at AccelLab, Inc. (Montreal, Quebec, 
Canada), accredited by the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) and in accordance with the protocol approved by the institutions 
animal care and use committee (IACUC).
Four Yucatan mini-swine implanted with BVS were used in this analysis. Animals were 
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administered oral acetylsalicylic acid (325 mg initial dose, 81 mg daily subsequently) 
and clopidogrel (300 mg initial dose and 75 mg daily subsequently) beginning three 
days prior to BVS implantation. Animals were tranquilised with ketamine (0.04 mg/
kg), azaperone (4.0 mg/kg), and atropine (25 mg/kg) intramuscularly. Anaesthesia was 
achieved with propofol, (1.66 mg/kg IV), and maintained with inhaled isofluorane (1-
3%) throughout the procedure. A vascular access sheath was placed in the femoral 
artery percutaneously. Before catheterisation, heparin (5,000 to 10,000 U) was injected 
to maintain an activated clotting time greater than 250 s. For each BVS deployment, an 
arterial segment was chosen so as to achieve a balloon-to-artery ratio of 1.1:1, ensuring full 
apposition based on angiographic assessment. Each animal received a single BVS revision 
1.1 in one of the three main coronary arteries. Although a 3.0×12 mm BVS was used in 
the animal studies, the design was the same as that used in the clinical study. Animals 
recovered from anaesthesia under veterinary care for future time point analysis following 
the procedure. All the devices were imaged by OCT immediately after implantation and 
at 28-day follow-up.
Oct Image acquisition and analysis
In both animal and human procedures, OCT pullbacks were obtained at baseline and 
follow-up with a Fourier-domain C7 system using a Dragonfly™ catheter (St. Jude Medical 
Inc., Saint Paul, MN, USA) 10-15 μm axial and 20-40 μm lateral resolution13 at a rotation 
speed of 100 frames/s with non-occlusive technique.14
After infusion of intracoronary nitroglycerine, the imaging wire was withdrawn by 
a motorised pullback at a constant speed of 20 mm/s, while Iodixanol 320 contrast 
(Visipaque™, GE Health Care, Cork, Ireland) was infused through the guiding catheter at a 
continuous rate of 2-4 mL/min.
A random sampling of 12 struts at each time point from both the animal and the human 
studies was selected using the following criteria: (1) OCT images were obtained with a 
Fourier-domain C7 system at both baseline and follow-up; (2) the luminal edge of the strut 
was perpendicular to the light source in order to minimise the effect of wire eccentricity 
and vessel-catheter misalignment; and (3) the strut was well-apposed.
Light intensity analysis was performed in the region surrounding the selected struts using 
ImageJ 1.43 u software (Wayne Rasband, National Institutes of Health, USA). The raw polar 
image was used to ensure that interpolation, dynamic range compression, or other image 
processing did not alter the signal and bias the analysis. Because the strut boundaries 
are expected to be found within the reflective frame, an intensity profile was created by 
averaging consecutive pixels aligned parallel to the frame boundary and spanning the 
whole reflective frame orthogonally through the frame boundaries beginning on the 
202   |    Chapter 9
adluminal side. Since the C7 system displays 500 A-lines per frame, 976 pixels per line, and 
a depth of field 5 mm, the axial dimension of a single pixel in raw polar coordinates is ca. 
5.12 µm for in	vivo	coronary imaging with this OCT catheter. Using the catheter dimensions 
as a standard (0.89 mm), we measured the pixel/µm conversion factor at 5.05 µm and used 
this for the measurements herein. The result is a two-dimensional profile plot of intensity 
versus distance through the centre of the strut. The following interfaces were analysed 
(Figure 1): lumen-polymer, defined as the optical signal generated by the adluminal border 
of the strut at baseline (LP-bl); lumen-neointima-polymer, defined as the optical signal 
generated by the adluminal border of the strut at follow-up (LNP-fu); polymer-vessel wall, 
defined as the optical signal generated by the abluminal border of the well-apposed 
strut at baseline or follow-up (PV-bl; PV-fu); lumen-vessel wall, defined as the optical signal 
generated by the vessel wall of a strut-free sec- tor at baseline or follow-up (LV-bl; LV-fu).
The data corresponding to each interface were individually summarised in plots of 
optical intensity versus distance, where the origin of the plot was located at the point 
corresponding to the strut centre and zero optical intensity (Figure 2). The centre of the 
strut was determined as the point equidistant from the points at which the intensity signal 
exceeded a consistent threshold value at the strut interior side of the adluminal and 
abluminal interfaces.
figure 1. Denomination of the different optical interfaces analyzed.
LNP-fu: Lumen-neointima-polymer at follow-up; LP-bl: Lumen-polymer at baseline; LV-bl: Lumen-vessel at baseline; 
LV-fu: Lumen-vessel at follow-up; PV-bl: Polymer-vessel at baseline; PV-fu: Polymer-vessel at follow-up.
Light intensity analysis of bioresorbable struts in vivo    |   203
PART
II
The curves for each type of interface were fi t to a Gaussian form given by:
  ,
where a is the maximum intensity of the curve, b is the midpoint of the Gaussian curve, 
and c is a function of the full-width-at-half-maximum (FWHM), namely  .
Coeffi  cients for the Gaussian curve fi ts were determined using an iterative least squares 
minimisation process (Figure 3). Gaussian curves were chosen to remain consistent with 
the practice commonly used for PSFs. Because the LSF diff ers from the PSF and includes 
scattering components, other functions commonly used to describe optical profi les, 
Lorentzian and exponential functions15-17, were also evalu- ated and found inferior to the 
Gaussian fi ts (data not shown). Where tissue was present, the LSF was derived through 
figure 2. Graphic representation of the 12 struts analyzed at baseline. 
The coordinate system origin is located at the calculated center of the strut (x-axis) and zero optical intensity (y-axis). 
The strut center is defi ned as the point equidistant to the rises of the adluminal (LP-bl interface) and abluminal (PV-bl 
interface) strut borders.
LP-bl: Lumen-polymer interface at baseline; PV-bl: Polymer-vessel interface at baseline.
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symmetry of a one-tailed Gaussian fit with the first peak defining the peak of the Gaussian 
function. Though the transition between polymer and tissue appears to be sigmoidal or 
step-like, mirroring a one-sided Gaussian function enabled comparison with the Gaussian 
fit of the uncovered strut. Additionally, the convolution of two Gaussian functions is a 
Gaussian function, and thus this best represented the optics of the system.
Two approaches were used to determine the location of strut interfaces. For struts without 
tissue coverage (e.g., LP-bl), the strut interface was assigned to the location of the peak 
of the signal intensity. The justification is that the high signal contrast of the LP interface 
represents an ideal LSF example, and the peak of the LSF defines the line. Alternatively, 
for interfaces adjacent to tissue (e.g., LNP-fu, PV-bl, PV-fu, LV-bl, LV-fu), the location of the 
half-max was assigned to the interface to represent the spatial location of intensity 
halfway between the low polymer intensity and high tissue intensity18. Because there 
was no normalisation of the intensity signal, the half-max was chosen to enable objective 
threshold based filtering. All strut width measurements were performed according to 
these definitions.
figure 3. Lumen-polymer interface curve fit.
LP-bl: Lumen-polymer interface at baseline.
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Statistical analysis
Non-linear least squares curve fits were compared with a Snedecor F-test using sum of 
squares for two separate curves and sum of squares of a single curve generated from 
combined data. Strut width measurements were compared using a two tailed Fisher’s 
student t-test. All the analysis was performed with Microsoft Excel 2003, SP3 with solver 
toolkit.
r e s u lt s
Results in human
Twenty-four patients in the ABSORB Cohort B study received OCT at baseline and 6-month 
follow-up. In only 12 of these cases were the images acquired with a Fourier-domain 
C7 system. One strut meeting the selection criteria of the study was randomly selected 
for each OCT pullback (12 at baseline, 12 at follow-up).Across all types of interface, the 
FWHM of the signal was greatest for LV-fu (56.91 µm) and least for LP-bl at baseline (25.86 
µm). Table 1 summarises the curve fit parameters for each interface type (Figures 4 and 
5). Neointimal coverage of struts resulted in an increase of the FWHM, and the curves 
corresponding to LP-bl and LNP-fu interfaces differed significantly (p<0.0001, Table 2). 
There was no significant difference between LNP-fu and PV-fu interfaces (LNP-fu vs. PV-
fu, p=0.347). However, the PV-bl interface differed significantly from the PV-fu interface 
(PV-bl vs. PV-fu, p=0.0004) as well as the LV-bl, LV-fu, and LPN-fu interfaces (PV-bl vs. LV-
bl, p<0.0001; PV-bl vs. LV-fu, p<0.0001; PV-bl vs. LPN-fu, p<0.0001). Measuring from peak 
to half-max (PV-bl to PV-bl) and half-max to half-max (LNP-fu to PV-fu) for baseline and 
follow-up, respectively (Figure 6), the average strut thickness was 158±11 μm at baseline 
and 152±20 μm at the 6-month follow-up (p=0.41), both of which are similar to the 
nominal BVS strut thickness (ca. 152 μm for the backbone only and ca. 158 μm for the 
backbone and coating).
table 1. Parameters characterizing the curve fit for each type of interface.
Interface
Swine human
Max Intensity FWhM (μm) Max Intensity FWhM (μm)
LP-bl 303.33 22.24 244.78 25.86
PV-bl 1118.22 50.69 544.32 45.32
LV-bl 801.67 49.42 338.71 52.00
LNP-fu 635.54 60.71 475.06 38.89
PV-fu 542.40 54.37 490.91 42.97
LV-fu 681.54 54.00 739.27 56.91
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Results In the swine Model
Three struts meeting the same selection criteria defined for the clinical sample were 
randomly selected in each of the four animals (12 at baseline, 12 at follow-up). The curve 
fit parameters for each interface had absolute values different than the ones reported in 
humans, but the same trends were observed.
Similar to the clinical samples, the FWHM increased when tissue was present. In swine 
samples, LNP-fu had the greatest FWHM at 60.71 µm, while LP-bl had the smallest FWHM 
figure 4. Fitting curves characterizing the different interfaces at baseline in human and swine studies.
FWHM: Full width at half max; LP-bl: Lumen-polymer at baseline; LV-bl: Lumen-vessel at baseline; PV-bl: Polymer-
vessel at baseline.
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figure 5. Fitting curves characterizing the different interfaces at follow-up in human (6 months) and swine (28 days) 
studies.
FWHM: Full width at half max; LNP-fu: Lumen-neointima-polymer at follow-up; LV-fu: Lumen-vessel at follow-up; PV-
fu: Polymer-vessel at follow-up.
at 22.24. Table 1 summarises the curve fit parameters for each interface (Figures 4 and 5). 
Neointimal coverage of struts resulted in an increase of the FWHM when going from LP-bl 
to LNP-fu (p<0.0001, Table 2). Paralleling the human results, the LNP and PV interfaces had 
similar FHWM at the 28-day follow-up. All other curves were significantly different from 
each other with p values less than 0.01.
Based upon the previously defined edge detection algorithm, the average strut thickness 
was 164±14 µm at baseline and 172±16 µm at the 6-month follow-up (p=0.28).
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figure 6. (a) Strut thickness measured from the peak intensity of the fitting curve for the adluminal interface to the 
half-max of the fitting curve for the abluminal interface at baseline, and (b) Strut thickness measured from the half-
max of the fitting curve for the adluminal interface to the half-max of the fitting curve for the abluminal interface at 
follow-up (human data).
table 2. Statistical comparison of curve fit: p-values from Snedecor F-tests.
Swine interface LP-bl PV-bl LV-bl LNP-fu PV-fu LV-fu
LP-bl -- <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PV-bl -- <0.0001 <0.0001 <0.0001 <0.0001
LV-bl -- <0.0001 <0.0001 0.005
LNP-fu -- 0.99 <0.0001
PV-fu -- <0.0001
LV-fu --
human interface LP-bl PV-bl LV-bl LNP-fu PV-fu LV-fu
LP-bl -- <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
PV-bl -- <0.0001 <0.0001 0.0004 <0.0001
LV-bl -- <0.0001 <0.0001 0.073
LNP-fu -- 0.347 <0.0001
PV-fu -- <0.0001
LV-fu --
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D I S C u S S I O N
The main findings of this study are: 1) the different interfaces between lumen, polymer, 
and vessel can be characterised in	vivo according to the peak intensity and the FWHM of 
the Gaussian fit of the raw OCT intensity signal; 2) considering the half-max of the LSF as 
the strut boundary when it is adjacent to tissue, the strut thickness remains the same at all-
time points and consistent with the nominal thickness of BVS struts given the resolution 
intrinsic to the OCT equipment.
To the best of our knowledge, this study is the first attempt to differentiate the interface 
between a translucent polymer and tissue on the basis of optical properties in	 vivo. It 
describes a methodology by which these interfaces may be defined that utilises LSFs to 
fit the raw OCT intensity signal and FWHM analysis to compensate for the convolution of 
polymer and tissue reflectivity.
The intensity of the OCT signal is a measurement of the back- scattering intensity of 
infrared light. The magnitude of changes in the refractive index on length scales greater 
than the wavelength of that light determines the backscattering intensity. In the case of 
a polymeric implant like the ABSORB BVS, a signal is produced at the boundary of the 
BVS strut, but there is no signal in the centre of the strut due to the homogeneity of the 
refractive index of the polymer.1,12 The FWHM of the axial reflectance at an interface has 
been reported as the true image resolution19. Though methodologies differ slightly from 
previous reports, the FHWM measurement for LP-bl reported here (22.24-25.86) may be 
consistent with the practical resolution of OCT in	 vivo for measurements of BVS struts. 
The absolute difference in the measured FWHM between human and swine is within the 
resolution of OCT. Additionally, slight variability in imaging catheters and the ability of 
the edge of the scaffold to be a perfect line could contribute to slight differences in the 
measured FWHM.
The LSF characterising the LP-bl interface is significantly different from that for interfaces 
where polymer is adjacent to tissue, because tissue increases backscattering in proximity 
to the interface and broadens the resulting backscattering signal. Hence, the FWHM 
increases. On the abluminal side of struts, the LSF also changes over time, as evidenced 
by the fact that the FWHM of the PV-bl and PV-fu interfaces differ significantly for both 
humans and swine.
Several factors may contribute to this result, including changes in the optical properties 
of the BVS near the interface or changes in the optical properties of the tissue due 
to pharmacological activity or foreign body response.Further bench and animal 
investigations will be needed to interrogate the mechanisms behind these observations.
As expected, the FWHM of the LNP-fu and PV-fu interfaces were not significantly different, 
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suggesting that optical changes at the BVS interface occur consistently in both locations 
over time.
Quantification of strut dimensions over time has been difficult due to the similarity of 
OCT backscattering signal from tissue and polymer. Utilisation of the LSF to characterise 
the OCT signal offers an objective tool by which the interface between tissue and polymer 
may be defined, resulting in a more consistent measurement of strut thickness.
According to the results reported here, no significant change in strut thickness is 
observed between baseline and six months, as the baseline measurements (158±11 
μm) were similar to the reported thickness of the device (ca. 158 μm). The finding that 
the strut thickness remains stable over this time scale is also consistent with the previous 
OCT results where a gross estimate of “mean strut core area” did not change significantly 
between baseline and six months in a cohort of 25 patients.12 Future investigation at 
longer time points will be required to evaluate changes in optical properties following 
further degradation and mass loss from the scaffold.
The second potential application of the LSF methodology applies to the objective 
assessment of tissue coverage of a BVS. Incomplete neointimal coverage of struts and 
incomplete endothelialisation are the morphologic features most strongly associated 
with stent thrombosis.20 Although OCT has been validated for the assessment of 
neointimal coverage after stenting in animal models,5-8 the inability to discriminate 
between neointima and fibrin/thrombus and the inability to detect endothelial rims 
thinner than the axial resolution of the equipment limit the specificity and the sensitivity 
of this technology, respectively. In metallic stents, the hyper-intense backscattering at the 
luminal edge of struts caused by the profound refractive index contrast between metal 
and tissue facilitates identification and accurate measurement of very thin layers of 
tissue covering the struts. Conversely, the assessment of tissue coverage of BVS is more 
challenging, because the refractive index contrast is less. For thin layers of tissue, the 
signal displayed is often indistinguishable from that generated by the LP interface alone, 
requiring more sophisticated signal processing to detect. In considering this issue, it is 
important to revisit the various length scales that frame the problem. Although OCT 
reflectivity can theoretically be caused by refractive index changes on a length scale as 
small as that of the wavelength of the OCT light (1.3 μm), the axial resolution of OCT is 
reported to be 10-15 µm13, and the FWHM of the LP-bl signal was measured at 22-26 
μm in the current study, The latter may rep- resent the practical resolution of OCT applied 
to polymeric materials. However, the presence of even thin layers of tissue broadens the 
FWHM, as reported herein, and consequently the LSF FWHM methodology might permit 
detection of tissue coverage even when the thickness of that coverage cannot be directly 
measured. A recent study demonstrated the potential of OCT analysis to discern between 
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tissue and fibrin/thrombus (i.e., specificity) in metallic stents.10 The LSF FWHM approach 
may constitute a step forward in improving sensitivity and provide an objective criterion 
for the assessment of neointimal coverage of BVS struts.
Besides the objective assessment of neointimal coverage and the differential diagnosis 
between neointima and fibrin10, the analysis of the raw linear OCT signal has been 
used to detect inflammation and to quantify the density of macrophages in the vessel 
wall21,22. An ongoing study is also using this technology to evaluate cardiac allograft 
vasculopathy (NCT01403142). All these fields constitute potential future applications 
for the hereby described LSF analysis, after adjusting the methodology. However, the 
diagnostic efficiency of LSF analysis is maximal when there exists a normal reference 
to compare: this uses to be readily available for study of intracoronary devices (post-
implant study), but it can be substantially more problematic for the study of the non-
stented vessel wall. Sub-cellular OCT appears as a more attractive alternative for the 
study of vessel inflammation and atherosclerosis in a near future23.
Limitations
Contrary to previous optical intensity analysis,10 the current study does not perform any 
normalisation of the signal intensity due to the lack of a reliable reference in the tissue or 
polymer. Therefore, the absolute intensity values are not directly comparable. The analysis 
was focused on the shape of the curves, represented by the LSF curve fit and FWHM 
calculation, which could explain the differences in absolute peak intensity between the 
human and swine results.
This study was performed on a random sampling of struts meeting specific inclusion 
criteria. This was necessary to circumvent challenging in	 vivo	problems, such as signal 
attenuation due to eccentricity of the imaging catheter and differences in interpolation as 
a function of distance from the light source. The described methodology cannot be directly 
applied to struts not meeting these criteria, e.g., struts lying oblique to the light beam, 
which are in fact the majority of struts, but further investigations to adapt this methodology 
for more general use are underway. The LSF analysis of raw linear OCT signal can be 
performed on any conventional commercially available OCT system, using simple specific 
software, but this analysis is still experimental and must be performed offline manually 
by experienced investigators. The assessment of oblique struts will require alignment of 
measurements perpendicularly to the adluminal strut surface, calculation of the angle of 
this adluminal surface with the light beam, and eventually deriving a correction factor. 
Automation of the analysis protocol will be essential before it can be used more broadly. 
Future validation studies to identify cut-off values, sensitivity, specificity, and predictive 
capability are still unknown.
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CO N C Lu S I O N S
Fitting the raw OCT backscattering signal to a Gaussian LSF facilitates identification of the 
interfaces between BVS struts and lumen or tissue. The resulting analysis enables more 
precise and consistent measurement of BVS strut thickness, which for the ABSORB Cohort 
B BVS remains unchanged from baseline to the 6-month follow-up and not different from 
the nominal value. It may also allow inferential detection of neointimal coverage that 
might not be detected with- out the benefit of this more sophisticated signal processing.
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A B S T R AC T 
Objectives We investigate the six month clinical outcome after implantation of 
a second generation 3.0mm Bioresorbable Everolimus-eluting Vascular Scaffolds 
(BVS) in small coronary vessels (<2.5mm).
Background BVS are a novel approach to treating coronary lesions and are untested 
in small vessels.
Methods The ABSORB Cohort B Trial is a multicentre single-arm, prospective, 
open-label trial in which 101 patients were enrolled. The pre-procedural RVD was 
assessed by quantitative coronary angiography during post-hoc analysis. The vessel 
size was overestimated, by visual assessment, in 41 patients prior to implantation 
of a 3.0mm BVS in vessels with a pre-procedural reference vessel diameter (RVD) 
<2.5mm. 
The study population was divided into two groups, group I (41 patients) with RVD 
<2.5mm and group II (60 patients) with RVD ≥2.5 mm. The composite endpoint 
of ischemia-driven major adverse cardiac events (ID-MACE), defined as ischemia-
driven target lesion revascularization (ID-TLR), myocardial infarction (MI) or cardiac 
death, were assessed. Out of the 45 patients scheduled for 6 month coronary 
angiography, 42 patients had the procedure performed with IVUS undertaken in 
40 of these patients. 
Results At 6 months no significant differences in ID-MACE (3/41, 7.3% vs. 2/60 cases, 
3.3% p=0.3933) were observed in the small and large vessel groups respectively. 
No cardiac deaths or episodes of in-scaffold thromboses were seen. Angiographic 
and IVUS follow-up demonstrated no differences in late lumen loss (0.16±0.18mm 
vs. 0.21±0.17mm, p=0.3525) or percentage lumen area stenosis (17.6±6.0% vs. 
19.8±8.5%, p=0.3643). 
Conclusion The second generation 3.0mm BVS appears to be safe in small vessels 
with similar clinical and angiographic outcomes compared to large vessels. 
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I N T R O D u C T I O N 
Fully bioresorbable drug-eluting vascular scaffolds (BVS, Abbott Vascular, Santa Clara, 
CA, USA) are a novel approach to treating coronary lesions in that they provide transient 
vessel support and drug delivery to the vessel wall. The first generation BVS demonstrated 
slightly higher acute and late recoil when compared to conventional metallic stents. (1,2) 
To further enhance support of the vessel wall, the strut design and the manufacturing 
processes of the polymer were modified, leading to the BVS revision 1.1; this device 
was subsequently investigated in the ABSORB Cohort B trial. Because of the single size 
availability of the BVS (3.0 mm in diameter), the target lesions were required to be located 
in vessels with a visual estimated vessel diameter of ≥2.5 mm and ≤3.3 mm. However, 
during the clinical use of the BVS, more than one third of the scaffolds were found to have 
been deployed in vessels with a pre-procedural reference vessel diameter (RVD) <2.5 mm. 
This protocol violation has provided the opportunity to assess the performance of the 3.0 
mm BVS device in these vessels. 
The purpose of this substudy is therefore to investigate the clinical and angiographic 
outcomes after implantation of the new generation of BVS in small coronary vessels (RVD 
< 2.5 mm). 
M E T h O D S 
Study design and population
The study design and device have previously been described (3). In brief, a total of 101 
patients were enrolled in the ABSORB Cohort B study and implanted with a 3mm BVS. 
Assessment of vessel size prior to BVS implantation was made by visual estimation of 
the operator. In the present post hoc analysis, the study population was divided into two 
groups based on the RVD prior to intervention. Group I included 41 patients (41 lesions) 
with a RVD <2.5mm and group II included 60 patients (61 lesions) with a RVD mm ≥2.5 
mm. Out of the 45 patients initially scheduled for 6 and 24-month coronary angiography, 
42 patients underwent the procedure at 6-month follow-up with IVUS analyses being 
performed in 40 cases. 
qCA and IVuS analysis
In all patients, analyses were undertaken by quantitative coronary angiography (QCA) 
using the Coronary Angiography Analysis System (Pie Medical Imaging, Maastricht, 
Netherlands). The reference vessel diameter was obtained by the interpolated method. 
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(4) Post procedural and follow-up scaffold segments were analyzed with phased array 
intravascular ultrasound (IVUS) catheters (EagleEye; Volcano Corporation, Rancho 
Cordova, CA, USA), with an automated pullback of 0.5 mm per second. Images were 
analyzed off-line with semiautomatic contours detection provided by dedicated software, 
as previously reported. (3) 
Statistical analysis 
Categorical variables are presented as counts and percentages. Continuous variables are 
presented as means ± SD. P-values are calculated with Fisher’s Exact test for binary variables 
and Wilcoxon’s Rank Sum test for continuous variables. All p-values are calculated for 
descriptive purposes and do not form part of formal hypothesis tests. Statistical analyses 
were performed using SAS (version 9.1.3).
R E S u LT S
Baseline	Characteristics	and	Procedural	Outcome
In the ABSORB Cohort B Trial, 101 patients were enrolled and 102 lesions treated with 
implantation of a BVS. 41 lesions had a RVD <2.5 mm and 61 lesions a RVD ≥2.5 mm 
(Figure 1). In the small vessel group, 34 (83%) lesions were located in the mid or distal part 
of main coronary arteries or in secondary branches. No significant differences in baseline 
demographics or clinical and angiographic characteristics were seen in both groups 
(Tables 1-2). Comparable pre-procedural percentage diameter stenoses (57.0±9.3% vs. 
60.3±10.3%, p =0.1000) and post-procedural acute gains (1.21±0.30 mm vs. 1.25mm±0.33 
mm, p= 0.4946) were observed.
Clinical	Outcomes
No statistically significant differences were observed in the incidences of both in-hospital 
(small vessel group: 2/41 cases, 4.9% and large vessel group 0/60 cases, 0%, p=0.1624) and 
6 month (small vessel group: 3/41 cases, 7.3% and large vessel group 2/60 cases, 3.3%, 
p=0.3933) MACE in both groups (Table 3). At 6 months, the incidences of ischemia driven 
TLR (1/41 patients, 2.4% vs. 1/60 patients, 1.7%, p=1.0000), TVR (2.6% vs. 1.7%, p=1.0000), 
and myocardial infarction (2/41 patients, 4.9% vs. 1/60 patients, 1.7%, p=0.5645) were 
similar in both groups with no cardiac deaths observed. At 6 months no episodes of 
scaffold thromboses, as defined by the Academic research Consortium (ARC)(5) definition, 
were reported. One episode of a non-ischemic driven TLR event was seen in the large 
vessel group.
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figure 1. Distribution of Pre-Implantation RVD in ABSORB Cohort B Trial Population.
More than one-third of the treated lesions (40.2%) in the ABSORB Cohort B trial had a pre-implantation reference 
vessel diameter (RVD) 2.5 mm. 
table 1. Baseline characteristics in intention–to-treat (ITT) population.
Small Vessels (<2.5mm) 
(N=41)
Large Vessels 
(>=2.5mm) (N=60)
P-value
Age (yrs) 62.4 ± 9.4 (41) 62.2 ± 8.7 (60) 0.9193
Male Gender 63.4% (26/41) 78.3% (47/60) 0.1169
Current Tobacco Use 22.0% (9/41) 13.6% (8/59) 0.2917
Diabetes 22.0% (9/41) 13.3% (8/60) 0.2875
Hypertension Requiring Medication 58.5% (24/41) 64.4% (38/59) 0.6757
Hypercholesterolemia Requiring Medication 85.4% (35/41) 73.3% (44/60) 0.2196
Family History of Coronary Artery Disease 60.5% (23/38) 50.8% (30/59) 0.4065
Prior PTCA 14.6% (6/41) 25.0% (15/60) 0.3180
Prior CABG 2.4% (1/41) 3.3% (2/60) 1.0000
Prior MI 17.5% (7/40) 30.0% (18/60) 0.2382
Target Vessel
 RCA 31.7% (13/41) 34.4% (21/61) 0.8326
 LAD 46.3% (19/41) 41.0% (25/61) 0.6845
 LCX 19.5% (8/41) 24.6% (15/61) 0.6332
American College of Cardiology/American Heart Association (ACC/AHA) Lesion Class 
 A 0.0% (0/40) 1.7% (1/60) 1.0000
 B1 52.5% (21/40) 56.7% (34/60) 0.6878
 B2 45.0% (18/40) 36.7% (22/60) 0.4143
 C 2.5% (1/40) 5.0% (3/60) 0.6479
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table 2. Baseline QCA characteristics pre and post procedure in intention–to-treat (ITT) population.
Small Vessels (<2.5mm) 
(N=41)
Larg Vessels (>=2.5mm) 
(N=60)
Difference 
[95% CI]
P-value
Pre Procedure
Reference Vessel Diameter (mm) 2.27 ± 0.15 (41) 2.83 ± 0.29 (61) -0.56 
[-0.65, -0.48]
<0.0001
Minimal Luminal Diameter (mm) 0.97 ± 0.20 (39) 1.12 ± 0.30 (59) -0.15 
[-0.25, -0.05]
0.0044
Percent Diameter Stenosis (%) 57.0 ± 9.3 (39) 60.3 ± 10.3 (59) -3.3 
[-7.3, 0.7]
0.1000
Post-Procedure
In-Scaffold Minimal Luminal Diameter 
(mm)
2.17 ± 0.22 (41) 2.37 ± 0.23 (61) -0.21 
[-0.30, -0.12]
<0.0001
In-Scaffold Percent Diameter Stenosis 
(%)
13.8 ± 4.0 (41) 16.2 ± 6.7 (61) -2.4 
[-4.5, -0.3]
0.0280
In-Scaffold Acute Gain (mm) 1.21 ± 0.30 (39) 1.25 ± 0.33 (59) -0.04 
[-0.17, 0.08]
0.4946
table 3. Adverse Events at 6-Month Follow-Up.
Small Vessels 
(<2.5mm) 
(N=41)
Large Vessels 
(>=2.5mm) 
(N=60)
P-value
ID-MACE (Cardiac Death, MI, ID-TLR) 7.3% (3/41) 3.3% (2/60) 0.3933
Cardiac Death 0.0% (0/41) 0.0% (0/60) NA
Myocardial Infarction (MI) 4.9% (2/41) 1.7% (1/60) 0.5645 
  QWMI 0.0% (0/41) 0.0% (0/60) NA 
  NQWMI 4.9% (2/41) 1.7% (1/60) 0.5645 
ID-TLR 2.4% (1/41) 1.7% (1/60) 1.0000 
  CABG 0.0% (0/41) 0.0% (0/60) NA 
  PCI 2.4% (1/41) 1.7% (1/60) 1.0000 
Non ID-TLR 0.0% (0/41) 0.0% (0/60) NA 
 CABG 0.0% (0/41) 0.0% (0/60) NA
 PCI 0.0% (0/41) 1.7% (1/60) 1.0000
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table 4. QCA Analysis at Baseline and 6-Month Follow-Up.
Small Vessels 
(<2.5mm) 
(N=20) 
Large Vessels 
(>=2.5mm) 
(N=25)
Difference 
[95% CI] 
P-value 
Baseline QCA Analysis 
Pre-Procedure
Reference Vessel Diameter (mm) 2.24 ± 0.17 (20) 2.96 ± 0.33 (25) -0.72 
[-0.88, -0.57]
<0.0001
Minimal Luminal Diameter (mm) 0.93 ± 0.22 (19) 1.15 ± 0.35 (25) -0.22 
[-0.40, -0.04]
0.0154
Percent Diameter Stenosis (%) 58.0 ± 11.1 (19) 60.8 ± 11.9 (25) -2.8 
[-9.9, 4.2]
0.4216
Post-Procedure
In-Scaffold Acute Gain (mm) 1.23 ± 0.37 (19) 1.29 ± 0.35 (25) -0.05 
[-0.28, 0.17]
0.6269
6-Month QCA Analysis 
In-Scaffold Late-Loss (mm) 0.16 ± 0.18 (19) 0.21 ± 0.17 (23) -0.05 
[-0.16, 0.06]
0.3525
In-Scaffold Percent Diameter Stenosis (%) 18.1 ± 7.2 (19) 20.2 ± 8.0 (23) -2.1 
[-6.8, 2.6]
0.3736
In-Scaffold Binary Restenosis 0.0% (0/19) 0.0% (0/23) 0.00% 
[Assump.  
not met]
NA
Six-month angiographic and IVuS results
QCA analyses at six-month were available in 42 patients (small vessel group: n=19, large 
vessel group: n=23). No statistical differences in-scaffold percentage diameter stenosis 
(18.1±7.2% vs. 20.2±8.0%, p=0.3736) and in scaffold late loss (0.16±0.18 mm vs. 0.21±0.17 
mm, p=0.3525) were observed between both groups. No cases of binary restenosis within 
the scaffold were evident in either group. (Table 4)
Grey-scale IVUS analysis (from 42 patients) demonstrated no statistically significant 
differences in the lumen area stenosis (17.6 ± 6.0 % vs. 19.8 ± 8.5 %, p=0.3643) or 
neointimal hyperplasia (NIH) area (0.06±0.12 mm2 vs. 0.09±0.12 mm2, p=0.4084) between 
the two groups. (Table 5).
However the comparison of IVUS results is limited by the small number of available data; a 
post-hoc power analysis showed that with this sample size, a difference in NIH area of 0.11 
mm² could be detected with 80% power.
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table 5. IVUS Analysis at Baseline and 6-Month Follow-Up.
Small Vessels 
(<2.5mm) 
(N=20) 
Large Vessels 
(>=2.5mm) 
(N=25)
Difference 
[95% CI] 
P-value 
Baseline IVUS Analysis
Average Vessel Area (mm2) 11.85 ± 3.36 (18) 16.40 ± 2.87 (22) -4.55 
[-6.59, -2.52]
<0.0001
Average Lumen Area (mm2) 5.84 ± 0.99 (18) 7.22 ± 0.96 (22) -1.38
[-2.01, -0.75]
<0.0001
Average Scaffold Area (mm2) 5.86 ± 0.98 (18) 7.16 ± 0.92 (22) -1.30 
[-1.91, -0.68]
0.0001
Average Plaque Area (mm2) 6.01 ± 2.66 (18) 9.18 ± 2.29 (22) -3.17 
[-4.79, -1.55]
0.0003
6 Months IVUS Analysis 
Average Vessel Area (mm2) 12.46 ± 3.26 (19) 16.28 ± 2.75 (21) -3.82 
[-5.76, -1.88]
0.0003
Average Lumen Area (mm2) 5.79 ± 0.93 (19) 6.87 ± 0.96 (21) -1.08 
[-1.68, -0.47]
0.0009
Average Scaffold Area (mm2) 5.84 ± 0.91 (19) 6.94 ± 0.94 (21) -1.10 
[-1.69, -0.51]
0.0006
Average Plaque Area (mm2) 6.67 ± 2.53 (19) 9.41 ± 2.15 (21) -2.74 
[-4.26, -1.23]
0.0008
Minimal Lumen Area (mm2) 4.78 ± 0.90 (19) 5.49 ± 0.87 (21) -0.72 
[-1.28, -0.15]
0.0143
Lumen Area Stenosis (%) 17.6 ± 6.0 (19) 19.8 ± 8.5 (21) -2.1 
[-6.8, 2.6]
0.3643
Area Obstruction (%) 1.1 ± 2.2 (19) 1.4 ± 1.9 (21) -0.3 
[-1.6, 1.0]
0.6363
Neointimal Hyperplasia Area (mm2) 0.06 ± 0.12 (19) 0.09 ± 0.12 (21) -0.03 
[-0.11, 0.05]
0.4084
Case Descriptions of MACE and Non ID-TLR Events
In the small vessel group, 3 MACE events were reported. In the first patient (RVD 2.05 
mm), six-month scheduled angiography disclosed a proximal edge stenosis in the mid 
RCA subsequently treated. Of note is that during the index procedure, the operator had 
deeply inserted the Amplatz guide catheter into the mid RCA; the possibility of endothelial 
denudation therefore cannot be excluded as a potential cause of the restenosis. In the 
second patient (RVD 2.15mm) predilatation of the lesion provoked a dissection which 
became occlusive after incomplete lesion coverage with the BVS. Subsequent bailout 
stenting was performed. The peak value of troponin was 0.8 µg/ml (ULN < 0.03 ng/ml), CK: 
521 U/L (ULN < 180 U/L) and CK-MB: 48 U/L (ULN < 5 U/L) and was adjudicated as peri-
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procedural NQMI. In the third patient (RVD 2.18 mm) a non-occlusive dissection occurred 
after lesion predilatation; the dissection was however fully covered with a BVS. The ECG 
remained unremarkable. Subsequent troponin, CK and CK-MB levels however peaked at 0.81 
μg/L (ULN <0.03 μg/L), 667 U/L (ULN < 150 U/L) and 97.2 ng/ml (ULN < 4 ng/ml) respectively.
In the large vessel group, 2 MACE were reported. In the first patient (RVD 2.51 mm) a 
BVS was implanted in the LAD with a myocardial bridge. Three months later, the patient 
presented with recurrent angina. Repeat coronary angiography demonstrated a diameter 
stenosis of 40% and 85% in diastole and systole respectively, resulting in the implantation 
figure 2. Small Vessel Treated With Implantation of BVS
Angiographic, optical coherence tomography (OCT), and intravascular ultrasound (IVUS) images before procedure, 
after procedure, and at 6-month follow-up are shown. The images show an example of a small vessel treated with a 
bioresorbable drug-eluting vascular scaffold (BVS) (pre-RVD 2.24 mm). (A) A visual comparison between the vessel-
treated segment and a 6-Fr catheter (1.98 mm) is highlighted. Pre-procedural angiography and quantitative coronary 
angiography (QCA) analysis revealed a minimal lumen diameter (MLD) of 0.65 mm. Post-procedural angiography (left 
panel) and QCA analysis demonstrated an MLD of 2.01 mm. At the 6-month follow-up (right panel), the MLD was 
2.23 mm. For illustrative purposes, the OCT (B) and IVUS (C) images are presented. These are corresponding frames 
taken from the MLD. A small side branch (*) located at the post-procedural MLD was used as a landmark for accurate 
matching of the images among different imaging modalities (angiography,
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of a metallic everolimus-eluting stent. In the second patient (RVD 2.74 mm) an iatrogenic 
non Q-wave MI (CK 600 U/L, CK-MB 72 U/L, ≥2X upper limit of normal) was caused by 
thrombus formation following an IVUS examination during a failed attempt at imaging 
the vessel with OCT.
In a separate patient, a 3.0 mm BVS was post-dilated with a larger 3.5mm semi-compliant 
balloon to 16 atm (expected diameter: 3.96 mm). Post procedural OCT revealed several 
scaffold pattern irregularities but with a 20% diameter stenosis, consequently no further 
intervention was carried out. Thirty-three days later the patient was readmitted due to 
recurrent nocturnal chest pain. Coronary angiography demonstrated a non-significant 
diameter stenosis of 23%. OCT however revealed multiple scaffold pattern irregularities 
in the proximal half of the BVS with several strut cross sections appearing in the middle 
of the lumen. A 3.5 mm drug eluting stent was deployed in the proximal BVS with a 
satisfactory result. This event was adjudicated as being a non-ischaemic driven TLR by the 
Clinical Events Committee (CEC).
D I S C u S S I O N
The present sub-study of ABSORB Cohort B is the first to report the use of a completely 
bioresorbable everolimus eluting scaffold in the setting of small vessel disease. The major 
findings of this sub-study are as follows: 1) patients who underwent BVS implantation 
in small vessels had 6-month clinical outcomes similar to patients who underwent the 
procedure in large vessels; 2) implantation of small vessels with a 3mm BVS was associated 
with an equivalent late luminal loss, percentage diameter stenosis and binary restenosis 
rates, compared to large vessels.
Small vessel coronary artery disease is a recognised challenging subset within the field 
of coronary artery intervention in that balloon angioplasty and bare metal stents have 
previously demonstrated unacceptable rates of restenosis and MACE. (6,7) The use of DES in 
this setting have however lead to more acceptable long-term results, although important 
differences in types of DES appear to exist. (8,9) 
In the present study despite the implantation of larger (3.0mm) BVS in small vessels 
(<2.5 mm), no significant differences in clinical outcomes were observed in both groups 
at 6 months. In the small vessel group all 3 cases may possibly have been explained by 
procedural related complications and not due to device failure itself. However due to the 
small sample size and low incidence rate in this study, caution should be made in making 
firm conclusions with regards to the safety and efficacy.
A high degree of vessel stretch and injury, smaller post-procedural lumen area and a high 
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metal density have all previously been proposed as contributing factors to explain the 
poorer outcomes associated with small vessels (10). Current consensus however is that the 
so called “bigger-is-better” paradigm (11) is likely to be the most plausible mechanism to 
explain the poorer outcomes associated with small vessel disease. Effectively, a smaller 
vessel size would be less able to accommodate the same absolute volume of NIH as a 
larger vessel, with the resultant increase in the rate of binary restenosis. The other 
potential concern is the thickness of the BVS struts (150 micrometers), as previous studies 
have suggested a link between thicker struts and an increased risk of restenosis; (12) these 
concerns however did not appear to be evident in this present study.
Vessels with RVD < 2.5 mm were treated with a 3.0 mm BVS scaffold pre-mounted on a 
3.0 mm diameter balloon. This factor may have played a role in the similar angiographic 
and clinical outcomes observed between the two groups. Further study of this device is 
currently being undertaken in the multicentre, ABSORB Extend Single Arm Study where 
the introduction of a 2.5 mm BVS device is planned. This 2.5 mm BVS device is actually the 
same scaffold as the 3.0 mm but crimped onto a smaller 2.5 mm balloon and is intended for 
the treatment of vessels ≥2.0 mm and ≤3.0 mm. This may aid in further understanding as 
to whether the impact of a larger (3.0 mm) deployment balloon size played any significant 
role in the excellent outcomes seen with the device in small vessels. 
It would therefore appear that the concerns of BVS implantation in small vessels may not 
be justified, whereas the risk of excessive post-dilatation of the BVS appears to be of more 
concern. Appropriate sizing of the vessel with QCA analysis and respect for the maximal 
diameter limits of the BVS are therefore currently required.
Study limitations
The present study is a post-hoc analysis and the number of patients is limited. Therefore 
p values presented are exploratory and should be interpreted with caution. Secondly, 
coronary angiography is limited to the detection of the lumen contour without taking 
into account the actual vessel size. IVUS allows assessment of the vessel size, this however 
was not performed prior to the BVS implantation in the present study.
CO N C Lu S I O N 
The 3.0 mm bioresorbable vascular everolimus eluting scaffold appears to be safe and 
effective in small vessels, with similar clinical and angiographic outcomes observed when 
compared to large vessels. 
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A B S T R AC T
Objectives This study sought to investigate in vivo the vascular response at the 
proximal and distal edges of the second-generation ABSORB everolimus-eluting 
bioresorbable vascular scaffold (BVS).
Background The edge vascular response after implantation of the BVS has not 
been previously investigated.
Methods The ABSORB Cohort B trial enrolled 101 patients and was divided into B1 
(n = 45) and B2 (n = 56) subgroups. The adjacent (5-mm) proximal and distal vessel 
segments to the implanted ABSORB BVS were investigated at either 6 months (B1) 
or 1 year (B2) with virtual histology intravascular ultrasound (VH-IVUS) imaging. 
Results At the 5-mm proximal edge, the only significant change was modest 
constrictive remodeling at 6 months (∆ vessel cross-sectional area: -1.80% [-3.18; 
1.30], p < 0.05), with a tendency to regress at 1 year (∆ vessel cross-sectional area: 
-1.53% [-7.74; 2.48], p = 0.06). The relative change of the fibrotic and fibrofatty 
(FF) tissue areas at this segment were not statistically significant at either time 
point. At the 5-mm distal edge, a significant increase in the FF tissue of 43.32% 
[-19.90; 244.28], (p < 0.05) 1-year post-implantation was evident. The changes in 
dense calcium need to be interpreted with caution since the polymeric struts are 
detected as “pseudo” dense calcium structures with the VH-IVUS imaging modality.
Conclusions The vascular response up to 1 year after implantation of the ABSORB 
BVS demonstrated some degree of proximal edge constrictive remodeling and 
distal edge increase in FF tissue resulting in nonsignificant plaque progression 
with adaptive expansive remodeling. This morphological and tissue composition 
behavior appears to not significantly differ from the behavior of metallic drug-
eluting stents at the same observational time points. (J Am Coll Cardiol Intv 
2012;5:656 – 65) 
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I N T R O D u C T I O N
The vascular response at the stent edges has been evaluated with first-generation drug-
eluting stents and appears to be dependent on the implanted device and the periprocedural 
induced vascular trauma because of the geographic miss (GM) phenomenon (1). The initial 
trial with the sirolimus- eluting stent - RAVEL (RAndomized study with the sirolimus-
eluting VElocity balloon-expandable stent in the treatment of patients with de novo 
native coronary artery Lesions) - demonstrated no significant edge effect, presum- ably 
due to the exceptional stent/lesion ratio of 2:1, due to the sole availability of stent length 
(18 mm). A significant proximal edge lumen loss was, however, observed in the SIRIUS 
(Sirolimus-Coated Bx Velocity Balloon- Expandable Stent in the Treatment of De Novo 
Native Coronary Artery Lesions) trial, which evaluated the same stent platform as in RAVEL, 
but with several stent lengths and diameters of the device in a more complex population. 
In the first-in-man TAXUS I trial, no edge effect was demonstrated with the use of the 
slow-release polymer formulation of the paclitaxel-eluting stent; conversely, in the TAXUS 
II trial, the slow-release and moderate-release polymer formulations of the paclitaxel-
eluting stent resulted in an edge lumen area loss (-0.54 ± 2.1 mm2 and -0.88 ± 1.9 mm2, 
respectively) at both the proximal and distal stent edges (2,3). In the BETAX (BEside TAXus) 
trial, using the Taxus Express drug-eluting stent, significant tissue compositional changes 
were observed, mainly due to an increase in the fibrofatty (FF) tissue component causing 
expansive remodeling at both stent edges (4). Pre-clinical research has demonstrated that 
the tissue response after stent implantation is exclusively composed of proteoglycan-
rich smooth muscle cells and fibrolipidic areas rich in collagen and reticular fibers (5). This 
iatrogenic entity of neointimal hyperplasia has been demonstrated to be usually focal 
and most commonly located at the proximal stent edge (6). The advent of scaffolds with 
bioresorbable properties and differing biological behavior compared with the currently 
used metallic devices, has prompted the re-evaluation of the edge vascular response 
using sound-based imaging modalities with tissue characterization properties. Such 
a modality is the virtual histology intravascular ultrasound (VH-IVUS), which allows for 
the evaluation of the vascular geometric changes and assessment of the atheromatous 
plaque progression/regression.
The purpose of this study is to investigate the edge effect after the implantation of the 
ABSORB bioresorbable vascular scaffold (BVS) in the assessment of the geometric and 
compositional changes of the segments adjacent to the 5-mm proximal and distal edges 
of the scaffolded vessel, in a population investigated at either 6 months or 1 year post 
scaffold implantation.
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M E T h O D S
Study design and population
The ABSORB Cohort B trial is a multicenter, ongoing, single- arm prospective, open-label 
trial assessing the safety and performance of the second-generation ABSORB BVS in the 
treatment of patients with a maximum of 2 de novo native coronary artery lesions. In 
total, 101 patients were enrolled and subdivided into 2 subgroups - Cohort B1 (n = 45) and 
Cohort B2 (n = 56) - according to the predefined study design. Both groups underwent 
invasive follow-up, Cohort B1 at 6 months and Cohort B2 at 1 year. Cohort B1 is currently 
undergoing a second VH-IVUS imaging of the scaffold edges at 2 -years and Cohort B2 will 
undergo the final VH-IVUS imaging evaluation at 3 years (Fig. 1).
In the present study, patients over the age of 18 years, who had either stable or unstable 
angina pectoris or silent ischemia, were suitable for inclusion. All treated lesions were de 
novo lesions in a native coronary artery with a maximum diameter of 3.0 mm, a length of 
<14 mm, a percent diameter stenosis >50% and <100%, and a Thrombolysis In Myocardial 
Infarction (TIMI) flow grade of >1. Major exclusion criteria were patients presenting with an 
acute myocardial infarction or unstable arrhythmias, or patients who had a left ventricular 
ejection fraction <30%, restenotic lesions, lesions located in the left main coronary artery, 
lesions involving an epicardial side branch >2 mm in diameter by visual assessment, and 
the presence of thrombus or another clinically significant stenosis in the target vessel.
The ethics committee at each participating institution approved the protocol, and each 
patient gave written in- formed consent before inclusion.
 figure 1. ABSORB Cohort B Study Design. 
The study design of the ABSORB Cohort B trial with the respective biological behavior of the ABSORB bioresorbable 
vascular scaffold, at the different time frames that virtual histology intravascular ultrasound (VH-IVUS) imaging was 
performed (yellow points). OCT = optical coherence tomography; QCA = quantitative coronary angiography.
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Treatment device
The ABSORB BVS (Abbott Vascular, Santa Clara, California) is a balloon-expandable device 
consisting of a polymer backbone of poly-L-lactide coated with a thin layer of a 1:1 
mixture of poly-D,L-lactide. The polymer controls the release of the antiproliferative drug 
everolimus, and forms an amorphous drug-eluting coating matrix that contains 100 f.Lg 
of everolimus/cm2 of scaffold. According to bench studies, the ABSORB BVS device has 
shown a dynamic biological behavior at 6 months, 1 year, and 2 years, at which time the 
complete bioresorption of the polymer backbone is expected (7).
At 6 months, a gradual and steep loss of the device radial strength in parallel to the continuous 
decrease of the device molecular weight is observed because of the depolymerization and 
hydrolysis after implantation. The molecular weight of the polymeric platform continues 
to decrease until 1 year, when the radial strength is completely eliminated, and the device 
represents a passive structure without any supportive vascular properties. At 2 years, the 
ABSORB BVS is considered fully resorbed, having been metabolized into CO
2
 and H
2
O 
through the Krebs cycle (Fig. 1). This dynamic behavior of the polymeric device at the 
above- mentioned time points prompts the in vivo evaluation of the vascular response at 
the scaffold edges with VH-IVUS imaging in parallel to its evolving biological behavior (8). 
Treatment procedure
Lesions were treated with routine interventional techniques that included mandatory 
pre- dilation with a balloon shorter and 0.5 mm smaller in diameter than the study device. 
The ABSORB BVS was implanted at a pressure not exceeding the rated burst pressure (16 
atm). Post-dilation with a balloon shorter than the implanted device was allowed at the 
discretion of the operator, as was bailout treatment.
quantitative IVuS and Vh-IVuS analysis
Geometric parameters in the complete 5-mm proximal and distal segments derived from 
the grayscale IVUS and VH-IVUS acquisition were analyzed in each separate frame—that 
is, vessel area, lumen area, plaque area, and tissue composition parameters—as absolute 
values. Furthermore, percentages were assessed for each cross section in the same region 
of interest. Both the proximal and distal vessel segments were further divided into 1-mm 
subsegments, numbered from 1 (adjacent to the scaffold) to 5, and underwent similar 
imaging evaluation as for the complete segment.
The tissue compositional analysis was obtained with a phased-array 20-MHz intravascular 
ultrasound catheter (Eagle Eye, Volcano Corporation, Rancho Cordova, California) after 
intracoronary administration of 100 to 200 f.Lg of nitroglycerin, using automated pullback 
at 0.5 mm/ second (30 frames/s). The raw radiofrequency data were capture gated to the 
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R-wave. The main principle of the VH-IVUS imaging technique is that both the envelope 
amplitude of the reflected radiofrequency signals, as under- taken with standard grayscale 
IVUS analyses, and the underlying frequency content is used to analyze the tissue 
components present in coronary plaques. The combined information is subsequently 
processed using auto regressive models and thereafter categorized into a classification 
tree that determines the 4 basic plaque tissue components: 1) fibrous tissue - dark green; 2) 
FF - light green; 3) necrotic core (NC) - red; and 4) dense calcium (DC) - white (9). All VH-IVUS 
analyses were performed offline using the pcVH 2.1 software (Volcano Corporation) by 
an independent clinical research organization (Cardialysis, Rotterdam, the Netherlands). 
At 6 months (Cohort B
1
, n = 45), 23 proximal and 18 distal edge segments were suitable 
for analysis with grayscale IVUS and VH-IVUS imaging. At 1 year (Cohort B
2
, n = 56), 25 
proximal and 30 distal edge segments were analyzable. 
The reasons for the reduced number of our final tested samples were: 1) the dropout 
of patients at follow-up (the attrition rate of the ABSORB Cohort B trial was ~ 20%) and 
exclusion of the unpaired samples from our final data; and 2) exclusion of cases, according 
to the standard operational procedure of the independent core laboratory (Cardialysis), 
with side-branch outgrowth of > 90° at the side of the scaffold edge that did not allow the 
analysis of the complete 5-mm segment and vessel wall out of the field of the view.
Statistical analysis
Discrete variables are presented as counts and percentages. Continuous variables are 
presented as medians and interquartile ranges. Comparison between baseline and 
follow-up was performed using the Wilcoxon signed rank test. Changes (differences) for 
each measurement were calculated as follow-up minus post- procedure values. Percent 
changes (differences) for each variable were calculated as follow-up post-rocedure/ post-
procedure X100%. A p value <0.05 was considered statistically significant. Data analyses 
were performed with SAS version 9.1 software (SAS Institute, Cary, North Carolina).
R E S u LT S
The baseline clinical and lesion characteristics of the pa- tients are demonstrated in Table 
1. The percent (%) changes (median [interquartile range]) of the vessel cross-sectional 
area (CSA), lumen CSA, and plaque CSA at the 5-mm proximal edge segment were at 6 
months: -1.80% [-3.18;1.30], (p < 0.05), -4.10% [-11.61; 8.79], (p = 0.22), and - 4.04% [-10.65; 
11.05] (p = 0.55); and at 1 year: - 1.53% [-7.74; 2.48], (p = 0.06), -5.32% [-12.36; 4.24], (p = 
0.07), and - 2.03% [- 8.39; 7.76], (p = 0.72), respectively. 
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The % changes of the vessel CSA, lumen CSA, and plaque CSA at the 5-mm distal edge 
segment were at 6 months: - 0.59% [-3.74; 7.09], (p = 0.71), -0.32% [-7.71; 7.20], (p = 0.97), 
and 7.0% [-11.97; 18.36], (p = 0.50); and at 1 year: 3.45% [-2.08; 6.91], (p = 0.07), 0.95% 
[-7.56; 7.48], (p = 0.77), and 5.73% [-6.49; 5.47], (p = 0.09), respectively (Table 2). The 
absolute geometric and tissue composition changes and the subsegmental analysis at 1 
year are tabulated in (Tables 3 and 4) and illustrated in Figs. 2, 3, and 4. The absolute tissue 
compositional changes at 6 months at both edges and the subsegmental analysis at the 
same time point are tabulated and illustrated in the Online Appendix.
The main findings of this study at the time point of 1-year post-implantation of the ABSORB 
BVS are as follows. Constrictive vascular remodeling at the proximal edge was evident 
without significant changes in tissue composition parameters. At the distal edge, tissue 
composition changes were evident with a significant increase in the FF tissue resulting in 
nonsignificant plaque progression and adaptive expansive remodeling (Fig. 2).
The edge effects following the implantation of either a metallic or a polymeric device have 
common etiological mechanisms, namely: 1) periprocedural or iatrogenic technical issues 
table 1. Baseline Clinical and Lesion Characteristics.
  6 Months  1 year
  Proximal Edge  Distal Edge  Proximal Edge  Distal Edge
  (n = 23)  (n = 18)  (n = 24)  (n = 29)
Age, yrs 62.41 ± 9.86 64.70 ± 9.83 59.21 ± 7.72 60.20 ± 7.72
Male 14 (61%) 12 (67%) 15 (63%) 20 (69.0%)
Current smoking 3 (13.0%) 1 (6%)  5 (21%) 2 (7%)
Diabetes 5 (22%) 3 (17%)  7 (29%) 6 (21%)
Hypertension 16 (70%) 13 (72%) 17 (74%) 19 (68%)
Hypercholesterolemia 22 (96%) 18 (100%) 18 (75%) 22 (76%)
Prior myocardial infarction 8 (35%) 7 (39%)  5 (21%) 3 (11%)
Unstable angina 3 (13%) 3 (17%)  4 (17%) 6 (21%)
Stable angina 16 (70%) 14 (78%) 14 (58%) 17 (59%)
Treated vessel
Right coronary artery 9 (39%) 7 (39%) 9 (36%) 8 (27%) 
Left anterior descending artery 6 (26%) 6 (33%) 10 (40%) 16 (53%) 
Left circumflex artery 7 (30%) 4 (22%) 6 (24%) 6 (20%)
ACC/AHA lesion class:
Type A 1 (4%) 1 (5%)   0 (0%)   0 (0%) 
Type B1 10 (44%) 9 (50%) 17 (71%) 22 (73%) 
Type B2 11 (48%) 8 (44%)   6 (25%)   7 (23%) 
Type C   1 (4%) 0 (0%)  1 (4%) 1 (3%)
RVD before intervention, mm 2.56 ± 0.43 2.78 ± 0.45 2.61 ± 0.33 2.50 ± 0.28
Values are mean ± SD or n (%).
ACC/AHA = American College of Cardiology/American Heart Association; RVD = reference vessel diameter.
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table 2. Summary of the % Changes of the Entire 5-mm Segment, at the Proximal and Distal Edges, Regarding 
Geometric and Plaque Composition Parameters 6 Months and 1 Year Following Implantation of the ABSORB BVS
Vessel CSA (mm2) Lumen CSA (mm2) Plaque CSA (mm2)
Proximal edge segment, (%) change
6 months (n = 23) -1.8 [-3.18; 1.30] -4.1 [-11.61; 8.79] -4.04 [-10.65; 11.05]
p value <0.05 NS NS
1 year (n = 25) -1.53 [-7.74; 2.48] -5.32 [-12.36; 4.24] -2.03 [-8.39; 7.76]
p value NS NS NS
Distal edge segment, (%) change
6 months (n = 18) -0.59 [-3.74; 7.09] -0.32 [-7.71; 7.20] 7 [-11.97; 18.36]
p value NS NS NS
1 year (n = 30) 3.45 [-2.08; 6.91] 0.95 [-7.56; 7.48] 5.73 [-6.49; 25.47]
p value NS NS NS
Dense Calcium (mm2) Fibrous (mm2) Fibrofatty (mm2) Necrotic Core (mm2)
Proximal edge segment, (%) change
6 months (n = 23) 12.02 [-31.62; 47.50] 4.44 [-16.83; 67.23] 10.3 [-46.38; 134.69]
p value NS NS NS NS
1 year (n = 25) -7.91 [-42.19; 17.26] -2.58 [-20.03; 11.86] -9 [-36.77; 87.41] -4.35 [-31.23; 30.40]
p value NS NS NS NS
Distal edge segment, (%) change
6 months (n = 18) 44.09 [22.81; 159.23] 4.07 [-18.83; 107.39] 8.21 [-37.77; 91.48] 23.59 [-19.89; 74.33]
p value <0.05 NS NS NS
1 year (n = 30) -20.57 [-50.22; 54.11] 18.87 [-11.14; 108.93] 43.32 [-19.90; 244.28] -6.25 [-44.20; 81.94]
p value NS NS <0.05 NS
p values in bold are statistically significant.
BVS _ bioresorbable vascular scaffold; CSA _ cross-sectional area; NS _ not significant.
affecting predominantly geometric parameters (1–11); 2) tissue composition characteristics 
of the lesion (12); and 3) local wall shear stress (WSS) conditions (13–15).
The GM phenomenon, associated with sirolimus-eluting stent implantation, was 
investigated in the STLLR (Stent Deployment Techniques on Clinical Outcomes of 
Patients Treated With the Cypher Stent) study and was reported to occur in nearly two-
thirds (66.5%) of the study group; almost one-half of the patients (47.6%) experienced 
longitudinal GM, over one-third (35.2%) axial GM, and 16.5%, a combination of the 
2 (1,10). Hoffmann et al. (10) demonstrated within the E-SIRIUS (European, multi- center, 
randomized, double blind trial of the SIRolImUS-coated Bx-Velocity stent in the treatment 
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of patients with de	novo coronary artery lesions)-IVUS substudy versus the SIRIUS-US (US, 
multicenter, ran- domized, double blind trial of the SIRolImUS-coated Bx-Velocity stent in 
the treatment of patients with de novo coronary artery lesions) trial, that both axial and 
longitudinal GM were reduced (from 5.9% to 2.1%) when periprocedural implantation 
parameters were taken into account, such as conservative pre-dilation, less forceful 
stent implantation (~16 atm), and selective postdilation with balloons shorter than the 
stent. Despite multiple technical guidelines regarding the ABSORB BVS delivery system 
to minimize the axial (burst pressure: 16 atm) and longitudinal (balloon shorter and 0.5 
mm smaller than the implanted device) GM phenomena, a significant proximal edge 
constrictive response was demonstrated at 6 months, whereas at 1 year, the constrictive 
remodeling was only observed in the following proximal subsegments, starting from the 
scaffold edge (subsegment 1: Δ -0.96 mm2, (p < 0.05); subsegment 2: Δ -0.71 mm2, (p < 
0.05); and subsegment 4: Δ -0.57(p < 0.05) (Figs. 3 and 4). The changes in WSS distribution 
adjacent to the stent edges post device implantation appear to follow alterations in vessel 
curvature and angulation, and have been reported to result in step-up regions of low 
 
figure 2. Grayscale IVUS and Corresponding VH-IVUS Still Frames at 1-Year After Implantation of the ABSORB BVS.
(a) Distal edge segment. At this segment a significant increase of the fibrofatty (FF) tissue was observed. VH-
IVUS demonstrates at this frame a change in FF tis- sue area from 0.07 to 0.14 mm2. Dense calcium (DC) and 
necrotic core tissue components changed from 2.39 mm2 and 3.7 mm2 to 2.07 mm2 and 1.8 mm2, respectively, as 
a consequence of the bioresorption process. (B) Scaffolded segment. The polymeric struts of the ABSORB BVS are 
detected as “pseudo” DC sur- rounded by a red, halo. (C) Proximal edge segment. At this segment some degree 
of proximal edge constrictive vascular remodeling was observed. Grayscale IVUS shows for this frame a change 
in the lumen area from 9.4 mm2 to 8.4 mm2 (The external elastic membrane has been extrapolated at the side of 
the side branch, [yellow asterisk]).
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figure 3. Subsegmental Analysis of the Geometric Changes at the Proximal and Distal Edges After Implantation of 
the ABSORB BVS. The analysis, per mm of the subsegments, was performed at 1-year follow-up. BVS = bioresorbable 
vascular scaffold.
figure 4. Subsegmental Analysis of the Tissue Composition Changes at the Proximal and Distal Edges After 
Implantation of the ABSORB BVS. The analysis, per mm of the subsegments, was performed at 1-year follow-up. BVS 
= bioresorbable vascular scaffold.
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shear stress, prone to neointimal growth (13–15).
Metallic devices have a more accentuated effect on vessel curvature and angulation 
compared to the ABSORB BVS; however, despite the clinical benefits associated with 
better conformability (16) of the ABSORB BVS device, proximal constrictive remodeling was 
observed at 1-year after implantation, and further investigations are required to evaluate 
the changes of WSS at the scaffold edges or the in-scaffold area. Moreover, any of the initial 
flow–tissue interaction effects caused by the implantation of this bioresorbable device 
are expected to potentially subside after a 2-year period when the bioresorption process 
is expected to be complete and the polymeric platform is fully transformed to CO
2
 and 
H
2
O, with no consequent remaining compliance mismatch (8,16). Samady et al. (17) recently 
demonstrated, in a cohort of 20 patients, that coronary segments with low WSS (step-up 
regions) are segments that develop constrictive remodeling, in contrast to the high-WSS 
segments that present excessive expansive remodeling with tissue composition changes, 
mainly due to an increase in DC and NC tissue components. These reported observations 
are in parallel with the present findings in this study regarding vessel geometry and tissue 
composition. The distal edge segment adjacent to the scaffold appeared to have major 
tissue composition changes with some degree of plaque progression, which caused a 
subsequent nonsignificant expansive remodeling. The VH-IVUS– derived tissue type that 
correlates with extracellular matrix is the FF tissue, which happens to be the one that 
increased the most (18). The DC tissue component appeared to have a biphasic response at 
this segment after the ABSORB BVS implantation with a significant increase at 6 months 
and a trend toward a decrease at 1-year follow-up; conversely, the NC tissue changed 
nonsignificantly following sequential modifications of DC tissue.
The changes in DC and NC tissue components at follow-up should be interpreted with 
caution since the ABSORB BVS is made of bioresorbable polymeric material recognized as 
“pseudo” DC and NC, parameters that have previously been reported as surrogate markers 
of the bioresorption process (19,20). In addition, the edges of the polymeric scaffold are not 
sharply demarcated since the vessel surrounding the imaging device are affected by the 
“to and fro” motion of the cardiac contraction, causing a “pseudoaxial” displacement of the 
IVUS catheter related to the arterial wall.
Indeed, the cardiac cycle can cause a mean axial displacement of the IVUS transducer of 
1.5 mm with a maximum distortion up to 6.5 mm; however, the use of electrocardio- gram 
gating during IVUS data acquisition reduces the axial movement to a maximum of 0.8 
mm (21–23) but does not fully prevent the imaging of the polymeric struts as “pseudo” DC 
in the adjacent edge of the implanted device. In keeping with the standard operational 
procedure of an independent core laboratory (Cardialysis), the quantification of the 
scaffold edges was initiated at the point where the visualization of the scaffold arc at each 
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frame was <360°, implying that the scaffold edge to some extent may include polymeric 
struts. The apparent increase in DC at 6 months, followed by a trend toward a reduction at 
1 year, accompanied by the parallel behavior of the NC, are attributed to the introduction 
of the bioresorbable device during the procedure and subsequent bioresorption process 
long term. Other possible factors that may have influenced the NC tissue component are 
the locally eluted drug everolimus and the systemic use of HMG-CoA inhibitors. Verheye 
et al. (24) recently demonstrated that everolimus—an inhibitor of the mammalian target 
of rapamycin (m-TOR)— has autophagic capabilities on macrophages, with a subsequent 
effect of diminishing NC formation, inflammation, and thrombosis. Hong et al. (25) reported 
a significant 13% relative reduction in plaque necrotic core volume, and a significant 27% 
relative increase in plaque FF content with the administration of HMG-CoA inhibitors, 
assessed with VH-IVUS at 1-year follow-up. Coronary endothelial dysfunction has been 
previously associated with underlying plaque composition, in particular high content of 
DC and NC. Lavi et al. (26) have demonstrated impaired endothelial-dependent vasomotion 
in vessel segments with underlying NC-rich plaques. Our group has recently demonstrated 
that the restored normal vasodilatory response to acetylcholine in coronary segments 
that have previously undergone implantation with an AB-SORB BVS, is associated with 
a reduction of NC (27), implying the potential restoration of the vasomotor function of the 
treated vessel with reductions of specific tissue components. Whether the present findings 
are due to the combined effects of locally eliminated m-TOR inhibitor everolimus, with the 
systemic use of the HMG-CoA inhibitors, or the natural history of the bioresorbable process 
of the implanted device, remains to be elucidated in future studies, where a potential 
restoration of the vasomotor function at the scaffold edges would be highly expected with 
the sustained tissue composition changes observed at 1-year follow-up. Furthermore, the 
combination of continuous polymer degradation and elaboration of the treated vessel 
from its foreign material beyond 1 year, with the restoration of vessel biological behavior 
(vasomotor function) and the interplay with pharmacological intervention may potentially 
eliminate the risk of late stent thrombosis. The clinical outcome of the ABSORB Cohort B 
trial at 1-year post implantation of the ABSORB BVS revealed a hierarchical major adverse 
cardiac event rate of 6.9%, with no episodes of scaffold thrombosis (according to the 
protocol or Academic Research Consortium definitions). Pre-scaffolding VH-IVUS analysis 
can give an insight into the extent of plaque and NC within and beyond the intended 
scaffolded segment. This latter point is potentially important, since full coverage of the 
lesion by the implanted device is the desired goal of the interventionalist, as incomplete 
coronary plaque coverage has been reported to effect long-term clinical events, especially 
in the presence of NC-containing plaques (11).
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Study limitations
The main limitation of our study is the small number of the investigated scaffold edges. 
The complete cohort (B1+B2) at the different time points without splitting the population 
would potentially have increased the sample size; this, however, was a predefined design 
of the study.
CO N C Lu S I O N S
The edge vascular response, with the use of the ABSORB BVS device at 1-year post 
implantation, demonstrates a degree of proximal edge constrictive remodeling and distal 
edge plaque compositional changes, a biological behavior similar to that observed with 
the metallic devices. Full bioresorption of the device, expected to occur in approximately 
2 years, will potentially allow for the evaluation and comparison of the exact biological 
composition of the treated vessel at the scaffold edges, utilizing the VH-IVUS imaging 
modality.
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A B S T R AC T 
Background The long-term results after second generation everolimus eluting 
bioresorbable vascular scaffold (Absorb BVS) implantation in small vessels are 
unknown. We investigated the impact of vessel size on long-term outcomes, after 
BVS implantation.
Methods In ABSORB Cohort B Trial out of the total study population (101 patients), 
45 patients were assigned to undergo 6-month and 2-year angiographic follow-up 
(Cohort B1) and 56 patients to have angiographic follow-up at 1-year (Cohort B2). 
The pre-RVD was < 2.5 mm (small-vessel group) in 41 patients and ≥ 2.5 mm (large-
vessel group) in 60 patients. Outcomes were compared according to pre-RVD.
Results At 2-year angiographic follow-up no differences in late lumen loss 
(0.29±0.16 mm vs. 0.25±0.22 mm, p=0.4391), and in-segment binary restenosis 
(5.3% vs. 5.3% p=1.0000) were demonstrated. In the small-vessel group, IVUS 
analysis showed a significant increase in vessel area (12.25±3.47 mm2 vs. 13.09±3.38 
mm2 p=0.0015), scaffold area (5.76±0.96 mm2 vs. 6.41±1.30 mm2 p=0.0008) and 
lumen area (5.71±0.98 mm2 vs. 6.20±1.27 mm2 p=0.0155) between 6-months and 
2-year follow-up. No differences in plaque composition were reported between 
groups at either time point. At 2-year clinical follow-up, no differences in ID-MACE 
(7.3% vs. 10.2%, p=0.7335), MI (4.9% vs. 1.7%, p=0.5662) or ID-TLR (2.4% vs. 8.5%, 
p=0.3962) were reported between small and large vessels. No deaths or scaffold 
thrombosis were observed.
Conclusion Similar clinical and angiographic outcomes at 2-year follow-up were 
reported in small and large vessel groups. A significant late lumen enlargement 
and positive vessel remodeling were observed in small vessels. 
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I N T R O D u C T I O N 
The first generation Absorb everolimus eluting bioresorbable vascular scaffold (Absorb 
BVS, Abbott Vascular, Santa Clara, CA, USA) has been previously tested in the First-In-
Man ABSORB Cohort A study, in a series of 30 patients [1, 2] with excellent long-term 
clinical results reported up to 4 years.[3] In the second generation Absorb BVS, further 
modifications in the manufacturing processes and scaffold design resulted in a more 
durable and uniform support and drug delivery to the vessel wall. [4, 5] This second 
generation Absorb BVS has subsequently been tested in the ABSORB Cohort B trial, which 
enrolled 101 patients. 
Due to the single size availability of this second generation scaffold (3.0 mm in diameter), 
in ABSORB Cohort B Trial the angiographic inclusion criteria were appropriately restrictive, 
in that the target lesion must have been located in a native coronary artery with pre-
procedural reference vessel diameter (RVD) of 3.0 mm. However within the study, it 
was found that the visual estimation of the RVD was often incorrect, with a significant 
number of Absorb BVS being deployed in vessels with a pre-RVD smaller than 2.5 mm by 
quantitative coronary angiography (QCA). Among the 102 treated-lesions, 41 lesions had 
a RVD < 2.5 mm (small-vessel group) and 61 lesions had a RVD mm ≥ 2.5 mm (large-vessel 
group)[6]. Comparable clinical and angiographic outcomes in small and large vessels have 
been previously reported six months post implantation.[6] 
A theoretical concern for the implantation of the BVS in small coronary arteries was the 
thick struts of this device, a characteristic that was reported in previous studies to be 
associated with an increased risk of restenosis especially with small vessel diameter.
In the present study we evaluate the impact of vessel size on clinical and angiographic 
outcomes at 1- and 2-year follow up after implantation of the second generation Absorb 
BVS. This follow-up time period is critical due to the expected loss of mechanical support 
of the Absorb BVS, the potential return of vasomotion properties of the treated vessel at 1 
year,[7, 8] and the expected substantial scaffold polymer bioresorption at 2 years.[5]
252   |    Chapter 12
M E T h O D S 
Study design and population
The study design and the study device have previously been described.[9] In brief, the 
ABSORB Cohort B Trial is a multicentre single-arm, prospective, open-label trial assessing 
the safety and performance of the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA). 
All patients were older than 18 years, and had a diagnosis of stable or unstable angina, 
or silent ischemia. As per-protocol, treated-lesions were a maximum of two, de-novo 
lesions in separate native coronary arteries with a visually estimated diameter of 3.0 mm, 
a length shorter than 14 mm and a percentage diameter stenosis greater than or equal to 
50% and less than 100%. Major exclusion criteria were patients presenting with an acute 
myocardial infarction or unstable arrhythmias, or those who had left ventricular ejection 
fraction less than 30%, restenotic lesions, lesions located in the left main coronary artery, 
lesions involving a side branch more than or equal to 2 mm in diameter, and the presence 
of thrombus or other clinically significant stenoses in the target vessel. The ethics 
committee at each participating institution approved the protocol and each patient 
gave written informed consent prior to inclusion. A total of 101 patients were enrolled 
in the ABSORB Cohort B study. Out of the total population, 45 patients (45 lesions) were 
assigned to undergo 6-month and 2-year angiographic follow-up (ABSORB Cohort B1), 
and 56 patients (57 lesions) 12-month angiographic follow-up (ABSORB Cohort B2). In 
the present investigation, evaluation of the impact of vessel size (RVD < 2.5 mm or RVD 
≥ 2.5 mm) on angiographic outcomes was undertaken at 1 year in the ABSORB Cohort 
B2 population and at 2 years in ABSORB Cohort B1 population; at the same time points, 
clinical outcomes in the entire ABSORB Cohort B population (i.e. ABSORB Cohort B1 plus 
B2) were also evaluated.
qCA analysis
Quantitative coronary angiography (QCA) analyses were performed with the Coronary 
Angiography Analysis System (Pie Medical Imaging, Maastricht, Netherlands). The 37 μm 
platinum radio-markers located at each end of the Absorb BVS aided in the localization of 
the non-radio-opaque scaffold for QCA. The following QCA parameters were computed: 
pre-procedural reference vessel diameter (RVD) calculated with interpolated method, [10] 
minimal luminal diameter (MLD), percentage diameter stenosis (%DS), in-scaffold acute 
gain and binary restenosis. Late loss was defined as the difference between the post-
procedural and follow-up minimal luminal diameter.
Furthermore, to adjust for the absolute change in MLD to the vessel size (pre-RVD) post-
procedurally and at follow-up, the reporting of relative gain and relative loss – previously 
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demonstrated to be more representative of the real injury to the vessel wall and the 
subsequent neointimal response[11, 12] – were undertaken. The absolute net gain, the net 
gain index and the loss index were also computed. 
Those parameters were defined as:
• Relative gain: (post-procedure MLD minus pre-procedure MLD) divided by vessel size. 
• Relative loss: (post-procedure MLD minus MLD at follow-up) divided by vessel size. 
• Absolute net gain: MLD at follow-up minus pre-procedure MLD. 
• Net gain index: net gain normalized for the vessel size and calculated as (MLD at follow-up 
minus pre-procedure MLD) divided by vessel size. 
• Loss index: this is the relation of late loss to acute gain and is calculated as (MLD at follow-up 
minus post-procedure MLD) divided by (post-procedure MLD minus pre-procedure MLD). 
IVuS and IVuS-Vh analysis
Scaffolded segments were analyzed post-procedurally and at follow-up with phased 
array intravascular ultrasound (IVUS) catheters (EagleEye; Volcano Corporation, Rancho 
Cordova, CA, USA). An automated pullback of 0.5 mm per second was utilized. IVUS 
images were analyzed off-line with semi-automatic contour detection provided by 
dedicated software. The vessel area, scaffold area, lumen area, plaque area, in-scaffold 
neointimal area and lumen area stenosis were measured using a computer based contour 
detection program. IVUS-VH provides tissue characterization using an autoregressive 
spectral analysis classification system. Each tissue component is quantified and color-
coded as follow: fibrous tissue in green, fibrofatty in greenish yellow, necrotic core in red 
and calcium in white. For each frame the absolute and the percentage amount of each 
tissue component is assessed.
OCT analysis 
As additional information an OCT data comparison between large and small vessels was 
performed in the subgroup of patients undergoing OCT imaging at baseline and follow-
up. In ABSORB Cohort B Trial OCT imaging was performed at baseline and follow-up in 
selected centers as an optional investigation. The OCT M3 (Time Domain-OCT) and C7 
(Fourier Domain-OCT) systems (LightLab Imaging Inc., Westford, MA, US) were used. The 
vessels were imaged using an automated pullback system at 20 mm/sec (C7XR system) 
and 3.0mm/sec (M3 system). During image acquisition, coronary blood was replaced by 
continuous flushing of contrast at 3.0-4.0 ml/sec. Cross-sectional images were acquired 
at 100 frames/sec for C7 and at 20 frames/sec for M3. The analysis of continuous cross-
sections was performed at each 1 mm longitudinal interval within the treated segment. 
Quantitative measurements were performed as previously described [7, 9, 13, 14] 
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Deﬁnitions
The composite end point of ischemia-driven major adverse cardiovascular events (ID-MACE) 
comprised cardiac death, myocardial infarction (MI, classified as Q-wave and Non-Q wave) 
and ischemia-driven target lesion revascularization (ID-TLR) by CABG or PCI. Angiographic 
restenosis was defined as a diameter stenosis ≥50% at the treated site at follow-up 
angiography. Cardiac death was defined as any death in which a cardiac cause could not be 
excluded. A diagnosis of Q-wave MI was made with evidence of new pathological Q waves 
on electrocardiogram (ECG). A diagnosis of non-Q-wave MI was made with an elevation of 
the creatinine kinase (CK) greater than or equal to twice the upper limit of normal, with 
an elevated CK-MB and the absence of new pathological Q waves. Ischemia-driven target 
lesion revascularization (ID-TLR) was defined by either of the three following definitions: I) 
revascularization of the target lesion associated with a positive functional ischemia study, 
II) ischemia symptoms and angiographic minimal lumen diameter stenosis ≥ 50% by core 
laboratory assessed quantitative coronary angiography (QCA), III) revascularization of a 
target lesion with diameter stenosis ≥ 70% by core laboratory assessed QCA, without either 
ischemic symptoms or a positive functional study. 
The ARC (Academic Research Consortium) definitions [15] for stent thrombosis were utilized 
for this study. The CEC (clinical events committee) reviewed and adjudicated all cases of 
safety endpoint events. 
Funding source and contributors 
Abbott Vascular funded the ABSORB Cohort B trial and the present sub-study. The Clinical 
Events Committee (CEC) comprised of qualified physicians (who were not investigators in 
the trial) was responsible for adjudicating all MACE-related endpoints. Imaging acquisitions 
were evaluated by an independent core laboratory (Cardialysis, Rotterdam, The Netherlands).
RD and PWS interpreted the data and drafted the report, which was critically revised for 
important intellectual content by all other authors. SV, XL and KMH approved the final 
version of the manuscript. 
S TAT I S T I C A L  A N A LyS I S 
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation (SD). P-values were calculated with Fisher’s Exact test for binary 
variables, Wilcoxon’s Rank Sum test for continuous variables and Wilcoxon Signed Rank test 
for paired comparison between the different time points. A p value <0.05 was considered 
statistically significant. Statistical analyses were performed using SAS (version 9.1.3).
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qCA analysis 
Pre-procedural mean RVD was significantly smaller in vessels with RVD < 2.5 mm; 
percentage diameter stenosis was similar between large and small vessels (Table 1).
Post-procedural MLD was significantly greater in large vessels, however the mean acute 
gain was similar between groups. After adjustment for vessel size, the relative gain was 
found to be significantly greater in the small-vessel group.
table1. Baseline QCA Analysis in ABSORB Cohort B1 and B2 (Intent-to-Treat Populations).
Cohort B2 Cohort B1
Small Vessels 
(<2.5mm) 
(N=21)  
(L=21)
Large Vessels 
(>=2.5mm) 
(N=35)  
(L=36)
P-value Small Vessels 
(<2.5mm) 
(N=20) 
(L=20)
Larger Vessels 
(>=2.5mm) 
(N=25) 
(L=25)
P-value
Baseline QCA Analysis 
Pre-Procedure
RVD (mm) 2.29 ± 0.14 (21) 2.74 ± 0.21 (36) <0.0001 2.24 ± 0.17 (20) 2.96 ± 0.33 (25) <0.0001
MLD (mm) 1.01 ± 0.17 (20) 1.10 ± 0.26 (34) 0.1191 0.93 ± 0.22 (19) 1.15 ± 0.35 (25) 0.0492
% DS 56.1 ± 7.27 (20) 59.9 ± 9.20 (34) 0.1939 57.97 ± 11.09 (19) 60.80 ± 11.88 (25) 0.3804
Post-Procedure
In-Scaffold MLD (mm) 2.16 ± 0.20 (21) 2.33 ± 0.23 (36) 0.0094 2.16 ± 0.24 (20) 2.44 ± 0.22 (25) 0.0007
In-Scaffold % DS 14.6 ± 5.17 (21) 15.6 ± 6.44 (36) 0.7096 13.23 ± 3.03 (20) 17.14 ± 7.02 (25) 0.0375
In-Scaffold Acute Gain (mm) 1.18 ± 0.22 (20) 1.22 ± 0.31 (34) 0.4792 1.23 ± 0.37 (19) 1.29 ± 0.35 (25) 0.6697
Relative Gain 0.51 ± 0.09 (20) 0.45 ± 0.11 (34 0.0542 0.55 ± 0.16 (19) 0.44 ± 0.12 (25) 0.0167
At 1- and 2-year follow-up no differences were reported in in-scaffold late loss, %DS and 
binary restenosis. Also after adjustment for vessel size, the relative loss, the absolute net 
gain, the net gain index and the loss index were similar between the small- and large-
vessel groups.
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table 2. QCA Analysis ABSORB and B2 at 12-month Follow-Up Cohort B1 at 24-month Follow-Up (Intent-to-Treat 
Populations).
Cohort B2 – 12-month follow-up - Cohort B1 – 24-month follow-up -
Small Vessels 
(<2.5mm) 
(N=21)  
(L=21)
Large Vessels 
(>=2.5mm) 
(N=35)  
(L=36)
P-value Small Vessels (< 
2.5mm)  
(N=20)  
(L=20)
Larger Vessels (≥ 
2.5mm)  
(N=25)  
(L=25)
P-value
In-Scaffold Late-Loss 
(mm)
0.27 ± 0.32  (20) 0.27 ± 0.32 (36) 0.8979 0.29 ± 0.16 (19) 0.25 ± 0.22 (19) 0.4391
In-Scaffold % DS 18.8 ± 10.5 (21) 22.5 ± 11.5 (36) 0.2114 20.72 ± 7.33 (19) 21.17 ± 8.11 (19) 0.7702
In-Scaffold Binary 
Restenosis
0.0% (0/21) 5.6% (2/36) 0.5263 0.0% (0/19) 0.0% (0/19) NA
In-Segment Binary 
Restenosis
0.0% (0/21) 5.6% (2/36) 0.5263 5.3% (1/19) 5.3% (1/19) 1.0000
Relative Loss 0.10 ± 0.14 (21) 0.10 ± 0.13 (36) 0.9073 0.13 ± 0.07 (18) 0.09± 0.08 (19) 0.1489
The Absolute Net Gain 0.92 ± 0.42 (20) 0.96 ± 0.35 (34) 0.9926 0.97 ± 0.32 (18) 1.02 ± 0.47 (19) 0.7267
The Net Gain Index 0.41 ± 0.18 (20) 0.34 ± 0.12 (34) 0.0564 0.43 ± 0.14 (18) 0.35 ± 0.16 (19) 0.1040
The Loss Index 0.23 ± 0.32 (19) 0.20 ± 0.22 (34) 0.8311 0.21 ± 0.16 (18) 0.23 ± 0.22 (19) 0.7041
IVuS and IVuS-Vh analysis 
In the large vessel group, paired per lesion IVUS grey scale analysis demonstrated a 
constant vessel area growth at each time point that became significant at 2-year follow-up 
associated with a similar plaque area enlargement. Scaffold area also showed a significant 
enlargement between 6 months and 2 years. Lumen area numerically increased in ABSORB 
cohort B1 between 6-month and 2-year follow-up but without reaching any statistical 
significance; with a borderline significant decrease in ABSORB Cohort B2 between baseline 
and 1-year follow-up (Table 3).
In the small vessel group, vessel area was observed to grow from baseline to 6-month 
and 2-year follow-up and was associated with a parallel growth in plaque area over time 
(Table 3). The scaffold area at 6-month follow-up did not show any enlargement but was 
observed to grow significantly from 6-month to 2-year follow-up. The lumen area followed 
a similar evolution over time with a significant late lumen enlargement from 6-month to 
2-year follow-up. (Table 3)
Comparison of small and large vessels at 1- and 2-year follow-up showed similar minimal 
lumen area, % lumen area stenosis and neointimal hyperplasia area between groups at 
each time point. (Table 3)
Paired per-lesion IVUS-VH analyses demonstrated a consistent reduction in dense calcium 
content over time that reached the significant level in the cohort B2 at 1-year follow-up 
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figure 1. Serial changes in plaque composition in small and large vessels treated with second generation BVS.
The dense calcium content (surrogate marker of scaffold bioresorption) decreased over time in both groups. No 
significant changes in necrotic core and a mild increase in fibro-fatty and fibrous tissue were consistently observed 
in both groups.
(large vessels 28.50 ± 9.05% vs 24.13 ± 7.84%, p=0.0041; small vessels 32.96 ± 11.65% 
vs 24.77 ± 7.75%, p=0.0047) but was not significant at 2-year in cohort B1. Fibrous and 
fibro-fatty tissue significantly increased at 1-year follow-up (Fibrous tissue: large vessels 
36.14 ± 10.89% vs 41.52 ± 9.75% p=0.0148; small vessels 31.28 ± 10.01% vs 39.98 ± 
9.25%, p=0.0104. Fibro-fatty large vessels 2.90 ± 2.40 % vs 4.35 ± 2.20 % p=0.0035; small 
vessels 2.50 ± 1.90 % vs 4.56 ± 2.79 %, p= 0.0120). No changes in percentage necrotic 
core were observed at either time point. No further differences in plaque compositional 
characteristics were detected between small and large vessels at 1-and 2-year follow-up. 
(Figure 1-2, Appendix Table 6)
OCT analysis
OCT data at baseline were available for the present analysis in 50 patients, 20 patients in 
the small vessel group and 30 in the large vessel group. Post-procedurally the incomplete 
stent apposition (ISA) area was similar in both groups. Mean scaffold area, minimal 
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scaffold area, mean lumen area and minimal lumen area were significantly larger in the 
large vessel group and this was observed also at 2-year follow-up. No differences in % 
uncovered struts, % lumen area stenosis and mean neointimal hyperplasia (NH) area were 
observed over time. (Table 4)
Clinical Outcomes
At 1-year follow-up, comparisons of clinical outcomes between small and large vessels, 
demonstrated no differences in MACE (small-vessel group: 3/41 cases, 7.3% and large-
vessel group 4/60 cases, 6.7%, p=1.0000), MI (small-vessel group: 2/41 cases, 4.9% 
and large-vessel group 1/60 cases, 1.7%, p=0.5645) or ischemia driven target lesion 
revascularization (TLR) (small-vessel group: 1/41 cases, 2.4%; large-vessel group 3/60, 
5.0%, p=0.6445). (Table 5, Appendix Figure 3)
At 2-year follow-up only 2 further events were reported, namely 2 ischemia-driven TLR, 
both in the large vessels group. (Appendix Figure 4) Comparisons of clinical outcomes 
between small and large vessels, demonstrated no differences in MACE, MI or ischemia 
driven target lesion revascularization (TLR). No deaths were reported in either group up to 
2 years. No episodes of definite, probable, or possible scaffold thrombosis were observed 
up to 2 years. (Table 5) 
figure 2. Comparison of plaque compositional findings between small and large vessels at 1- and 2-year follow-up.
Small and large vessels showed similar plaque composition at both follow-up time points..
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table 5. Adverse Events at 12- and 24-Month Follow-Up in the entire population (Cohort B1 and B2) (Intent-to-Treat 
Population).
Cohort B1 and B2
12-Month Follow-up
Cohort B1 and B2
24-Month Follow-up
Small Vessels 
(<2.5mm) 
(N=41)
Large Vessels 
(>=2.5mm) 
(N=60)
P-value Small Vessels 
(<2.5mm) 
(N=41)
Large Vessels 
(>=2.5mm) 
(N=60)
P-value
MACE (Cardiac Death, MI, 
ID-TLR)
7.3% (3/41) 6.7% (4/60) 1.0000 7.3% (3/41) 10.2% (6/59) 0.7335
Cardiac Death 0.0% (0/41) 0.0% (0/60) NA 0.0% (0/41) 0.0% (0/59) NA 
Myocardial Infarction (MI) 4.9% (2/41) 1.7% (1/60) 0.5645 4.9% (2/41) 1.7% (1/59) 0.5662 
QMI 0.0% (0/41) 0.0% (0/60) NA 0.0% (0/41) 0.0% (0/59) NA 
NQMI 4.9% (2/41) 1.7% (1/60) 0.5645 4.9% (2/41) 1.7% (1/59) 0.5662 
ID-TLR (PCI) 2.4% (1/41) 5.0% (3/60) 0.6445 2.4% (1/41) 8.5% (5/59) 0.3962 
Scaffold Thrombosis 0.0% (0/41) 0.0% (0/60) NA 0.0% (0/41) 0.0% (0/60) NA
D I S C u S S I O N 
The present study investigated the long-term clinical and angiographic outcomes 
following the implantation of the second generation Absorb everolimus eluting 
bioresorbable vascular scaffold in small and large vessels. The major findings are: I) 
similar angiographic results were observed up to 2-year follow-up and the significant 
larger relative gain attained in the small-vessel group at the index procedure, that did 
not translate into greater relative late lumen loss, percentage diameter stenosis or binary 
restenosis at 2 years; II) IVUS grey scale analyses in the small vessel group demonstrated 
expansive vessel remodeling associated with a significant late lumen enlargement; III) 
Both the small- and large- vessel groups, treated with a 3.0 mm Absorb BVS, showed a 
similar and low rate of cardiovascular events
Angiographic results
In the ABSORB Cohort B Trial, vessels with a RVD < or ≥ 2.5 mm were both treated with a 3.0 
mm device. Both groups demonstrated a similar pre-procedural MLD and post-procedural 
in-scaffold acute gain. Following adjustment for vessel size, it was demonstrated that the 
relative gain was significantly greater in the small-vessel group compared to the large-
vessel group. 
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In previous studies, a larger relative gain was observed to be an independent predictor of 
restenosis, with a direct relationship between relative gain and the subsequent relative 
loss at follow-up. [11, 16] 
Schwartz et al [17] previously demonstrated that neointimal growth is proportional to the 
degree of vessel injury during the index procedure, and more specifically to the disruption 
of the internal elastic membrane. Consequently if we consider the relative gain as a 
surrogate measurement of the vessel injury induced by treatment, a greater luminal re-
narrowing in vessels with a greater luminal relative gain is not surprising.[18] 
Theoretically a similar relative gain and injury in small and large vessels would produce 
a similar quantitative neointimal response. In this situation small vessels would be less 
able to accommodate the same absolute amount of neointimal tissue compared to large 
vessels. [19, 20]
These considerations suggest that optimal acute and long-term outcomes after coronary 
interventions may result from the appropriate balance between luminal gain and vascular 
injury. 
In the present study the implantation of a 3.0 mm Absorb BVS in vessels with RVD < 2.5 
mm produced a significantly larger angiographic relative gain in small vessels compared 
to large vessels. At 1-and 2-year follow-up no differences in relative loss and percentage 
diameter stenosis were evident. Furthermore the net gain index (describing the outcome 
of intervention relating the pre MLD to the MLD at follow-up),[11] and the loss index (relating 
late loss to acute gain)[12] were also similar between the small- and large-vessel groups.
These data suggest that the slightly higher relative gain in the present series of small 
vessels, was associated with a favorable balance between vessel injury and luminal 
expansion, followed by comparable long-term clinical and angiographic outcomes 
between groups.
IVuS grey scale analyses
IVUS geometrical analyses demonstrated that at 1- and 2-year follow-up, minimal lumen 
area, percentage lumen area stenosis and neointimal hyperplasia area were similar 
between small and large vessels. Specifically, the neointimal hyperplasia area in both the 
small and large vessel groups and at both time points was limited and at the resolution 
limit of the imaging technique, [21] thus making even a statistically significant difference 
poorly relevant. IVUS analyses demonstrated also a consistent growth in vessel area 
over time irrespectively of vessel size; this observation was associated with an increase 
in plaque area but also with an increase in scaffold area, that was observed to occur in 
both large and small vessel at 2-year follow-up. These findings are consistent with the 
planned scaffold bioresorption process. During the first months after implantation the 
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Absorb BVS plays a role similar to conventional metallic DES, providing essentially a vessel 
mechanical scaffolding and drug elution. Between 6 months and 1 year the gradual 
polymer degradation leads to a progressive loss in scaffold structural integrity, and as 
recently demonstrated the return of the vasomotion properties of the treated segment 
at 12-month follow-up.[8] 
Furthermore, whilst at 6-months lumen area slightly decreased as would be expected after 
conventional metallic stent implantation, at 2-year follow-up a late lumen enlargement 
was observed, that reached statistical significance in the small vessel group. 
A largely accepted theory for the higher rates of restenosis and clinical events in small 
vessels is that a smaller lumen area is less able to accommodate the same amount of 
neointimal tissue compared to a larger lumen area. [19] Therefore, in this scenario a late 
lumen enlargement may play a key role in the prevention of restenosis in the small vessels 
lesions subset. 
These data also suggest that the potential concern related to the implantation of the 
present thick strut BVS (strut thickness 157 μm) in vessels with small lumen area may be 
unfounded.  
IVuS-Vh analysis
The dense calcium content has been previously used as a surrogate marker of polymer 
bioresorption [22, 23, 24] and in the present study was observed to decrease in parallel to a mild 
increase in fibro-fatty and fibrous tissue over time in both groups reaching the statistically 
significant level at 1-year follow-up in the Cohort B2 population. Compositional analyses 
also disclosed no significant changes in necrotic core content in both groups over time, 
consistently with previous histological studies reporting no relevant inflammatory 
response associated with Absorb BVS implantation.[5] (Figure 1-2, Appendix table 6)
OCT analysis 
The OCT analysis showed a larger mean scaffold area, minimal scaffold area, mean lumen 
area and minimal lumen area, in large vessels compared with small vessels with similar 
post-procedural % lumen area stenosis, demonstrating a larger stent deployment and 
vessels size in the large vessel group.
Notably at baseline the mean incomplete stent apposition (ISA) area was similar between 
the two groups reducing the possibility that the increased positive vessel remodeling in 
the small vessel group was due to an artificial improved stent apposition and drug elution 
in this population. 
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At 2-year follow-up similar neointimal growth was observed between small and large 
vessels and in only in one patient for each group was detectable incomplete stent 
apposition. 
Clinical outcomes 
A small vessel diameter is a well-recognized independent predictor of a higher rate of 
in-stent restenosis and poorer clinical outcomes [25, 26] with bare metal stents and first and 
second generation drug eluting stents.[27, 28, 29]
In the present study, the long-term clinical outcomes after implantation of the second 
generation Absorb BVS in small vessels were similar to that observed in large vessels, with 
low and comparable rates of MI and ischemia-driven TLR. Notably, no death or in-scaffold 
thrombosis events were reported at 2-year follow-up.
The two clinical events reported between 6 and 12 months and the further 2 between 1 
and 2 years all occurred in the large vessel group. (Appendix Figure 3 and 4) Furthermore 
the three events that occurred in the small vessel group up to 6 months were likely to have 
been related to baseline procedural complications, rather than device failure per	se.[6]
However, it should be highlighted that due to the limited patients population and low 
incidence rate in this study, caution should be made in making conclusions with regards 
to the safety.
In conclusion, treatment of small vessels with second generation Absorb BVS was 
observed in the present report to be associated with similar angiographic, IVUS and long-
term clinical outcomes compared to large vessels. The expected loss of structural integrity 
of the Absorb BVS device, and the return of the vasomotor properties of the treated vessel, 
unhindered by a metallic cage, translated into further beneficial positive remodeling and 
late lumen enlargement, which was particularly relevant in the small vessel group. 
Study limitations
The present study is a post-hoc analysis of the ABSORB Cohort B Trial. Due to the limited 
patient population, the p values were calculated for descriptive purposes and should be 
considered as exploratory and hypothesis generating. Further investigations are needed 
to fully investigate the impact of vessel size on clinical and angiographic outcomes after 
Absorb BVS implantation.
In Absorb Cohort B the bioresorbable vascular scaffold was implanted in discrete lesions 
located in native coronary arties excluding restenotic lesions, lesions located in the left 
main coronary artery, lesions involving a side branch more than 2 mm in diameter, and 
lesions with presence of thrombus or another clinically significant stenosis in the target 
vessel. We therefore cannot exclude that the implantation of BVS in different and more 
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complex lesions could have been associated with different results. 
During the ABSORB Cohort B study only the 3 mm BVS was available. A novel BVS 2.5mm 
mm is currently under clinical evaluation in two separate studies (the multicenter ABSORB 
Extend Single-Arm Study and the ABSORB II Randomized Controlled Trial) possibly aiding 
in further understanding on the performance of this device in the small vessels scenario. 
Quantitative coronary angiography that in the present paper was used to define vessel 
size is characterized by the detection of the angiographic lumen contour without any 
evaluation of the actual vessel wall size.
CO N C Lu S I O N 
In the present study the implantation of the 3.0 mm ABSORB everolimus eluting 
bioresorbable vascular scaffold in coronary arteries with RVD < 2.5 mm appears safe, 
with angiographic and clinical outcomes similar to those in large vessels at 1- and 2-year 
follow-up. A favourable balance between acute luminal gain and vascular injury and the 
observed significant late lumen enlargement may be the possible explanation for the 
encouraging long-term results in small vessels.
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A P P E N D I x  I I
Case descriptions of clinical events
Events	between	6-	and	12-month	follow-up	
Between 6- and 12-month follow-ups, two new ID-TLRs were observed in the large-vessel 
group; no clinical events occurred in the small vessel group within this time period.
The fi rst patient (RVD 2.81 mm) was a 76-year-old male, with treated hypercholesterolemia, 
family history of premature CAD, previous PTCA with metallic stent in the middle part of 
LAD (non-target lesion). The patient presented with stable angina, Canadian Cardiovascular 
Society Angina Classifi cation Class III.
Initial coronary angiography revealed a signifi cant lesion in the proximal LAD. After pre-
dilatation with a semi-compliant balloon (2.5x12mm) to 16 ATM, a 3.0x18mm Absorb BVS 
was deployed in the proximal LAD to a maximal implantation pressure of 14 ATM. The % 
diameter stenosis was reduced to 12% post procedure. Post dilatation was not performed. 
On review of the cine-angiograms, it was also observed that the scaff old was deployed 
slightly distal to the segment pre-dilated with a modest geographical miss. (Appendix 
Figure 3)
figure 3. Clinical events between 6-month and 1-year follow-up. 
Two target lesion revascularizations occurred both in large vessels (namely in the proximal left anterior descending 
artery). Of note in one case (A, left panel) the Absorb BVS was deployed slightly distally in the pre-dilated region 
(white line). Vascular response to vessel injury can therefore not be excluded as cause of restenosis at the proximal 
edge (platinum markers indicated by the white arrows). In the second case (B, right panel) restenosis developed 
in the mid segment of the BVS (B, upper panel). The magnifi ed scaff olded segment (B, lower panel) shows the 2 
platinum markers (black arrows) and the focal in-scaff old restenosis (white arrows).
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On day 358, the patient was hospitalized due to unstable angina pectoris. ECG revealed 
sinus bradycardia (53/minute), normal axis and conduction. Angiography disclosed a 
scaffold proximal edge stenosis. Direct stenting in overlap with the area of the study device 
was performed with a metallic Xience V everolimus eluting stent 3.0x15 mm with a good 
angiographic result. The CEC adjudicated this event per protocol as ischemia driven target 
lesion revascularization. In this case geographical miss during scaffold deployment, and 
the subsequent vascular response to injury after predilatation, are the probable causes for 
repeat revascularization. 
In the second case (RVD 2.64 mm), a 57-year old man with treated hypercholesterolemia, 
former tobacco use, history of ischemic cardiomyopathy and unstable angina, Braunwald 
class II, normal cardiac enzymes, was treated for a significant focal lesion in the proximal 
LAD. After pre-dilatation with a semi compliant balloon 2.5 x 10 mm (12 atm), a 3.0 x 
18 mm Absorb BVS (12 atm) was implanted and post-dilated with a 3.0x10 mm non-
compliant balloon (20 atm).
On day 353 the patient was readmitted due to chest pain with elevation of troponin 
(0.3µg/L, ULN=0.03µg/L), normal CK (89U/L, ULN=200U/L) and normal CK-MB (5.4µg/L, 
ULN=6.73µg/L). ECG showed an incomplete RBB and anteroseptal sub-epicardial ischemia. 
Cardiac ultrasound revealed anterior hypokinesis with a LVEF of 50%. Angiography was 
performed on day 354 revealing a significant in-scaffold restenosis (Figure 2) that was 
treated with a metallic Xience V everolimus eluting stent. Whether this restenosis resulted 
by an intrinsic patient’s resistance to everolimus as antiproliferative drug or was secondary 
to a different mechanism [30] remains speculative. The CEC adjudicated the event per 
Protocol as ischemia-driven TLR.
Events	between	1-	and	2-year	follow-up	
The first case (RVD 2.72 mm) was a 63-year-old female with a medical history of 
hyperlipidemia and hypertension both requiring medication. She presented with a positive 
functional ischemia study due to two vessel disease and normal cardiac biomarkers.
After pre-dilatation with a 2.5 x 15 mm Monorail compliant balloon at 12 atm, one 3.0 
x 18 mm Absorb BVS was deployed with an investigator assessed 80% DS lesion in the 
proximal RCA (CASS #1) with a maximal implantation pressure of 14 atm. Post-scaffold 
dilatation was performed with a 3.25 x 12 mm NC balloon at a maximal pressure of 16 
atm. The investigator assessed DS was reduced from 80% to < 10 % post procedure. The 
patient was discharged on Day 4 and aspirin and clopidogrel were used during the index 
procedure per protocol.
On Day 363 the patient was hospitalized due to Braunwald Class II unstable angina. 
Cardiac biomarkers were within normal limits and the ECG demonstrated no signs of 
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ischemia. Coronary angiography revealed a patent study Absorb BVS with a core lab 
assessed 26% DS of target lesion, and an investigator assessed 60% DS lesion in the distal 
LMCA, an 80% DS ostial lesion of LCX and a 70% DS ostial lesion of RCA. The core lab 
assessed a bifurcation lesion at LMCA-LAD-LCX and bifurcation lesion at distal RCA-RPDA, 
and the lesion in the distal RCA as signifi cant. The IVUS investigator assessment confi rmed 
good index PCI result and critical LMCA and ostial RCA stenosis. No intervention was 
performed and the patient was referred for cardiac surgical follow-up. On Day 439 the 
patient underwent CABG revascularization with SVG to the distal RCA and proximal LCX, 
and LIMA to the mid LAD. In addition, a left ICA endarterectomy was performed for critical 
stenosis without symptoms. The patient’s hospital course was unremarkable and she was 
discharged on Day 477. Aspirin and clopidogrel were ongoing at the time of this event. The 
investigator considered the event as not related to the study device or study procedure 
and not caused by a malfunction of the study device. The CEC adjudicated the event per 
protocol as ischemia-driven TVR by CABG and ischemia-driven NTVR x 2 by CABG. The 
CEC adjudicated the event per ARC as a clinically indicated TVR by CABG and clinically 
indicated NTVR x 2 by CABG. 
On Day 590 the patient was hospitalized due to Braunwald Class II unstable angina with an 
elevated CK-MB of 25 U/L (ULN 24 U/L). Coronary angiogram revealed a core lab assessed 
16% DS lesion in the proximal RCA and 60% DS lesion in the mid RCA. On Day 591, after 
pre-dilatation with a 2.5 x 15 mm balloon catheter at 12 atm, one 4.0 x 38 mm metallic DES 
was implanted across the lesion in the mid RCA (CASS # 2) on the edge of index Absorb 
figure 4. Clinical events between 1- and 2-year follow-up. 
Two additional target lesion revascularizations occurred in large vessels, namely proximal left anterior descending 
artery (A, left panel) and proximal-mid right coronary artery (B, right panel). 
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BVS (CASS #1) at 12 atm with good results confirmed by IVUS. The investigator assessed 
the event as not related to the study device or procedure and not caused by a malfunction 
of the study device. The patient was discharged on Day 591 and aspirin and clopidogrel 
were ongoing on the time of this event. The CEC adjudicated the event per protocol as 
ischemia-driven TLR by PCI. 
The second patient (RVD 2.96 mm) was a 62 year old male former tobacco user with a history 
of hypertension requiring medication and COPD. He presented with CCS Class III stable 
angina due to single vessel disease with normal cardiac biomarkers. After pre-dilatation 
with a 2.5 x 12 mm compliant balloon catheter at 12 atm, one 3.0 x 18 mm Absorb BVS was 
deployed across an investigator assessed 90% DS lesion in the proximal LAD (CASS #12) 
with a maximum implantation pressure of 14 atm. Post-scaffold dilatation was performed 
with a 3.25 x 12 mm non-compliant balloon catheter at a maximal pressure of 16 atm 
followed by 3.5 x 8 mm proximal non compliant balloon catheter dilatation at a maximal 
pressure of 12 atm. OCT showed a good scaffold apposition and expansion apart from a 
rim of unopposed struts at the very proximal portion of the scaffold where the vessel was 
ectatic. There were no procedural complications and the patient was discharged on Day 1. 
Aspirin and clopidogrel were used during the index procedure per protocol.
Angiography performed on Day 346 revealed the study Absorb BVS in the proximal LAD to 
be widely patent with a mild area of disease noted in the mid LAD distal to the scaffolded 
segment. IVUS and OCT showed the scaffold to be well apposed and expanded with thin 
neo-intimal coverage. The proximal struts that were unapposed at the index procedure 
were noted to be covered with a thin rim of tissue. 
On Day 564 the patient was hospitalized with Braunwald Class I unstable angina. 
Angiography performed on Day 567 revealed a corelab assessed 74% DS in-scaffold 
restenosis in the proximal LAD (CASS #12) with no thrombosis or occlusion. The troponin 
was elevated with a peak value of 1.66 ng/ml (ULN 0.04 ng/ml) with normal CK. On Day 571 
the patient underwent PCI revascularization with one 3.0 x 18 mm Xience V everolimus 
eluting metallic DES successfully deployed across the lesion in the proximal LAD at 16 
atm and post dilated with 3.5 x 8 mm non compliant balloon at 22 atm with good result. 
The investigator assessed the event as related to the study device and not caused by a 
malfunction of the study device. The patient was discharged on Day 572. Aspirin and 
clopidogrel were ongoing at the time of the event. 
The CEC adjudicated the event per protocol as ischemia-driven TLR by PCI. 
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ABSORB II Randomized Controlled Trial
A Clinical Evaluation to Compare the Safety, Efficacy 
and Performance of the Absorb Everolimus Eluting 
Bioresorbable Vascular Scaffold System Against the 
Xience Everolimus Eluting Coronary Stent System in 
the Treatment of Subjects with Ischemic Heart Disease 
caused by De	Novo Native Coronary Artery Lesions: 
Rationale and Study Design
Roberto Diletti, MD; Patrick W. Serruys, MD, PhD; Vasim Farooq, MBChB, MRCP; 
Krishnankutty Sudhir, MD, PhD; Cecile Dorange, MSc; Karine Miquel-Hebert, PhD; 
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A B S T R AC T
Background Currently no data are available on the direct comparison between 
the Absorb everolimus eluting bioresorbable vascular scaffold (Absorb BVS) and 
conventional metallic drug eluting stents. 
Methods The ABSORB II Study is a randomized, active-controlled, single-blinded, 
multicenter clinical trial aiming to compare the second generation Absorb BVS 
with the XIENCE everolimus eluting metallic stent. Approximately 501 subjects will 
be enrolled on a 2:1 randomization basis (Absorb BVS: XIENCE) in approximately 40 
investigational sites across Europe and New Zealand. Treated lesions will be up to 
2 de	novo	native coronary artery lesions, each located in different major epicardial 
vessels, all with an angiographic maximal luminal diameter between 2.25 mm and 
3.3 mm as estimated by on-line quantitative coronary angiography (QCA), and a 
lesion length of ≤48 mm. Clinical follow-up is planned at 30 days, 180 days and 
at 1, 2 and 3 years. All subjects will undergo coronary angiography, intravascular 
ultrasound (IVUS) and IVUS-virtual histology (IVUS-VH) at baseline (pre- and post-
device implantation) and at 2-year angiographic follow-up. The primary end point 
is superiority of the Absorb BVS versus XIENCE in terms of vasomotor reactivity of 
the treated segment at 2 years- defined as the QCA quantified change in the mean 
lumen diameter pre- and post-nitrate administration. The co-primary endpoint 
is the non-inferiority (reflex to superiority) of the QCA derived minimum lumen 
diameter (MLD) at 2 years post nitrate minus MLD post procedure post nitrate by 
QCA. In addition all subjects allocated to the Absorb BVS group will undergo MSCT 
imaging at 3 years. 
Conclusions The ABSORB II RCT (ClinicalTrials.gov NCT01425281) is designed to 
compare the safety, efficacy and performance of Absorb BVS against the XIENCE 
everolimus eluting stent in the treatment of de	novo	native coronary artery lesions.
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I N T R O D u C T I O N 
The Absorb everolimus eluting bioresorbable vascular scaffold (Absorb BVS) was 
developed to provide a novel approach to treating coronary artery lesions with transient 
vessel support and drug delivery. 
Preclinical evaluation in animal model demonstrated substantial polymer degradation at 
2-years post Absorb BVS implantation, with complete disappearance of the Absorb BVS 
strut ‘footprint’ in the vessel wall within a 4-year period, with no significant inflammatory 
response associated with BVS implantation at short or long-term follow-up(1)
The first generation Absorb BVS was tested in the ABSORB Cohort A Trial and demonstrated 
promising results with a low clinical event rate at 5 years follow-up.(2) The device was 
however limited by slightly higher late recoil compared to conventional metallic platform 
stents.(3,4) Improvements in design were therefore introduced in the second generation 
Absorb BVS, notably an enhanced mechanical strength, more durable support to the 
vessel wall, a reduced maximum circular unsupported surface area and a more uniform 
strut distribution and drug delivery. The performance of this next generation Absorb BVS 
was subsequently investigated in the ABSORB Cohort B Trial (5,6) which reported excellent 
clinical results up to 1-year follow-up. (7)
To date, the treatment of coronary artery disease with the second generation Absorb BVS 
has been investigated in a limited number of patients with relatively simple coronary 
lesion complexity. Furthermore no randomized comparison between the Absorb BVS and 
conventional metallic drug-eluting stent has yet been undertaken. 
Therefore, the ABSORB II controlled randomized trial (ClinicalTrials.gov NCT01425281) 
comparing the metallic everolimus-eluting stent XIENCE with the Absorb BVS will be 
initiated and treatment will be expanded to include subjects with small target vessels 
diameter and long lesion length.
Investigational Device
The second generation Absorb BVS (Abbott Vascular, Santa Clara, CA, USA) is a balloon 
expandable device consisting of a polymer backbone of Poly-L lactide (PLLA) coated with 
a thin layer of a 1:1 mixture of an amorphous matrix of Poly-D, L lactide (PDLLA) polymer, 
and 100 micrograms/cm2 of the anti-proliferative drug everolimus. Two platinum markers 
located at each Absorb BVS edge allow for accurate visualization of the radiolucent Absorb 
BVS during angiography or other imaging modalities. The PDLLA controls the release of 
everolimus, 80% of which is eluted within the first 30-days. Both PLLA and PDLLA are 
fully bioresorbable. The polymers are degraded via hydrolysis of the ester bonds and the 
resulting lactate and its oligomers are quickly transformed to pyruvate and metabolized in 
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the Krebs energy cycle. Small particles, less than 2 μm in diameter, have also been shown 
to be phagocytised and degraded by macrophages.(8) According to preclinical studies the 
time for complete bioresorption of the polymer backbone is 2 to 3 years.(1) 
Control Device
The XIENCE (Abbott Vascular, Santa Clara, CA, USA) is a balloon expandable metallic 
platform stent manufactured from a flexible cobalt chromium alloy with a multicellular 
design, and coated with a thin (7.8 μm) non-adhesive, durable, biocompatible acrylic and 
fluorinated everolimus releasing copolymer.
The delivery system to be used in both arms of the trial will utilize the same principle 
of operation as other Abbott Vascular Rapid Exchange (RX) coronary stent systems and 
coronary dilation catheters. 
Treatment Strategy
Quantitative assessment of target vessel diameter by on-line quantitative coronary 
angiography (QCA) is required at baseline after nitroglycerin for appropriate ABSORB BVS 
or XIENCE stent size selection. The required range for target vessel diameter is assessed 
in terms of the on-line QCA parameters distal Dmax and proximal Dmax, which refer to 
maximum lumen diameter evaluated prior to pre-dilatation up to 5-10 mm distal and 
proximal to the boundaries of the lesion length defined by QCA. A 3.5 mm ABSORB BVS 
or XIENCE should be used when both the proximal and distal mean lumen diameter are 
within the upper limit of 3.8 mm and the lower limit of 3.0 mm. A 3.0 mm ABSORB BVS or 
XIENCE stent must be used when both the proximal and distal mean lumen diameter are 
within the upper limit of 3.3 mm and the lower limit of 2.5 mm. A 2.5 mm ABSORB BVS or 
XIENCE stent must be used when both the proximal and distal mean lumen diameter are 
within the upper limit of 3.0 mm and the lower limit of 2.25 mm. Both the proximal mean 
lumen diameter and the distal mean lumen diameter need to be within the upper and 
lower limits specified for the scaffold/stent size. Overlap will be allowed. (Table 1)
Dual Antiplatelet Therapy
All subjects will receive ≥75 mg of aspirin daily after the index procedure and throughout 
the length of the clinical investigation. All subjects will be maintained at a minimum of 75 
mg of clopidogrel daily or a minimum of 10 mg of prasugrel daily for a minimum of 180 
days following the procedure leading to a dual antiplatelet therapy for a minimum of 180 
days. If a subject develops sensitivity to clopidogrel or prasugrel, they may be switched to 
ticlopidine according to standard hospital practice. 
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table 1. Device sizes to be used in the study according to the maximum lumen diameter (Dmax) by online QCA only.
Device
Lesion and Device Sizes
Dmax Lesion Length
ABSORB BVS
Scaffold diameter
2.5 mm ≥ 2.25 mm and ≤ 3.0 mm
≤ 48 mm
Scaffold Length: 18, 28 mm
3.0 mm ≥ 2.5 mm and ≤ 3.3 mm
≤ 48 mm
Scaffold Length: 18, 28 mm
3.5 mm ≥ 3.0 mm and ≤ 3.8 mm
≤ 48 mm
Scaffold Length: 12, 18, 28 mm
XIENCE
Stent diameter
2.5 mm ≥ 2.25 mm and ≤ 3.0 mm
≤ 48 mm
Scaffold Length: 18, 28 mm
3.0 mm ≥ 2.5 mm and ≤ 3.3 mm
≤ 48 mm
Scaffold Length: 18, 28 mm
3.5 mm ≥ 3.0 mm and ≤ 3.8 mm
≤ 48 mm
Scaffold Length: 12, 18, 28 mm
The anti-platelet therapy can be halted for clinical indications if required, however must 
be resumed as soon as possible per-physician discretion.
Trial design and objective
The ABSORB II Randomized Controlled Trial (RCT) is intended to continue to evaluate the 
safety and efficacy of the Absorb BVS, and to directly compare it to the metallic drug-
eluting stent XIENCE. 
XIENCE stent and Absorb BVS share the same basic MULTI-LINK design and both devices 
are similar in terms of drug, drug dose density, and elution profile. 
The ABSORB II RCT is a prospective, randomized, active-controlled, single-blinded, parallel 
two-arm, multi-center clinical trial. A total of approximately 501 subjects (334 in the Absorb 
BVS group and 167 in the XIENCE stent group) will be randomized in approximately 40 
sites in Europe and New Zealand. The trial protocol allows the treatment of up to 2 de	novo	
native coronary artery lesions, each located in different major epicardial vessels, with a 
maximal lumen diameter comprised between 2.25 mm and 3.8 mm as assessed by on-line 
quantitative coronary angiography (QCA), and a maximum lesion length ≤ 48 mm. 
All subjects will be screened per the protocol inclusion and exclusion criteria prior to 
enrolment. Subjects will have clinical follow-up at 30 days, 180 days and at 1, 2 and 3 
years. All subjects will undergo coronary angiography, intravascular ultrasound (IVUS) and 
IVUS-virtual histology (VH) imaging pre- and post- device implantation and at 2 years post 
index procedure. 
Subjects from the Erasmus Medical Centre (MC) Rotterdam, The Netherlands will also 
undergo intravascular imaging with near infrared spectroscopy (Lipiscan) pre- and post- 
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device implantation and at 2 years post index procedure. 
All subjects allocated to the Absorb BVS arm will undergo MSCT imaging at 3 years post 
index procedure. Subjects will be unblinded after completion of the 2-year follow-up for 
the co-primary endpoints. 
The primary objective of the ABSORB II RCT is to compare the safety, efficacy and 
performance of Absorb BVS against the XIENCE stent in the treatment of subjects with 
ischemic heart disease caused by de novo native coronary artery lesions. 
The ABSORB II RCT is intended to show superiority of Absorb BVS versus XIENCE stent, in 
terms of the primary endpoint of vasomotor reactivity as assessed by the change in mean 
lumen diameter pre- and post-nitrate and at 2-year invasive follow-up with QCA, and non-
inferiority (reflex to superiority) in terms of the co-primary endpoint of angiographic late 
loss at 2-year follow-up (minimum lumen diameter (MLD) at 2 years post nitrate minus 
MLD post procedure post nitrate by QCA). 
All invasive procedures may be deferred to 3 years depending on the results of the ABSORB 
Cohort B trial.
This trial will be conducted in accordance with the Clinical Investigational Plan, the 
Declaration of Helsinki, ISO 14155 standards and the appropriate local legislation(s). The 
conduct of the trial will be approved by the appropriate Ethics Committee (EC) of the 
respective clinical site and as specified by local regulations.
PAT I E N T  S E L E C T I O N 
Subjects enrolled into the clinical trial will be male or female derived from the general 
interventional cardiology population. The clinical trial will randomize up to approximately 
501 subjects. Subjects meeting the general inclusion and exclusion criteria (Table 2, Table 
3) will be asked to sign an informed consent. Non-routine laboratory assessments specific 
to the clinical investigation will not be performed before an informed consent has been 
signed. 
Screening failures will be captured on a paper-screening log. 
After successful pre-dilatation of the first target lesion, subject ID, randomization number 
and treatment arm will be assigned by a central allocation service (interactive voice / 
interactive web-based randomization service).
Subjects will be randomized in a 2:1 ratio to Absorb BVS versus XIENCE stent. Randomization 
will be further stratified by diabetes mellitus status and number of planned target lesions. 
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table 2. Inclusion criteria.
General Inclusion Criteria
• Subject must be at least 18 years of age and less than 85 years of age. 
• Subject must agree not to participate in any other clinical investigation for a period of three years following 
the index procedure. This includes clinical trials of medication and invasive procedures. Questionnaire-based 
studies, or other studies that are non-invasive and do not require medication are allowed. 
• Subject is able to verbally confirm understanding of risks, benefits and treatment alternatives of receiving the 
ABSORB BVS and he/she or his/her legally authorized representative provides written informed consent prior 
to any Clinical Investigation related procedure, as approved by the appropriate Ethics Committee. 
• Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia). 
• Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery 
• Subject must agree to undergo all clinical investigation plan-required follow-up visits, exercise testing, blood 
draw as well as adherence to ESC Guidelines and completion of quality of life questionnaires and of a subject 
diary to collect information including but not limited to tobacco usage, food intake, daily exercise and body 
weight. 
Angiographic Inclusion Criteria
• One or two de novo native lesions each located in a different epicardial vessel. 
• If two treatable lesions meet the eligibility criteria, they must be in separate major epicardial vessels (LAD with 
septal and diagonal branches, LCX with obtuse marginal and/or ramus intermedius branches and RCA and 
any of its branches). 
• Lesion(s) must have a visually estimated diameter stenosis of ≥50% and <100% with a TIMI flow of ≥1.
• Lesion(s) must be located in a native coronary artery with Dmax by on-line QCA of ≥2.25 mm and ≤3.3 mm. 
• Lesion(s) must be located in a native coronary artery with lesion(s) length by on-line QCA of ≤48 mm.
• Percutaneous interventions for lesions in a non-target vessel are allowed if done ≥30 days prior to or if planned 
to be done 2 years after the index procedure. 
• Percutaneous intervention for lesions in the target vessel are allowed if done >6 months prior to or if planned 
to be done 2 years after the index procedure
table 3. Exclusion criteria.
General Exclusion Criteria
• Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication 
specified for use in the study (clopidogrel and prasugrel and ticlopidine, inclusive), everolimus, poly (L-lactide), 
poly (DL-lactide), cobalt, chromium, nickel, tungsten, acrylic and fluoro polymers or contrast sensitivity that 
cannot be adequately pre-medicated. 
• Subject has a known diagnosis of acute myocardial infarction (AMI) at any time preceding the index procedure 
and relevant cardiac enzymes (according to local standard hospital practice) have not returned within normal 
limits at the time of procedure. 
• Evidence of ongoing acute myocardial infarction in ECG prior to procedure 
• Subject has current unstable arrhythmias. 
• Left ventricular ejection fraction (LVEF) < 30%. 
• Subject has received a heart transplant or any other organ transplant or is on a waiting list for any organ 
transplant. 
• Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or after the 
procedure. 
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General Exclusion Criteria
• Subject is receiving immunosuppressant therapy and/or has known immunosuppressive or autoimmune 
disease (e.g. human immunodeficiency virus, systemic lupus erythematosus, rheumatoid arthritis, severe 
asthma requiring immunosuppressive medication, etc.). 
• Subject is receiving chronic anticoagulation therapy that can not be stopped and restarted according to local 
hospital standard procedures. 
• Elective surgery is planned within 2 years after the procedure that will require discontinuing either aspirin, 
clopidogrel, prasugrel or ticlopidine. 
• Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3, a WBC of <3,000 cells/mm3, or 
documented or suspected liver disease (including laboratory evidence of hepatitis) 
• Known renal insufficiency (e.g., eGFR <60 ml/kg/m2 or serum creatinine level of >2.5 mg/dL, or subject on 
dialysis). 
• History of bleeding diathesis or coagulopathy or will refuse blood transfusions. 
• Subject has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the 
past 6 months. 
• Pregnant or nursing subjects and those who plan pregnancy in the period up to 3 years following index 
procedure. (Female subjects of child-bearing potential must have a negative pregnancy test done within 28 
days prior to the index procedure and contraception must be used during participation in this trial) 
• Other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, 
cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound 
the data interpretation or is associated with a limited life expectancy. 
• Subject is already participating in another clinical investigation that has not yet reached its primary endpoint.
• Subject is belonging to a vulnerable population (per investigator’s judgment, e.g., subordinate hospital staff or 
sponsor staff ) or subject unable to read or write
Angiographic Exclusion Criteria
• Target lesion which prevents adequate (residual stenosis at target lesion(s) is ≤ 40% by visual assessment) 
coronary pre-dilatation. 
• Target lesion in left main trunk. 
• Aorto-ostial target lesion (within 3 mm of the aorta junction). 
• Target lesion located within 2 mm of the origin of the LAD or LCX. 
• Target lesion located distal to a diseased (vessel irregularity per angiogram and >20% stenosed lesion) arterial 
or saphenous vein graft. 
• Target lesion involving a bifurcation lesion with side branch ≥2 mm in diameter, or with a side branch <2mm 
in diameter requiring guide wire protection or dilatation. 
• Total occlusion (TIMI flow 0), prior to wire crossing 
• Excessive tortuosity (≥ two 45° angles), or extreme angulation (≥90 °) proximal to or within the target lesion.
• Restenotic from previous intervention 
• Heavy calcification proximal to or within the target lesion. 
• Target lesion involves myocardial bridge. 
• Target vessel contains thrombus as indicated in the angiographic images. 
• Additionally clinically significant lesion(s) (≥ 40% diameter stenosis by visual assessment) for which PCI may be 
required <2 years after the index procedure. 
• Subject has received brachytherapy in any epicardial vessel (including side branches) 
• Subject has a high probability that a procedure other than pre-dilatation and study device implantation and 
(if necessary) post-dilatation will be required at the time of index procedure for treatment of the target vessel
table 3. Continued
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Follow-up schedule 
Subjects will be followed for a 3-year period post index procedure with clinical and 
invasive imaging follow-up. (Figure 1)
 figure 1. Clinical investigation fl ow chart.
*Clinical Laboratory: blood sample (to be obtained before exercise testing) to aid in the adjustment of medical 
treatment and adherence to ESC guidelines. **QoL: Quality of Life using the Seattle Angina Questionnaire (SAQ), the 
SF-12 Health Survey and the EuroQoL EQ-5D Health Survey. This information will be collected at the indicated time 
points. ***Lipiscan analysis will be done at the Erasmus MC only. ****Exercise test to be done prior to any required 
imaging procedure and after blood draws. The offi  ce imaging visit at 2 years (including exercise testing, coronary 
angiogram, IVUS, IVUS-VH, Lipiscan, SF12, EuroQoL EQ-5D and SAQ) may be changed to 3 years depending on cohort 
B 2 year imaging data. In that case the 2 year imaging visit would be replaced by an offi  ce visit where exercise testing, 
SF12, EuroQoL EQ-5D, SAQ, adherence to ESC Guidelines per protocol medication, concomitant medication and 
adverse events would be reviewed.
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Clinical follow-up
Clinical visit follow-up including blood sampling will be performed in all patients at 30 
days, 180 days, 1, 2 and 3 years days post-procedure. A central laboratory will be used for 
blood analysis of troponin, CK, CK-MB, fasting total cholesterol, fasting LDL cholesterol, 
fasting HDL cholesterol, fasting triglycerides, HbA1c, fasting blood glucose levels. 
These blood samples for central laboratory will be obtained before or at the time of the 
procedure; the results will not be reviewed at the procedure time. 
Local analyses may be performed in parallel to any blood results that are relevant for 
appropriate protocol compliance, subject care and treatment optimization. 
Exercise testing will be required at 180 days, 1, 2 and 3 years post-procedure, to be 
performed prior to any required imaging procedure and after blood sampling. Exercise 
tests will be performed at each investigational site according to local clinical practise.
All patients and treating physicians will be asked to adhere to the European Society of 
Cardiology (ESC) Guidelines(9) in terms of tobacco usage, exercise, healthy food intake, 
maintaining an adequate weight (body mass index) and waist circumference, achieving 
target blood lipid levels and blood pressure control. These parameters will be evaluated 
at pre-procedure, 30 days, 180 days, 1, 2 and 3 years post-procedure.
Quality of life questionnaires will be undertaken in the ABSORB II RCT to provide 
a complementary evaluation of the effectiveness of the Absorb BVS system. The 
questionnaires will be collected at pre-implantation, 180 days, 1, 2 and 3-year follow-up 
and will include both the overall health status, assessed using the SF-12 Health Survey and 
the EuroQoL EQ-5D survey and disease-specific quality of life, assessed using the Seattle 
Angina Questionnaire (SAQ) 
Intravascular Imaging follow-up
Angiography	
All subjects will undergo coronary angiography at pre- and post-device implantation and 
at 2-year follow-up 
Grey	Scale	Intravascular	Ultrasound	(IVUS)	-	Virtual	Histology	(VH)
IVUS and IVUS-VH assessment will be performed in all patients after coronary angiography, 
at pre- and post-implantation and at 2-year follow-up. Pre-procedural IVUS and IVUS-VH 
will be performed before pre-dilatation of each target lesion. If not technically feasible, 
(i.e. the IVUS catheter cannot cross the lesion) pre-dilatation with a small balloon 
dilatation catheter is allowed for IVUS catheter access. IVUS and IVUS-VH are intended for 
documentary purposes only and not for vessel sizing, thus this will not impact on inclusion/
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exclusion decision-making processes. In case of two target lesions, pre-procedural IVUS 
and IVUS-VH will be performed for the second lesion after the treatment of the first lesion. 
near Infrared spectroscopy (lipiscan)
A Near infrared spectroscopy sub-study will take place in Erasmus MC only. Analyses 
will be performed at pre- and post-device implantation and at 2-year follow-up. NIRS 
assessment will be performed after IVUS and IVUS-VH at each time point. All invasive 
imaging procedures at 2 years may be deferred to 3 years depending on the results of the 
ABSORB Cohort B 2-year imaging follow up data.
multi slice Computed tomography (msCt) 
A MSCT scan is mandatory for all subjects in the Absorb BVS arm at 3 years follow-up. 
Endpoints 
Primary	Endpoints	and	Rationale	
The co-primary endpoints of the clinical trial are: 1) Vasomotion assessed by change in 
Mean Lumen Diameter between pre- and post-nitrate at 2 years by QCA (superiority) and 
2) Minimum lumen diameter at 2 years post nitrate minus minimum lumen diameter post 
procedure, post nitrate by QCA (non-inferiority, reflex to superiority). (Table 4) 
Secondary clinical and imaging endpoints are reported in Table 4.
S TAT I S T I C A L  CO N S I D E R AT I O N S 
Sample	Size	Calculations	and	Assumptions	
The sample size calculation is based on the first co-primary endpoint (superiority for 
vasomotion assessed by change in mean lumen diameter between pre- and post-nitrate 
at 2 years by QCA). The following assumptions were considered: 
1) Two-tailed superiority t-test; 2) α = 0.05; 3) Power = 90%; 4) Randomization ratio 2:1 
(Absorb BVS arm : XIENCE stent); 5) Based on previous vasomotion data at 2 years after 
BVS implantation,(10) The true change in mean lumen diameter between pre- and post-
nitrate at 2-year follow-up is assumed to be 0.07 mm for Absorb BVS and 0 mm for XIENCE 
stent; 6) The standard deviation is assumed to be 0.20 mm.
Based on the above assumptions 260 lesions in the Absorb BVS arm and 130 lesions 
in the XIENCE stent arm will be required for the study. The attrition rate observed in 
ABSORB Cohort A and SPIRIT II at 2-year was 24%, we expect an additional loss of 5% for 
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table 4. Clinical angiographic and imaging endpoints.
Clinical Endpoints 
Acute success 
• Device success (lesion based analysis) 
• Procedural success (subject based analysis) 
Clinical Endpoint (at 30 and 180 days, 1, 2, and 3 years follow-up) 
• Component
- Death (Cardiac, Vascular, Non-Cardiovascular) 
- Myocardial Infarction (MI: QMI and NQMI)* 
- Target Lesion Revascularization (TLR) 
Clinically-indicated TLR (CI-TLR) 
Not clinically-indicated TLR (NCI-TLR) 
- Target Vessel Revascularization (TVR) 
Clinically-indicated TVR (CI-TVR) 
Not clinically-indicated TVR (NCI-TVR) 
- Non-Target Vessel Revascularization (NTVR) 
Clinically-indicated NTVR (CI-NTVR) 
Not clinically-indicated NTVR (NCI-NTVR) 
- All coronary revascularization 
• Composite Endpoints 
Death/All MI 
Cardiac Death/TV-MI/CI-TLR (Target Lesion Failure (TLF)) (Device-oriented endpoint) 
Cardiac Death/All MI/CI-TLR (Major Adverse Cardiac Events (MACE)) 
Cardiac Death/All MI/CI-TVR (Target Vessel Failure (TVF)) 
Death/All MI/All revascularization (DMR) (Subject-oriented endpoint) 
• Scaffold/Stent Thrombosis 
Timing (acute, sub-acute, late and very late) 
Evidence (Definite, Probable and Possible) 
quality of Life (qoL) related Endpoints 
• Health status will be assessed using the SF-12 Health Survey and the EuroQoL EQ-5D at pre-implantation, 180 
  days, 1, 2 and 3 years follow-up. 
• Disease-specific QoL will be assessed using the Seattle Angina Questionnaire (SAQ) at pre-implantation, 180 
  days, 1, 2 and 3 years follow-up. 
Angiographic Endpoints 
• In-segment LL post-nitrate at 2* years; 
• Proximal LL (proximal defined as within 5 mm of tissue proximal to scaffold/stent placement) post-nitrate at 
  2* years; 
• Distal LL (distal defined as within 5 mm of tissue distal to scaffold/stent placement) post-nitrate at 2* years; 
• In-scaffold/In-stent, in-segment, proximal and distal Minimum Luminal Diameter (MLD) post-nitrate post-
  procedure and at 2* years; 
• In-scaffold/In-stent, in-segment, proximal and distal % Diameter Stenosis (DS) post-nitrate post-procedure 
  and at 2* years; 
• In-scaffold/In-stent, in-segment, proximal and distal Angiographic Binary Restenosis (ABR) rate post-nitrate at 
  2* years; 
• In-scaffold/in-stent net gain (being the change in MLD between 2* years versus pre-implantation) post-nitrate; 
• Change in Mean and Minimal lumen diameter at 2* years follow-up from pre-nitrate to post-nitrate by 
  angiography 
• In-scaffold/in-stent %Diameter Stenosis (DS) at 2* years pre- and post-nitrate by angiography
• Conformability assessed by change in curvature and angulation between pre-, post-procedure and follow-up
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unmatched pre and post nitrates and about 10% of patients with dual lesions. Therefore 
approximately 501 subjects will be randomized in ABSORB II, with approximately 334 in 
the Absorb BVS arm and 167 in the XIENCE stent arm. 
Considering the 390 lesions available for QCA assessments, the study has more than 89% 
power to detect non-inferiority in the second co-primary endpoint of MLD at 2 years post 
nitrate minus MLD post procedure post nitrate by QCA (assuming the true means are 
equal in both groups with a standard deviation of 0.45 mm and a non-inferiority margin 
(δ) of 0.14mm). 
The power calculations were performed using PASS 11 (Hintze, J. 2011).
IVuS Endpoints
• Minimal Lumen Area (MLA) by IVUS post-nitrate at 2* years 
• Percentage of patients with late gain (IVUS MLA post procedure post-nitrate < IVUS MLA 2 years follow-up 
  post-nitrate) without IVUS malapposition 
• Change of total plaque (tissue between lumen and external elastic membrane) within scaffold/stent by IVUS 
  post-nitrate between post-implantation and 2* years 
• Mean/ Minimal Vessel diameter/area/volume pre-procedure, post-procedure and at 2* years;
• Mean/ Minimal Scaffold/Stent diameter/area/volume pre-procedure, post-procedure and (if analyzable) at 2* 
  years; 
• Mean/Minimal Lumen diameter/area/volume pre-procedure, post-procedure and at 2* years, including 
  change in MLA between post-procedure and follow-up; 
• Plaque behind metallic stent area/volume post-procedure and at 2* years; 
• Plaque behind polymeric scaffold area/volume post-procedure and at 2* years (if analyzable);
• Mean/ maximal neointima hyperplasia in the metallic stent area/volume/percentage at 2* years;
• Mean/ maximal neointima hyperplasia in the polymeric scaffold area/volume/percentage at 2* years (if 
  analyzable); 
• Incomplete apposition (post-implantation), persisting incomplete apposition, late acquired incomplete 
  apposition and resolved incomplete apposition at 2* years (if analyzable); 
• Total Plaque area/volume pre-procedure, post-procedure and at 2* years, including change in total plaque 
  between pre-procedure and follow-up; 
IVuS-Vh Endpoints 
• Dense Calcium Volume, Area, % , pre-procedure, post procedure and at 2* years; 
• Necrotic Core Volume, Area, % , pre-procedure, post procedure and at 2* years; 
• Fibro-Fatty Volume, Area, % , pre-procedure, post procedure and at 2* years; 
• Fibrous Volume, Area, % , pre-procedure, post procedure and at 2* years; 
Near Infrared Spectroscopy Endpoint (sub-study in Erasmus MC)
• Change in Lipid Core Burden index from pre-implantation to post-implantation and 2* years follow-up. 
MSCT Endpoints (subjects in the ABSORB BVS arm only) 
The following MSCT endpoints will be examined in the ABSORB BVS arm only 
• Descriptive analysis of vascular and scaffold morphology at 3 years 
• Measurement of lumen area and diameter (min, max, mean), %DS and % Area Stenosis (AS) at 3 years 
table 4. Continued..
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Co-Primary	Endpoints	Analysis	
The co-primary endpoints will be analyzed for the Intent-to-Treat (ITT) population, 
on a lesion basis. For the endpoint of vasomotion assessed by change in Mean Lumen 
Diameter between pre- and post-nitrate at 2 years by QCA, the comparison will be tested 
using a 2-sided t-test at the 0.05 significance level. For the endpoint of MLD at 2 years 
post nitrate minus MLD post procedure post nitrate by QCA, non-inferiority will be tested 
using a one-sided asymptotic test at the 0.05 significance level, considering the non-
inferiority margin of 0.14mm. If non-inferiority is met with higher value in the Absorb BVS 
arm, then superiority will be tested using a 2-sided t-test at the 0.05 significance level. If 
the normality assumption is untenable, non-parametric tests may be considered. In order 
for the trial to be successful, the criteria for superiority should be met for the co-primary 
endpoint of vasomotion and the criteria for non-inferiority should be met for the co-
primary endpoint of MLD at 2 years post nitrate minus MLD post procedure post nitrate. 
In addition, as a secondary analysis, the co-primary endpoints will be analyzed on the per 
treatment evaluable (PTE) population. 
Secondary	Endpoint	Analyses	
Analyses of other secondary endpoints will be descriptive and will be performed on both 
the ITT and PTE populations. For binary variables such as TVF, TLR, and clinical procedure 
success, counts, percentages, and exact 95% confidence intervals using Clopper-Pearson’s 
method will be calculated. For continuous variables such as diameter stenosis, means, 
standard deviations, and 95% confidence intervals for the mean using the Gaussian 
approximation will be calculated.
Study management 
The ABSORB II Trial is funded by Abbott Vascular. The Data Safety Monitoring Board (DSMB) 
will monitor the safety of subjects and/or efficacy throughout the subject enrolment 
and on an on-going basis. The Clinical Events Committee (CEC) will be comprised of 
qualified physicians who are not investigators in the trial. The CEC will be responsible 
for adjudicating all MACE-related endpoints. Central lab cardiac enzymes values will be 
used for event adjudication (in case central lab values would not be available, the local 
lab results will be used). Imaging acquisitions will be evaluated by an independent core 
laboratory (Cardialysis, Rotterdam, The Netherlands).
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D I S C u S S I O N
The introduction in the last decade of drug-eluting coronary stents marked an important 
progress in the field of coronary artery disease treatment. The inhibition of neointimal 
growth by locally delivering anti-proliferative drugs, translated into a reduction in intra-
stent restenosis lowering the need for repeated revascularizations. (11,12)
However metallic stent placement is not devoid of important long-term limitations. 
The metallic implant results in a permanent caging of the vessel, preventing late lumen 
enlargement, jailing side branches, precluding non-invasive imaging and further surgical 
revascularization of stented segments.(13) Moreover, in spite of the beneficial effect of 
neointimal inhibition, the antiproliferative drug elution has been shown to interfere with 
the vascular healing processes thus providing the background for phenomena such as 
delayed strut coverage and persistent or acquired malapposition, implicated in causing 
late and very late stent thrombosis.(14,15) 
Given this background the new everolimus eluting bioresorbable vascular scaffolds have 
been introduced in the attempt to overcome the above-mentioned limitations and in 
the ABSORB II trial will be compared to the current standard of metal DES in terms of 
vasomotion and late loss at 2-year follow-up.
Vasomotion plays an important role in the regulation of coronary blood flow, ensuring the 
maintenance of an appropriate coronary flow pressure and impaired vasomotor activity 
of coronary vessels has been shown to be associated with an increased risk of future 
cardiovascular events.(16-18) Restoration of vasomotor activity is therefore desirable after 
percutaneous revascularization, and is a suitable endpoint for the evaluation of coronary 
artery disease treatment with drug-eluting stents/scaffolds in randomized trials. 
Minimum lumen diameter at 2 years minus post procedural minimum lumen diameter 
(late lumen loss) is a direct measurement of neointimal hyperplasia and the best 
mechanistic measurement of procedural-related hemodynamic narrowing. This endpoint 
is reported to be both theoretically and clinically correlated with binary restenosis and 
target vessel revascularization (TVR).(19) Late lumen loss has been also previously observed 
to be a reliable and powerful end point across drug-eluting stent platforms studies.
(20,21) Consequently the MLD at 2 years minus the post implantation MLD at baseline is 
considered a suitable endpoint for evaluation of the performance of drug-eluting stents/
scaffolds in the present randomized trial.
In addition to the theoretical advantages, namely the possibility for further surgical 
revascularization and a potential reduction in events such as late scaffold thrombosis after 
the complete scaffold bioresorption,(13) the implantation of the Absorb BVS has previously 
been demonstrated not to preclude the non-invasive imaging of the treated arteries at any 
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stage of patient follow-up, (10,22) and the restoration of coronary vasomotion was observed 
to return after 1 year post scaffold implantation. (7) Moreover the Absorb BVS placement has 
been associated with the formation of a neointimal layer that may potentially represent a 
de	novo circumferential plaque thick cap - after scaffold bioresorption - with the potential 
function of plaque stabilization. (23) 
From a physiological perspective, complete scaffold bioresorption exposes the vessel 
wall to the cyclical strain of blood pulsatility. Previous studies have suggested that the 
mechanical stimuli induced by a pulsatile blood flow increases the release of nitric 
oxide (NO) and prostacyclin (24) and is associated with a reduction of monocyte adhesion 
providing a fundamental atheroprotective effect.(25-28)
Biomechanical stimuli also modulate endothelial cell morphology, proliferation, apoptosis, 
(29,30) elongation and realignment, (31) extracellular matrix production(32) and inflammatory 
signals.(33) 
Pulsatile flow and its mechanical action on vessel wall is associated with a down regulation 
of NADPH oxidase activity, present in the endothelium, vascular smooth muscle cells, 
fibroblasts, and monocytes (34,35) with a consequent reduction in reactive oxygen species 
formation. (36,37)
Previous reports have demonstrated that reactive oxygen species, such as superoxide and 
hydrogen peroxide inactivates nitric oxide and provokes the formation of oxidants that 
induces both low-density lipoprotein (LDL) oxidation and expression of monocyte chemo-
attractant proteins on endothelial cells with subsequent monocyte binding and trans-
endothelial migration, that are both fundamental processes in atherogenesis. (38-41) 
The restoration of the beneficial cyclical strain, (7,42) and the consequent reduction in 
reactive oxygen species formation may therefore have an impact on both endothelium-
dependent vasodilation and atherogenesis. 
In addition, the above-mentioned phenomena will take place in a micro-environment 
treated with the mTOR (mammalian Target Of Rapamycin) inhibitor everolimus. The 
protein mTOR is a key serine-threonine kinase playing a central role in the regulation of cell 
growth, proliferation and survival. On a molecular level everolimus forms a complex with 
the cytoplasmic protein FKBP-12,(43) this complex binds to mTOR and inhibits its signalling 
function, thus inhibiting growth factor-stimulated proliferation of vascular smooth muscle 
cells which is triggered by injury to endothelial cells and leads to neointima formation. (44)
In the new scenario of a coronary vessel free of metallic caging, the concomitant scaffold 
drug elution at early stages, (45) medical therapy (46-48) and changes in life style (49,50) may all 
play a key additional role to facilitate phenomena such as plaque regression, expansive 
remodeling and late luminal enlargement. 
An analysis of vasoreactivity in scaffolded segments at 12- and 24- month follow-up with 
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both endothelial-depend and -independ agents, has been recently reported, showing 
that endothelial dysfunction in those regions is correlated to the amount of plaque 
burden and necrotic core content. (51) 
These data support the hypothesis that an improvement of plaque composition and 
plaque burden could have a beneficial impact also on post scaffolding vasomotion 
resembling the behaviour of native non-stented segments. 
Consequently, in the ABSORB II RCT, special attention will be paid to the adherence to 
guidelines for the prevention of cardiovascular disease.(9) Patients enrolled will be followed 
regarding their life style habits and compliance to medical treatment and efforts will be 
made to aid subjects in following recommendations by notifying any non-satisfactory 
result in collaboration with their treating physician(s). 
 In conclusion, the present trial will provide a randomized direct comparison between the 
everolimus-eluting bioresorbable vascular scaffold and the everolimus-eluting metallic 
stent. In addition this study aims to present a new approach to coronary artery disease 
treatment that integrates transient mechanical revascularization, drug elution, medical 
treatment and life style changes into a single strategy to restore coronary blood flow and 
vessel physiology. 
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Aims We evaluated the feasibility and the acute performance of the everolimus-
eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients 
presenting with ST-segment elevation myocardial infarction (STEMI).
Methods and results The present investigation is a prospective, single-arm, 
single-centre study, reporting data after the BVS implantation in STEMI patients. 
Quantitative coronary angiography and optical coherence tomography (OCT) 
data were evaluated. Clinical outcomes are reported at the 30-day follow-up. 
The intent-to-treat population comprises a total of 49 patients. The procedural 
success was 97.9%. Pre-procedure TIMI-flow was0 in 50.0% of the patients; after 
the BVS implantation, a TIMI flow III was achieved in 91.7% of patients and the 
post-procedure percentage diameter stenosis was 14.7±8.2%. No patients had 
angiographically visible residual thrombus at the end of the procedure. Optical 
coherence tomography analysis performed in 31 patients showed that the post-
procedure mean lumen area was 8.02±1.92 mm2, minimum lumen
area 5.95±1.61 mm2, mean incomplete scaffold apposition area 0.118±0.162 
mm2, mean intraluminal defect area 0.013±+0.017 mm2, and mean percentage 
malapposed struts per patient 2.80±3.90%. Scaffolds with >5% malapposed struts 
were 7. At the 30-day follow-up, target-lesion failure rate was 0%. Non-target-
vessel revascularization and target vessel myocardial infarction (MI)were reported. 
A non-target-vessel non-Q-wave MI occurred. No cases of cardiac death or scaffold 
thrombosis were observed.
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I N T R O D u C T I O N
Primary percutaneous coronary intervention has been demonstrated to be superior to 
thrombolytic strategy and is currently the treatment of first choice for patients presenting 
with ST-segment elevation myocardial infarction (STEMI) in experienced centres with 
limited time delay.1 First-generation drug-eluting stents (DES) have been shown to 
reduce the need for repeat revascularization compared with bare-metal stents (BMS),2 – 4 
and the newer-generation DE S with improved biocompatibility of polymers may lower 
the rate of clinical events also in acute patients.5,6 However, the implantation of metal 
devices is not devoid of important limitations, such as permanent caging of the vessel 
with permanent impairment of coronary vasomotion, side branch jailing, impossibility 
of late lumen enlargement, non-invasive imaging and future surgical revascularization 
of stented segments.7 Moreover, in spite of the beneficial effect of neointimal inhibition, 
the antiproliferative drug elution has been shown to interfere with the vascular healing 
processes providing the background for delayed strut coverage and persistent or acquired 
malapposition.8,9 The above-mentioned limitations can be proposed for both stable and 
acute patients; however, primary stenting has additional specific characteristics that should 
be highlighted. Stent placement in acute thrombotic lesions has been reported to be an 
independent predictor of late stent malapposition after the BMS10 or DES11 implantation. 
Possible explanations for this phenomenon could be the thrombus sequestration behind 
the struts—which subsequently resolves—and the vasoconstriction during the acute 
phase. Both these factors may predispose to stent underdeployment, malapposition and 
finally to stent thrombosis. The everolimus-eluting bioresorbable vascular scaffold (BVS) 
has been designed to overcome the general limitations of the metallic stents and recently 
has been shown to provide excellent results for the treatment of stable patients.12,13 
However, so far very limited data are available on the use of this novel device in patients 
with acute coronary syndromes (ACS).14,15 Given this background, a pilot study investigating 
the feasibility and acute performance of the BVS for the treatment of patients presenting 
with STEMI was initiated.
302   |    Chapter 14
M E T h O D S
Rationale
As of 1 September 2012, the BVS (ABSORB; Abbott Vascular, Santa Clara, CA, USA) has been 
commercially available in the Netherlands. Based on previous experience and available 
evidence, reported in ABSORB Cohort A and B Trial13,16 our institution initiated the use of 
BVS for the treatment of patients presenting for PCI in everyday clinical practice, with a 
preference for patients with a good life expectancy as demonstrated by the presence of 
limited co-morbidities. As these patients might have more complex lesions compared 
with the ABSORB study patients16,17 the BVS-EXPAND registry was initiated. The BVS-
EXPAND also included patients with ACS (unstable angina or non-STEMI). After the first 
experience with ACS patients and an interim analysis, a decision was made to extend BVS 
utilization to the treatment of STEMI. As an additional measure for assessing the safety of 
a treatment approach with BVS in STEMI, optical coherence tomography (OCT) imaging 
was performed, according to clinical judgment, for a more comprehensive evaluation of 
the acute procedural outcome.
Study design
The present report is an investigator initiated, prospective, single arm, single-centre study 
to assess feasibility and performance of the second-generation everolimus-eluting BVS 
for the treatment of patients presenting with STEMI. Subjects enrolled were patients 
of ≥18-year-old admitted with STEMI, defined as at least 1 mm ST-segment elevation 
in two or more standard leads or at least 2 mm in two or more contiguous precordial 
leads or new left bundle branch block within 12 h after the onset of symptoms. Culprit 
lesions were located in vessels within the upper limit of 3.8 mm and the lower limit 
of 2.0 mm by online quantitative coronary angiography (QCA). The absorb BVS was 
implanted according to the manufacturer’s indication on target vessel diameter ranges 
and absorb BVS diameters to be used. The absorb BVS with a nominal diameter of 2.5 
mm was implanted in vessels ≥ 2.0 and ≤ 3.0 mm by online QCA; the 3.0 mm BVS was 
implanted in vessels ≥ 2.5 and ≤3.3 mm by online QCA; the 3.5 mm BVS was implanted 
in vessels ≥ 3.0 and ≤3.8 mm. Given the manufacturer’s indication on maximum scaffold 
expansion, for each nominal diameter a further expansion of 0.5 mm was allowed. 
Enrolled subjects were willing to comply with specified follow-up evaluation and to be 
contacted by telephone. Exclusion criteria comprise pregnancy, known intolerance to 
contrast medium, uncertain neurological outcome after cardiopulmonary resuscitation, 
previous percutaneous coronary intervention with the implantation of a metal stent, left 
main (LM) disease previous coronary artery bypass grafting (CABG), age superior to 75 
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years, and participation to another investigational drug or device study before reaching 
the primary endpoints. The enrolment period started on 1November 2012 and ended on 
30 March 2013. Dual antiplatelet therapy after the BVS implantation was planned to have 
a duration of 12 months. Baseline and post-BVS implantation QCA analysis, OCT analyses 
at post-BVS implantation, and clinical outcomes at the 30-day follow-up were evaluated.
Deﬁnitions
Success rates were defined as follows: device success was the attainment of <30% final 
residual stenosis of the segment of the culprit lesion covered by the BVS, by angiographic 
visual estimation. Procedure success was defined as device success and no major 
periprocedural complications (Emergent CABG, coronary perforation requiring pericardial 
drainage, residual dissection impairing vessel flow—TIMI-flow II or less). Clinical success 
was defined as procedural success and no in-hospital major adverse cardiac events 
(MACE). All deaths were considered cardiac unless an undisputed non-cardiac cause was 
identified. Myocardial infarction (MI) and scaffold thrombosis were defined according 
to the Academic Research Consortium definition.18 Target-lesion revascularization (TLR) 
was defined as clinically driven if at repeat angiography the diameter stenosis was >70%, 
or if a diameter stenosis >50% was present in association with (i) presence of recurrent 
angina pectoris, related to the target vessel; (ii) objective signs of ischaemia at rest (ECG 
changes) or during exercise test, related to the target vessel; and (iii) abnormal results 
of any functional diagnostic test. The device-oriented endpoint target-lesion failure was 
defined as the composite of cardiac death, target-vessel MI, or ischaemia-driven TLR. 
Major adverse cardiac events defined as the composite of cardiac death, any re-infarction 
(Q- or non-Q-wave), emergent bypass surgery (CABG), or clinically driven TLR. Target-
vessel failure (TVF) was defined as cardiac death, target-vessel MI, or clinically driven TVR.
Ethics
This is an observational study, performed according to the privacy policy of the Erasmus 
MC and to the Erasmus MC regulations for the appropriate use of data in patient-oriented 
research, which are based on international regulations, including the declaration of 
Helsinki. The BVS received the CE mark for clinical use, indicated for improving coronary 
lumen diameter in patients with ischaemic heart disease due to de novo native coronary 
artery lesions with no restriction in terms of clinical presentation. Therefore, the BVS can 
be currently used routinely in Europe in different settings comprising the acute MI without 
a specific written informed consent in addition to the standard informed consent to the 
procedure. Given this background, a waiver from the hospital Ethical Committee was 
obtained for written informed consent, as according to Dutch law written consent is not 
required, if patients are not subject to acts other than as part of their regular treatment.
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Study device
The second-generation everolimus-eluting BVS is a balloon expandable device consisting 
of a polymer backbone of poly-L-lactide acid (PLLA) coated with a thin layer of amorphous 
matrix of poly-D and -L-lactide acid (PDLLA) polymer (strut thickness 157 µm). The PDLLA 
controls the release of the antiproliferative drug everolimus (100 µg/cm2), 80% of which 
is eluted within the first 30 days. Both PLLA and PDLLA are fully bioresorbable. The 
polymers are degraded via hydrolysis of the ester bonds and the resulting lactate and its 
oligomers are metabolized by the Krebs cycles. Small particles (<2 µm in diameter) may 
be also phagocytized and degraded by macrophages.19 According to preclinical studies, 
the time for complete bioresorption of the polymer backbone is ~2–3 years.20 The BVS 
edges contain two platinum markers for accurate visualization during angiography or 
other imaging modalities.
quantitative coronary angiography analysis 
Quantitative coronary angiography (QCA) analyses were performed using the Coronary 
Angiography Analysis System (Pie Medical Imaging, Maastricht, Netherlands). Analyses 
were performed at pre-procedure, after thombectomy, after balloon dilatation, and after 
the BVS implantation with a methodology already reported.21
In case of thrombotic total occlusion, pre-procedure QCA analysis was performed as 
proximally as possible from the occlusion (in case of a side branch distally to the most 
proximal take off of the side branch). Intracoronary thrombus was angiographically 
identified and scored in five grades as previously described.22 Thrombus grade was 
assessed before procedure and after thombectomy. The QCA measurements included 
reference vessel diameter (RVD)—calculated with interpolate method—percentage 
diameter stenosis, minimal lumen diameter (MLD), and maximal lumen diameter (Dmax). 
Acute gain was defined as post-procedural MLD minus pre-procedural MLD (MLD 
value equal to zero was applied when culprit vessel was occluded pre-procedurally). 
Complications occurring any time during the procedure, such as dissection, spasm, distal 
embolization, and no-reflow were reported. As additional information, MI SYNTAX I and MI 
SYNTAX II scores providing long-term risk stratification for mortality and MACE in patients 
presenting with STEMI were assessed.23
Optical coherence tomography image acquisition and analysis
Optical coherence tomography imaging after the BVS implantation was encouraged in 
all patients but was not mandatory, subordinated to device availability and left at the 
operator’s discretion. Therefore, OCT imaging of the culprit lesion after treatment was 
performed in a subset of the population. The image acquisition was performed with 
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C7XR imaging console and the Dragonfly intravascular imaging catheter (both St. Jude 
Medical, St. Paul, MN, USA). Image acquisition has been previously described.24 Briefly, 
after positioning the OCT catheter distally to the most distal scaffold marker, the catheter 
is pulled back automatically at 20 mm/s with simultaneous contrast infusion by a power 
injector (flush rate 3–4 mL/s). In cases where the entire scaffold region was not imaged in 
one pullback, a second more proximal pullback was performed for complete visualization. 
Images were stored and analyzed offline. Analysis of the OCT images was performed 
with the St Jude/Lightlab offline analysis software (St. Jude Medical), using previously 
described methodology for BVS analysis.17 Analysis was performed in 1-mm longitudinal 
intervals within the treated culprit segment, after exclusion of frames with <75% lumen 
contour visibility. Lumen, scaffold, and incomplete scaffold apposition (ISA) area were 
calculated in accordance with standard methodology for analysis of bioresorbable 
scaffolds17 (Figure 1A and B), while in sites with overlapping scaffolds, analysis was 
performed using previously suggested modifications25 (Figure 1D). Specifically, the lumen 
contour is traced at the lumen border and in the abluminal (outer) side of apposed struts, 
while in the case of malapposed struts the contour is traced behind the malapposed 
struts. In cases where the scaffold struts are completely covered by tissue or thrombus, 
the lumen contour is traced above the prolapsing tissue (Figure 1C). The scaffold area is 
traced following interpolation of points located in the mid-point of the abluminal border 
of the black core in apposed struts and the mid-point of the abluminal strut frame border 
in malapposed or side branch-related struts, so that the scaffold area is identical to the 
lumen area in the absence of ISA and tissue prolapse. Incomplete scaffold apposition area 
is traced in the case of malapposed struts as the area delineated between the lumen and 
scaffold contours (Figure 1B). A special consideration should be mentioned concerning 
BVS analysis in MI with the presence of increased tissue prolapse and residual thrombus 
post-implantation 21,26 (Figures 1C and 2). Tissue prolapsed area can be quantified as the 
difference between the scaffold and the lumen area. For the calculation of prolapse area, 
in the case that one or more scaffold struts are completely covered by thrombus or tissue, 
the total black core area of these struts is also measured. Prolapse area is then calculated 
as [scaffold area + ISA area - lumen area - embedded black core area]. The area of non-
attached intraluminal defects (e.g. thrombus) is also measured. Atherothrombotic area is 
then calculated as the sum of prolapse area and intraluminal defect area and normalized as 
a percent ratio of the scaffold area (atherothrombotic burden, ATB).21,26 It should be noted 
that in the case of bioresorbable scaffolds where measurements of the scaffold area are 
performed using the abluminal side of the scaffold struts, ATB is overestimated compared 
with metal platform stents where measurements of the stent area are performed from 
the adluminal (inner) side of the struts. Additionally, flow area was assessed as [scaffold 
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area + ISA area - atherothrombotic area - total strut area] and the minimal flow area was 
recorded. A scaffold strut is defined as incompletely apposed when there is no contact 
between the abluminal border of the strut and the vessel wall. This does not include struts 
located in front of side branches or their ostium (polygon of confluence region), which 
are defined as side branch-related struts. Intraluminal struts that are part of adjacent 
clusters of apposed struts in overlapping scaffolds are also not considered malapposed.25 
For illustrative proposes, OCT bi-dimensional images are reported by three-dimensional 
rendering by dedicated software (Intage Realia, KGT, Kyoto, Japan)17 (Figures 2 and 3).
 
figure 1. Flow-chart of the study.
From 1st November 2012 to 30th April 2013 a total of 267 patients presented with acute myocardial infarction. 
Twenty-one of those patients were treated percutaneously but without any stent implantation (thrombectomy or 
balloon dilatation alone). Seventy-four had a culprit lesion located in a coronary vessel with a vessel diameter out of 
the range availability of the BVS (i.e reference vessel diameter > 4.0 mm). The remaining 172 patients were treated 
in 123 cases with metal stents and 49 were enrolled in the present study. Out of those 172 patients only 125 were 
meeting the inclusion and exclusion criteria of the present study; thus the patients implanted with BVS constitute the 
39% of the patients eligible for the present investigation
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Statistical analysis
Continuous variables are presented as mean and standard deviation, and categorical 
variables are reported as count and percentages. Descriptive statistics was provided for all 
variables. The present study is intended to be a ‘first experience investigation’ evaluating 
feasibility and acute performance of the everolimus-eluting BVS for the treatment of 
patients presenting with STEMI. A patient population of at least 30 patients was planned 
to be included in the present study. Comparisons among multiple means were performed 
with analysis of variance (one-way ANOVA). Score (Wilson) confidence intervals were 
reported for measures of success. Type A intraclass correlation coefficients (ICCs) for 
absolute agreement were used for assessing intra- and interobserver agreement, while 
measurement error and 95% limits of agreement were assessed by Bland–Altman analysis. 
The ICCs were computed with a two-way random effects model (single measures). All 
statistical tests were performed with SPSS, version 15.0 for windows (IL, USA).
 
figure 2. Methodology of OCT analysis.
A. Good scaffold apposition and absence of ISA or tissue prolapse; B. ISA; C. Sites with high tissue prolapse and 
struts completely covered by thrombus; D. Overlapping scaffolds. Upper panel shows baseline images, middle 
panel quantitative measurements, lower panel methodology for analysis. Abbreviations: ISA=incomplete scaffold 
apposition, ATA=atherothrombotic area
308   |    Chapter 14
R E S u LT S
From 1 November 2012 to 30 April 2013, a total of 267 patients presented with acute MI. 
Twenty-one of those patients were treated percutaneously without any stent implantation 
(thrombectomy or balloon dilatation alone). Seventy-four had a culprit lesion located in 
a coronary vessel with a vessel diameter out of the range availability of the BVS (i.e. RVD 
>4.0 mm). Out of the remaining 172 patients, 125 were meeting the inclusion and none 
of the exclusion criteria of the present study (47 patients excluded for age, previous PCI or 
CABG, left main disease). Seventy-six of those patients were treated with metal stents and 
49 cases (48 implanted with BVS) were enrolled in the present study (Figure 4, Table 1). 
Therefore, the patients implanted with BVS constitute the ~38% of the patients eligible for 
the present investigation. Baseline clinical characteristics of the 172 patients (49 patients 
included in the intent-to-treat population and 123 patients implanted with metal stents) 
 
 
 
figure 3. BVS implantation in a culprit and a non-culprit lesion in myocardial infarction. 
A. Coronary angiography demonstrating a stenotic lesion in proximal LAD (proximal non-culprit lesion) and a total 
occlusion of the mid LAD (culprit lesion). B. Angiography following thrombus aspiration. C. Angiography following 
implantation of a 3.5x12mm BVS at the proximal LAD lesion and a 3.0x28mm BVS at the mid LAD lesion. D. OCT image 
from the proximal non-culprit lesion showing absence of tissue prolapse and thrombus in the 3.5x12mm scaffold. E. 
and F. OCT images from the culprit lesion showing complete coverage of the BVS by tissue prolapse and presence 
of small amount of intraluminal defect. G. Three-dimensional OCT rendering in the proximal non-culprit lesion with 
complete scaffold visualization indicating the absence of prolapsing material. H. Conversely, in the 3-dimensional 
rendering of the culprit lesion, the morphology of the BVS cannot be fully visualized due to high levels of tissue 
prolapse (*).
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with vessels size in the range of the BVS availability are reported in Table 1. In the intent-to-
treat population thirty-eight patients were male (77.6%), mean age was 58.9±10.5 years. 
Lesions were distributed as follows: left anterior descending 21 (42.9%), right coronary 
artery 22 (44.9%), and circumfl ex 6 (12.2%). Baseline clinical data of the enrolled patients 
were compared with the general population presenting with acute MI and implanted with 
a metal stent in vessels theoretically suitable for BVS implantation. Minimal diff erences 
were observed between the two groups. Namely, age 58.9±10.5 vs. 66.4±12.2, P <0.001 
and previous PCI 0% vs. 12.2%, P = 0.007. All the other clinical characteristics of the two 
populations did not show any signifi cant diff erence.
Mean door-to-balloon timewas 31.3±19.5 min. All patients were treated with unfractionated 
heparin at the dose of 70–100 UI/kg and dual antiplatelet therapy (aspirin plus, prasugrel 
in 45 patients or clopidogrel in 4 patients). Manual thrombectomy was performed in 38 
patients. In 16 cases, direct stenting was performed; a total of 65 scaff olds were implanted 
figure 4. BVS implantation in a thrombotic bifurcation lesion treated with provisional approach. 
Coronary angiography pre intervention. B. Angiography following BVS implantation in the LAD, showing pinching of 
the ostium of the diagonal (D). C. Final angiographic result following side-branch dilation with 2.0x15mm balloon. D. 
E. F. J. OCT cross-sectional images and l-mode after BVS implantation showing the compromise of the side-branch 
after implantation and presence of thrombus at the side-branch ostium. G. H. I. K. OCT cross-sectional images and 
l-mode after side-branch dilation, showing the opening of the carina of the side branch. L. M. Three-dimensional 
reconstructions confi rm the opening of the side-branch ostium.
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(12 patients received overlapping scaffolds—overlap was systematically intended to be 
minimal). The scaffolds lengths used were 12, 18, and 28 mm, with scaffolds diameters 
2.5, 3.0, and 3.5 mm. Mean scaffold length per-lesion was 26.40±13.86 mm, mean scaffold 
diameter per-lesion was 3.2±34 mm. A highly supportive wire was used in five cases and 
radial approach was performed in 26 patients (53.0%) (Table 2). The procedural success 
was 97.9% (48/49 patients); in one patient, the delivery of the BVS was unsuccessful (due 
to the remarkable vessel tortuosity was not possible to advance the BVS at the site of the 
lesion) and a metallic DES was implanted. Clinical success was 97.9% (48/49 patients). 
table 1. Baseline clinical characteristics intent-to-treat population and patients treated with metallic stent in the 
enrolment period.
Clinical characteristics BVS (N=49) Metal stents (N=123) p value
Age (y) 58.9±10.5 66.4±12.2 <0.001
Male n. (%) 38 (77.6) 93 (75.6) 0.845
Hypertension n. (%) 19 (38.8) 53/105 (50.5) 0.225
Hypercholesterolemia n. (%) 11 (22.4) 30/100 (30.0) 0.435
Diabetes n. (%) 4 (8.2) 14/116 (12.1) 0.590
Smoke n. (%) 27 (69.2)  46/116 (39.7) 0.120
Family history of CAD n. (%) 12 (24.5) 31/95 (32.6) 0.343
Prior Cerebrovascular accident n. (%) 0 (0) 13 (10.6) 0.021
Peripheral vascular disease n. (%) 1 (2.0) 8 (6.5) 0.449
Kidney disease n. (%) 1 (2.0) 7 (5.7) 0.442
Prior MI n. (%) 1 (2.0) 14 (11.4) 0.070
Prior PCI n. (%) 0 (0.0) 15 (12.2) 0.007
Prior CABG n. (%) 0 (0.0) 3 (2.4) 0.559
COPD n. (%) 2 (4.1) 5 (4.1) 1.000
Culprit vessel 0.624
LM n. (%) 0 (0) 2 (1.6)
LAD n. (%) 21 (42.9) 52 (42.3)
RCA n. (%) 22 (44.9) 46 (37.4)
LCX n. (%) 6 (12.2) 21 (17.1)
SVG n. (%) 0 (0) 2 (1.6)
Patients with vessels diameters not feasible for BVS implantation (i.e. reference vessel diameter larger than 4.0 mm) 
were excluded CAD=coronary artery disease; PCI=percutaneous coronary intervention; CABG=Coronary artery 
bypass graft; COPD=Chronic obstructive pulmonary disease; LAD=left anterior descending; RCA=right coronary 
artery; LCX=circumflex. Data are expressed as mean ± SD or number and proportion, n. (%).
BVS for treatment of STEMI   |   311
PART
III
quantitative coronary angiography analysis
The QCA is reported only in patients implanted with BVS. In 50.0% of those patients, pre-
procedure TIMI-flow was 0 and the RVD was 2.94±0.77 mm. In the non-totally occluded 
vessels, the RVD was 2.62±0.63 mm, with an MLD of 0.75±0.44 mm and a mean diameter 
stenosis of 70.8±12.5%. After thrombectomy and balloon dilatation, TIMI-flow grade 0 
was present in 2.5 and 0.0% of patients, respectively, and TIMI-flow III in 52.5 and 59.3% of 
the cases, respectively. After the scaffold implantation, there were no cases of TIMI flow 0, 
table 2. Procedural data Intent-to-treat population.
Procedural data N =49
Medications
  Aspirin n. (%) 49 (100)
  Prasugrel n. (%) 45 (91.8)
  Clopidogrel n. (%) 4 (8.2)
  Glycoprotein IIb/IIIa antagonists n. (%) 17 (34.7)
  Unfractionated heparin n. (%) 49 (100)
Mean door-to-balloon time (min) 31.3 ± 19.5
Manual Thrombectomy n. (%) 38 (77.5)
Direct stenting n. (%) 16 (32.7)
Pre-dilatation n. (%) 33 (67.3)
Mean pre-dilatation balloon diameter per-lesion (mm) 2.6±0.67
Post-dilatation n. (%) 10 (20.4)
Mean post-dilatation balloon diameter per-lesion (mm) 3.5±0.47
Overlapping n. (%) 12 (24.5)
  Overlap scaffolds diameters 3.5 mm – 3.5 mm n. (%) 5 (10.2)
  Overlap scaffolds diameters 3.5 mm – 3 mm n. (%) 5 (10.2)
  Overlap scaffolds diameters 3.5 mm – 2.5 mm n. (%) 1 (2.0)
  Overlap scaffolds diameters 3 mm – 2.5 mm n. (%) 1 (2.0) 
Total number of scaffolds n. 65
Mean scaffolds per-lesion  n. 1.35±0.60
Mean scaffold length per-lesion (mm) 26.40±13.86
Mean scaffold diameter per lesion (mm) 3.2±34
Supportive wire n. (%) 5 (10.2)
Radial approach n. (%) 26 (53.0)
Data are expressed as mean ± SD or number and proportion, n. (%).
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table 3. Angiographic analysis in patients implanted with BVS.
Angiographic data N=48
Pre-procedure
TIMI flow grade, %(n)
   0 50.0% (23/46)
   1 15.2% (7/46)
   2 21.7% (10/46)
   3 13.0% (6/46)
Thrombus burden index, %(n)
   0 0.0% (0/46)
   1 6.5% (3/46)
   2 17.4% (8/46)
   3 13.0% (6/46)
   4 13.0% (6/46)
   5 50.0% (23/46)
Total occlusion (n=23)
   RVD, mm 2.94 ± 0.77
Non-total occlusion (n=23)
   RVD, mm 2.62 ± 0.63
   Minimal lumen diameter, mm 0.75 ± 0.44
   Diameter stenosis, % 70.8 ± 12.5
After thrombectomy
TIMI flow grade, %(n)
   0 2.5% (1/40)
   1 7.5% (3/40)
   2 37.5% (15/40)
   3 52.5% (21/40)
Thrombus burden index, %(n)
   0 0.0% (0/40)
   1 30.0% (12/40)
   2 35.0% (14/40)
   3 22.5% (9/40)
   4 10.0% (4/40)
   5 2.5% (1/40)
After pre-dilatation
TIMI flow grade, %(n)
   0 0.0% (0/27)
   1 7.4% (2/27)
   2 33.3% (9/27)
   3 59.3% (16/27)
Before BVS implantation
   RVD, mm 2.63 ± 0.53
   Minimal lumen diameter, mm 1.21 ± 0.46
   Diameter stenosis, % 53.2 ± 16.1
   Dmax, mm 3.01 ± 0.52
BVS for treatment of STEMI   |   313
PART
III
and a TIMI-flow III was achieved in 91.7% of patients, the mean post-procedure in-scaffold 
% diameter stenosis was 14.7±8.2%, in-scaffold MLD was 2.44±0.49 mm (Table 3). No 
angiographically visible residual thrombus was observed at post-procedure.
Optical coherence tomography ﬁndings
Optical coherence tomography analysis was performed in a subgroup of 31 patients 
implanted with BVS. Mean lumen area was 8.02±1.92 mm2, minimum lumen area 
5.95±1.61 mm2, and minimum flow area 5.62±1.66 mm2. Incomplete scaffold apposition 
(ISA) was observed in 20 patients with a mean ISA area of 0.118±0.162 mm2 and a mean 
percentage of malapposed struts per patients equal to 2.80±3.90%. The mean prolapse 
area was 0.60±0.26 mm2, and the mean intraluminal defect area was 0.013±0.017 mm2. 
Scaffolds with >5% malapposed struts were 7 (Table 4). The OCT analysis stratified by 
scaffold size (5 BVS 2.5 mm, 13 BVS 3.0 mm, 24 BVS 3.5 mm) showed different lumen, 
Angiographic data N=48
Post-procedure
TIMI flow grade, %(n)
   0 0.0% (0/48)
   1 0.0% (0/48)
   2 8.3% (4/48)
   3 91.7% (44/48)
In-scaffold
   RVD, mm 2.86 ± 0.52
   Minimal lumen diameter, mm 2.44 ± 0.49
   Diameter stenosis, % 14.7 ± 8.2
In-segment
   RVD, mm 2.74 ± 0.59
   Minimal lumen diameter, mm 2.20 ± 0.53
   Diameter stenosis, % 21.8 ± 12.0
MI syntax score I * 10.0 (7.0-15.0)
MI syntax score II * 7.0 (4.25-10.0)
Dominant right coronary artery, %(n) 93.8% (45/48)
Scaffold-to-artery ratio 1.19 ± 0.24
Complications, %(n)
   Dissection 6.3% (3/48)
   Spasm 4.2% (2/48)
   Distal embolism 14.6% (7/48)
   No-reflow 2.1% (1/48)
Data are expressed as mean±SD or proportion (%). * MI syntax score I and II are expressed as median (interquartile 
range).
table 3. Continued.
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table 4. OCT findings post-implantation in patients implanted with BVS .
OCT variables N=31
Analyzed length, mm 28.16±13.29
Analyzed struts, n 245±135
Minimum lumen area, mm2 5.95±1.61
Mean lumen area, mm2 8.02±1.92
Lumen volume, mm3 225.78±113.63
Minimum scaffold area, mm2 6.69±1.94
Mean scaffold area, mm2 8.54±1.97
Scaffold volume, mm3 240.07±118.48
Minimum flow area, mm2 5.62±1.66
ISA area, mm2 (n=20) 0.118±0.162
Mean prolapse area, mm2 0.60±0.26
Mean intraluminal defect area, mm2 0.013±0.017
Maximum intraluminal defect area, mm2 0.094±0.077
Mean atherothrombotic area, mm2 0.61±0.27
Mean atherothrombotic burden, % 7.29±3.12
Malapposed struts per patient, % 2.80±3.90
Scaffolds with at least 1 malapposed strut, n (%) 20 (64.5)
Scaffolds with >5% malapposed struts, n (%) 7 (22.6)
ISA=incomplete scaffold apposition; Data are expressed as mean ± SD or number and proportion, n. (%).
table 5. OCT findings post-implantation stratified by scaffold size in patients implanted with BVS
OCT variables
Scaffold size 2.5mm (N=5) 3.0mm (N=13) 3.5mm (N=24) p 
Analyzed length, mm 18.80±1.30 22.23±6.46 21.33±7.38 0.628
Minimum lumen area, mm2 4.08±0.24 5.60±0.93 7.18±1.58 0.001
Mean lumen area, mm2 5.42±0.75 7.18±1.03 9.25±1.72 0.001
Minimum scaffold area, mm2 4.53±0.51 6.13±1.02 8.06±1.82 0.001
Mean scaffold area, mm2 5.62±0.28 7.66±0.88 9.82±1.70 0.001
Minimum flow area, mm2 3.84±0.28 5.17±0.86 6.77±1.60 0.001
ISA area, mm2 (n=25) 0.190±0.318 (n=3) 0.063±0.072 (n=10) 0.133±0.177 (n=12) 0.429
Mean prolapse area, mm2 0.40±0.19 0.54±0.27 0.62±0.29 0.246
Mean intraluminal defect area, mm2 0.007±0.008 0.016±0.021 0.012±0.018 0.628
Maximum intraluminal defect area, mm2 0.072±0.081 0.102±0.086 0.068±0.065 0.096
Mean atherothrombotic area, mm2 0.40±0.19 0.56±0.27 0.64±0.30 0.237
Mean atherothrombotic burden, % 6.00±4.66 7.42±3.79 6.20±3.39 0.594
ISA=incomplete scaffold apposition; Data are expressed as mean ± SD or number and proportion, n. (%).
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scaffold, and flow areas, but similar amounts of incomplete stent apposition, plaque 
prolapse, and intraluminal mass areas (Table 5). In three cases, the observation of scaffold 
malapposition by OCT, guided an additional post-dilatation and in one patient the 
visualization of considerable intraluminal thrombus as assessed by OCT led to a repeated 
thrombus aspiration. Intra-observer variability was excellent. Intraclass correlation 
coefficients were 0.999 for lumen area and 0.999 for scaffold area, and the corresponding 
measurement errors and limits of agreement were 0.01 mm2 (-0.12 to 0.15 mm2) for lumen 
area and -0.01 mm2 (-0.20 to 0.17 mm2) for scaffold area. Similarly, inter-observer intraclass 
correlation coefficients were 0.997 for lumen area and 0.987 for scaffold area, and the 
corresponding measurement errors and limits of agreement were -0.01 mm2 (-0.30 to 0.28 
mm2) for lumen area and -0.22 mm2 (-0.68 to 0.24 mm2) for scaffold area.
Clinical outcomes
At the 30-day follow-up, the rate of the device-oriented endpoint, target-lesion failure, 
was 0%. None of the patients experienced target-vessel re-infarction, emergent bypass 
surgery, or clinically driven TLR. No cases of cardiac death or scaffold thrombosis were 
reported. The MACE rate was 2.6% as one patient, after discharge developed a non-
Q-wave MI related to a non-target-vessel lesion and underwent a non-target-vessel 
revascularization within the 30 days post-procedure. This was the only event reported in 
the studied population (Table 6).
table 6. Clinical outcomes at 30-day follow-up Intent-to-treat population
Clinical events N=49 95% CI
Target lesion failure (0/49) 0% (0-7.41)
Target vessel failure (0/49) 0% (0-7.41)
Cardiac death (0/49) 0% (0-7.41)
Target vessel myocardial infarction (0/49) 0% (0-7.41)
   Q-Wave myocardial infarction (0/49) 0% (0-7.41)
   Non Q-Wave myocardial infarction (0/49) 0% (0-7.41)
Clinically driven target vessel revascularization (0/49) 0% (0-7.41)
Any myocardial infarction (1/49) 2.6% (0-10.69)
   Q-Wave myocardial infarction (0/49) 0% (0-7.41)
   Non Q-Wave myocardial infarction (1/49) 2.6% (0-10.69)
Major Adverse Cardiac Events (1/49) 2.6% (0-10.69)
Non-target vessel revascularization (1/49) 2.6% (0-10.69)
Definite or probable scaffold thrombosis (0/49) 0% (0-7.41)
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D I S C u S S I O N
The everolimus-eluting BVS has been tested so far only in elective patients with stable, 
unstable angina, or silent ischaemia;16,17,27 – 29showing promising results up to 4-year follow-
up30 for the first generation and up to 2 years for the second-generation BVS.12,13,31 The 
present study represents an early investigation reporting clinical and angiographic data 
on the use of the second-generation BVS for the treatment of patients presenting with 
STEMI and evaluating acute results with high-resolution intracoronary imaging (OCT). A 
high device, procedural, and clinical success rates were observed with all the scaffolds 
achieving a residual stenosis <30% and no in-hospital MACE. Such data are supportive 
of feasibility and good acute performance of the BVS for the treatment of patients with 
acute MI.
Angiographic data
The everolimus-eluting BVS was implanted in patients presenting with ST-segment 
elevation and a thrombus burden 4 or 5 in 63.0% of the cases. A theoretical concern 
related to the implantation of the BVS in such thrombotic lesions is the fact that scaffold 
positioning and placement may need a more aggressive lesion preparation (predilatation) 
compared with standard metal devices, due to its slightly higher profile. We hypothesized 
that this strategy might be prone to an increase in distal embolization following balloon 
inflations, favouring no-reflow and reducing the rate of final TIMI-flow III. However, the 
analysis of the post-procedural angiographies revealed a TIMI-flow III in 91.7% of the cases; 
such results are in line with recently reported large trials evaluating the performance of 
metallic stents in patients presenting with acute MI.5,6 Less thrombus embolization may 
result from a different pattern of thrombus dislodgment and compression to the arterial 
wall after deployment of a device with a larger strut width (157 mm) compared with 
currently available metallic stents. The percentage of vessel wall area covered by the 
BVS polymer (scaffold/vessel ratio) has been previously evaluated to be 26%,32 a value 
considerably higher compared with what observed for conventional metallic DES (i.e. EES 
provides a percentage stent/vessel ratio equal to 12%).32 This characteristic of the BVS 
might be associated to an increased capacity of capturing debris and thrombotic material 
behind the struts before embolization to distal microcirculation. This so-called snow 
racket concept (entrapment of thrombotic material between the stent and the vessel) is 
currently the basis for the design of novel devices and clinical studies.33
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Optical coherence tomography ﬁndings
Given its high resolution, OCT allows the assessment of in vivo strut apposition and 
presence of thrombus.24,34 – 36 The present analysis was performed at 1 mm intervals in the 
OCT pullback. Although, the possibility for a more strict assessment of OCT analysis in 
thrombotic lesion may be considered,21 this methodology is the current standard applied 
in our institution for clinical studies, and the most commonly used in the literature. 
Previous reports defined a stent malapposed if at least 5% of struts were observed to 
be malapposed;37,38 in the present investigation, only seven scaffolds (22.6%) investigated 
with OCT showed a strut malapposition of >5%, with an overall mean struts malapposition 
equal to 2.8±3.90%. A recently reported study using a similar methodology to investigate 
malapposition after metallic balloon expandable stent implantation in STEMI patients 
showed a total of 37.1% malapposed stents (stents with >5% malapposition) with a mean 
percentage of strut malapposition equal to 5.99±7.28%.38 In addition, the mean ISA area 
was 0.118±0.162 mm2, a value in line with data reported for metallic stent implantation 
in patients presenting with STEMI.21,38 Similarly, the amount of intraluminal defect after 
scaffold implantation was minimal and comparable with what is observed in metallic 
stents.21 Notably, these results were consistent among different scaffold sizes.
Clinical outcomes
In the present series, none of patients treated with BVS experienced a clinical event related 
to the treated vessel at the 30-day follow-up. These observations support the feasibility 
of BVS implantation in patients presenting with acute STEMI. Data showed in the present 
report with optimal acute performance in terms of final TIMI-flow and scaffold apposition 
may suggest that everolimus-eluting BVS could be considered for the treatment of 
patients presenting with STEMI, however, due to the limited number of patients and 
events, caution should be made in reaching firm conclusions. Further larger studies are 
needed to fully evaluate the performance of the present device in STEMI patients. 
Limitations
The present study represents a feasibility study with a limited number of patients. The 
small sample size does not allow reaching conclusions in terms of clinical outcomes. The 
lack of a head-to-head comparison with the current standard of care is a major limitation 
of the present study. A longer follow-up is needed to fully evaluate the performance of 
this novel device in patients presenting with acute MI. During the enrolment period, the 
implantation of either metallic stent or BVS in STEMI patients was left to the operator’s 
discretion; this methodology may be prone to selection bias. Therefore, these data should 
not stimulate at the current state of knowledge the use of BVS in patients presenting 
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with acute MI. Larger randomized studies are needed to confirm these preliminary 
observations.
CO N C Lu S I O N
In the present investigation, the implantation of the everolimus-eluting BVS was observed 
to be feasible in patients presenting with STEMI with optimal acute performance. These 
data are preliminary and need further confirmation in randomized controlled trials to 
define the true role of BVS for the treatment of patients presenting with acute myocardial 
infarction.
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A B S T R AC T
The present article focuses on recent innovations and possible future perspectives 
in the reperfusion treatment of ST-segment elevation myocardial infarction 
(STEMI). Among these, the shift from the femoral to the radial vascular access, 
the recent availability of bioresorbable coronary scaffolds, other innovative forms 
of stents specifically designed for STEMI patients, the use of cardio-protective 
strategies, as well as the possibility of including autologous bone marrow stem 
cell transplantation as part of the treatment of patients with STEMI are described 
and commented as a glance into the future. This article integrates the supplement 
of EuroIntervention addressing specific topics related to reperfusion strategies 
during STEMI in dedicated chapters.
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VA S C u L A R  ACC E S S
One of the most relevant changes introduced in the field of the primary percutaneous 
coronary interventions (PCI) compared to the initial experiences relates to the vascular 
access. The use of the radial artery instead of the femoral artery in the specific setting 
of STEMI translates into a significant reduction in mortality mostly due to the reduction 
of bleeding as investigated in the RIFFLE and the RIVAL Trials. (1, 2) Of note, the significant 
reduction of mortality offered by the radial vascular access was particularly evident in 
patients presenting with STEMI compared with other forms of acute coronary syndromes 
(ACS). These data were subsequently confirmed by a large post-hoc analysis(3) and several 
additional investigations. (4-6)
Although the femoral artery may be preferred in some patients, such as those with a very 
weak radial pulse, or patients needing left ventricular hemodynamic support, or right 
ventricular pacing during the primary PCI, the radial access should be probably embraced 
as default for STEMI patients after adequate training in elective cases. It is worthy 
mentioning that the use of dedicated femoral closure devices has not reduced the risk of 
complications associated to the femoral puncture.(7)
However, considering the fact that the rate of complications for expert femoral operators 
could be very low, the recommendation to develop radial access skills is mainly aimed 
at preparing a change for future generations of internationalists, rather than requiring a 
change in clinical practise to experts.
M E C h A N I C A L  R E P E R F u S I O N 
Primary percutaneous coronary intervention is superior to fibrinolysis by reducing 
mortality, re-infarction, and stroke, also improving patency of the infarct-related artery, 
reducing the severity of the residual stenotic lesion, with an overall better left ventricular 
function.(8-10)
Furthermore, performing coronary angiography in STEMI allows the immediate and 
accurate risk stratification based on the knowledge of the degree of the coronary artery 
disease and invasive hemodynamic parameters. For all these reasons primary PCI is 
currently the recommended treatment of first choice for patients presenting with STEMI 
when performed in experienced centres and limited time delay.(11)
Nevertheless, fibrinolysis remains a first line approach in many areas of the world where 
primary PCI is not an option, or at least is not “the first option available”. 
Therefore, fibrinolysis, is common as treatment of choice in many developing Countries as 
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well as in some regions of developed Countries not covered by a permanent and effective 
primary PCI service.(12) The optimization of the social impact of reperfusion treatment will 
continue expanding such approach in many areas of the world before a systematic access 
to well trained cathlabs could become a reality, education and training of paramedics 
being the first step of this worldwide commitment.
P R I M A R y  P E R C u TA N E O u S  CO R O N A R y  I N T E R V E N T I O N S 
Balloon-expandable stents 
Bare metal stent (BMS) implantation during primary PCI was initially associated with improved 
angiographic result and decreased need for target vessel revascularizations(13, 14) compared 
with balloon angioplasty but failed in adding a clear advantage in terms of mortality.
The introduction of the first generation drug eluting stents (DES) brought a further 
reduction of restenosis with a subsequent lower rate of repeat revascularizations but 
again without providing benefits on mortality and re-infarction(15) and the enthusiasm 
related to DES implantation in STEMI patients was tempered by the observation of higer 
rates of late and very late stent thrombosis.(16)
The high thrombotic burden and vessel vasoconstriction present in the acute phase 
leading to stent under-sizing and late malapposition in addition to polymer-related 
persistent inflammation and delayed vessel healing were identified as mechanisms 
involved in DES thrombosis(16)
Second generation DES with different drugs, biocompatible polymers, better stent designs 
and thinner struts, have overcome most of the limitations of first generation DES. The use 
of the second generation everolimus eluting stents (EES) with durable fluoro-polymer in 
STEMI reduced target lesion and target vessel revascularisation compared to BMS (2.1% 
vs 5.0%, p=0.003, and 3.7% vs 6.8%, p=0.0077, respectively) at 1-year follow-up with a 
lower incidence of stent thrombosis (definite stent thrombosis 0.5% vs 1.9%; definite or 
probable stent0.9% vs 2.5%, p=0.019).(17)
Biolimus A9 eluting stents with biodegradable polymer tested in comparison with BMS 
reduced the occurrence of the composite of cardiac death, target vessel-related re-
infarction, and ischemia-driven target-lesion revascularization (4.3% vs 8.7%, p=0.004) at 
1-year follow-up after primary PCI,(18) although the individual endpoints of death and re-
infarction remained unchanged.
The introduction of next generation DES with thinner struts, and newer polymers, as well 
as the development of new stents dedicated to the treatment of STEMI patients may 
further improve the present clinical results.
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Self-expanding stents
Self-expanding stents allowing low-pressure deployment were initially developed in the 
attempt to reduce the vessel injury and the neointimal response after stent implantation. 
In the specifi c setting of STEMI, the use of oversized balloons and high-pressure dilatation 
might trigger distal embolization and no-refl ow with a reduction of myocardial savage. 
Therefore, the concept of gentle deployment and delayed self-expansion has been recently 
applied as an option for STEMI patients (Figure 1) and a thin struts self-expanding, nitinol, 
stent has been recently tested in patients presenting with acute myocardial infarction 
and compared with currently available balloon-expandable stents(19) showing less struts 
malapposition at 3 days after implantation as assessed by optical coherence tomography, 
with similar clinical outcomes at 6 months between the two study arms. Dedicated larger 
clinical studies are currently needed to further investigate the clinical value of this new 
technology.
 
figure 1. Diff erent devices and mechanisms of revascularization.
New generation DES provides reduced incidence of target lesion revascularisation and very low rate of stent 
thrombosis. Self-expanding stents with gentle deployment and delayed self-expansion could allow for a theoretical 
reduction in distal embolization and less malapposition compared to balloon-expandable stents. Mesh-covered 
stents with the presence of a micronet mesh is intended to trap thrombotic material between the stent and the 
arterial wall thus potentially reducing the risk of distal embolization. The implantation of bioresorbable scaff olds 
provides revascularization, and after bioresorption, restoration of vasomotor function, vessel compliance and 
cyclic strain in response to pulsatile fl ow, re-establishing the coronary physiology, potentially allowing for positive 
remodeling and late lumen enlargement.
330   |    Chapter 15
Mesh-Covered Stent
Microvascular dysfunction after primary PCI is associated with increased infarct size and 
worse clinical outcomes.(20-23)
Although many factors might promote such phenomenon, distal embolization of 
thrombotic debrides from the culprit lesions during the stent deployment seems to play 
a key role. Mechanical and pharmacological approaches have been previously tested to 
reduce the impact of thrombus embolization often with non-definitive results. However, 
despite the appealing concept of protecting the distal microcirculation with dedicated 
devices for distal or proximal capture of thrombo-emolic debris, randomized trials failed 
to demonstrate a relevant clinical advantage of these strategies.(24, 25)
Recently, a BMS covered with a polyethylene terephthalate micronet mesh was introduced 
in the clinical arena. The presence of a micronet mesh is intended to trap thrombotic 
material between the stent and the arterial wall thus theoretically reducing the risk 
of distal embolization. (Figure 1) Several reports showed safety and feasibility of this 
technology, and a randomized trial has been performed comparing the rate of complete 
(≥70%) ST-segment resolution measured at 60 to 90 min post-procedure, between mesh-
covered stents and standard stents.(26)
This endpoint was significantly improved in patients treated with mesh-covered stents 
(57.8% vs. 44.7%; p = 0.008), with also superior rate of TIMI 3 flow (91.7% vs. 82.9%, p = 
0.006) with equivalent myocardial blush grade 2 or 3 (83.9% vs. 84.7%, p = 0.81) compared 
with standard stents. Although a mesh-covered stent in STEMI could have interesting 
implications especially in relation with the reduction of thrombus dislodgment and 
embolization, its BMS nature and the presence of a permanent polyethylene micronet 
mesh, suggest the need for a careful assessment of the restenosis rate.
Bioresorbable vascular scaffolds (BVS)
Bioresorbable technologies represent a potential step forward in endovascular 
interventions. Its applicability in the STEMI setting (Figure 2) may provide additional 
benefit to that could be maximized in young patients with long life expectancy. Acute 
coronary syndromes (ACS) and STEMI are often the first clinical manifestation of coronary 
artery disease (CAD) in young subjects and the possibility of coronary artery treatment 
without permanent metallic implants, could have important implications in the long-term 
patient’s perspective.  
Two studies have been recently published reporting feasibility and safety of Absorb BVS 
implantation specifically in STEMI patients(27, 28) and few other investigations with small 
series of STEMI and NSTEMI (29)
Implantation of Absorb BVS in STEMI patients yielded high procedural success rate. 
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Thrombus aspiration and lesion preparation was performed in a high percentage of 
patients as recommended because of the higher profi le of the scaff old compared with 
standard stents. A theoretical concern regarding Absorb BVS implantation in STEMI, is 
that a more extensive lesion preparation, could result in increased distal embolization 
and a higher risk of no-refl ow. However this eff ect was not reported in none of the above-
mentioned preliminary evaluations. The deployment of a device with a larger strut width 
(Absorb BVS 157µm) compared to metallic stents could induce a diff erent pattern of 
thrombus dislodgment, with a percentage of vessel wall area paved by the BVS (scaff old/
vessel ratio) reaching 26%, a higher value compared to metallic DES (i.e. EES provides a 
percentage stent/vessel ratio equal to 12%).(30) This characteristic might be associated 
 
figure 2. Treatment of an acute myocardial infarction with an Absorb BVS and 6-moth invasive follow-up.
Upper panel: angiographic images at the index procedure and at mid-term (6-month) follow-up showing optimal 
lumen patency.
Lower panel: Optical coherence images showing the presence residual thrombus after thrombus aspiration but not 
after BVS implantation supporting the concept of increased thrombus sequestration between the struts and the 
vessel wall due to BVS wider struts (snow shoes concept). At 6-month follow-up the scaff old appear patent and fully 
covered with a thin layer of neointimal tissue.
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with an increased capacity of capturing thrombotic material behind the struts reducing 
distal embolization (snow-shoes concept).(27) The perspective of vessel healing without 
a permanent metallic cage is of particular interest as providing revascularization, and 
after bioresorption, restoration of vasomotor function, vessel compliance and cyclic strain 
in response to pulsatile flow, re-establishing a normal coronary physiology, potentially 
allowing for positive remodeling and late lumen enlargement. (Figure 1)
Given the very limited data on the clinical use of the Absorb BVS in acute patients several 
aspects need to be carefully evaluated, among them the incidence of scaffold thrombosis, 
and the optimal anti-platelet strategy.
C A R D I O - P R OT E C T I O N :  M yO C A R D I A L  CO N D I T I O N I N G
Ischemic pre-conditioning (IPC)
Myocardial conditioning is a broad term used to describe the intriguing finding that 
brief, non-lethal episodes of myocardial ischemia and reperfusion applied to an organ or 
tissue render the heart resistant to a subsequent episode of sustained, lethal ischemia-
reperfusion injury.(31) (Figure 3)
However, the requirement to implement the IPC stimulus before the onset of ischemia has 
restricted its clinical application to elective procedures in which the ischemic episode can 
be anticipated, such as cardiac surgery.
Interestingly, the IPC stimulus was found to be also effective when applied to an organ or 
tissue distant from the target organ requiring protection (remote ischemic conditioning). 
In fact, brief ischemic episodes of the circumflex artery significantly reduced myocardial 
infarct size following sustained occlusion of the left anterior descending artery in dogs 
(ie, remote intra-cardiac conditioning, and a 15-min period of small intestine or renal 
ischaemia was also capable of limiting infarct size (ie, remote inter-organ conditioning). 
(32, 33) The observation that transient ischaemia and reperfusion of the limb could also elicit 
remote inter-organ conditioning facilitated the translation of this endogenous cardio-
protective phenomenon into the clinical field(34) and two clinical trials evaluated the effect 
of remote ischemic preconditioning in STEMI.(35) Bøtker et al. showed that four 5-minutes 
arm cuff inflations and deflations applied by ambulance personnel during transport to 
the hospital, was capable of increasing myocardial salvage and decreasing infarct size at 
1 month(35) Importantly, the greatest advantage was observed in patients presenting with 
occlusion of the left anterior descending artery, suggesting that patients most likely to 
benefit are those sustaining large anterior infarctions. A subsequent trial has confirmed 
the protective effects of remote conditioning (three 3/4-minutes cycles of arm cuff 
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infl ations and defl ations) in patients undergoing primary PCI on myocardial infarct size as 
measured by serum levels of troponin I(36) and that the addition of morphine appeared to 
increase the benefi cial eff ect of remote ischemic per-conditioning. Most importantly, the 
follow-up study of the trial by Bøtker et al. demonstrated that the reduction in infarct size 
obtained with remote ischemic per-conditioning before hospital admission translated 
into a signifi cant reduction in major adverse cardiovascular events at fi ve years, that was 
principally driven by a reduction of mortality.(37)
Ischemic post-conditioning
A further form of myocardial conditioning is ischemic post-conditioning.(38) (Figure 3) In 
2003, Zhao et al. reported that brief interruptions of coronary blood fl ow at the onset of 
reperfusion were also able to induce cardio-protection in canine hearts. The investigators 
demonstrated that this technique resulted in a 43% reduction in myocardial infarct size 
following 60 min of left anterior descending artery occlusion(38) This concept provided a 
 
figure 3. Timing of diff erent conditioning strategies in relation to ischemia and reperfusion periods.
Panel A: Ischemic pre-conditioning (IPC) with episodes of myocardial ischemia and reperfusion applied before 
reperfusion. Ischemic post-conditioning (IPOC) with episodes of myocardial ischemia and reperfusion applied after 
reperfusion. Pharmacological conditioning (PharmaC) with drugs intended to mimic the cardio-protective eff ects of 
myocardial conditioning. 
Panel B: Remote ischemic conditioning. Remote ischemic pre-conditioning (RIPC) with episodes of ischemia and 
reperfusion applied before reperfusion, to an organ or tissue distant from the target organ requiring protection 
(myocardium). Remote ischemic per-conditioning (RIPerC) with episodes of ischemia and reperfusion applied during 
reperfusion, to an organ or tissue distant from the myocardium. Remote ischemic (RIPoC) post-conditioning with 
episodes of ischemia and reperfusion applied after reperfusion, to an organ or tissue distant from the myocardium.
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new strategy of intervention that could be applied at the time of myocardial reperfusion 
for patients presenting with STEMI, and immediately sparked the interest of clinical 
investigators. 
The first clinical application in patients with STEMI demonstrated that interrupting 
reperfusion (with four cycles of 1-minute low pressure inflations and deflations of the 
angioplasty balloon immediately after direct stenting of the infarct related artery) 
resulted in a 36% reduction in infarct size as assessed by creatine kinase release over 
72h(39) However, recent trials provide inconsistent results.(40) The value of ischemic post-
conditioning is currently being investigated among others in the DANAMI-3 Trials 
(ClinicalTrials.gov identifier NCT01435408). An overview of these clinical studies can be 
seen in Table 1.
Pharmacological conditioning
Over the last few decades, research into the mechanisms of myocardial conditioning 
has revealed the function of multiple receptors, signal transduction pathways, and end-
effectors, all of which are amenable to pharmacological manipulation. These efforts 
enable drugs to be used to mimic the cardio-protective effects of the different forms of 
myocardial conditioning. Experimental observations showing that drugs are capable of 
limiting infarct size when administered just prior to or at the onset of reperfusion have 
resulted in several clinical studies evaluating these drugs. However, many investigations 
yielded negative results, largely due to a lack of consistent preclinical data, poor study 
design, or delayed drug administration, as previously suggested(41) 
The signal transduction pathways involved in both pre- and post-conditioning seem 
to converge at the mitochondria and studies with agents that are known to preserve 
mitochondrial function are currently ongoing. (CIRCUS and the CYCLE, both involving 
ciclosporin; ClinicalTrials.gov identifiers NCT01502774 and NCT01650662 respectively, 
and EMBRACE (involving Bendavia; ClinicalTrials.gov identifiers NCT01572909) and 
MitoCare (involving TR040303; European Commission FP7 project number 261034). The 
results of these studies are eagerly awaited to validate the smaller pilot trials conducted 
so far.
Future perspectives
In brief, there might be a role of ischemic conditioning as strategy with potential for 
preserving cell viability after a prolonged ischemic insult. Although scientifically appealing, 
the available evidence related to pharmacologic interventions to preconditioning is 
still insufficient to envision its imminent clinical applicability. The invasive nature of the 
mechanic post-conditioning interventions, on the other hand, limits their use to patients 
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table 1. Ischemic postconditioning in patients with STEMI
Study N Ischemic 
Time (min)
Postconditioning 
protocol 
(cycles x 
duration)
Result
Laskey et al.(50) (2005) 17 342 2 x 90s ↔ peak CK; ↑ CBF and STR 
Staat et al.(39) (2005) 30 318 4 x 60s ↓ 72-h AUC CK (36%); ↑ MBG 
Ma et al.(51) (2006) 94 396 3 x 30s ↓ peak CK (28%); ↑ wall motion score index at 8 
wks
Yang et al.(52) (2007) 41 288 3 x 30s ↓ peak CK (28%); ↓ IS (27%) at 1 wk (SPECT)
Thibault et al.(53) (2008) 38 282 4 x 60s ↓ 72-h AUC CK (40%); ↓ IS (39%) at 6 mo (SPECT); 
7% increase LVEF at 1 y 
Laskey et al.(54) (2008) 24 225 2 x 90s ↓ peak CK (19%); ↑ CBF and STR 
Zhao et al.(55) (2009) 75 348 / 432 3 x 30s / 3 x 60s ↓ TnI at 1 wk; ↑ LVEF at 1 wk (60s>30s>control)  
Lønborg et al.(56) (2010) 118 248 4 x 30s ↓ IS (19%) at 3 mo (CMR); 31% increase MSI 
Sörensson et al.(57) (2010) 76 175 4 x 60s ↔ 48-h AUC CK-MB/TnT; ↔ MSI at 1 wk (CMR); 
significant increase MSI when risk zone >30% of 
left ventricle 
Garcia et al.(58) (2010) 43 267 4 x 30s ↓ peak CK (11%) and CK-MB (20%); ↑ MBG 
Xue et al.(59) (2010) 43 285 4 x 60s ↓ 72-h AUC CK-MB (26%); ↓ IS (46%) at 1 wk 
(SPECT); ↑ STR 
Freixa et al.(40) (2012) 79 328 4 x 60s ↔ IS at 1 wk or 6 mo (CMR); worse MSI at 1 wk
Thuny et al.(60) (2012) 50 252 4 x 60s ↓ peak/AUC CK; ↓ IS and edema at 3 d (CMR)
Tarantini et al.(61) (2012) 78 203 4 x 60s Trend toward increased IS at 1 mo (CMR)
Engstrøm et al.(62) (2012) 2,000 NA 4 x 30s Ongoing phase 3 study investigating the effect of 
IPOC on death and hospitalization for heart failure
Mewton et al.(63) (2013) 50 289 4 x 60s ↓ IS and MVO at 3 d (CMR) 
Dwyer et al.(64) (2013) 102 150 4 x 30s ↔ IS and trend towards increased MSI at 3 d 
(CMR)
Hahn et al.(65) (2013) 700 196 4 x 60s ↔ STR >70% or MBG 
Roubille et al.(66) (2014) 90 263 4 x 60s ↔ peak/AUC CK or TnI; ↔ IS or MVO at 5 d (CMR)
Limalanathan et al.(67) (2014) 272 198 4 x 60s ↔ peak TnT; ↔ MBG or STR; ↔ IS or MSI at 4 mo 
(CMR)
Bodi et al.(68) (2014) 101 190 4 x 60s ↔ peak CK-MB; ↔ MBG or STR; ↔ IS or MVO at 1 
wk (CMR)
↔ denotes neutral effect; ↑, improved; ↓, reduced; AUC, area under the curve; CBF, coronary blood flow; CK, creatine 
kinase; CK-MB, creatine kinase-myocardial band; CMR, cardiac magnetic resonance; IS, infarct size; LVEF, left ventricular 
ejection fraction; MBG, myocardial blush grade; MSI, myocardial salvage index; MVO, microvascular obstruction; NA, 
not admissible; SPECT, single photon emission computed tomography; STR, ST-segment resolution; TnI, troponin I; 
and TnT, troponin T. 
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undergoing invasive reperfusion, but the potential of mechanical remote ischemic 
preconditioning as obtained with the simple compression of the arm using a pressure 
cuffing may provide relevant clinical implications.
C E L L  T h E R A P y
If enlarging treatment availability to the largest possible number of STEMI patients should 
be the start-point of efforts to improve reperfusion treatment and survival worldwide, 
the regeneration of myocardial tissue after cellular death represents the ultimate end-
point; an option that may dramatically transform the natural history of the ischemic heart 
disease. 
Two different forms of cell treatment have been envisioned and developed in this setting. 
One is the implantation of bone marrow stem cells during or early after primary PCI, the 
other is that of implanting the cells during the chronic phase of the disease in patients 
who have evolved into advanced forms of chronic heart failure after myocardial infarction. 
The demonstration of continued cell division within the adult heart following myocardial 
infarction(42) and the capability of bone marrow-derived progenitor/stem cells (BMSCs) to 
trans-differentiate into cardiomyocytes, improving left ventricle (LV) function after STEMI 
was demonstrated in the mouse model at the end of the nineties(43) Such an amazing 
finding fuelled continuous research, followed by a substantial number of human clinical 
trials in the last decade. 
Initial studies yielded promising results, in particular data from the first human trial by 
Strauer et al. (44) Subsequently, only a modest or no increase in LV function and reduction 
in the infarct size were observed.(45-47) 
Today, none of the published trials has been able to replicate the magnitude of the 
functional improvement observed in the animal experiments. Autologous BMSCs, 
which consist of haematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs) and 
endothelial progenitor cells (EPCs), account for the most studied adult stem cells; these 
are obtained through a bone marrow aspiration under local anesthesia, isolated and 
cultivated, using variable protocols in the different trials. Upcoming trials are testing the 
efficacy of allogeneic MSCs, thus not requiring cells isolation and re-implantation (AMICI 
trial, number NCT01781390; Prochymal-2 trial, number NCT 00877903), according to some 
promising results derived from animal experiments. Other possible source accounting for 
the variability of the clinical results derives from the different techniques for percutaneous 
delivering of the BMSCs into the infarcted area of the left ventricle, with consequent 
variable retention rates. Cell delivery has been performed by the simple anterograde 
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intracoronary injection, by peri-adventitial administration, by retrograde trans-venous 
and endo-ventricular catheters. Such technical differences may account for a large part 
of the diverging findings in these studies. Moreover, other procedural factors have been 
brought into question such as the timing of cells delivery (ranging from 1 to 18 days 
after the acute event), the kinetics of the delivery (from continuous infusion to multiple 
injections), the cells processing protocols and the dose of the cells administered. 
Moreover, other cells types such as autologous or allogeneic mesenchymal stem cells, 
adipose tissue–derived regenerative cells, or cardiosphere-derived cells have also been 
tested in the STEMI setting with some benefits, but these results are strongly limited by the 
small number of treated patients. In addition, systemic administration of a haematopoietic 
cytokine, the granulocyte colony-stimulating factor (G-CSF), has been tested in this 
setting, for its effect of enhanced translocation of BMSCs to the infarcted region post-
STEMI. Despite the solid molecular demonstration of the activity of this cytokine, trials 
involving its use in patients with acute myocardial infarction have shown discrepancy in 
results, with poor or no improvement in LV function. 
Cell delivery immediately after reopening the occluded artery actually bares the interesting 
perspective of using stem cells derived from young and healthy donors that can be stored 
in a shelf, readily available directly after primary PCI, and administered in an allogeneic 
setting, with the obvious logistic simplification. To date, the intracoronary infusion of 
bone marrow-derived mononuclear cell although safe, did not enhance cardiac function 
on MRI-derived parameters, nor did it improve clinical outcome, as recently demonstrated 
in a meta-analysis of 22 randomized studies(48) Conversely, the elective implantation of 
autologous adult bone marrow-derived stem cells as a treatment for chronic ischemic 
heart disease and heart failure provided beneficial clinical effect in terms of mortality and 
long-term performance status in patients suffering from chronic ischemic heart disease 
and heart failure. Cell therapy in this setting has been investigated with similar techniques 
and methodology as was done in STEMI patients. Intracoronary delivery of BMSCs was 
tested in the STAR-Heart study, which confirmed the beneficial effects of cell therapy 
in 191 patients with chronic heart failure in terms of improved LV function, improved 
patients’ exercise capacity and decreased in long-term mortality when compared with 
a control group of 200 patients who declined to undergo active intervention at 5 years 
follow-up(49) Similarly, the trans-endocardial injection of BMSCs has also been shown to be 
safe with potential beneficial effects, as well as the subcutaneous G-CSF administration. 
Results of cell therapy in patients with chronic heart failure after STEMI maintain are 
currently of high interest due to relevant therapeutic perspectives. The currently ongoing 
intensive investigation in this field will probably add in further understanding on the 
future real role of stem cells in the therapeutic horizon of STEMI patients.
338   |    Chapter 15
R E F E R E N C E S
1. Jolly SS, Yusuf S, Cairns J, Niemela K, Xavier D, Widimsky P, et al. Radial versus femoral access for coronary 
angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel 
group, multicentre trial. Lancet. 2011;377(9775):1409-20.
2. Romagnoli E, Biondi-Zoccai G, Sciahbasi A, Politi L, Rigattieri S, Pendenza G, et al. Radial versus femoral 
randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial 
Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. Journal of 
the American College of Cardiology. 2012;60(24):2481-9.
3. Mamas MA, Ratib K, Routledge H, Neyses L, Fraser DG, de Belder M, et al. Influence of arterial access site 
selection on outcomes in primary percutaneous coronary intervention: are the results of randomized 
trials achievable in clinical practice? JACC Cardiovascular interventions. 2013;6(7):698-706.
4. Bernat I, Horak D, Stasek J, Mates M, Pesek J, Ostadal P, et al. ST-segment elevation myocardial infarction 
treated by radial or femoral approach in a multicenter randomized clinical trial: the STEMI-RADIAL trial. 
Journal of the American College of Cardiology. 2014;63(10):964-72.
5. Baklanov DV, Kaltenbach LA, Marso SP, Subherwal SS, Feldman DN, Garratt KN, et al. The prevalence 
and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial 
infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). Journal of the American 
College of Cardiology. 2013;61(4):420-6.
6. Mehta SR, Jolly SS, Cairns J, Niemela K, Rao SV, Cheema AN, et al. Effects of radial versus femoral artery 
access in patients with acute coronary syndromes with or without ST-segment elevation. Journal of the 
American College of Cardiology. 2012;60(24):2490-9.
7. Biancari F, D’Andrea V, Di Marco C, Savino G, Tiozzo V, Catania A. Meta-analysis of randomized trials on 
the efficacy of vascular closure devices after diagnostic angiography and angioplasty. American heart 
journal. 2010;159(4):518-31.
8. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary 
angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. 
JAMA : the journal of the American Medical Association. 1997;278(23):2093-8.
9. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute 
myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.
10. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate 
coronary angioplasty with intravenous streptokinase in acute myocardial infarction. The New England 
journal of medicine. 1993;328(10):680-4.
11. Task Force on the management of STseamiotESoC, Steg PG, James SK, Atar D, Badano LP, Blomstrom-
Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients 
presenting with ST-segment elevation. European heart journal. 2012;33(20):2569-619.
12. Danchin N, Puymirat E, Steg PG, Goldstein P, Schiele F, Belle L, et al. Five-year survival in patients with 
ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French 
Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort. 
Circulation. 2014;129(16):1629-36.
13. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with 
or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial 
Infarction Study Group. The New England journal of medicine. 1999;341(26):1949-56.
14. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, 
with or without abciximab, in acute myocardial infarction. The New England journal of medicine. 
2002;346(13):957-66.
Future perspectives in STEMI    |   339
PART
III
15. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, et al. Paclitaxel-eluting stents versus bare-
metal stents in acute myocardial infarction. The New England journal of medicine. 2009;360(19):1946-59.
16. Webster MW, Ormiston JA. Drug-eluting stents and late stent thrombosis. Lancet. 2007;370(9591):914-5.
17. Sabate M, Cequier A, Iniguez A, Serra A, Hernandez-Antolin R, Mainar V, et al. Everolimus-eluting stent 
versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of 
a randomised controlled trial. Lancet. 2012;380(9852):1482-90.
18. Raber L, Kelbaek H, Ostojic M, Baumbach A, Heg D, Tuller D, et al. Effect of biolimus-eluting stents with 
biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute 
myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA : the journal of the American 
Medical Association. 2012;308(8):777-87.
19. van Geuns RJ, Tamburino C, Fajadet J, Vrolix M, Witzenbichler B, Eeckhout E, et al. Self-expanding versus 
balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-
expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovascular interventions. 
2012;5(12):1209-19.
20. Kitabata H, Kubo T, Ishibashi K, Komukai K, Tanimoto T, Ino Y, et al. Prognostic value of microvascular 
resistance index immediately after primary percutaneous coronary intervention on left ventricular 
remodeling in patients with reperfused anterior acute ST-segment elevation myocardial infarction. JACC 
Cardiovascular interventions. 2013;6(10):1046-54.
21. van de Hoef TP, Bax M, Meuwissen M, Damman P, Delewi R, de Winter RJ, et al. Impact of coronary 
microvascular function on long-term cardiac mortality in patients with acute ST-segment-elevation 
myocardial infarction. Circulation Cardiovascular interventions. 2013;6(3):207-15.
22. Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, et al. Prognostic value of the Index of 
Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 
2013;127(24):2436-41.
23. Anderson TJ, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, et al. Microvascular function 
predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their 
Endothelium (FATE) study. Circulation. 2011;123(2):163-9.
24. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal microcirculatory protection during 
percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized 
controlled trial. JAMA : the journal of the American Medical Association. 2005;293(9):1063-72.
25. Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, et al. Randomized evaluation of the effects 
of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous 
catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation. 
2005;112(10):1462-9.
26. Stone GW, Abizaid A, Silber S, Dizon JM, Merkely B, Costa RA, et al. Prospective, Randomized, Multicenter 
Evaluation of a Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) in ST-Segment 
Elevation Myocardial Infarction: The MASTER Trial. Journal of the American College of Cardiology. 2012.
27. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, et al. Everolimus-eluting 
bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation 
myocardial infarction: BVS STEMI first study. European heart journal. 2014;35(12):777-86.
28. Kocka V, Maly M, Tousek P, Budesinsky T, Lisa L, Prodanov P, et al. Bioresorbable vascular scaffolds in acute 
ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’. European heart 
journal. 2014;35(12):787-94.
29. Gori T, Schulz E, Hink U, Wenzel P, Post F, Jabs A, et al. Early outcome after implantation of Absorb 
bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes. EuroIntervention 
: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the 
European Society of Cardiology. 2014;9(9):1036-41.
340   |    Chapter 15
30. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, et al. Incidence and short-
term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting 
bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial 
in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. JACC Cardiovascular 
interventions. 2013;6(3):247-57.
31. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic 
myocardium. Circulation. 1986;74(5):1124-36.
32. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ‘preconditioning’ protects remote 
virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-9.
33. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD. Myocardial protection by brief 
ischemia in noncardiac tissue. Circulation. 1996;94(9):2193-200.
34. Yetgin T, Manintveld OC, Groen F, Tas B, Kappetein AP, van Geuns RJ, et al. The emerging application of 
remote ischemic conditioning in the clinical arena. Cardiology in review. 2012;20(6):279-87.
35. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, et al. Remote ischaemic 
conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial 
salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375(9716):727-34.
36. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, et al. Cardioprotective role 
of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by 
opioid action. JACC Cardiovascular interventions. 2010;3(1):49-55.
37. Sloth AD, Schmidt MR, Munk K, Kharbanda RK, Redington AN, Schmidt M, et al. Improved long-term 
clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic 
conditioning as an adjunct to primary percutaneous coronary intervention. European heart journal. 
2014;35(3):168-75.
38. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by 
ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. American 
journal of physiology Heart and circulatory physiology. 2003;285(2):H579-88.
39. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L’Huillier I, et al. Postconditioning the human heart. Circulation. 
2005;112(14):2143-8.
40. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, et al. Ischaemic postconditioning revisited: 
lack of effects on infarct size following primary percutaneous coronary intervention. European heart 
journal. 2012;33(1):103-12.
41. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ. Reperfusion injury in humans: a review of clinical trials 
on reperfusion injury inhibitory strategies. Cardiovascular research. 2007;74(3):343-55.
42. Beltrami AP, Urbanek K, Kajstura J, Yan SM, Finato N, Bussani R, et al. Evidence that human cardiac 
myocytes divide after myocardial infarction. The New England journal of medicine. 2001;344(23):1750-7.
43. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted 
myocardium. Nature. 2001;410(6829):701-5.
44. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium 
by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation. 
2002;106(15):1913-8.
45. Surder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, et al. Intracoronary injection of bone 
marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left 
ventricular function. Circulation. 2013;127(19):1968-79.
46. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Effect of the use and timing of bone 
marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME 
randomized trial. JAMA : the journal of the American Medical Association. 2012;308(22):2380-9.
Future perspectives in STEMI    |   341
PART
III
47. Assmus B, Leistner DM, Schachinger V, Erbs S, Elsasser A, Haberbosch W, et al. Long-term clinical outcome 
after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial 
infarction: migratory capacity of administered cells determines event-free survival. European heart 
journal. 2014;35(19):1275-83.
48. de Jong R, Houtgraaf JH, Samiei S, Boersma E, Duckers HJ. Intracoronary stem cell infusion after 
acute myocardial infarction: a meta-analysis and update on clinical trials. Circulation Cardiovascular 
interventions. 2014;7(2):156-67.
49. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intracoronary Stem cell 
Transplantation in 191 patients with chronic heARt failure: the STAR-heart study. European journal of 
heart failure. 2010;12(7):721-9.
50. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary 
intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. 2005;65(3):361-7.
51. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial 
function and LV recovery after myocardial infarction. J Interv Cardiol. 2006;19(5):367-75.
52. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG, et al. Reduction in myocardial infarct size by postconditioning 
in patients after percutaneous coronary intervention. J Invasive Cardiol. 2007;19(10):424-30.
53. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit of postconditioning. 
Circulation. 2008;117(8):1037-44.
54. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and 
ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a 
benefit of postconditioning. Catheter Cardiovasc Interv. 2008;72(2):212-20.
55. Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y, et al. A 60-s postconditioning protocol by percutaneous 
coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. 
Apoptosis. 2009;14(10):1204-11.
56. Lonborg J, Kelbaek H, Vejlstrup N, Jorgensen E, Helqvist S, Saunamaki K, et al. Cardioprotective effects 
of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, 
evaluated by magnetic resonance. Circ Cardiovasc Interv. 2010;3(1):34-41.
57. Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K, et al. Effect of postconditioning on 
infarct size in patients with ST elevation myocardial infarction. Heart. 2010;96(21):1710-5.
58. Garcia S, Henry TD, Wang YL, Chavez IJ, Pedersen WR, Lesser JR, et al. Long-term follow-up of patients 
undergoing postconditioning during ST-elevation myocardial infarction. J Cardiovasc Transl Res. 
2011;4(1):92-8.
59. Xue F, Yang X, Zhang B, Zhao C, Song J, Jiang T, et al. Postconditioning the human heart in percutaneous 
coronary intervention. Clin Cardiol. 2010;33(7):439-44.
60. Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, et al. Post-conditioning reduces 
infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 
2012;59(24):2175-81.
61. Tarantini G, Favaretto E, Marra MP, Frigo AC, Napodano M, Cacciavillani L, et al. Postconditioning during 
coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int J Cardiol. 2012.
62. Pell TJ, Baxter GF, Yellon DM, Drew GM. Renal ischemia preconditions myocardium: role of adenosine 
receptors and ATP-sensitive potassium channels. Am J Physiol. 1998;275(5 Pt 2):H1542-7.
63. Mewton N, Thibault H, Roubille F, Lairez O, Rioufol G, Sportouch C, et al. Postconditioning attenuates no-
reflow in STEMI patients. Basic Res Cardiol. 2013;108(6):383.
64. Dwyer NB, Mikami Y, Hilland D, Aljizeeri A, Friedrich MG, Traboulsi M, et al. No Cardioprotective Benefit of 
Ischemic Postconditioning in Patients With ST-Segment Elevation Myocardial Infarction. J Interv Cardiol. 
2013;26(5):482-90.
342   |    Chapter 15
65. Hahn JY, Song YB, Kim EK, Yu CW, Bae JW, Chung WY, et al. Ischemic Postconditioning During Primary 
Percutaneous Coronary Intervention: The Effects of Postconditioning on Myocardial Reperfusion 
in Patients With ST-Segment Elevation Myocardial Infarction (POST) Randomized Trial. Circulation. 
2013;128(17):1889-96.
66. Roubille F, Mewton N, Elbaz M, Roth O, Prunier F, Cung TT, et al. No post-conditioning in the human heart 
with thrombolysis in myocardial infarction flow 2-3 on admission. Eur Heart J. 2014;35(25):1675-82.
67. Limalanathan S, Andersen GO, Klow NE, Abdelnoor M, Hoffmann P, Eritsland J. Effect of ischemic 
postconditioning on infarct size in patients with ST-elevation myocardial infarction treated by primary 
PCI results of the POSTEMI (POstconditioning in ST-Elevation Myocardial Infarction) randomized trial. J 
Am Heart Assoc. 2014;3(2):e000679.
68. Bodi V, Ruiz-Nodar JM, Feliu E, Minana G, Nunez J, Husser O, et al. Effect of ischemic postconditioning on 
microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients 
and of an experimental model in swine. Int J Cardiol. 2014;175(1):138-46.
Future perspectives in STEMI    |   343
PART
III

Chapter 16
Self-correction Property a Novel Feature  
of Bioresorbable Coronary Scaffolds
Roberto Diletti, MD; Jurgen M.R. Ligthart, RT; Rakesh Ramdhan, RT; 
Nicolas M. Van Mieghem, MD, PhD 
International Journal of Cardiology 214 (2016) 417–418
346   |    Chapter 16
TO  T h E  E D I TO R
Bioresorbable scaffolds represent a novel paradigm for coronary artery treatment, 
providing transient vessel scaffolding and drug elution. These devices were developed 
to overcome the limitations of metallic stents such as permanent caging of the artery, 
impaired vasomotion and jailing of side-branches while allowing non-invasive imaging 
of the treated segment and preserving the option for surgical revascularizations after 
resorption.
On the other hand the current bioresorbable technology is not devoid from limitations. 
The polymeric nature of the scaffold makes this device prone to structural fractures if 
expanded over a certain limit.[1] In addition the larger struts thickness could be associated 
with a delayed vascular healing and scaffold coverage especially at the overlapping 
segments, thus theoretically facilitating the occurrence of scaffold thrombosis.[2]
Malapposition may also be a relevant issue. Malapposed thick struts could trigger 
thrombus formation and should be corrected by high pressure post-dilatation, yet at the 
risk of scaffold disruption. 
Recently a novel bioresorbable coronary scaffold eluting novolimus (DESolve Novolimus-
Eluting Bioresorbable Coronary Scaffold Elixir Medical Corporation, Sunnyvale, California) 
has been introduced in the clinical arena. An interesting feature of this device is the 
so-called “self-correction” property. In case of under-expansion and malapposition the 
scaffold will self-expand up to its nominal diameter, theoretically allowing for a gentle 
correction of the malapposition without post-dilatation.[3]
We tested this feature in vitro deploying a 3.25 x 18 mm scaffold in a 3.5 mm diameter 
silicon coronary phantom (when choosing the diameters we took into account the 2x150 
μm strut thickness) within saline solution at 37 °C. We intentionally deployed the scaffold 
at 4 atm displaying initial under-expansion. An optical coherence tomography (OCT) 
catheter was immediately advanced into the under-expanded scaffold and the OCT signal 
continuously recorded.
The scaffold showed a progressive expansion in diameter and correction for malapposition 
with an improvement that was evident already after 15 minutes and that proceeded 
for the following hour with a nearly complete resolution of both under-expansion and 
malapposition. (Figure 1, Video 1) The scaffold area showed a progressive enlargement, 
reaching a 21% increase at the end of the process. This bench test represents the first clear 
evidence of the self-correction process in the novolimus eluting coronary scaffold.
The self-correcting property could have relevant clinical implications with respect to the 
incidence of scaffold malapposition and subsequent thrombosis. This feature could be 
valuable in 1) tapered vessels where a low-pressure deployment could ensure correct 
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apposition at both the distal edge with minimal risk of edge dissection and at the larger 
proximal edge by relying on the self-correction; 2) in bifurcation lesions to preclude 
the need for proximal optimisation (POT); 3) thrombotic lesions, where the presence of 
vasoconstriction and thrombus are recognized factors facilitating stent under-sizing and 
malapposition.
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A B S T R AC T
Background Limited data are currently available on the performance of everolimus 
eluting bioresorbable vascular scaffold (BVS) for treatment of coronary lesions 
representative of daily practice. 
Methods This is a prospective, mono-center, single-arm study. Patients were 
presenting with stable, unstable angina, or non-ST segment elevation myocardial 
infarction caused by de novo stenotic lesions in native coronary arteries. No 
restrictions were applied to lesion complexity. Procedural results and 6-manth 
clinical outcomes were reported.
Results A total of 180 patients have been evaluated in the present study, with 
249 treated coronary lesions. Device Success per lesion was 99.2%. A total of 119 
calcified lesions were treated with results comparable among severe, moderate and 
non-calcified lesions in term of percentage diameter stenosis (%DS) (20.3±10.5%, 
17.8±7.7%, 16.8±8.6%; p=0.112) and acute gain (1.36±0.41mm, 1.48±0.44mm, 
1.56±0.54 mm; p=0.109). A total of 54 bifurcations were treated, side-branch 
ballooning after main vessel treatment was often performed (33.3%). The rate of 
side-branch impairment was low and comparable to metallic stents (9.3%). Total 
occlusions were 29, after BVS implantation %DS was not different from other lesion 
types (17.2±9.4%, vs 17.7±8.6%; p=0.780). At one year, all-cause mortality was 
reported in 3 cases. A total of 5 target lesion revascularizations and 4 non-target 
vessel revascularisations were reported. Four cases of definite scaffold thrombosis 
occurred; none of them was acute or subacute.
Conclusions The implantation of the everolimus eluting bioresorbable vascular 
scaffold in an expanded range of coronary lesion types and clinical presentations 
was observed to be viable with promising angiographic results and mid-term 
clinical outcomes.
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The everolimus eluting bioresorbable vascular scaffolds (BVS) represent a novel approach 
for treatment of coronary artery disease. Similarly to conventional metal stents the 
absorb BVS provide acute lumen gain, vessel scaffolding and drug elution to the vessel 
wall immediately after implantation.(1) However, at variance of standard stents, the 
polymeric structure of this device allows a gradual bioresorption of the implant over 
time.(2) Complete scaffold bioresorption is hypothesized to offer several advantages over 
permanent metal devices comprising re-acquirement of physiological vasomotion, late 
lumen enlargement, non-invasive imaging and future treatment with bypass grafting.(3-
5) In addition the absence of a foreign body could avoid phenomena such as permanent 
side-branch jailing, late acquired malapposition and the occurrence of late and very late 
stent thrombosis.(5) 
The absorb BVS has been initially tested in humans in two cohort studies, both showing 
promising results in terms of surrogate and clinical endpoints.(6-9) However, being those 
studies an early evaluation of this technology, they were characterized by a patient 
population showing stable coronary artery disease and relatively simple lesions. The first 
randomized data in very selected patients (Absorb II, Absorb Japan) supported the further 
development of this technique.
At the current state of the art, very limited data are available on BVS performance in real-
world patients, including those presenting with acute coronary syndromes and complex 
coronary lesions. A lack of information is especially evident when considering important 
lesion subsets such as calcified plaques, long lesions, bifurcations, and total occlusions. 
Given this background, the present study aims to reports angiographic and clinical 
data after an expanded clinical use of the second generation BVS, implanted in patients 
admitted with different clinical presentations including acute coronary syndromes and 
having a broad range of coronary lesion types.
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This is an investigator initiated, prospective, single-centre, single-arm post market study, 
aiming to evaluate the feasibility safety and performance of the absorb BVS for treatment 
of patients with coronary artery disease in routine clinical practice. Enrolled patients 
were subjects presenting with stable, unstable angina, or non-ST segment elevation 
myocardial infarction caused by de	novo stenotic lesions in native coronary arteries. No 
restrictions were applied to lesion complexity. Due to the absorb BVS size availability, a 
Dmax (proximal and distal mean lumen diameter) within the upper limit of 3.8 mm and 
the lower limit of 2.0 mm by online QCA was required. Exclusion criteria were minimal and 
comprised allergies or contraindications to antiplatelet medication, female patient with 
childbearing potential or currently breastfeeding, acute ST segment elevation myocardial 
infarction and post CABG patients. As per hospital policy patients with a previously 
implanted metal DES in the intended target vessel were also excluded. Also, although old 
age was not an exclusion criterion, BVS were in general reserved for younger patients, and 
left to operator’s interpretation of biological age. A hybrid approach combining BVS with 
small DES or large DES where necessary was also not recommended.
All patients were treated with DAPT according to current guidelines. DAPT was prescribed 
for one year after PCI. Prasugrel was standard therapy for ACS presenting patients while 
Clopidogrel was initiated for Stable angina patients only.
Ethics 
This is an observational study, performed according to the privacy policy of the Erasmus 
MC, and to the Erasmus MC regulations for the appropriate use of data in patient-oriented 
research, which are based on international regulations, including the declaration of 
Helsinki. The BVS received the CE mark for clinical use, indicated for improving coronary 
lumen diameter in patients with ischemic heart disease due to de novo native coronary 
artery lesions with no restriction in terms of clinical presentation. Therefore the BVS can be 
currently used routinely in Europe in different settings without a specific written informed 
consent in addition to the standard informed consent prior to the procedure. Therefore, 
a waiver from the hospital Ethical Committee was obtained for written informed consent, 
as according to Dutch law written consent is not required, if patients are not subject to 
acts other than as part of their regular treatment. Specific written informed consent post 
procedure was asked for a detailed follow-up program.
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Study device 
The device used in the present study is the second generation Absorb BVS (Abbott 
Vascular, Santa Clara, CA, USA); a balloon expandable scaffold with a polymer backbone 
of Poly-L lactide Acid (PLLA) coated with a thin layer of a 1:1 mixture of an amorphous 
matrix of Poly-D and L lactide acid (PDLLA) polymer, controlling the realise of 100 
micrograms/cm2 of the anti-proliferative drug everolimus. Two platinum markers located 
at each Absorb BVS edge allowing for accurate visualization of the radiolucent Absorb BVS 
during angiography or other imaging modalities. Approximately 80% of the drug is eluted 
within the first 30-days. Both PLLA and PDLLA are fully bioresorbable. The polymers are 
degraded mainly via hydrolysis resulting oligomers of lactate metabolized by Krebs cycle. 
Small particles, less than 2 μm in diameter, have also been shown to be phagocytised and 
degraded by macrophages.
Deﬁnitions 
Device Success was defined as the attainment of <30% final in segment residual stenosis 
after absorb BVS implantation, by angiographic visual estimation. Procedure Success was 
defined as device success and no major peri-procedural complications (Emergent CABG, 
coronary perforation requiring pericardial drainage, residual dissection impairing vessel 
flow – TIMI-flow II or less -). Clinical success was defined as procedural success and no 
in-hospital major adverse cardiac events (MACE). All deaths were considered cardiac 
unless an undisputed non-cardiac cause was identified. Myocardial infarction (MI) and 
scaffold thrombosis were defined according to the Academic Research Consortium (ARC) 
definition. Any Target lesion revascularization (TLR) was defined as clinically driven if at 
repeat angiography a diameter stenosis >70% was observed, or if a diameter stenosis 
>50% was present in association with recurrent angina pectoris; objective signs of 
ischaemia (ECG changes) at rest or during exercise test, likely to be related to the target 
vessel; abnormal results of any invasive functional diagnostic test. 
Target lesion failure was defined as the composite of cardiac death, target vessel myocardial 
infarction, or ischemia driven target lesion revascularization. Major adverse cardiac events 
(MACE), defined as the composite of cardiac death, any re-infarction (Q or Non Q-Wave), 
emergent bypass surgery (CABG), or clinically driven target lesion revascularization (TLR). 
Target vessel failure (TVF) was defined as cardiac death, target vessel myocardial infarction 
(MI), or clinically driven target vessel revascularization (TVR). Delivery failure was defined 
as opening of scaffold from its cover and insertion into the guiding-catheter without final 
implantation. 
All potential events were adjudicated by a local independent Clinical Events Committee 
(CEC). 
356   |    Chapter 17
quantitative coronary angiography 
Quantitative coronary angiography (QCA) analyses were performed using the Coronary 
Angiography Analysis System (Pie Medical Imaging, Maastricht, Netherlands). 
The QCA measurements we performed pre and post BVS implantation. The 37 μm platinum 
radio-markers located at each end of the Absorb BVS aided in the localisation of the non-
radio-opaque scaffold for QCA. Analysed parameters included reference vessel diameter 
(RVD) - calculated with interpolate method - percentage diameter stenosis (%DS) and 
minimal lumen diameter (MLD). Acute gain was defined as post-procedural MLD minus 
pre-procedural MLD. The angiographic analysis were performed by three investigators 
(YI, YO and RD) who where extensively trained in an experienced core-lab (Cardialysis BV, 
Rotterdam, The Netherlands) 
A calcified coronary culprit lesion was defined as already reported(10) ‘readily apparent 
densities noted within the apparent vascular wall at the site of the stenosis.’ By qualitative 
assessment of the angiograms, target lesions were classified as severe (‘radioopacities 
noted without cardiac motion prior to contrast injection generally involving both sides of 
the arterial wall’), moderate (‘densities noted only during the cardiac cycle prior to contrast 
injection’), or none/mild (lesions other than severe and moderate calcified lesions). The 
Inter- and intra-observer variability in the qualitative analysis of coronary calcium on 
coronary angiograms have been already reported. (11)
To provide insights on the coronary bifurcation treatment with BVS we performed a full 
analysis of techniques and material used and we reported the occurrence of side-branch 
impairment, an end-point already reported in the literature as “side-branch trouble”(12) 
and defined as follow: at least 1 of the following procedural parameters: 1) Side-branch 
TIMI flow grade <3 after main vessel stenting; 2) need of guide-wire(s) different from the 
workhorse wire to rewire side-branch after main vessel scaffolding; 3) failure to rewire the 
side-branch after main vessel scaffolding; or 4) failure to dilate the side-branch after main 
vessel scaffolding and side-branch rewiring.
Statistical analysis
Categorical variables are reported as counts and percentages, continuous variables as 
mean ± standard deviation; p values were calculated with Fisher’s Exact test for binary 
variables, Wilcoxon’s Rank Sum test for continuous variables. Comparisons among 
multiple means were performed with analysis of variance (1-way ANOVA). A p value<0.05 
was considered statistically significant. Statistical analyses were performed using SPSS, 
version 15.0 for windows (IL,US).
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From September 2012 to July 2013 a total of 1529 percutaneous coronary interventions 
were performed in our center. A total of 180 patients have been enrolled in the present 
study, with 249 treated coronary lesions. A total of 1157 patients were treated with 
standard second generation drug eluting stents. The remaining cases were treated with 
bare metal stents, dedicated bifurcation stents, balloon angioplasty only or thrombectomy 
only. Baseline clinical characteristics of the patients implanted with bioresorbable devices 
compared with those of the patients implanted with second generation drug eluting 
metal stents are reported in Table 1. We observed that patients treated with bioresorbable 
devices were overall younger, more frequently smokers, and had a lower rate of prior 
myocardial infarction, PCI and CABG. Therefore, this patient population is slightly different 
from the general population treated with percutaneous coronary intervention in everyday 
practice. However, the observed differences are in line with the predefined exclusion 
criteria.
table 1. Baseline clinical characteristics.
Clinical characteristics N = 180 N=1157
Age 60.6 ± 10.6 66.1 ± 11.7 <0.001
Male n. (%) 134 (74.4%) 850 (73.5%) 0.69
Hypertension n. (%) 94 (52.2%) 661 (57.1%) 0.54
Hypercholesterolemia n. (%) 84 (46.7%) 504 (43.6%) 0.18
Diabetes n. (%) 32 (17.8%) 231 (19.9%) 0.80
Smoke n. (%) 99 (55.0%) 481 (41.6%) < 0.001
Peripheral vascular disease n. % 19 (10.6%) 101 (8.7%) 0.32
CVA n. (%) 14 (7.8%) 87 (7.5%) 0.73
Kidney disease n. (%) 11 (6.1%) 122 (10.5%) 0.06
Prior MI n. (%) 30 (16.7%) 305 (26.3%) 0.01
Prior PCI n. (%) 17 (9.4%) 358 (30.9%) < 0.001
Prior CABG n. (%) 0 (0.0%) 118 (10.2%) < 0.001
COPD n. (%) 11 (6.1%) 71 (6.1%) 0.81
History of heart failure n. (%) 10 (5.6%) 70 (6.0%) 0.74
CVA= cerebrovascular accident; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; 
COPD = chronic obstructive pulmonary disease. Data are expressed as mean ± standard deviation or number and 
proportion.
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Seventy-three patients (40.6%) showed multivessel disease. A total of 109 lesions (43.8%) 
were classified as type B2 or C, mean lesion length was 25.86 mm, bifurcation lesions with 
side-branch ≥ 2 mm were 54, a total of 119 lesion were defined with severe or moderate 
calcification and in 29 case was present a total occlusion. (Table 2)
table 2. Lesion characteristics.
Lesion characteristics N = 180, L= 249
Number of Diseased Vessel
One vessel disease 107 / 180 (59.4%)
Two vessel disease 61 / 180 (33.9%)
Three vessel disease 12 / 180 (6.7%)
Number of Treated Lesions per vessel (%)
0 lesion 1/ 249 (0.4%)
1 lesion 189 / 249 (75.9%)
2 lesions 54 / 249 (21.7%)
3 lesions 4 / 249 (1.6%)
4 lesions 1 / 249 (0.4%)
Lesion Location (%)
LAD 120 / 249 (48.2%)
LCX 55 / 249 (22.1%)
RCA 66 / 249 (26.5%)
DIAGONAL 7 / 249 (2.8%)
LMCA/Ramus 1 / 249 (0.4%)
AHA/ACC Lesion Classification (%)
A 38 / 249 (15.3%)
B1 103 / 249 (41.4%)
B2 63 / 249 (25.3%)
C 46 / 249 (18.5%)
Lesion Length (mm) 25.86 ± 13.64
Range min, max (mm) 5.32 - 80.01
Bifurcation Lesion n. (%) 54 / 249 (21.7%)
Total Occlusion (%) 29 / 249 (11.6%)
Calcification Lesion (%) 119/ 249 (47.8%)
Data are expressed as mean ± standard deviation or number and proportion.
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Lesion preparation was performed in a large part of the cases mainly through balloon 
predilatation (89.2%); rotational atherectomy was necessary in 4.8% of cases. Multiple 
scaffold implantation per lesion was allowed and often performed, (31.7%) up to the 
implantation of 5 scaffolds.
No scaffold dislodgment was reported. 
Bailout with drug eluting metal stents was performed in only 2 cases. Balloon post-
dilatation was performed in a remarkable percentage of cases (45.0%) with often a 
balloon/scaffold ratio > 1.0 (41.8%). (Table 3)
The overall device, procedure and clinical success rates per lesion, were respectively 
99.2%, 98.8% and 98.8%.
table 3. Procedural data per-lesion analysis.
Lesion characteristics L= 249
Number of Scaffold or stent – per lesion (%)
Average 1.41± 0.75
0 scaffold or stent 1 / 249 (0.4%)
1 scaffold or stent 169 / 249 (67.9%)
2 scaffolds or stents 61 / 249 (24.5%)
3 scaffolds or stents 10 / 249 (4.0%)
4 scaffolds or stents 7 / 249 (2.8%)
5 scaffolds or stents 1 / 249 (0.4%)
Overlapping  78 
Overlapping BVS-BVS 76
Overlap scaffolds diameters 3.5mm-3.5mm,n (%) 20 (26.3%)
Overlap scaffolds diameters 3.5mm-3.0mm,n (%) 15 (19.7%)
Overlap scaffolds diameters 3.5mm-2.5mm,n (%) 3 (3.9%)
Overlap scaffolds diameters 3.0mm-3.0mm,n (%) 15(19.7%)
Overlap scaffolds diameters 3.0mm-2.5mm,n (%) 15 (19.7%)
Overlap scaffolds diameters 2.5mm-2.5mm,n (%)  8 (10.5%)
Overlapping BVS-Metal 2 (2.6%)
Bailout scaffold/stent (%) – per lesion
with BVS 8 / 249 (3.2%)
with Metallic stent 2 / 249 (0.8%)
Pre dilatation (%) 222 / 249 (89.2%)
Type of predilatation balloon*
Non-compliant 16 / 203 (7.9%)
Semi-compliant 187 / 203 (92.1%) 
The usage of scoring (scoreflex or cutting) 9 / 219 (4.1%)
Average size of balloon 2.52 ± 0.36
Balloon / artery (pre RVD) Ratio < 1 (excluding total occlusion before procedure) 100 / 184 (54.3%) 
Balloon / scaffold ratio ≤1 198 / 202 (98.0%) 
Balloon 0.5mm smaller ≤ scaffold size 172/202 (85.1%) 
Max pressure 13.95 ± 2.86
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table 3. Continued.
Lesion characteristics L= 249
Use of other devices for lesion preparation 
Rotational Atherectomy 12 / 249 (4.8%)
Manual Thrombectomy 11 / 249 (4.4%)
Daughter Catheter 5 / 249 (2.0%)
Buddy wire 18 / 249 (7.2%)
Post dilatation (%) 112 / 249 (45.0%)
Type of postdilatation balloon**
Compliant 32 / 110 (29.1%) 
Noncompliant 78 / 110 (70.9%) 
Average size of balloon 3.27 ± 0.46 mm
Max pressure 15.58± 3.46
Balloon / Artery < 1 25 / 110 (22.7%)
Balloon > Scaffold size 46 / 110 (41.8%)
Balloon > Scaffold size+0.25mm 15 / 110 (13.6%)
Device Success per lesion (%) 247 / 249 (99.2%)
Procedure Success per lesion (%) 246 / 249 (98.8%)
Clinical Success per lesion 246 / 249 (98.8%) 
*Type of predilatation balloon is reported in a subgroup of 203 patients. ** Type of posdilatation balloon is reported in 
a subgroup of 110 patients. Data are expressed as mean ± standard deviation or number and proportion.
table 4. Quantitative coronary angiography analysis (QCA).
qCA data N = 180, L = 249
QCA pre-procedure 
RVD (mm) 2.63 ± 0.43
MLD (mm) 0.90 ± 0.35
% DS (%) 64.8 ± 14.5
Proximal Dmax (mm) 3.92 ± 8.28
Distal Dmax (mm) 2.89 ± 2.31
QCA Post-procedure In-scaffold
RVD (mm) 2.89 ± 0.42
DS (%) 17.6 ± 8.65
MLD (mm) 2.41 ± 0.41
Scaffold length 29.44± 15.71
Acute gain (mm) 1.51 ± 0.49
TIMI grade 2 2 / 249 (0.8%)
TIMI grade 3 247 / 249 (99.2%)
Data are expressed as mean ± standard deviation or number and proportion.
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QCA	analysis	
The mean pre-procedure reference vessel diameter (RVD) was 2.63 ± 0.43 mm, with a 
mean percentage diameter stenosis (%DS) of 64.8 ± 14.5% and a mean minimal lumen 
diameter (MLD) equal to 0.90 ± 0.35 mm. Post-procedure %DS was 17.60 ± 8.65 % with a 
mean MLD equal to 2.41 ± 0.41 mm reflecting a mean acute gain of 1.51 ± 0.49 mm. TIMI 
3 flow was observed in 99.2% of the final angiograms. (Table 4, Figure 1)
figure 1. Vessel and scaffold diameters.
Cumulative frequency distribution of the reference vessel diameter the proximal end distal diameter in relation with 
the scaffold nominal size implanted.
Bifurcation	Lesions	
A total of 54 lesions were located at the site of a bifurcation with a side-branch ≥ 2.0 
mm. In 51 cases a provisional side branch technique was used, in addition 1 T stenting, 1 
culotte, 1 T-stenting with small protrusion techniques were performed. In 18 cases branch 
wire protection was used, pre-dilatation and post-dilatation of the main vessel was often 
performed. Side branch dilatation post MV stenting was necessary in 18 lesions. A final 
TIMI flow <3 in the main vessels (MV) was observed in only one case, at the side-branch 
this was reported in 3 lesions. Failure to re-wire the side-branch was never reported but in 
one case the operator was unable to re-cross the scaffold with a small balloon of 1.5 mm 
in diameter. (Table 5) The overall of rate of side-branch impairment was 9.3% (5/54)
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table 5. BVS implantation in Bifurcation lesions.
Procedural characteristics  L=54
LAD 38
CX 12
RCA 4
Involvement of both SB and MV (Medina 111, 101, 011) 15 (27.8%)
1 Scaffold Technique 51 (94.4%)
Provisional T 51 (94.4%)
T-stenting 1 (1.8%)
Culotte 1 (1.8%)
TAP 1 (1.8%)
MV pre-dilatation 44 (81.4%)
MV post-dilatation 26 (44.4%)
SB pre-dilatation 6 (11.1%)
SB dilatation post MV Scaffolding 18 (33.3%)
Kissing balloon 3 (5.6%)
Proximal optimization technique 26 (44.4%)
Final MV TIMI flow <3 1 (1.8%)
Side-branch Timi flow <3 3 (5.6%)
Failure to rewire the SB 0 (0%)
Different wire from the workhorse to rewire SB after MV scaffolding 2 (3.7%)
Failure to dilate SB 1 (1.8%)
Composite of side-branch impairment 5 (9.3%)
Data are expressed as mean ± standard deviation or number and proportion.
Calcified	lesions
A total of 119 calcified lesions were treated with BVS ,33 with severe calcification, 86 with 
moderate calcification, (Figure 2) and compared with non-calcified lesions. Given a non 
significant difference in pre-procedure RVD, MLD and %DS no differences were observed 
after treatment between calcified and non calcified lesions in terms of MLD (Severe 
calcified 2.38 ± 0.38 mm, moderate calcified 2.41 ± 0.39 mm, non-calcified 2.42 ± 0.43 
mm; p=0.889), %DS (Severe calcified 20.3 ± 10.5 %, moderate calcified 17.8 ± 7.7%, non-
calcified 16.8 ± 8.6%; p=0.112) and acute gain (Severe calcified 1.36 ± 0.41mm, moderate 
calcified 1.48 ± 0.44 mm, non-calcified 1.56 ± 0.54 mm; p=0.109). These results were 
achieved with an overall higher use of buddy wires in calcified lesions (severe calcified 
18.2%, moderate calcified 9.3%, non-calcified 3.0%; p=0.016)
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Lesion preparation was more aggressive in calcified lesions with a higher use of rotational 
atherectomy (Severe calcified 18.2%, moderate calcified 4.7%, non-calcified 1.5%; p<0.001) 
and scoring balloons (Severe calcified 15 .2%, moderate calcified 3.5%, non-calcified 0.8%; 
p=0.001). Success rates were high in calcified vessels showing no significant differences 
when compare do non-calcified ones. Device success in severe calcified lesions was 97.0%, 
in moderate calcified 100% and in non-calcified 99.2%; p=0.251. (Table 6)
table 6. BVS implantation in calcified lesions.
Procedural characteristics Severe 
calciﬁcation
(L = 33)
Moderate 
calciﬁcation
(L =86 )
No 
calciﬁcation
(L =130 )
P value
Lesion preparation
Rotational Atherectomy ,% (n) 18.2% (6/33) 4.7% (4/86) 1.5% (2/130) <0.001
Scoring balloon ,% (n) 15.2% (5/33) 3.5% (3/86) 0.8% (1/130) 0.001
Daughter catheter ,% (n) 3.0% (1/33) 2.3% (2/86) 1.5% (2/130) 0.886
Buddy wire,% (n) 18.2% (6/33) 9.3% (8/86) 3.0% (4/130) 0.016
Average size of balloon 2.48 ± 0.38 2.55 ± 0.35 2.52 ± 0.36 0.702
Non-compliant balloon ,% (n) 13.3% (4/30) 9.5% (7/74) 5.1% (5/99) 0.276
QCA pre-procedure
RVD (mm) 2.51 ± 0.35 2.66 ± 0.43 2.64 ± 0.46 0.256
MLD (mm) 0.97 ± 0.40 0.92 ± 0.36 0.87 ± 0.34 0.358
% DS (%) 62.3 ± 13.5 65.0 ± 12.6 65.3 ± 15.7 0.592
Lesion length 36.11 ± 2.34 27.99 ± 1.54 22.11 ± 1.16 <0.001
QCA post-procedure
RVD (mm) 2.97 ± 0.38 2.93 ± 0.39 2.85 ± 0.46 0.244
MLD (mm) 2.38 ± 0.38 2.41 ± 0.39 2.42 ± 0.43 0.889
% DS 20.3 ± 10.5 17.8 ± 7.7 16.8 ± 8.6 0.112
Acute gain (mm) 1.36 ± 0.41 1.48 ± 0.44 1.56 ± 0.54 0.109
Device Success per lesion, % (n) 97.0% (32/33) 100% (86/86) 99.2% (129/130) 0.251
Procedure Success per lesion, % (n) 97.0% (32/33) 98.8% (85/86) 99.2% (129/130) 0.571
Clinical Success (per lesion), % (n) 97.0% (32/33) 98.8% (85/86) 99.2% (129/130) 0.571
Data are expressed as mean ± standard deviation or number and proportion.
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figure 2. Calcifi ed lesion.
Angiogram showing a long lesion in the RCA (panel A). IVUS pre-procedure (Panel a) shows at the MLA more than 
180 degrees superfi cial calcium (*). Panel B shows the angiogram after pre-dilatation (semi-compliant balloon 
3.0 x 20mm). IVUS (panel b) shows clear “cracks” in the calcium (arrowheads), reducing the plaque resistance, thus 
suffi  ciently prepared for BVS implantation. Panels C and c show respectively the result on angiogram and on IVUS 
after implanting a BVS 3.5 x 28mm. 
table 7. BVS implantation in Total occlusions.
 Occluded
(L =29)
Non-occluded
(L
 
= 220)
P value
QCA post-procedure 
RVD (mm) 3.01 ± 0.47 2.88 ± 0.41 0.103
MLD (mm) 2.51 ± 0.53 2.40 ± 0.39 0.163
% DS (%) 17.2 ± 9.4 17.7 ± 8.6 0.780
Acute gain (mm) - 1.51 ± 0.49 -
Procedural characteristics
Daughter catheter, % (n) 3.4% (1/29) 1.8% (4/220) 0.465
Buddy wire, % (n) 10.3% (3/29) 6.8% (15/220) 0.449
Type of fi rst wire (after recanalization)
Supportive 54.2% (13/ 24) 2.1% (4/195) <0.001
Non-supportive 45.8% (11/24) 97.9% (191/195) <0.001
Device Success after disobstruction per lesion, % (n) 100% (29/29) 99.1% (218/220) 1.0
Procedure Success after disobstruction per lesion, % (n) 100% (29/29) 98.6% (217/220) 1.0
Clinical Success after disobstruction per lesion, % (n) 100% (29/29) 98.6% (217/220) 1.0
Data are expressed as mean ± standard deviation or number and proportion.
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Total	Occlusions	
Vessels showing a total occlusion were 29. After vessel desobstruction total occluded 
vessel were treated with BVS achieving a fi nal MLD and %DS not diff erent from other 
lesion types (MLD: 2.51 ± 0.53 mm vs 2.40 ± 0.39; p=0.163; %DS: 17.2 ± 9.4% vs 17.7 ± 
8.6%; p=0.780), with a high rate of fi nal device success (96.6% vs 98.2%; p=0.465) and 
procedure success (96.6% vs 98.6%; p=0.393). To reach those results supportive wires 
were used much more frequently in occluded vessels (54.2% vs 2.1%; p<0.001). (Table 7, 
Figure 3)
figure 3. Chronic total occlusion and bifurcation.
Top panels show from left to right the angiograms pre-procedure, after recanalization and scaff old implantation (BVS 
3.0 x 28mm with the sequential post dilatation of the diagonal and the scaff old in the main branch) and 2-month 
follw-up with partial distal vessel positive remodeling. Characters a-c indicate the positions of the OCT cross-sections. 
OCT (St.Jude Lightlab Dragonfl y™) post procedure show distal a well deployed scaff old (Panel A), an well opened 
carina with the diagonal branch (Panel B *) and the overlap of the proximal marker with the septal branch (Panel C *). 
The 3D reconstruction (Intage realia™, Cybersystems, Tokyo, Japan) shows the opening of the struts at the carina with 
the diagonal branch. (Arrowhead bottom panel).
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figure 4. Chro nic total occlusion and bifurcation.
The angiogram top left shows the long lesion in the LAD. The mid-panel shows the markers of the two overlapping 
scaff olds (a & c distal BVS 3.0 x 28mm and b & d proximal BVS 3.5 x 18mm). The top right shows the fi nal result 
with the OCT cross-section positions indicated by a to d). OCT (St.Jude Lightlab Dragonfl y™) shows a well deployed 
scaff old. Panels B & C show the markers of respectively the proximal and distal scaff olds (*), indicating an overlap of 
approximately 1 mm. 
Long	Lesions 
In a total of 79 lesions (31.7%) more than one device was implanted (Figure 4). The mean 
lesion length treated with BVS was 25.86 ± 13.64 mm. The maximum lesion length covered 
by BVS was 80.01 mm. Overlapping of BVS with BVS was often performed with a total of 
76 overlapping scaff olds. The great majority (96%, 73/76) were performed using scaff old 
of the same diameter or with a maximum of 0.5 mm diff erence in nominal diameter. In 3 
cases a 3.5 mm scaff old was placed in overlap with a 2.5 mm device. 
Clinical	outcomes 
Survival data at 12 months after the procedure were available for 99.4 % of patients. A 
questionnaire was sent to all living patients with specifi c queries on re-hospitalization 
and cardiovascular events. For patients who suff ered an adverse event at another center, 
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medical records or discharge letters from the other institutions were systematically 
reviewed. General practitioners and referring physicians were contacted for additional 
information if necessary.
At 12-month follow-up all cause-death was reported in 3 cases. A total of 5 target lesion 
revascularizations and 4 non-target vessel revascularisations were reported. Four definite, 
scaffold thrombosis (ST) occurred within one year after index procedure; none of them 
was acute or sub-acute. Of note, one of those cases was meeting the ARC criteria for ST 
but no clear thrombus was observed by optical coherence tomography (OCT). In the 
remaining 3 cases, severe calcification, bifurcation lesion and long overlap were observed 
but BVS underexpansion was the factor that was present in all of them. 
D E S C R I P T I O N  O F  T h E  S C A F F O L D  T h R O M B O S I S  C A S E S 
Case 1 
A 59-year old male patient, smoker, with history of cerebrovascular accident and stable 
angina pectoris, was treated after predilatation on long lesion involving the ostial left 
anterior descending (LAD) and the bifurcation with the first diagonal (D1), using a BVS 3.5 
x 28mm. Despite a postdilatation was performed with a 3.5 non-complaint (NC) balloon 
at high pressure, the BVS remained under-expanded with an impaired flow in the first 
diagonal. At the day 111 post PCI the patient was re-admitted with NSTEMI, while being 
on DAPT, and angiographically was observed a total re-occlusion of the LAD beginning 
from the ostium. After predilatation a DES 3.5 x32mm was implanted. Of note, at day 
81 after the second PCI the patients was again re-admitted for instable angina pectoris 
caused by a re-occlusion also of the metal stent in the proximal LAD. The patients was 
treated with CABG.
Lesion key characteristics: Ostial	lesion,	long	lesion,	bifurcation,	impaired	side-branch	TIMI	flow	
and	BVS	underexpansion
Case 2 
A 69-year old male with history of dyslipidaemia and hypertension was admitted with 
NSTEMI. Angiographically was observed a long, severely calcified, chronic total occlusion 
(CTO) of the proximal and mid LAD with severe calcification and involvement of D1. After 
Predilatation, 2x 3.5 x 18mm BVS were implanted. The procedure was complicated by 
pinching of D1 and thrombus formation. Additional ballooning of the ostium of the side-
branch was performed, but at the end of the procedure remained BVS underexpansion 
and haziness in the mid LAD. Despite continued DAPT usage the patient developed at day 
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47 a non-Q wave MI due to definite scaffold thrombosis in the proximal LAD, which was 
treated with thrombectomy and DES implantation. 
Lesion key characteristics: CTO,	 long	 lesion,	 bifurcation,	 severe	 calcification,	 thrombus	
formation	and	BVS	underexpansion	
Case 3 
A 65-year old male patient, smoker, with history of hypertension was admitted with NSTEMI, 
due to a sub-occlusive lesion in the LAD located at the site of a tortuous trifurcation with 
the first and second diagonal. The initial TIMI flow was 1. After predilatation, a 3.0 x 18mm 
BVS was implanted and after postdilatation a TIMI III flow was achieved. At day 142 on 
DAPT the patient was re-admitted with NSTEMI. Angiographically a proximal BVS edge 
sub-total restenosis was observed with a distal TIMI flow 1. A DES stent 3.5 x38mm was 
deployed covering the BVS and a large proximal segment. Of note, this case was meeting 
the ARC criteria for stent thrombosis and was adjudicated as such by the CEC, but should 
be mentioned that an OCT performed before predilatation did not showed any clear 
intraluminal thrombus. 
Lesion key characteristics: tortuous	trifurcation	(no	thrombus	by	OCT)	
Case 4 
A 70-year old male, with severe peripheral vascular disease, diabetes mellitus, 
dyslipidaemia, hypertension, and reduced left ventricular function was admitted with 
stable angina pectoris. Angiography revealed, a long and severely calcified lesion mid 
LAD involving two bifurcations (D1 and D2). Aggressive preparation was performed 
with rotational atherectomy and high-pressure dilatations with NC and cutting balloons. 
Two overlapping BVS were placed with a quite long segment of overlap (5 mm). Despite 
extensive postdilatation under-expansion remained at the end of the procedure. Five 
months after index PCI, the patient underwent non-cardiac surgery. The antiplatelet 
therapy was interrupted (both aspirin and clopidogrel) and the patient developed 
a NSTEMI due to a scaffold thrombosis that was treated with balloon dilatation and 
eptifibatide. Unfortunately, the patient died few days later because of heart failure.
Lesion key characteristics: Severe	calcification,	bifurcation,	long	overlap,	no	antiplatelet	
therapy	and	BVS	underexpansion	
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D I S C u S S I O N 
The present investigation represents en evaluation of the feasibility of BVS implantation in 
everyday clinical practise reflected by in a wide range of coronary lesions subsets including 
bifurcations, calcified vessels, chronic total occlusions and long lesion in patients with 
stable coronary artery disease and acute coronary syndromes. At variance of previous 
reports we also aimed to provide a detailed description of procedural data en techniques 
that were used to allow the use of this novel device in challenging subsets. 
Bifurcation	lesions	
A common concern regarding this technology is the fact that implantation of the BVS 
in bifurcation lesions might result into side-branch compromise due to the thick strut 
nature of this device. In keeping with this concept, a recent study performed by our group 
showed that BVS deployment could be associated with an increased small (≤0.5 mm) side-
branch occlusion and a consequent increase of enzymes release after procedure.(13)
However, in the present report the effect of BVS implantation in what is commonly 
considered a bifurcation lesion (with a side branch ≥ 2 mm) was specifically investigated. 
Rewiring of the side-branch in those cases and consequent ballooning (mainly with small 
balloon 1.5-2 mm in diameter) of the SB ostium is feasible as we already reported(13) and 
safe also in terms of scaffold geometry and fracture.(14,15) In the present study side-
branch ballooning was performed in one third of the patients (33%, 18/54) with promising 
results. In majority of the cases this was done with sequential ballooning and proximal 
optimization technique (POT), kissing balloon only in 3 cases.
Taking into consideration the rates of TIMI flow < 3 in the main vessel or in the side-branch, 
the rate of failure to rewire the side-branch and failure to dilate the side-branch, the BVS 
performed at least as good as metallic stents according to historical data. (12)
In addition the rate of the composite endpoint of side-branch impairment (9.3%) was 
observed to be encouraging especially when compared with data recently reported by 
Burzotta et al. with rates of side-branch impairment in sirolimus and everolimus eluting 
stents respectively 16% and 11%. (12) These data are supportive of the concept that BVS 
could be used safely in bifurcation lesions with side-branch ≥ 2.0 mm with a single scaffold 
approach and could provide results similar to metallic stents.
Calcified	lesions	
A total of 119 calcified lesions with a considerable percentage of heavily calcified plaques, 
were treated with BVS. A large number of those lesions were located in diffusely diseased 
vessels with an overall mean treated lesion length of more than 36 mm (severe calcified 
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group). QCA analysis showed final MLD, %DS, acute gain and device, procedural and 
clinical success not different from non-calcified lesions. These results were obtained at 
the cost of a more aggressive lesion preparation with a considerable use of rotational 
atherectomy and scoring balloons. 
Such approach is needed to facilitate the delivery of the scaffold given its slightly higher 
profile compared with second generation DES. In addition appropriate lesion preparation 
could avoid scaffold under-expansion or need for aggressive post-dilatation. This strategy 
could be relevant also when using metallic stents. (16) Our data might suggest feasibility 
of BVS implantation in calcified vessels with optimal results given an adequate lesion 
preparation.
On the other hand, should be mentioned that many of the advantages proposed for BVS 
namely the restoration of the vasomotion and vessel physiology could be minimized in 
artery at a very advanced stage of the atherosclerosis process even considering the fact 
that patients with diffused calcified vessels have also a multivessel disease,(17) that might 
benefit from a temporary implant allowing future surgical treatments. 
Total	occlusions
Successful re-canalization of total occlusions has been previously associated with a 
significant improvement in angina symptoms (18,19) and complete coronary revascularization 
was demonstrated to have an important impact on long-term clinical outcomes.(20) 
Vessels with total occlusions have peculiar characteristics in terms of vascular remodeling; 
this is a dynamic process involving regulation of vascular cell migration and mitosis and 
apoptosis rates in response to several factors comprising blood flow and pressure, shear 
stress, circumferential stretch and wall tension.(21) Reduction or even more absence of 
blood flow in totally occluded vessels might promote negative remodeling and plaque 
growth; on the other hand restoration of flow could have an opposite effect.
Recently, Park J.J. and colleagues reported, at 6-month follow-up after successful total 
occlusion revascularization, a flow-dependent vascular remodeling process in human 
coronary arteries, associated with increases in lumen diameter, lumen area and external 
elastic membrane area.(22) This process was observed in a large part of treated vessels 
(69%) with a mean lumen diameter increase of 0.40 ± 0.34 mm. IVUS analysis of those 
vessels revealed that the amount of incomplete stent apposition increased significantly 
during 6 months in patients with positive remodeling and lumen area increase but not in 
those without lumen area increase. 
In this scenario choosing a metal stent based on the vessel diameter at the index procedure 
might lead to stent under-sizing.
Given this background a theoretical advantage of BVS implantation in patients with total 
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occlusion is the fact that it might allow at mid-term follow-up, after the loss of scaffold 
mechanical integrity, late lumen enlargement without late acquired malapposition, as at 
that time the remnants of the bioresorbable implant can follow the vessel remodeling.
Long	lesions	and	overlap	
In the present series several lesions were treated with more than one scaffold up to a 
maximum of 5 scaffolds for a maximum lesion length of 80 mm. Operators were advised 
to minimize the extension of overlapping segment using a marker-to-marker technique.
In the metal stent era, long segments treatment has been associated to an increased risk of 
stent thrombosis,(23-25) and could results in prevention of future surgical revascularisations. 
Both these issues could be overcome with the use of bioresorbable technologies and the 
introduction in the near future of bioresorbable scaffold with thinner struts could mitigate 
the effect of overlap on delayed vascular healing.
Clinical	outcomes	
The mid-term clinical outcomes of this study revealed a relatively reassuring safety profile 
of the BVS when used in a large range of lesion type and in patients with either stable 
symptoms or acute coronary syndromes. The event rate in this study is only minimal 
higher compared to the results in non-complex patients as treated in the randomized 
Absorb II and Absorb Japan studies (26,27). In other European registries like GHOST-EU and 
AMC registries (28,29) initial event rate is in general higher compared to the selected patients 
studies, although results seem to be better in more recent registries like the Milan registry 
(30) and ASSURE BVS (31) where more BVS specific implantation protocols where applied. 
Regarding the occurrence of scaffold thrombosis (ST), at variance of previous reports 
no acute or sub-acute STs were observed in the present investigation. This datum could 
be related to procedural characteristics including a meticulous lesion preparation pre 
BVS implantation and an advanced stage in learning curve of the operators in terms of 
BVS implantation. The revision of the cases with ST revealed that several factors might 
be associated with such event comprising severe lesion calcification, the presence of 
bifurcations, long overlap and antiplatelet therapy discontinuation. However, the factor 
that was particularly consistent was scaffold under-expansion. Previous investigations 
described stent underexpansion as an important predictor of ST with both bare metal 
stents and DES,(32-36) with an impact on the occurrence of ST that was hypostasized to 
be superior to stent malapposition.(37) The mechanisms behind these findings could be 
the fact that stent underexpansion translates into an abnormal shear stress. In particular 
increased radial transport of blood components and low wall shear stress, were described 
to promote platelet-dependent thrombosis.(38) In addition the impact of underexpansion 
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on shear stress could be potentiated by the presence of the BVS thick struts.(39) 
Although, given the small number of patients and event reported in the present study it is 
not possible to reach firm conclusions, our findings suggest that optimal BVS expansion, 
with lesion preparation and appropriate scaffold postdilatation, should be pursued given 
the possible relevant clinical implications. 
Limitations
The present report is an investigator initiated, single center, single arm study. The choice 
for BVS implantation was left to operator discretion, this could be source of selection bias. 
The absence of a comparator arm is limiting the interpretation of our data. The limited 
number of patients does not allow reaching firm conclusions on clinical outcomes. The 
mid-term follow-up is preventing the availability of information on long-term safety and 
efficacy.
CO N C Lu S I O N
The implantation of the everolimus eluting bioresorbable vascular scaffold in an expanded 
range of coronary lesion types and clinical presentations was observed to be viable with 
promising angiographic results and mid-term clinical outcomes. Larger studies with 
longer follow-up and a direct comparison with currently available metallic drug eluting 
stents are needed to fully evaluate the possible additional value of the bioresorbable 
technologies an all comers setting.
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A B S T R AC T 
Bioresorbable vascular scaffolds have been recently introduced as a novel paradigm 
for coronary artery disease treatment allowing temporary vessel support and drug 
delivery without long term coronary caging, potentially reducing the long-term 
limitation of metallic stents.
The scientific community have rapidly embraced this concept and bioresorbable 
devices have been introduced in clinical practice.
However, despite the fact that bifurcation lesions represent a large and challenging 
subset in the field of interventional cardiology, this subgroup of lesions have 
been avoided in the initial experience with bioresorbable scaffolds and clear 
recommendations on methodological approaches are lacking.
In the present report we describe the various techniques for bifurcation treatment 
with bioresorbable scaffolds and the theoretical advantages and disadvantages of 
this technology in different scenarios, with a glimpse to challenging subsets and 
possible complications.
Therefore, we aim to provide experience based insights and practical guidance for 
bioresorbable scaffold implantation in bifurcation lesions.
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I N T R O D u C T I O N 
Bifurcation lesions represent a technically challenging subset of percutaneous coronary 
interventions (PCI) accounting for 15-20% of all procedures (1,2). Despite the several 
technological revolutions in stent designs, PCI for bifurcation lesions is associated with 
worse clinical outcomes compared with non-bifurcation lesions(3). Bare metal stents 
(BMS) were associated with high restenosis rates irrespectively of the bifurcation 
technique adopted.(4-10) Drug eluting stent technology significantly reduced neointimal 
proliferation, restenosis rate and target lesion revascularization, yet clinical results 
remained inferior to non-bifurcations lesions.
In particular, the ostium of the side-branch was identified as the site most frequently 
affected by increased atherogenesis and restenosis.(11,12) In addition, bifurcation treatment 
was reported to be associated with an higher risk of stent thrombosis,(13,14) probably 
triggered by delayed vascular healing and incomplete neointimal coverage(15) 
Bioresorbable scaffolds were recently introduced as a novel paradigm for coronary artery 
disease treatment, potentially reducing the long-term limitation of metallic stents, such 
as vessel caging, permanent side-branch jailing and impairment of vasomotion.(16) The 
scientific community rapidly embraced and introduced this bioresorbable concept into 
clinical practice.
However, bifurcation lesions have been avoided in the initial experience with bioresorbable 
scaffolds and clear recommendations on methodological approaches are lacking.
The present report aims to provide experience based insights and practical guidance for 
bioresorbable scaffold implantation in bifurcation lesions.
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A P P R O AC h  TO  B I F u R C AT I O N  T R E AT M E N T, 
O N E -  O R  T W O - S C A F F O L D  S T R AT E G y 
The provisional 1-stent approach is the technique of first choice in the current era 
of bifurcation stenting. The main vessel is stented first and only if needed subsequent 
ballooning and stenting of the side-branch (SB) is performed (17-22) 
Dedicated research will reveal whether the same paradigm holds for the second-generation 
everolimus eluting bioresorbable vascular scaffold (BVS). In principle at least for the first 6 
months, the current BVS technology behaves like other metallic devices (revascularization, 
drug elution and vessels scaffolding), therefore supporting a generalization of metal 
stents results in bifurcation lesions also to this novel device. On the other hand, the strut 
thickness and the polymeric nature of the device allowing full bioresorption over time, 
differentiate the BVS from the latest generation drug eluting metal stents (DES).
The large BVS strut thickness (157 µm) results in a higher device profile, reduced 
deliverability and may predispose to more scaffold thrombosis. From a technical 
perspective, it may be more difficult to rewire through a previously deployed thicker 
strut device. Furthermore a two-stent technique typically requires final kissing balloon 
(FKB) inflation to optimize stent deployment and apposition and obtain adequate 
carina coverage. FKB may impose excessive mechanical stress to the polymeric scaffold 
that could eventually damage its integrity and impair long-term clinical outcome. All 
these considerations could suggest the provisional T-stenting as first choice also when 
implanting a BVS in bifurcation lesions. 
On the other hand, particular anatomical substrates such as large SB diameter with 
significant narrowing may justify a 2 stent/scaffold technique. This hypothesis, applied 
to metal stents, was tested in the recently presented Nordic Baltic IV study evaluating 
provisional approach vs 2 stent technique (mainly culotte) in bifurcations with SB ≥ 
2.75 mm and showing a trend towards improved short term outcomes in the 2 stent 
arm.(23) A similar concept was reported in the DKCRUSH-II study(24) evaluating true 
bifurcation lesions with a reference vessel diameter comprised between 2.5 and 4.0 in 
both branches and comparing double kissing crush (DK crush) or provisional stenting 
techniques, with a significant reduction of target lesion revascularization (TLR) and target 
vessel revascularization (TVR) in the DK crush group. An additional trial, the EBC II study 
comparing culotte vs provisional stenting in bifurcation with SB≥2.5 mm and significant 
disease is currently ongoing and could add further to our understanding on the indication 
for a complex approach in bifurcation lesions. 
In conclusion, a simple provisional T-scaffolding approach (Figure 1) could be the most 
appropriate in the majority of the bifurcation lesions (similarly as for metal stents). In 
selected cases with large side-branches, a 2-scaffold technique could be considered.
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figure 1. Flow chart of the Provisional T-scaffolding.
One-scaffold strategy 
In a one-scaffold strategy (provisional T-scaffolding) only the main vessel is treated with 
BVS implantation. Meticulous lesion preparation has an important role in facilitating an 
easy delivery of the device and optimal deployment; in the specific setting of BVS use, the 
adoption of predilatation with non-compliant balloons with a nominal size equal to the 
intended BVS and inflated at high pressure, may be a reasonable strategy.
Predilatation of the side-branch gives the obvious advantage of an increased SB ostium 
lumen before scaffolding and could reduce the diameter stenosis after scaffolding 
lowering the need for rewiring and ballooning. On the other hand predilatation of the SB 
may lead to ostial damage and dissection with an increased risk for bailout SB scaffolding. 
Currently available data on this topic report conflicting results with SB predilatation 
probably increasing the overall rate of target lesion failure(25) but potentially having some 
benefit in case of true bifurcation lesions.(26) 
When choosing the size of the BVS in bifurcation lesions, several models may be applied 
to understand the degree of distal diameter reduction in relation to the side-branch size 
and guide optimal BVS size selection (27-30).
The maximum diameter proximal to the bifurcation requires particular attention (31). To 
ensure adequate apposition in the proximal part of the bifurcation, the size of the BVS 
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should allow safe expansion up to the estimated proximal maximal diameter (Dmax). 
Given the reported long term safety and efficacy of minimal under-expansion of slightly 
oversized BVS in small vessels,(32,33), a low-pressure inflation of a BVS sized on the basis 
of the proximal Dmax, planning a subsequent proximal optimization (POT) could be a 
reasonable strategy. When using this approach initial low-pressure scaffold deployment 
should be considered a key factor to avoid distal edge dissection and bailout interventions. 
On this regard distal Dmax could be considered for scaffold sizing in case of minimal 
mismatch between the proximal and distal bifurcation segment, taking into account the 
possibility for an additional POT using up to 0.5 mm bigger balloons.
The proximal optimization technique, (34) a concept already reported for bifurcation 
stenting with metal devices, could have additional advantages with a thick strut device 
like the BVS. Reduction of proximal malapposition could lower the occurrence of scaffold 
thrombosis at the bifurcation site, in addition as the wider BVS strut might be associated 
with difficult SB re-wiring and ballooning, the oblique BVS shape after POT at the site of 
the SB ostium could facilitate re-crossing. 
figure 2. Proximal optimization technique (POT). Upper panel (A) a low pressure inflation of a BVS sized on the 
basis of the proximal Dmax ensure distal optimal apposition e low risk of distal dissection. Middle panel (B) proximal 
optimization with a non complaint balloon inflated on the basis of the proximal Dmax. Lower panel (C) final result 
after POT with an oblique BVS shape at the site of the side branch possibly facilitating re-crossing.
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Side-branch ballooning and Sequential ballooning 
In case of side-branch compromise, re-wiring the SB through the BVS struts should be 
attempted. Ideally such manoeuvre should be performed after the POT to minimize the 
chances of wire placement behind malapposed struts. The feasibility of side branch re-
wiring and side-branch ostium ballooning through the BVS struts has been previously 
reported.(35,36)
In a bifurcation phantom model, Ormiston et al.(37) deployed a 3.0 and 3.5 mm BVS in the 
main branch, and after rewiring inflated 2.0, 2.5 and 3.0 mm balloons up to 14 atm at the 
ostium of the SB. In those experiments, the 2.0 mm balloon did not cause any fracture. The 
2.5 mm balloon was associated with a 13% scaffold fracture and the 3.0 mm balloon 19%. 
In the same report SB dilatations with a 3.0 mm non-compliant balloon in a 3.0 mm scaffold 
up to 10 atm pressure were not likely to cause fractures whilst a similar strategy but with 
higher SB balloon pressures was associated with scaffold structure discontinuity.(37)
Also as expected with metal stents, the inflation of a balloon in the ostium of the SB could 
be associated with main vessel (MV) scaffold distortion and consequent malapposition 
opposite to the SB ostium and MV scaffold narrowing immediately distal to the SB. 
Therefore it is recommended to perform a second MV post dilatation in a sequential 
manner after SB ballooning (sequential ballooning).
Kissing Balloons
The strain created by the overlapping kissing balloons can fracture the BVS circular rings 
potentially extending to the entire length of the scaffold segment where the 2 balloons 
are overlapping translating into a relevant scaffold fracture (scaffold “unzipping”). (38)
An alternative strategy is the adoption of a mini kissing balloon post dilatation (mini-
KBPD) approach also named “snuggle balloon dilatation”.(39) With this technique, the 
final optimization of the bifurcation is performed with simultaneous dilatation of the 2 
balloons but with a minimal protrusion in the MV of the SB balloon. 
Practically the snuggle technique requires placement of the proximal marker of the SB 
balloon in the MV just proximal to the SB ostium.(37) The SB balloon is inflated first. This 
technique may safely enlarge the SB ostium with minimal MV scaffold distortion. Of note, 
the risk of BVS fracture increased exponentially for pressures higher than 5 atm (37). 
In aggregate, we suggest to avoid true kissing balloon inflations whenever possible and 
prefer POT in combination with sequential ballooning and recommend confirmation of 
the final result with intravascular imaging.
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Need for bailout SB Scaffolding/stenting
Both metallic stents and additional BVS can be considered for bail-out techniques such 
as T-stenting or T-stenting and small protrusion (TAP). BVS has a higher profile compared 
to contemporary metallic DES, which may affect crossing the BVS towards the SB and 
mandate aggressive SB ostium dilatation with increased risk of MV BVS damage. 
Meticulous sizing and BVS positioning in the SB is crucial to avoid excessive strut 
protrusion in the MV. Interestingly, TAP with BVS may have the unique advantage of a 
complete coverage of the SB ostium with a complete disappearance of the protruding 
struts over time.
In conclusion in case of bailout SB stenting with reverse T-stenting or TAP, complete 
bifurcation coverage with BVS may be challenging and sometimes use of metal DES may 
technically be the ultimate solution.
T W O - S C A F F O L D  A P P R O AC h
A 2-scaffold technique may be needed in selected bifurcation anatomies.
The same principles that are valid for metallic stents could be applied to the bioresorbable 
technology (BVS) with some important caveats.
Culotte technique
The culotte technique has been fully described previously.(2) In brief the SB is scaffolded 
first, followed by rewiring the MB through the scaffold and performing balloon inflation. 
Subsequently a 2nd scaffold is inflated through the first scaffold into the MB. The SB is then 
rewired and the case is completed with kissing balloon inflations. 
The Culotte technique implies double scaffold coverage in the proximal segment of the 
main vessel and in principle results in complete carina coverage.(40) The culotte technique 
fits best when there is only a limited size mismatch between the branches.
This technique performed with metal stents has been evaluated in several studies. (17,40-43) 
Feasibility of the culotte technique with BVS has been shown.(44) Theoretically BVS could 
be appealing with this technique since over time the scaffolds will resorb, avoiding a 
permanent multilayer of metal in the coronary artery, leaving a smooth carina and virtually 
eliminating persistent device-malapposition or delayed healing at the side branch ostium. 
However, from a purely technical point of view the implantation procedure per se could 
be hindered by the relatively high crossing profile of the BVS, reasonably requiring an 
optimal back-up guide catheter, highly supportive wires and a relatively aggressive lesion 
preparation and initial scaffold dilatation. In addition although a strategy of “mini-culotte” 
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should be applied, the proximal part of the vessel will be covered by 2 layer of a thick 
strut polymeric material that could increase the risk of delayed vessel healing and scaffold 
thrombosis. 
Finally the kissing balloon recommended when performing culotte with metal stents, will 
determine cells opening, distortion and mechanical stretch of both implanted devices 
increasing the probability of scaffold fracture.
Given these considerations and in absence of solid clinical data, the culotte technique 
with the current generation of bioresorbable devices is not recommended and should be 
performed only if strctly necessary with extreme caution. We recommend meticulous case 
preparation including 1) appropriate supportive guiding catheters and guidewires; 2) 
aggressive lesion preparation with the use of adequately sized balloons in main and side 
branches; 3) Minimization of the proximal overlap 4) POT; 5) sequential final ballooning 
avoiding classical FKB (snuggle technique can be a valid alternative, avoiding high 
pressures); 6) Confirmation of the final result with intravascular imaging such as optical 
coherence tomography.
figure 3. Culotte technique performed with bioresorbable vascular scaffolds in a chronically occluded vessel.
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Crush techniques 
The crush technique has been extensively evaluated with metal stents, with various 
procedural modifications like double crush, mini-crush and double kissing crush 
techniques. 
The common denominator is the crushing and deformation of the proximal protruding 
segment of the side branch scaffold, that is implanted first, followed by a second scaffold 
implantation in the main vessel. 
Thereafter, the side branch needs to be rewired through the cells of the two devices 
to complete the procedure with a final kissing balloon (Figure 4). Currently, even with 
metals stents, a mini-crash approach is largely recommended over the classic crush to 
minimize the extent of multiple layers in the main vessel. In the context of BVS, the impact 
of crushing the polymeric struts has been preliminary explored in bench testing showing 
technical feasibility of this approach.(45) 
figure 4. Crush technique performed with bioresorbable vascular scaffolds.
However, the crush technique implies the presence of 3 overlapping layers of 157 µm 
each in the proximal vessel, a condition that is prompt to malapposition, underexpansion, 
long-term uncoverage and increased risk of thrombosis. This background could be even 
worsened by the possible occurrence of areas of malapposition between the carina and 
the 2 scaffolds mainly due to the geometrical deformation of the SB scaffold.(45) 
The use of a mini-crush technique would reduce the amount of polymeric material 
crushed against the vessel wall and it should be preferred to a classical crush. 
The DK-crush has never been reported with BVS. Although this technique could bring 
some advantages when performed with metal stents (easier re-crossing and expanded 
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SB ostial area) with BVS the following issues arise; 1) the above mentioned limitation of 
crush per se, 2) the mechanical stress of the kissing balloon with theoretical increased risk 
of scaffold fracture. 
Given those considerations, at the current status of the art in bioresorbable technologies 
there is common agreement among authors not to favour crush techniques with BVS. 
T-stenting
The T-stenting technique provides a good solution in case of bifurcation with angle close 
to 90 degrees. A fundamental aspect of this technique is to precisely deploy the side-
branch scaffold to ensure optimal SB ostial coverage. 
To achieve such results, radiopaque markers at each scaffold edge could be used as 
reference (43).
figure 5. T-scaffolding performed in a bifurcation lesion with a favourable angle. 
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(In the everolimus eluting bioresorbable vascular scaffold, the proximal polymeric ring of 
a 3.5-mm BVS protrudes 1.4 mm from the proximal radiopaque platinum marker when 
crimped and 1mm when the scaffold is deployed).
A practical approach would be to align the proximal marker to the carina. This will warrant 
sufficient protrusion into the main branch to allow for complete coverage of the bifurcation 
and avoiding excessive protrusion into the main vessels that would convert the technique 
into a mini-crush.(46) The final result should be optimized by POT. Intravascular imaging 
might be indicated to confirm results.
v-stenting
The V-technique implies the delivery and simultaneous implantation of two devices. 
One scaffold is advanced in the side branch, the other in the main branch creating a new 
proximal carina.(47-49) 
The V-technique is particularly suitable for bifurcations with medina classification 0,1,1 
and classically regarded as appropriate for bifurcations with a very proximal location in 
the coronary tree (i.e. ostial left anterior descending and circumflex). Bifurcation angles 
less than 90 degrees are preferable for this approach given the fact that the 2 scaffolds are 
forming a new carina. When this new carina is considerably (≥ 5 mm) extended proximally, 
this technique has been named as simultaneous kissing stents/scaffolds (50) 
figure 6. Left main bifurcation lesion treated with V-scaffolding technique. Distal left main lesion (A), predilatation 
(B), simultaneous kissing Scafoold implantation (C), final result (D). Optical coherence appearance of the polymeric 
neocarina (mid panel).
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If executed in a medina 0,1,1 lesion, struts will not jail the access to either of the two 
branches with no need for strut re-crossing. Intravascular imaging might be indicated to 
confirm results. 
T h E  R O L E  O F  I N T R AVA S C u L A R  I M AG I N G 
Intravascular imaging, both IVUS and OCT contributed to our understanding of the 
mechanisms of side-branch compromise after bifurcation stenting.(51-54) OCT with its higher 
resolution may have a specific role in guiding bifurcation treatment with bioresorbable 
technologies.(55,56)
 Invasive imaging may provide detailed insights on plaque morphology and distribution 
pre intervention(57) and may elucidate the concept of carina shift. 
OCT may guide SB rewiring, a classification system was introduced taking into account 
the different compartments the ostium of the SB could be divided into when implanting 
BVS with potential implications on neointimal growth and strut coverage and providing 
a detailed guide for optimal SB re-wiring specifically when using BVS.(58) After main vessel 
treatment, OCT guidance for distal stent/scaffold cell re-crossing towards the SB has 
figure 7. Accurate assessment of SB ostia from one single MB pullback obtained with a reconstruction of the cross-
sections perpendicular to the SB centreline.
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been demonstrated to be feasible and to reduce the rate of strut malapposition at the 
SB ostium.(59) In addition, the recent development of software for three-dimensional (3D) 
OCT reconstruction enables formal spatial characterisation of the strut position at the site 
of the SB ostium.(52,60)
Post scaffold implantation OCT is a reliable tool to assess malapposition, underexpansion, 
scaffold fractures, struts protrusion in the MB and the need for additional manoeuvres (i.e 
post dilatation, POT, etc.). 
Although the use of intravascular imaging should not be considered mandatory, we 
recommend invasive imaging to achieve optimal results, especially during the initial 
phase of the BVS implantation learning curve, or in case of complex procedures involving 
2-scaffold techniques. It should be acknowledged that OCT imaging might disclose 
defects in implantation such as scaffold fractures that are not yet clearly codified in terms 
of management. 
Ideally, a comprehensive evaluation of bifurcation treatment with a 2-scaffold technique 
implies OCT pullbacks from both branches. The QAngioOCT 1.0 (Medis Specials Bv, Leiden, 
the Netherlands) is a new software tool to reconstruct the cross-sections perpendicular 
to the SB centreline to obtain more accurate assessment of SB ostia from one single MB 
pullback (61,62)
C h A L L E N G I N G  S u B S E T S 
Left main 
Limited data exists on the use of everolimus eluting vascular scaffolds implantation in the 
left main (LM) coronary artery.(63-65). The current limited size availability of BVS with the 
largest device being a 3.5 mm with a maximal postdilatation limit at 4.0 mm has drastically 
limited the use of this scaffold for left main disease. In addition the potential need for SB 
dilatation with large balloons ≥2.5 mm (i.e. towards the LCX artery), might translate into 
scaffold disruption.
Furthermore, a 2-scaffold strategy could imply the presence of multi-layered thick scaffold 
struts or their protrusion in the distal LM (in case of TAP), with a theoretical increased risk 
of thrombosis.
As previously hypothesized,(66) a LM lesion not involving the ostium of the LCX may be 
more suitable for BVS implantation. 
Intravascular imaging should be considered to elucidate size, plaque burden and 
distribution in both MB and SB .(66) 
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The introduction of novel devices such as the novolimus eluting coronary scaffold (67) with 
a wider safety margin for expansion and thinner struts and/or the next generation BVS 
could improve the usage and the treatment options with bioresorbable technologies in 
left main coronary artery disease. 
In-stent restenosis 
Limited data are currently available on the use of bioresorbable devices for treatment of 
in-stent restenosis (ISR).(68-70) 
Conceptually the implantation of a bioresorbable scaffold in such lesions could be 
appealing, as it would ensure a higher vessel scaffolding and longer drug delivery 
compared with simple balloon or drug eluting balloon angioplasty, avoiding at the same 
time the permanent multiple layer of metal in the coronary artery. For this indication 
we would recommend proper pre-dilatation and meticulous scaffold evaluation after 
implantation by invasive imaging. 
Thrombotic lesions 
Intracoronary thrombus, with the concomitant presence of a relevant side branch 
at the lesion site, is not an unusual finding during acute coronary syndromes and the 
feasibility of BVS implantation in thrombotic lesions has been recently reported.(71-73) Initial 
thrombectomy may improve visualization of the target vessel and thus sizing. Again a 
single-scaffold provisional approach should be the first choice. Bioresorbable scaffolds 
may have particular features appealing for thrombotic lesions: 1) Wider struts may 
reduce thrombus dislodgment and distal embolization;(71) 2) The so-called self-correction 
property of the recently introduced novolimus eluting coronary scaffold (67) could limit 
under-sizing and malapposition. 
CO M P L I C AT I O N S 
Abrupt side-branch closure 
Initial concerns were raised regarding the fact that implantation of bioresorbable scaffolds 
in bifurcation lesions might result into a higher side-branch impairment, compared to 
metallic stents, due to the presence of thick struts in front of the SB ostium. In keeping 
with this concept, BVS deployment seemed to be associated with more small (≤0.5 mm) 
side-branch occlusions and consequent cardiac enzyme release after the procedure.
(74) Whether this finding also holds when applied to what is commonly considered a 
bifurcations lesion (with a side branch ≥ 2 mm) is unsettled.
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Rewiring of the side-branch in those cases and consequent ballooning (mainly with an 
undersized balloon 1.5-2 mm in diameter) of the SB ostium is feasible and safe also in 
terms of scaffold geometry and fracture.(37,45) 
Scaffold fracture 
Although the structural discontinuity of the polymeric struts at a later stage is a 
programmed fate of the scaffold as part of the bioresorption process, scaffold disruption 
during the index procedure is an iatrogenic phenomenon that is associated with clinical 
events. 
The identified reason for scaffold fracture during implantation is the overexpansion 
beyond the safety limits of the device. Therefore postdilatation with bioresorbable 
scaffolds should be performed with a balloon no larger than 0.5 mm above the nominal 
scaffold diameter. Dilatation of the SB ostium can be safely performed with 1.5 mm or 2.0 
mm balloon. The risk of scaffold damage increases with 2.5 mm and 3.0 mm balloons at 
high pressure.(37) Kissing balloon techniques might lead to relevant scaffold damage. 
figure 8. Scaffold fracture after kissing balloon.
Sequential ballooning and the snuggle technique may be more appropriate with 
bioresorbable scaffolds.
The clinical impact of scaffold fracture and how to approach it when discovered is unclear. 
In a recent post hoc analysis of the ABSORB Cohort B study, the reported incidence of 
acute scaffold disruption was low, (2 cases, 3.9%), yet associated with a target lesion 
revascularization (TLR) at 1 month in 1 patient.(75) 
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Scaffold disruption diminishes its local support to the vessel wall and the presence of struts 
floating in the lumen could induce flow disturbance triggering small thrombus formation.
(75,76) Novel bioresorbable devices with wider safety limits in terms of overexpansion are 
currently being tested.(67)
Dissections
Main vessel dissection Bioresorbable scaffolds implantation demands appropriate lesion 
preparation, which may predispose to coronary dissection due to balloon dilatation. 
Optimal scaffold coverage of the dissected segment is thus mandatory. In particular 
remaining edge dissections after stenting have been associated with an increased risk of 
stent thrombosis in the early phases after implantation.
Side branch dissection When treating bifurcation lesion a common complication is 
side-branch impairment after provisional scaffolding of the main vessel. Subsequent 
SB ballooning may be associated with SB dissection prompting a bailout treatment 
(T-stenting or T-stenting and small protrusion). The high BVS profile may impair proper 
SB access with additional bioresorbable scaffolds. In such cases a hybrid approach with a 
metallic stent in the side-branch could be considered.
F u T u R E  P R O S P E C T I V E 
Implantation of bioresorbable devices in coronary bifurcation lesions results in 
the formation of a smooth neointimal membranous neocarina and complete strut 
disappearance facing the SB ostium over time (77). However, the presence of struts at the 
ostium of the SB can also lead to the formation of endoluminal neointimal bridges as 
results of strut coverage. Concerns about long-term SB patency(58) were refuted as these 
tissue bridges progressively thinned over time suggesting a probable benign nature of 
those formations.(78) This concept also holds true for 2-scaffold techniques implying the 
presence of struts in the vessel lumen such us the TAP technique.
Future improvements in the bioresorbable technology are thinner struts with less 
polymeric material at the site of the SB ostia, with easier scaffold delivery and potentially 
improved vascular healing. 
394   |    Chapter 18
CO N C Lu S I O N
A one-scaffold strategy, namely provisional T-scaffolding with meticulous lesion 
preparation and proximal optimization should be considered the strategy of choice for the 
vast majority of the cases. In selected cases, a two-scaffold approach could be considered 
with intravascular imaging representing a useful tool for procedural optimization. Future 
technical improvement of the bioresorbable scaffolds could facilitate the expanded use of 
these devices in bifurcation lesions.
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A B S T R AC T
Aims The bioresorbable vascular scaffolds (BVS) represent a novel therapeutic 
option for the treatment of coronary artery diseases. The objective of this study 
is to evaluate the feasibility and clinical outcomes following BVS deployment in 
complex chronic coronary total occlusions (CTO).
Methods and Results The present report is a multi-centre registry evaluating 
results after BVS implantation in challenging CTOs lesion defined as J-CTO score≥2 
(difficult or very difficult). 
A total of 105 patients were included in the present analysis. The mean J-CTO score 
was 2.61 (difficult 52.4%, very difficult 47.6%). Device-success and procedural-
success were 98.1% and 97.1% respectively. Retrograde approach was used in 
25.7% of the cases. After wire-crossing predilatation was performed in all cases with 
a mean predilatation balloon diameter of 2.69 ± 0.32 mm. The mean scaffold length 
was 59.75±25.85 mm, with postdilatation performed in 89.5 % of the cases and a 
mean postdilatation balloon diameter of 3.35±0.44 mm. Post-PCI minimal lumen 
diameter was 2.50±0.51 mm, percentage diameter stenosis was 14.53±10.31 %. 
Multislice CT scan was performed in a subgroup of patients (32.4 %) at 6-month post 
index-procedure and only in 2 cases was observed scaffold restenosis. At 6-month 
follow-up the MACE rate was 3.1%, with one case of late scaffold thrombosis at 47 
days after index procedure. No case of mortality occurred.
Conclusions The present report suggests feasibility of BVS implantation in complex 
CTO lesion, given adequate lesion preparation and post-dilatation, with good 
acute angiographic results and mid-term clinical outcomes. 
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I N T R O D u C T I O N
Successful recanalization of chronic total occlusions (CTO) by percutaneous coronary 
intervention (PCI) has been associated with angina relief, improved left ventricular 
function,1-3 reduction in the rate of myocardial infarction and coronary artery bypass 
grafting with an overall improved patient survival,4-10 even in patients with well-developed 
collateral circulation.10 
However, despite the recent advancement in techniques and materials, success rate for 
PCI in CTO is significantly lower compared to other lesion subsets11, 12 and although the 
presence of CTO have been reported in a remarkable percentage of the patients with 
coronary artery disease undergoing elective angiography13, 14 this lesion subset represents 
only a minority of the target lesion treated with PCI.14, 15 In addition, CTOs are often long 
lesions requiring the implantation of multiple metallic stents resulting in a “full metal 
jacket” treated artery,16 potentially increasing the risk of thrombosis and restenosis.17 
Furthermore, many patients with CTO show extensive coronary disease, requiring 
multivessel revascularization,5, 6, 8, 18 potentially benefiting from bypass graft surgery.
Given this background, the introduction of bioresorbable vascular scaffolds provides 
a novel therapeutic option for the treatment of chronic total occlusions, allowing 
revascularization without permanent caging of long coronary segments, potentially 
reducing the long term events related to the presence of metallic stents and maintaining 
the option for future surgical revascularizations.
Bioresorbable technologies have shown so far promising results in relatively simple 
coronary lesions,19, 20 but there are very limited data and experience on the use of BVS 
in complex scenarios, especially in CTO lesions. Initial experience in this subgroup 
was reported in limited cohorts21-23 with no specific evaluation of BVS performance in 
challenging CTO lesions. 
Therefore, the objective of the present study is to evaluate the feasibility and mid-term 
BVS performance after implantation in coronary chronic occluded vessels presenting 
characteristics likely to make the procedure challenging according to the J-CTO score.24 
M E T h O D S  
This is a multicentre single arm study conducted to evaluate the feasibility, procedural 
results and mid-term performance of the Absorb BVS (Abbott Vascular, Santa Clara, CA, 
USA) for the treatment of patients with complex CTO lesions.
Enrolled patients were male or female subjects presenting with silent ischemia, stable 
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angina pectoris or acute coronary syndromes, candidates for percutaneous treatment 
of coronary CTO lesions. Lesion difficulty was graded according to the J-CTO score, 
lesions defined as to be “easy” (J-CTO score 0) or at intermediate difficulty (J-CTO score 
1) were excluded from the analysis and only complex cases defined as those with J-CTO 
score of ≥2 (difficult or very difficult)24 were evaluated. Exclusion criteria comprised 
contraindications to antiplatelet medication, maximal vessel diameter > 4 mm, female 
patient with childbearing potential or currently breastfeeding and acute ST-segment 
elevation myocardial infarction.
Study device
The study device is the second generation Absorb BVS which is a balloon expandable 
scaffold with a polymer backbone of Poly-L lactide Acid (PLLA) coated with a thin layer of a 
1:1 mixture of an amorphous matrix of Poly-D and L lactide acid (PDLLA) polymer, eluting 
100 micrograms/cm2 of everolimus. Approximately 80% of the drug is eluted within the 
first 30-days. Two radiopaque platinum markers positioned at the ends of the scaffold allow 
for accurate visualization of the radiolucent Absorb BVS during angiography. Both PLLA 
and PDLLA are fully bioresorbable. The polymers are degraded via hydrolysis of the ester 
bonds, and the resulting lactate and its oligomers are quickly transformed to pyruvate 
and metabolized in the Krebs energy cycle. Small particles, less than 2μm in diameter, 
have also been shown to be phagocytized and degraded by macrophages. According to 
preclinical studies, the time for complete bioresorption of the polymer backbone is 2 to 
3 years.
Study Procedure
All patients underwent PCI according to standard practice.25, 26 Vascular access and either 
antegrade or retrograde approach (Figure 1, Figure 2,) were determined depending on 
anatomy and at operator discretion. Vessel sizing pre BVS implantation was conducted 
after intracoronary injection of nitroglycerine and only after confirmation of successful 
wire crossing into the true lumen either by contrast injection or intravascular ultrasound 
(IVUS). The Absorb BVS was deployed gradually in stepwise increments of 2 atm every 
5 seconds.27 If more than one BVS was necessary, they were implanted from the distal 
to the proximal part of the target vessel in a minimal marker-to-marker overlapping 
manner. IVUS was performed mainly for procedural guidance. After implantation, optical 
coherence tomography (OCT) was performed in a patient subgroup of 10 patients to 
assess scaffold expansion and incomplete strut apposition (ISA). 
All patients were placed on a treatment regime of dual antiplatelet therapy for at least 12 
months followed by lifelong aspirin.
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figure 1. Successful implantation of bioresorbable vascular scaffolds using an antegrade strategy.
Occlusion length was 29.7mm and J-CTO score was 3. The lesion had a blunt stump (white star) with good distal 
landing zone (black star) (Panel A). Successful crossing was achieved with antegrade approach and confirmed with 
antegrade contrast injection (Panel B). Predilation (Panel C) was performed with a non-compliant 3.0mm balloon. 
Two BVS 3,5 x 18 mm and one 3.0 x 28mm were implanted in overlap (Black arrow) (Panel D). Final snuggle kissing 
balloon dilation was performed at the bifurcation (Panel E) with good angiographic result (Panel F). Optimal scaffold 
expansion and apposition was seen on Optical Coherence Tomograpy (OCT) post deployment. MLA- Minimal lumen 
area; MSD- Minimum scaffold diameter.
figure 2. Successful implantation of bioresorbable vascular scaffolds in a right coronary artery with a chronic total 
occlusion using a retrograde strategy.
The lesion had a blunt stump (white star) with good distal landing zone (black star) (Panel A). Good septal collaterals were 
seen from contralateral contrast injection. Successful crossing was achieved with a Conquest ProTM wire on CorsairTM 
microcatheter support (Panel B and C). Predilation (Panel D) was performed before scaffolds deployment (two BVS 3,5 x 
28mm and one 3.0 x 28mm in an overlap) (Panel E) with good angiographic result (Panel F).
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figure 3. BVS implantation in a calcified chronic total occlusion using an antegrade strategy.
 The lesion had a blunt proximal stump and multiple calcifications (marked *) (Panel A). J-CTO score was 2. Successful 
wire crossing was achieved with antegrade approach and confirmed with antegrade contrast injection (Panel B). 
Predilation was performed with a 3.0 x 20 mm semi-compliant balloon at maximum inflation pressure of 16 atm 
(Panel C). Panel D shows the left anterior descending artery after predilation BVS before implantation. Two scaffolds 
(BVS 3.5 x 28mm and 2.5 x 28mm were deployed in overlap) and postdilated with a non-compliant balloon 3.5 x 
12mm (Panel F) with good final angiographic result (Panel G- dashed lines indicating scaffolds location)
figure 4. Subintimal BVS implantation.
Final result at the index procedure after subintimal tracking, true lumen re-entry and subintimal BVS implantation 
(Panel A). 2-year angiographic appearance (Panel B) with an in-scaffold restenosis (circled area). Panel D and E long-
term vascular healing after BVS subintimal implantation. Panel C in-scaffold restenosis. MSD- Mean scaffold Diameter 
MLA- Mean lumen area.
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quantitative coronary angiography
Quantitative coronary angiography (QCA) analyses were performed using the Coronary 
Angiography Analysis System (Pie Medical Imaging, Maastricht, Netherlands). The QCA 
measurements we performed pre and post BVS implantation. Angiographic views with 
minimal foreshortening of the lesion and limited overlap with other vessels were used. 
Pre-procedure QCA analysis was performed as proximally as possible from the occlusion 
(in case of a side branch, distally to the most proximal take off of the side branch) as 
already described.28 For each lesion, the following QCA parameters were measured in 
diastole: minimal lumen diameter (MLD), reference vessel diameter (RVD), percentage of 
area stenosis, and occlusion length. For each lesion, was computed the J-CTO score which 
has been shown to correlate well with lesion complexity and procedural outcomes.
OCT image acquisition and analysis
The C7 system or the Ilumien Optis system and the corresponding DragonFly or DragonFly 
Duo imaging catheters (St. Jude Medical, St Paul, Minneapolis, Minnesota) were used for 
image acquisition. The OCT catheter was advanced distal to the treated segment, and an 
automated pullback was performed at 20mm/s with simultaneous contrast injection at 
a rate of 3 to 4 ml/s using a power injector. Two sequential pullbacks were performed to 
enable assessment of the entire scaffolded/ stented segment when required.
The OCT measurements were performed offline using the QCU-CMS software, (Medis 
Medical Imaging Systems, Leiden, The Netherlands). Analysis was performed at 1-mm 
intervals within the entire scaffolded segment and proximal and distal edge segments. 
Lumen and scaffold area and diameter measurements were performed in the region 
of interest, as appropriate, (Figure 4) using standard methodology for the analysis of 
bioresorbable scaffolds.28-30 Eccentricity index and Symmetry index were additionally 
calculated as previously reported.31-33 
Study deﬁnitions
Device Success was defined as successful BVS implantation with the attainment of 
<30% final in segment residual stenosis by angiographic visual estimation after Absorb 
BVS implantation. Procedure Success was defined as device success and no major peri-
procedural complications (Emergent CABG, coronary perforation requiring pericardial 
drainage, residual dissection impairing vessel flow – TIMI-flow II or less). Clinical success 
was defined as procedural success and no in-hospital major adverse cardiac events 
(MACE). All deaths were considered cardiac unless an undisputed non-cardiac cause was 
identified. Myocardial infarction (MI) and scaffold thrombosis were defined according to 
the Academic Research Consortium (ARC) definition.34 Any Target lesion revascularization 
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(TLR) was defined as clinically driven if at repeat angiography a diameter stenosis >70% 
was observed, or if a diameter stenosis >50% was present in association with recurrent 
angina pectoris; objective signs of ischaemia (ECG changes) at rest or during exercise 
test, likely to be related to the target vessel; abnormal results of any invasive functional 
diagnostic test.
Major adverse cardiac events (MACE) was defined as the composite of cardiac death, any 
re-infarction (Q or Non Q-Wave), emergent bypass surgery (CABG), or clinically driven 
target lesion revascularization (TLR). 
Statistical Analysis
Categorical variables are reported as counts and percentages and continuous variables 
are reported as mean ± standard deviation. Statistical analyses were performed using 
SPSS, version 20.0 for Windows (IL,US).
R E S u LT S
Patient demographics
Baseline demographics of the patients (n=105) are presented in Table 1. Mean age was 
59.40 ± 8.96, 89.5 % of the patients were male, 33.3% had diabetes mellitus, 68.6 % 
presented with stable angina.
Angiographic and lesion characteristics
The most frequently treated vessel was the right coronary artery (44.8%), 35.2% of the CTO 
were located at the proximal/ostial coronary segment, 28.6% cases involved a bifurcation 
lesion with aside branch ≥ 2 mm and 56.2% of the cases showed a multivessel disease, 
74.3% of the lesions had occlusion length ≥ 20 mm and 43.8% bridging collaterals at the 
level of the occlusion. Rentrop grade 3 collaterals were present in 29.5% of the lesions.
The mean J-CTO score was 2.61 with nearly half (47.6 %) of the CTO lesions being very 
difficult (J-CTO score ≥3). (Table 2)
Quantitative coronary angiography showed a Pre-treatment reference vessel diameter 
of 2.71 ± 0.55 mm, Post-PCI mean MLD of 2.50 ± 0.51 mm with a percentage diameter 
stenosis of 14.53 ± 10.31%. (Table 2)
Procedural Characteristics
Procedural characteristics are shown in Table 3. The majority of the cases (62.9%) were 
performed with a bi-femoral approach with a frequent use of contralateral injection. 
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table 1. Baseline Demographic and Clinical Characteristics.
n=105
Age, yrs 59.40 ± 8.96
Male gender % 89.5
History of smoking% 48.6
Diabetes mellitus% 33.3
Dyslipidemia% 72.4
Hypertension% 69.5
Family History of CAD% 21.9
Myocardial Infarct% 29.5
Prior PCI% 46.7
Prior CABG% 2.9
Silent ischemia% 5.7
Stable angina% 68.6
Acute coronary syndrome% 23.8
Congestive cardiac failure% 1.9
Values specified as percentages or mean with standard deviation. CAD=coronary artery disease, PCI=percutaneous 
coronary intervention, CABG= coronary artery bypass graft
table 2. Baseline Lesion and Angiographic Characteristics.
n=105
Left anterior descending artery%  41.9
Left circumflex/ marginal% 12.4
Right coronary artery% 44.8
Ostial-proximal % 35.2
Mid% 61.9
Distal% 2.8
Bifurcation % 28.6
Single vessel disease% 43.8
Two-vessel disease% 40.0
Three-vessel disease% 16.2
Severe tortuosity% 26.7
Blunt stump% 60.0
Calcification present% 70.5
Bending > 45 degrees% 49.5
Occlusion ≥ 20mm% 74.3
Retry lesion% 11.4
(Any) Side branch present% 65.7
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n=105
(Any) Bridge collateral present% 43.8
Rentrop grade 3 collateral% 29.5
Bad landing zone% 34.3
Bad distal vessel% 26.7
CTO J-score% 2.61 ± 0.75
Easy (J-CTO score 0) % 0 
Intermediate (J-CTO score 1) % 0
Difficult (J-CTO score 2) %  52.4
Very Difficult (J-CTO score ≥3) %  47.6
   J-CTO score 3 37.1
   J-CTO score 4 7.6
   J-CTO score 5 2.9
Pretreatment reference vessel diameter, mm 2.71 ± 0.55
Pretreatment Diameter stenosis, % 100,0 
Post-treatment minimal lumen diameter, mm 2.50 ± 0.51
Post-treatment reference vessel diameter, mm 2.88 ± 0.51
Post-treatment diameter stenosis, % 14.53 ± 10.31
Values specified as percentages or mean with standard deviation. 
Successful lesion crossing with retrograde strategy occurred in 25.7% of the procedures. 
Predilatation was performed in every lesion with a mean predilatation balloon diameter 
of 2.69 ± 0.32 mm. Guide-wires used for successful crossing included the Conquest Pro 
9/12 (12.4%), Gaia First/ Second/ Third (11.4%), Miracle Bros 3/6 (8.6%) and Pilot 150/200 
(19.0%). A total of 256 BVS were implanted with a mean number of scaffolds implanted 
per lesion equal to 2.44 ± 1.12, with 79 overlaps, a total scaffold length per lesion of 59.75 
± 25.85 mm and a mean scaffold diameter per lesion of 3.00 ± 0.31 mm. Postdilation was 
performed in 89.5% of the cases. 
OCT measurements Post scaffold deployment
Post scaffold deployment imaging of the scaffolds with the use of OCT was performed in 
10 cases (18.2%). Mean lumen area was 7.31± 1.28 mm2, with a minimum lumen area 5.35 
±1.53 mm2 and residual area stenosis of 6.83 ± 26.44%. Mean ISA area was 0.03 ± 0.04 
mm2. Mean eccentricity index 0.86 ± 0.04 and symmetry index was 0.37 ±0.10. (Table 4)
Clinical Outcomes
Device success and procedural success were 98.1% and 97.1% respectively. During the 
index procedure two patients required bailout stenting with metal stents and in one case 
was observed a final TIMI II flow. No other major peri-procedural complications such as 
table 2. Continued.
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table 3. Procedural Characteristics.
n=105
Vascular access 
Single access, femoral 22.8
Single access, radial 9.5
Double access, femoral and radial 4.8
Double access, both femoral 62.9
Contralateral injection 63.8
Intravascular imaging
Intravascular ultrasound 55.2
Optical coherence tomography 9.5
Successsful antergrade strategy 74.3
Successsful Retrograde strategy 25.7
Number of guidewires used per lesion 3.27 ± 1.69
Guidewire or CTO Devices used for crossing
Conquest Pro 9/12 12.4
Fielder XT-R/FC 23.8
Gaia First/ Second/ Third 11.4
Miracle Bros 3/6 8.6
Pilot 150/200 19.0
Sion/Sion Black/ Sion Blue 6.7
Ultimate Bro 5.7
BMW 1.9
CrossIT 100/200 XT/ Progress 8.6
Whisper 1.9
Predilation performed 100
Use of OTW balloon 8.6
Microcatheters used 85.7
Cutting balloon/ rotation artherectomy (11/1) 11.4
Maximum predilation balloon diameter, mm 2.73 ± 0.43
Maximum predilation pressure, atm 14.97 ± 2.72
Total number of scaffolds impanted 256
Number of scaffolds per lesion 2.44± 1.12
Overlapping scaffolds 79.0
Total scaffold length per lesion, mm 59.75 ± 25.85
Mean scaffold diameter per lesion, mm 3.00 ± 0.31
Maximum scaffold implantation pressure, atm 13.82 ± 2.93
Postdilation performed 89.5
Maximum postdilation balloon diameter, mm 3.35 ± 0.44
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n=105
Procedure time, min 167.06 ± 78.28
Fluroscopy time, min 60.95 ± 35.16
Contrast volume, mls 334.63 ± 138.01
Antiplatelet therapy 
Aspirin 100.0
Clopidogrel 47.6
Prasugrel 28.6
Ticagrelor 23.8
OTW- over the wire. Values specified as percentages or mean with standard deviation. 
table 4. Optical Coherence Tomography Measurements post scaffold deployment.
n=10 
Analyzed length/mm 36.64 ±11.64
Reference lumen area/mm2 6.00 ± 1.88
Minimum lumen area/mm2 5.35 ±1.53
Mean lumen area/mm2 7.31 ±1.28
Lumen volume/mm3 254.02 ± 79.47
Maximum scaffold diameter/mm 3.85 ± 0.45
Minimum scaffold diameter/mm 2.42 ± 0.32
MSA/mm2 5.84 ±1.31
Mean scaffold area/mm2 7.71 ±1.37
Scaffold volume/mm3 268.81 ± 93.51
RAS/% 6.83 ± 26.44
EI 0.86 ± 0.04
EI at MSA 0.84 ±0.06
SI 0.37 ±0.10
Device with ISA detected 6 
Mean ISA area/mm2 0.03 ± 0.04
Total struts 3,387
Malapposed struts 39
Mean prolapse area/mm2 0.53 ± 0.42
Edge Dissection 8 (80.0)
EI-Eccentricity index
ISA-Incomplete strut apposition
MSA- Minimum scaffold area
RAS-Residual area stenosis
SI- Symmetricity index
Values are expressed as mean ± standard deviation. 
table 3. Continued.
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scaffold thrombosis were reported. No episodes of severe in hospital adverse events were 
observed.
The 6-month follow up was completed in 91.4% of the cases. One patient developed late 
scaffold thrombosis at 47 days post-procedure. The patient had 3 Absorb BVS scaffolds 
(3.0 x 28mm; 3.5 x 18mm and 3.5 x 18mm in an overlapping manner) implanted in the 
left anterior descending artery CTO (J-CTO score 3). The lesion was predilated with a 
3.0mm balloon and postdilated with a 3.5mm noncompliant balloon. He presented with 
a Non ST-segment Elevation Myocardial Infarct, the coronary angiogram showed scaffold 
thrombosis involving the treated artery and further PCI was performed (thrombectomy, 
implantation of a drug eluting metal stent and intravenous infusion of eptifibatide). Two 
additional clinically driven target lesion revascularisations were reported, one of those 
was performed after observation by CT scan of re-occlusion of the 3.0 x 28mm Absorb BVS 
scaffold previously implanted in the left circumflex artery the patient was symptomatic 
and a treatment was carried out at 6 months post-procedure with a metallic drug eluting 
stent. No cases of mortality were seen. The overall MACE rate was therefore 3.1%
Computed Tomography scans were performed at 6 months in 34 patients, only in two 
cases was observed scaffold restenosis. After clinical re-evaluation of these two patients, 
1 case (above-mentioned) underwent TLR whereas the other case give the absence of 
symptoms and of inducible ischemia was managed conservatively.
D I S C u S S I O N
Coronary chronic total occlusions are classically regarded as a challenging subset 
burdened by low procedural success and poorer clinical outcomes when compared to 
other lesion types. Even though the introduction of drug eluting stents has reduced 
the rate of in-stent restenosis, the adoption of these devices is not devoid of limitations 
especially in chronically occluded vessels.
Treatment of CTOs often implies stenting of long coronary segments with permanent 
vessel caging of large part of the artery. This is not only associated with a possible 
increased risk of restenosis and stent thrombosis, but is also precluding future surgical 
revascularizations in patients that often show diffuse and multivessel atherosclerosis as 
also confirmed in the present report with 56.2% of the patients having multivessel disease.
In addition after recanalization of CTOs, a flow-dependent positive vascular remodeling 
process has been reported and has been associated with progressive increase in lumen 
diameter, external elastic membrane (EEM) diameter, lumen area and EEM area.35-37 Park 
and colleagues35 reported that this increase in lumen dimensions is followed by an 
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increased incomplete stent apposition at 6-month follow-up in patients treated for CTO 
lesions. Theoretically, the bioresorption process could eliminate this limitation as the 
scaffold remnants can follow the vessel wall motion already between six months and one 
year after implantation.20
Recently, small series of CTOs treated with BVS with slightly lower lesion complexity has 
been reported, with outcomes comparable to ours.21-23 The present investigation focused 
specifically on complex chronically occluded coronary lesions, excluding all cases scored 
as easy or intermediately difficult according to de J-CTO score, with nearly half of the 
occlusions defined as very difficult. Our data suggests feasibility of BVS implantation 
also in the challenging subset of complex CTO lesions, with optimal acute scaffold 
expansion and apposition given an appropriate lesion preparation and a high rate of final 
postdilatation. The final angiographic results showed a post-PCI minimal lumen diameter 
of 2.50 ± 0.55 with a very low percentage diameter stenosis (14.53 ± 10.31 %) associated 
with a final TIMI 3 flow achieved practically in the entire population. Such promising acute 
results are in line with angiographic data obtained in previous reports evaluating the BVS 
as well as metallic DES implantation in CTO lesions21, 23, 38 
These data were obtained after an aggressive lesion predilatation with maximum balloon 
diameter close to the reference vessel diameter and to the nominal scaffold diameter. 
Postdilatation was performed in a large number of cases with balloons bigger than the 
nominal scaffold diameter (up to 0.5 mm exceeding the scaffold diameter). This approach 
translated also into an optimal device apposition with a very low incomplete scaffold 
apposition area as assessed by OCT and facilitated optimal scaffold expansion. On this 
regard, a common concern when hypothesising the use of BVS in CTO lesion is the fact 
that the presence of diffusely diseased vessels with extensive calcifications may affect the 
scaffold expansion. In the present investigation was observed a mean scaffold eccentricity 
and symmetry index resembling results previously reported for BVS and for metal DES 
in non-chronically occluded vessels.31-33 These findings suggest that the concern on 
BVS optimal expansion in CTO lesions might not be justified if an appropriate lesion 
preparation and scaffold postdilatation is performed. (Figure 3) 
The encouraging angiographic results were followed by mid-term clinical outcomes 
showing an overall survival and target lesion revascularisation comparable the everolimus 
eluting stent in CTO lesions.39 However, given the limited number of patients and the low 
event rate this data should be considered as simply descriptive and hypothesis generating.
A current limitation of the bioresorbable technology is the high strut thickness that could 
be associated with a delayed vascular healing and endothelialisation especially at the site 
of the overlap. In addition the larger profile of this device compared with last generation 
metallic DES could represent an important obstacle when approaching tortuous, calcified 
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vessels. Technical scaffold improvement such as new delivery systems, reduction in strut 
thickness and in the crossing profile, are awaited for an improvement of the current device 
performance. 
Our results support feasibility of BVS implantation in CTO lesion even in complex scenarios, 
the theoretical advantages of this new technology need to be evaluated in further larger 
studies focused on direct comparison with standard metal drug eluting stents and 
analysing angiographic, intravascular imaging and clinical results at long-term follow-up.
Limitations
This is a single arm retrospective study, as such procedural and clinical outcomes cannot 
be directly compared with lesions treated with drug eluting metallic stents. Given the 
limited number of patients and the low rate of events clinical outcomes data should be 
considered as purely descriptive and hypothesis generating. The BVS was used as per 
operator discretion, this methodology may be source of selection bias. The number of 
OCT performed in the present study is very limited and results should be considered as 
descriptive and hypothesis generating.
CO N C Lu S I O N
The findings provided by the present investigation suggest feasibility of BVS implantation 
for treatment of complex CTO lesions. In this setting, good procedural and mid term 
clinical outcomes may be achieved given adequate lesion preparation and scaffold 
postdilatation. 
Clinical Implications
Our seminal observations suggest feasibility of bioresorbable scaffold implantation in 
patients with chronic total occlusion and complex anatomies supporting an expansion of 
the BVS use also in this setting, potentially extending the theoretical advantages of this 
novel technology. Optimal antiplatelet regimen, accurate comparison with the current 
generation metallic DES and long-term performance remain to be evaluated.
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A S S E S S M E N T  O F  CO R O N A R y  AT h E R O S C L E R O S I S  W I T h 
I N T R AVA S C u L A R  I M AG I N G 
The understanding of the atherosclerotic process is fundamental to achieve an adequate 
treatment of the coronary artery disease. The first part of the present thesis is focused on 
the characterisation of the coronary plaques using intravascular imaging; the use of such 
technologies allows us to assess the plaques characteristics and composition. In particular 
the combination of different imaging modalities (i.e. intravascular ultrasound virtual 
histology and optical coherence tomography) could be appropriate to fully investigate 
lesion vulnerability.
Plaque rupture and subsequent activation of the clotting cascade resulting in sudden 
intraluminal
thrombosis are thought to be the most frequent cause of acute coronary syndromes.1, 2 
In pathology, precursor lesions, known as thin-cap fibroatheromas (TCFA), are characterized 
by a large pool of necrotic core covered by a thin fibrous cap <65 μm3. The resolution of 
current intravascular ultrasound (IVUS) systems (100 to 200 μm) constitutes an important 
limitation of this technique for the measurement of fibrous cap thickness. On the other 
hand, optical coherence tomography (OCT), has higher resolution (10 to 20 μm) but low 
signal penetration.4 Therefore, combining the two imaging modalities might provide a 
more accurate method to investigate TCFAs5, 6 
In addition the full understanding of the plaque morphology and composition may guide 
the appropriate strategy when treating coronary lesions. The presence of a large amount of 
circumferential calcium could be the underlying reason to initiate a coronary intervention 
with an aggressive lesion preparation approach (i.e. rotablation, cutting balloon, high 
pressure non compliant ballooning). Such information maybe of paramount importance 
especially when implanting bioresorbable devices, as an optimal lesion preparation and 
scaffold deployment has been identified as key factors to facilitate good angiographic 
results and clinical outcomes.
Continuous developments in invasive and non-invasive imaging allow a detailed 
visualization of coronary pathology, considerably increasing our knowledge about plaque 
growth and rupture while prospective natural history of atherosclerosis studies observed 
a link between plaque morphology and future clinical outcomes.7 
However, the invasive treatment of a potential culprit lesion in asymptomatic patients can 
be justified only if stent implantation is completely safe. Initial reports demonstrated an 
unacceptable high risk of complications in non flow limiting lesions treated with balloon 
angioplasty or bare metal stents, whereas the new developments in stent design may 
have reduced the risk of complications, but they have not eradicated them.8 
426   |    Summary and Conclusions
The alteration of vessel wall physiology as well as the risk of neoatherosclerosis and 
inflammatory reaction to a permanent foreign body remains considerable pitfalls of 
metallic stents. 
Bioresorbable scaffold is a recent technology introduced to address the above-mentioned 
drawbacks. These devices have the ability to dissolve after restoring the patency of the 
vessel allowing the coronary artery to maintain its physiologic integrity.9 
Recent reports demonstrated that the neointimal tissue developed postimplantation of a 
bioresorbable scaffold can seal the underlying plaques, whereas studies in animal models 
showed that the neointimal tissue has features associated with plaque stability.10, 11 
These initial reports may support the use of bioresorbable scaffolds for paving diseased 
coronary segments with vulnerable plaques, but long-term follow-up data are required to 
elucidate this prospective.
 At the current state of the art, given our inability to accurately predict which of the 
detected vulnerable plaques will rupture, when this will occur, and whether this event 
will have clinical implications an invasive sealing of potential culprit lesions cannot be 
justified. 
However, the revolution occurring in invasive and non-invasive imaging and the advances 
in molecular biology are expected to provide additional information about atherosclerotic 
disease progression/regression, probably allowing us to predict with a higher accuracy 
events and plaque ruptures. Although, few years ago, the early detection and invasive 
passivation of future culprit lesions appeared as an unrealistic dream, it is currently 
regarded as a future potentiality.
I N I T I A L  E x P E R I E N C E  W I T h  B I O R E S O R B A B L E  S C A F F O L D S 
The everolimus eluting bioresorbable vascular scaffold (BVS) consists of a backbone of 
poly-L-lactide (PLLA) coated with poly-D,L-lactide (PDLLA) that contains and controls the 
release of the antiproliferative drug everolimus. It has been initially evaluated in humans 
in a small cohort study, the Absorb Cohort A trial enrolling 30 patients12 and showing 
feasibility of implantation of this novel technology, with an acceptable in-stent late loss at 
6-month follow-up (0.44 ±0.35 mm).
The first generation of BVS showed a slightly higher acute recoil compared with 
conventional metallic platform stents,13 and at 6 months, an 11.8% reduction in scaffold 
area and a 24.3% decrease in minimal luminal area were documented and defined “late 
recoil.”12, 14
Although the short- and long-term results of the ABSORB cohort A trial were favourable, 
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reinforcement of the mechanical performance of the device and prolongation of its 
mechanical integrity up to 6 months were regarded as potential improvements of this 
technology.
To enhance the mechanical strength of the struts and to reduce immediate and late 
recoil,14 the strut design and the manufacturing process of the polymer were modified in 
the revised version, BVS 1.1. The new design has in-phase zigzag hoops linked by bridges 
that allow a more uniform
strut distribution, reduce maximum circular unsupported surface area, and provide more 
uniform vessel wall support and drug release.15 In addition, a modified manufacturing 
process has resulted in a lower hydrolysis (in vivo degradation) rate of the polymer, thus 
preserving its mechanical integrity for a longer period of time.10 The BVS revision 1.1 was 
tested in 101 patients of the ABSORB cohort B study.
The Part II of the present thesis represents an overview of initial investigations performed 
in the very early phase of our knowledge on this technology. 
We learned, that the late shrinkage and the performance of the second generation BVS 
improved by changing the manufacturing process of the polymer, reducing the maximum 
circular unsupported surface area16, and modifying the bioresorption profile. 
We assessed such improvement in the bioresorption process with IVUS-Virtual histology 
(VH).
IVUS-VH misrepresents polymeric struts as dense calcium and necrotic core so that 
their presence and disappearance could be used as potential artifactual surrogate of 
bioresorption17 
The particular polymeric composition of the scaffold lead to slightly different geometrical 
properties of this device compared with metal when implanted in coronary arteries, 
particularly in terms of lower eccentricity index and a higher symmetry index18 without 
apparently affecting clinical outcomes.
The bioresorbable vascular scaffold is a totally novel paradigm for coronary artery 
treatment and a novel approach for implantation should be considered, in particular an 
initial concern raised from the possibility of fracturing the scaffold by over-expanding it. 
The appropriate sizing of the vessels before implantation was regarded as a key point 
for an optimal implantation and the adoption of the proximal and distal maximal lumen 
diameters (DMAX) as reverences added in important information on how to perform an 
optimal deployment.
The polymeric nature of the device was also associated to a novel way to display stent 
contours when performing intravascular imaging, with the consequent need for a deep 
understanding of the new images. In particular the assessment of strut coverage became 
more challenging with the standard optical coherence tomography (OCT).
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Strut coverage after implantation is expressing endothelialisation and the overall vascular 
healing and could be related to future events like scaffold thrombosis.
Struts imaged with OCT post-implantation typically appear as a box-shaped highly 
reflective frame that marks the refractive index change at the lumen-polymer and polymer-
tissue interfaces.10, 19 Unlike metallic stents, the assessment of coverage with BVS is more 
challenging, because the backscattering from thin neointimal layers mixes with that from 
the polymer interface and can be difficult to discern in a conventional analysis of the log-
transformed OCT signal. On the other hand fitting the raw OCT backscattering signal to 
a Gaussian line spread functions (LSF) facilitates identification of the interfaces between 
BVS polymer and lumen or tissue. Such analysis enables more precise measurement of 
the strut thickness and an objective assessment of coverage. A similar concept has been 
recently used in randomized trials comparing BVS with metal stents.20 
The initial experience with bioresorbable vascular scaffold implantation in humans showed 
promising results also in terms of clinical and angiographic outcomes when considering 
relatively challenging scenarios such as small vessels21 with a vascular response similar to 
what observed in metal stents.22 
Given this background a randomized trial was initiated to compare BVS with current 
generation metallic drug eluting stents and also aiming to present a new approach to 
coronary artery disease treatment that integrates transient mechanical revascularization, 
drug elution, medical treatment and life style changes into a single strategy to restore 
coronary blood flow and vessel physiology. 
B I O R E S O R B A B L E  S C A F F O L D S  F O R  T R E AT M E N T  O F 
CO M P L E x  L E S I O N S  A N D  PAT I E N T S  W I T h  AC u T E  CO R O N A R y 
S y N D R O M E S 
After the introduction of BVS and the preliminary results in relatively simple lesions and 
stable patients the devices received the CE mark for clinical use, indicated for improving 
coronary lumen diameter in patients with ischemic heart disease due to de novo native 
coronary artery lesions with no restriction in terms of clinical presentation. Therefore the 
BVS can be currently used routinely in Europe in different settings comprising complex 
lesions and the acute myocardial infarction without a specific written informed consent in 
addition to the standard informed consent to the procedure. Our institution was the first 
simultaneously with the group of Prague to report results after BVS implantation in acute 
myocardial infarction.23, 24
And both analyses showed very similar results supporting feasibility the BVS implantation 
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in patients presenting with acute myocardial infarction, with high rate of final TIMI-flow III 
and good scaffold apposition.
These evidences not only diffused the idea, within the scientific community, that acute 
thrombotic lesions could be treated with bioresorbable devices but some authors 
identified the soft ruptured plaques as an appealing subset for the implantation of 
polymeric devices given the easily distensibility of such lesions.25 
At the current state of the art the implantation of this device in the entire spectrum of 
complex lesions encountered during the daily practice is still matter of debate.
In particular the implantation technique has been profoundly changed since the initial 
experience when most of the operator were reluctant to the idea of an aggressive 
postdilatation. 
Accumulating data on the expanded use of the bioresorbable technology in daily practice 
suggest the importance of an appropriate lesion preparation and even more an adequate 
postdilatation to optimize deployment and expansion.
This evolution of the implantation technique allowed us to implant this device in real 
challenging subsets like calcified lesions, bifurcations and total occlusions.
In particular thank to the collaboration of many expert in chronic total occlusion (CTO) 
treatment we were able to report promising data after implantation of this novel device 
also in complex CTO that probably represent the most challenging subset in interventional 
cardiology.
CO N C Lu S I O N S
The bioresorbable technologies represent a novel concept for treatment of coronary 
artery disease providing revascularization with transient vascular support and drug 
delivery. This novel therapy has been termed as vascular restoration therapy as after 
bioresorption the coronary vessel will be able to re-acquire the physiological vasomotion, 
without metallic caging, exposed to the pulsatile blood flow and potentially free to have 
positive remodeling and late lumen enlargement.
Given the peculiar mechanical properties and the polymeric nature of this device, it should 
not be considered just another stent in the clinical arena but a separated way of treating 
patients. This implies that a dedicated technique of implantation should be adopted with 
a meticulous lesion preparation, particular attention to the expansion limits and high 
pressure postdilation in the majority of the cases. 
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The theoretical advantages of these novel technologies could be potentially beneficial 
for every patient but the implantation of bioresorbable scaffold should be probably 
primarily considered in those subjects where these advantages could be maximized. 
In particular, young patients who could benefit from having coronaries free of metal 
for many years, patients with multivessel disease that could in future be candidate for 
surgical revascularisations and acute patients were vasoconstriction could be associated 
with stent undersizing and very long-term malapposition.
The current bioresorbable devices are not devoid of limitations. The higher profile of 
the second generation BVS make the scaffold delivery slightly more challenging than 
standard metal stents especially in tortuous calcified vessels. The higher strut thickness 
might delay the endothelialisation and coverage facilitating platelet aggregation and the 
occurrence of thrombotic events. 
However, this technology is probably in a very early phase of its development and similar 
clinical outcomes compared to metals DES that have been optimised for more than fifteen 
years should be considered already a great achievement. Technical improvements of 
the scaffold with the introduction of thinner struts more similar to those of the current 
generation DES, a wider range of available sizes and less strict expansion limits are currently 
awaited. Such improvements could reduce the technical gap between bioresorbable and 
metal and facilitate a larger adoption of this technology in clinical practice.
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k A R A k T E R I S E R I N G  VA N  CO R O N A I R E  AT h E R O S C L E R O S E 
M E T  I N T R AVA S C u L A I R E  I M AG I N G 
Het begrip van het atherosclerotisch proces is fundamenteel voor het bereiken van een 
adequate behandeling van coronaire hartziekte. Het eerste deel van dit proefschrift 
is gericht op de karakterisering van de coronaire plaques met gebruikmaking van 
intravasculaire beeldvorming; het gebruik van dergelijke technologieën stelt ons in 
staat de karakterisering en samenstelling van de plaques te beoordelen. Met name 
de combinatie van verschillende beeldvormingsmodaliteiten (d.w.z. intravasculaire 
ultrasound, virtuele histologie en optische coherentietomografie) zou geschikt zijn voor 
een volledig onderzoek van de laesiekwetsbaarheid.
Plaqueruptuur en daaropvolgende activering van de stollingscascade leidend tot plotse 
intraluminale trombose, vormen naar men denkt de vaakst voorkomende oorzaak van 
acute coronaire syndromen.1, 2 
In de pathologie worden precursorlaesies, bekend als thin-cap fibroatheromas (TCFA) 
gekarakteriseerd door een grote pool van necrotische kern, bedekt door een dunne 
fibreuze kap < 65 μm3. De resolutie van de huidige intravasculaire ultrasoundsystemen 
(IVUS) (100 tot 200 μm) vormt een belangrijke beperking van deze techniek voor de 
meting van de dikte van de fibreuze kap. Anderzijds heeft optische coherentietomografie 
(OCT) een hogere resolutie (10 tot 20 μm) maar een lage signaalpenetratie.4 Daarom zou 
combinatie van de twee beeldvormingsmodaliteiten een nauwkeurige methode kunnen 
bieden voor het onderzoeken van TCFA’s5, 6 
Bovendien kan volledig begrip van de plaquemorfologie en -samenstelling een leidraad 
zijn voor de juiste strategie bij de behandeling van coronaire laesies. De aanwezigheid van 
een grote hoeveelheid omringend calcium zou de onderliggende reden kunnen zij voor 
het initiëren van een coronaire interventie met een agressieve laesiepreparatiebenadering 
(d.w.z. rotablatie, snijballon, high pressure non compliant ballooning). Dergelijke informatie 
kan van zeer groot belang zijn, met name bij de implantatie van bioresorbeerbare stents, 
omdat is vastgesteld dat optimale laesiepreparatie en scaffoldgebruik de belangrijkste 
factoren zijn voor het vergemakkelijken van goede angiografische resultaten en klinische 
uitkomsten.
Continue ontwikkelingen op het gebied van de invasieve en non-invasieve beeldvorming 
maken een gedetailleerde visualisatie mogelijk van coronaire pathologie, wat een 
aanzienlijke vermeerdering betekent van onze kennis over plaquegroei en -ruptuur, 
terwijl de prospectieve natuurlijke voorgeschiedenis van atherosclerose-onderzoeken 
een koppeling aangaf tussen plaquemorfologie en toekomstige klinische uitkomsten.7 
De invasieve behandeling van een potentiële culprit laesie bij asymptomatische 
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patiënten kan echter alleen gerechtvaardigd zijn als stent-implantatie geheel veilig is. 
De eerste meldingen toonden een onaanvaardbaar hoog risico op complicaties in niet-
flowbeperkende laesies behandeld met ballonangioplastiek of bare-metal-stents, terwijl 
de nieuwe ontwikkelingen op het gebied van stent-ontwerp het risico op complicaties 
verminderd hebben maar niet doen verdwijnen.8 
De verandering van de vaatwandfysiologie en het risico op neoatherosclerose en 
ontstekingsreactie op een permanent vreemd lichaam blijven een aanzienlijk nadeel van 
metalen stents. 
Bioresorbeerbare scaffold is een recente technologie die is geïntroduceerd om de 
bovengenoemde bezwaren aan te pakken. Deze stents hebben het vermogen om op te 
lossen na het herstellen van de doorgankelijkheid van het vat, waardoor de coronairarterie 
zijn fysiologische integriteit behoudt.9 
Recente rapporten toonden dat het neo-intimale weefsel dat wordt ontwikkeld na 
implantatie van een bioresorbeerbare scaffold de onderliggende plaques kan verzegelen, 
terwijl onderzoeken in diermodellen toonden dat het neo-intimale weefsel kenmerken 
heeft die zijn geassocieerd met plaquestabiliteit.10, 11 
Deze eerste rapporten kunnen het gebruik van bioresorbeerbare scaffolds voor zieke 
coronaire segmenten met kwetsbare plaques ondersteunen, maar langetermijnfollow-
upgegevens zijn vereist om deze verwachting te verklaren.
 Bij de huidige stand van de techniek zal, gegeven ons onvermogen om nauwkeurig te 
voorspellen welke van de kwetsbare plaques zullen scheuren, wanneer dit zal gebeuren 
en of dat voorval klinische implicaties zal hebben een invasieve sealing van mogelijke 
culprit laesies niet zijn gerechtvaardigd. 
De revolutie die gaande is op het gebied van invasieve en non-invasieve beeldvorming 
en de vooruitgang in de moleculaire biologie zal echter naar verwachting aanvullende 
informatie opleveren over progressie/regressie van atherosclerotische ziekte, waardoor 
wij waarschijnlijk met grotere nauwkeurigheid voorvallen en plaquerupturen kunnen 
voorspellen. Hoewel een aantal jaren geleden de vroege detectie en invasieve passivering 
van toekomstige culprit laesies een onrealistische droom leek, wordt dit momenteel 
gezien als een mogelijkheid voor de toekomst.
E E R S T E  E R VA R I N G  M E T  B I O R E S O R B E E R B A R E  S T E N T S
De everolimus-eluderende bioresorbeerbare vasculaire scaffold (BVS) bestaat uit een 
backbone van poly-L-lactide (PLLA) bekleed met poly-D,L-lactide (PDLLA) dat het 
antiproliferatieve geneesmiddel everolimus bevat en dat afgeeft. Het is in eerste instantie 
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beoordeeld bij mensen in een klein cohortonderzoek, het Absorb Cohort A-onderzoek 
waarin 30 patiënten werden ingeschreven12 en dat de haalbaarheid aantoonde van 
implantatie van deze nieuwe technologie, met een aanvaardbare in-stent late loss bij 
follow-up na 6 maanden (0,44 ±0,35 mm).
De eerste generatie BVS toonde een iets hogere acute recoil vergeleken met conventionele 
metalen platformstents,13 en na 6 maanden werden een 11,8% reductie in het 
scaffoldgebied en een 24,3% afname in het minimale luminale gebied gedocumenteerd 
en gedefinieerd als “late recoil”.12, 14
Hoewel de kortetermijn- en de langetermijnresultaten van het ABSORB cohort 
A-onderzoek gunstig waren, werden versterking van de mechanische prestaties van het 
implantaat en verlenging van de mechanische integriteit ervan tot 6 maanden gezien als 
mogelijke verbeteringen van deze technologie.
Om de mechanische sterkte van de steunen te vergroten en onmiddellijke en late recoil 
te verminderen,14 werden het steun-ontwerp en het fabricageproces van het polymeer 
gewijzigd in de herziene versie, BVS 1.1. Het nieuwe ontwerp heeft in-fase zigzag hoops 
gekoppeld door bruggen die een uniformere steunverdeling mogelijk maken, het maximale 
circulaire niet-ondersteunde vlak verkleinen en uniformere vaatwandondersteuning en 
geneesmiddelafgifte bieden.15 Bovendien heeft een gewijzigd fabricageproces geleid 
tot een lager hydrolysepercentage (afbraak in vivo) van de polymeer, waardoor de 
mechanische integriteit daarvan langer behouden blijft.10 De BVS-revisie 1.1 werd getest 
bij 101 patiënten uit het ABSORB cohort B onderzoek.
Deel II van dit proefschrift geeft een overzicht van de eerste onderzoeken uitgevoerd in 
de zeer vroege fase van onze kennis over deze technologie. 
We hebben ontdekt dat de late krimping en de prestaties van de tweede generatie BVS 
verbeterden door het veranderen van het fabricageproces van de polymeer, wat een 
vermindering betekent van het maximale circulaire niet-ondersteunde vlak16 en het 
veranderen van het bioresorptieprofiel. 
We beoordeelden een dergelijke verbetering in het bioresorptieproces met IVUS-Virtuele 
Histologie (VH).
IVUS-VH geeft een verkeerde voorstelling van polymerische steunen als dichte calcium en 
necrotische kern zodat hun aanwezigheid en verdwijning zou kunnen worden gebruikt 
als potentieel artifactueel surrogaat van bioresorptie17 
De specifieke polymerische samenstelling van de scaffold leidt tot verschillende 
geometrische eigenschappen van deze stent vergeleken met metaal bij implantatie in 
coronairarteriën, met name in termen van een lagere eccentriciteitsindex en een hogere 
symmetrie-index18 zonder kennelijk invloed te hebben op de klinische uitkomsten.
De bioresorbeerbare vasculaire scaffold is een geheel nieuw paradigma voor coronaire-
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arteriebehandeling en een nieuwe benadering voor implantatie zou overwogen moeten 
worden, met name een initieel punt van zorg gelet op de mogelijkheid van breuk van de 
scaffold door deze te sterk te expanderen. De juiste maatvoering van de vaten voorafgaand 
aan implantatie werd beschouwd als een zeer belangrijk punt voor een optimale 
implantatie en het gebruik van de proximale en distale maximale lumendiameters 
(DMAX) wordt toegevoegd aan belangrijke informatie over hoe optimaal gebruik kan 
worden bereikt.
De polymerische aard van het implantaat werd ook in verband gebracht met een nieuwe 
manier voor het weergeven van de stentcontouren bij het uitvoeren van intravasculaire 
beeldvorming, met de daaruit voortvloeiende behoefte aan een diepgaand begrip van 
de nieuwe beelden. Met name de beoordeling van steuncoverage werd moeilijker met de 
standaard optische coherentietomografie (OCT).
Steuncoverage na implantatie geeft endothelialisatie en totale vasculaire genezing aan 
en zou gerelateerd kunnen zijn aan toekomstige voorvallen zoals scaffoldtrombose.
Steunen waarvan beelden worden gemaakt met OCT post-implantatie worden 
meestal weergegeven als een doosvormig uiterst reflectief frame dat de refractieve 
indexverandering bij de lumen-polymeer en polymeerweefselinterfaces weergeeft.10, 19 
In tegenstelling tot metalen stents is de beoordeling van coverage met BVS moeilijker, 
omdat de backscattering uit dunne neo-intimale lagen wordt vermengd met die uit de 
polymeerinterface en moeilijk te onderscheiden kan zijn in een conventionele analyse van 
het log-getransformeerde OCT-signaal. Anderzijds vergemakkelijkt het passen van het 
ruwe OCT backscatteringsignaal bij een Gaussian line spread functions (LSF) identificatie 
van de interfaces tussen BVS-polymeer en lumen of weefsel. Een dergelijke analyse maakt 
nauwkeuriger meting mogelijk van de steundikte en een objectieve beoordeling van de 
coverage. Een soortgelijk concept is reeds gebruikt in gerandomiseerde onderzoeken ter 
vergelijking van BVS met metalen stents.20 
De eerste ervaring met bioresorbeerbare vasculaire scaffold-implantatie bij de mens 
toonde veelbelovende resultaten, ook in termen van klinische en angiografische 
uitkomsten bij het overwegen van relatief moeilijke scenario’s zoals kleine vaten21 met 
een vasculaire respons soortgelijk aan die die is waargenomen bij metalen stents.22 
Gegeven deze achtergrond werd een gerandomiseerd onderzoek gestart ter 
vergelijking van BVS met de huidige generatie metalen drug-eluting stents ook gericht 
op het presenteren van een nieuwe benadering van behandeling van ziekte van de 
coronairarterie die voorbijgaande mechanische revascularisatie, geneesmiddelafgifte, 
medische behandeling en leefstijlveranderingen integreert in één enkele strategie om de 
coronaire bloedstroom en de vaatfysiologie te herstellen. 
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B I O R E S O R B E E R B A R E  S C A F F O L D S  V O O R  B E h A N D E L I N G  VA N 
CO M P L E x E  L A E S I E S  E N  PAT I ë N T E N  M E T  AC u T E  CO R O N A I R E 
S y N D R O M E N 
Na de introductie van BVS en de voorlopige resultaten in relatief eenvoudige laesies en bij 
stabiele patiënten kregen de stents een CE-markering voor klinisch gebruik, geïndiceerd 
voor verbetering van de coronaire lumendiameter bij patiënten met ischemische 
hartziekte als gevolg van de novo native coronairarterielaesies zonder beperking in 
termen van klinische presentatie. Daarom kan de BVS momenteel als routine worden 
gebruikt in Europa in verschillende settings bestaande uit complexe laesies en acuut 
myocardinfarct zonder een specifieke schriftelijke geïnformeerde toestemming naast de 
standaard geïnformeerde toestemming voor de procedure. Onze instelling was tegelijk 
met de groep uit Praag de eerste die resultaten rapporteerde na BVS-implantatie bij acuut 
myocardinfarct.23, 24
En beide analyses toonden zeer soortgelijke resultaten ter ondersteuning van de 
haalbaarheid van de BVS-implantatie bij patiënten met acuut myocardinfarct, met een 
hoge uiteindelijke TIMI-flow III en goede scaffold-appositie.
Deze bewijzen deden het idee binnen de wetenschappelijke gemeenschap vervagen dat 
acute trombotische laesies behandeld zouden kunnen worden met bioresorbeerbare 
stents, maar sommige auteurs identificeerden de zachte gescheurde plaques als een 
aantrekkelijke subset voor de implantatie van polymerische implantaten, gegeven de 
gemakkelijke uitzetbaarheid van dergelijke laesies.25 Bij de huidige stand van de techniek 
is de implantatie van deze stent in het gehele spectrum van complexe laesies die men 
tegenkomt in de dagelijkse praktijk nog steeds een punt van discussie.
Met name de implantatietechniek is sterk veranderd sinds de eerste ervaring toen 
de meeste operateurs terughoudend waren wat betreft het idee van een agressieve 
postdilatatie. 
Verzamelde gegevens over het uitgebreide gebruik van de bioresorbeerbare technologie 
in de dagelijkse praktijk suggereren het belang van een passende laesiepreparatie en nog 
meer een adequate postdilatatie om plaatsing en expansie te optimaliseren.
Deze ontwikkeling van de implantatietechniek heeft ons in staat gesteld tot het 
implanteren van deze stent in werkelijk moeilijke subsets zoals verkalkte laesies, bifurcaties 
en totale occlusies.
Met name dankzij de medewerking van veel deskundigen op het gebied van behandeling 
van chronische totale occlusie (CTO) konden we veelbelovende data melden na implantatie 
van dit nieuwe implantaat, ook bij complexe CTO die waarschijnlijk de moeilijkste subset 
in de interventiecardiologie vertegenwoordigen.
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CO N C Lu S I E S
De bioresorbeerbare technologieën vertegenwoordigen een nieuw concept voor de 
behandeling van coronairarterielijden dat revascularisatie biedt met tijdelijke vasculaire 
ondersteuning en geneesmiddeltoediening. Deze nieuwe behandeling wordt vasculaire 
restauratietherapie genoemd omdat na bioresorptie het coronairvat weer fysiologische 
vasomotie kan verkrijgen, zonder metalen caging, blootgesteld aan de pulserende 
bloedstroom en potentieel vrij voor positieve hermodellering en late lumenvergroting.
Gegeven de bijzondere mechanische eigenschappen en de polymerische aard van 
deze stent moet deze niet worden gezien als gewoon een andere stent in de klinische 
arena maar als een afzonderlijke manier om patiënten te behandelen. Dit impliceert dat 
een speciale implantatietechniek moet worden toegepast met een zeer nauwgezette 
laesiepreparatie, specifieke aandacht voor de expansiegrenzen en in de meeste gevallen 
hoge druk na dilatatie. 
De theoretische voordelen van deze nieuwe technologieën zouden mogelijk gunstig 
kunnen zijn voor elke patiënt, maar de implantatie van bioresorbeerbare scaffolds zou 
waarschijnlijk primair kunnen worden overwogen bij die proefpersonen bij wie het 
meeste uit deze voordelen gehaald zou kunnen worden. Met name jonge patiënten die 
jarenlang zouden kunnen profiteren van kransslagaders zonder metaal, patiënten met 
ziekte van meerdere vaten die in de toekomst in aanmerking zouden kunnen komen 
voor chirurgische revascularisaties en acute patiënten bij wie vasoconstrictie in verband 
gebracht zou kunnen worden met een te kleine stent en zeer langdurige slechte appositie.
De huidige bioresorbeerbare stents zijn niet zonder beperkingen. Het hogere profiel van 
de tweede generatie BVS maakt de scaffoldplaatsing iets moeilijker dan die van standaard 
metalen stents, met name in tortueuze verkalkte vaten. De grotere steundikte zou de 
endothelialisatie en de coverage kunnen vertragen, wat bloedplaatjesaggregatie en het 
optreden van trombotische voorvallen vergemakkelijkt. 
Deze technologie bevindt zich waarschijnlijk in een zeer vroege fase van ontwikkeling en 
soortgelijke klinische uitkomsten vergeleken met metalen DES die gedurende meer dan 
vijftien jaar steeds beter zijn geworden moeten al als een uitstekend resultaat worden 
beschouwd. Technische verbeteringen van de scaffold met de introductie van dunnere 
steunen die meer lijken op die van de huidige generatie DES, een breder assortiment 
beschikbare maten en minder strikte expansiegrenzen worden momenteel verwacht. 
Dergelijke verbeteringen zouden de technische kloof tussen bioresorbeerbare en metalen 
stents kunnen verkleinen en een breder gebruik van deze technologie in de klinische 
praktijk vergemakkelijken.
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Phd traInIng   
In-depth courses date eCts
NIHES Course “Introduction to Data-analysis” 2010 1.5
NIHES Course “Modern Statistical Methods” 2010 1.5
International Conferences & Simposia (0.3 ECTS points/day) Date and Location ECTS
Vulnerable plaque meeting Cascais, 18-22 June 2011 1.2
EuroPCR 2011 Paris, 17-20 May 2011 1.2
EuroPCR 2012 Paris, 15-18 May 2012 1.2
EuroPCR 2013 Paris, 21-24 May 2013 1.2
EuroPCR 2014 Paris, 20-23 May 2013 1.2
EuroPCR 2015 Paris, 17-20 May 2013 1.2
TCT 2011 San Francisco, 7-11 November 2011 1.5
TCT 2012 Miami, 22-26 October 2012 1.5
Optics in Cardiology Rotterdam 11-13 March 2015 0.9
ESC 2015 London, 29 Aug-02 Sept 2015 1.5
Bioresorbable Vascular Scaffold Course 2014 Boston, 25-26 July 2014 0.6
ACCA Congress Geneva, 18-20 October 2014 0.9
PCR Focus Group 2012 Rotterdam, 08-09 March 2012 0.6
GISE 2010 - The Italian Society of Invasive Cardiology Congress Genoa, 19-22 October 2010 1.2
GISE 2011 - The Italian Society of Invasive Cardiology Congress Genoa, 11-14 October 2011 1.2
GISE 2012 - The Italian Society of Invasive Cardiology Congress Genoa, 3-5 October 2012 0.9
GISE 2013 - The Italian Society of Invasive Cardiology Congress Genoa, 9-11 October 2013 0.9
GISE 2015 - The Italian Society of Invasive Cardiology Congress Genoa, 27-30 October 2015 1.2
SIC 2014 - The Italian Society of Cardiology Congress Rome, 13-15 December 2014 0.9
SIC 2013 - The Italian Society of Cardiology Congress Rome, 14-16 December 2013 0.9
SIC 2012 - The Italian Society of Cardiology Congress Rome, 15-17 December 2012 0.9
SIC 2011 - The Italian Society of Cardiology Congress Rome, 10-12 December 2011 0.9
BVS Meeting Cordova, 20-21 April 2015 0.6
CTO Summit Turin, 14-15 April 2015 0.6
Euro CTO Club Istanbul, 18-19 September 2015 0.6
Chronic Total Occlusion Summit New York, 23-24 February 2016 0.6
DRES 2015 Nijkerk, 11-12 June 2015 0.6
Taiwan Absorb Symposium Taiwan, 5 July 2014 0.3
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teaChIng aCtIvItIes
lecturing date and location eCts
Zorgacademie Bijscholing “PCI bifurcatie en hoofdstam” Rotterdam, 16 April 2016l 0.3
Zorgacademie Bijscholing “Bio - absorbeerbare stents (BVS) en 
pericardvocht”
Rotterdam, 09 December 2014 0.3
Zorgacademie Bijscholing “DAPT” Rotterdam, 24 April 2014 0.3
Zorgacademie Bijscholing Rotterdam, 18 December 2013 0.3
Conference Presentations/lectures date and location eCts
EuroPCR 2011 (1 oral presentation) Paris, 17-20 May 2011 0.6
EuroPCR 2012 (3 oral presentations) Paris, 15-18 May 2012 1.8
EuroPCR 2013 (2 oral presentations) Paris, 21-24 May 2013 1.2
EuroPCR 2014 (1 oral presentation) Paris, 20-23 May 2013 0.6
EuroPCR 2015 (1 oral presentation) Paris, 17-20 May 2013 0.6
TCT 2011 (1 oral presentation) San Francisco, 7-11 November 2011 0.6
TCT 2012 (1 oral presentation) Miami, 22-26 October 2012 0.6
Optics in Cardiology (1 oral presentation) Rotterdam 11-13 March 2015 0.6
ESC 2015 (1 oral presentation) London, 29 Aug-02 Sept 2015 0.6
Bioresorbable Vascular Scaffold Course 2014 (4 oral presentations) Boston, 25-26 July 2014 2.4
PCR Focus Group 2012 (3 oral presentations) Rotterdam, 08-09 March 2012 1.8
GISE 2010 - The Italian Society of Invasive Cardiology Congress 
(1 oral presentation)
Genoa, 19-22 October 2010 0.6
GISE 2011 - The Italian Society of Invasive Cardiology Congress 
(2 oral presentations)
Genoa, 11-14 October 2011 1.2
GISE 2012 - The Italian Society of Invasive Cardiology Congress 
(1 oral presentation)
Genoa, 3-5 October 2012 0.6
GISE 2013 - The Italian Society of Invasive Cardiology Congress 
(1 oral presentation)
Genoa, 9-11 October 2013 0.6
GISE 2015 - The Italian Society of Invasive Cardiology Congress 
(3 oral presentations)
Genoa, 27-30 October 2015 1.8
SIC 2014 - The Italian Society of Cardiology Congress 
(1 oral presentation)
Rome, 13-15 December 2014 0.6
SIC 2013 - The Italian Society of Cardiology Congress 
(1 oral presentation)
Rome, 14-16 December 2013 0.6
SIC 2012 - The Italian Society of Cardiology Congress 
(4 oral presentatios)
Rome, 15-17 December 2012 2.4
SIC 2011 - The Italian Society of Cardiology Congress 
(1 oral presentation)
Rome, 10-12 December 2011 0.6
BVS Meeting (1 oral presentation) Cordova, 20-21 April 2015 0.6
CTO Summit (1 oral presentation) Turin, 14-15 April 2015 0.6
DRES 2015 (1 oral presentation) Nijkerk, 11-12 June 2015 0.6
Taiwan Absorb Symposium (4 oral presentations) Taiwan, 5 July 2014 2.4
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